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Abstract 
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the most common age-
related neurodegenerative disorders, affecting millions of people worldwide. There 
are currently no effective or curative therapies for the treatment of these diseases. 
Genetic studies have demonstrated that mitochondrial dysfunction and oxidative 
stress play key roles in the pathogenesis of both AD and PD. Therefore, genetic or 
pharmacological interventions targeting these effectors may prove to be useful 
therapeutic strategies. In my thesis, I focus on the transcriptional cofactor PGC-1α, a 
key modulator in many biological processes, including mitochondrial biogenesis, the 
oxidative stress defence system, the circadian clock, and protein quality control. The 
possible relevance of this gene in the pathogenesis of AD and PD came to light with 
the demonstration that PGC-1α gene expression levels are decreased in the post-
mortem brain tissues of both AD and PD patients.  
 
Consistent with this, I have shown that up-regulation of PGC-1α in the neurons of a 
Drosophila model of Aβ toxicity rescues lifespan, the behavioural phenotypes and 
circadian rhythm disruption. I demonstrated that amelioration of Aβ toxicity is 
associated with improved mitochondrial homeostasis and activation of the ER 
unfolded protein response (UPRER). In keeping with this, I also found that rifampicin, 
an antibiotic used in the treatment of tuberculosis and leprosy, also activated the 
UPRER and rescued the neurotoxicity in Aβ-expressing flies. These findings suggest 
that stimulating the UPRER, either by increasing intraneuronal PGC-1α levels or 
through oral administration of rifampicin, may offer significant therapeutic benefits in 
AD.  
 
Contrary to the results seen using Aβ-expressing flies, I demonstrated that over-
expression of PGC-1α did not rescue the neurotoxic phenotypes in Drosophila models 
of familial PD, lacking PINK1 or parkin.  
 
Given an increasing ageing population coupled with the high prevalence of age-
related diseases there is an urgent need for the development of pharmacological 
agents that can improve healthy aging. PGC-1α has been identified as a novel 
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modulator of fly ageing. The precise mechanisms involved however have not been 
fully elucidated.  
 
Here I also identified the transcription factor GA-binding protein (dGABPα), 
downstream of PGC-1α, as a key modulator of fly ageing. dGABPα gain-of-function 
extends female lifespan via mechanisms beyond dietary restriction (DR), with an 
associated reduction in IIS/mTOR signalling. In addition, over-expression of dGABPα 
improved gut homeostasis by delaying age-related over-proliferation of intestinal 
stem cells. Additionally, dGABPα gain-of-function flies showed resistance to 
xenobiotic stress. Finally, I demonstrated that dGABPα up-regulated ImpL2, the 
insulin ligand binding protein, which down-regulates IIS and extends lifespan. Given 
the evolutionary conserved effects of reduced IIS/mTOR signalling, these findings 
suggest that GABPα may be an important modulator of mammalian ageing and a 
potential therapeutic target in the treatment of age-related diseases. 
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Research impact 
Alzheimer’s disease (AD) is a progressive brain disorder that causes cellular 
dysfunction and eventually neuronal loss. Clinically this results in memory loss as 
well as more widespread cognitive dysfunction. In America alone, more than 5 
million people are living with AD, and this number is predicted to triple by 2050. AD 
is the 6th leading cause of death in the U.S., and there is currently no cure or disease-
modifying therapy available.  
 
The main objective of this project was to investigate the neuroprotective properties of 
PGC-1α using the fruit fly Drosophila melanogaster models of Aβ toxicity. PGC-1α, 
the captain of the mitochondrion, is the key modulator of energy metabolism. The 
possible relevance of this protein in AD pathogenesis was highlighted by work 
demonstrating that human post-mortem brains display reduced PGC-1α levels. These 
findings suggest that elevating PGC-1α expression or activity pharmacologically, or 
via other means, may prove to be an useful therapeutic strategy.  
 
My work demonstrated that up-regulation of PGC-1α may be neuroprotective, with 
overexpression of PGC-1α rescuing the neurotoxic phenotypes in Aβ-expressing flies 
in vivo. My study also elucidated the mechanisms associated with the neuroprotective 
effect of PGC-1α, including improved mitochondrial homeostasis, activation of the 
unfolded protein response, both of which have been implicated in AD pathogenesis. I 
also found that metformin and rifampicin, two drugs already licensed for human use, 
rescued Aβ toxicity through similar mechanisms of activation as PGC-1α. My 
findings thus highlight the potential therapeutic benefits of either increasing the 
intraneuronal levels of PGC-1α, or pharmacologically targeting the UPRER by oral 
administration of metformin or rifampicin, in treating AD.  Future studies are now 
warranted in mammalian models and in clinical trials. 
 
Genetic manipulations and dietary restriction (DR) in model organisms have proven 
that lifespan extension is achievable. Most importantly, these same interventions offer 
protection against a number of age-related diseases and therefore improve general 
health. Considerable current research efforts are being made to identify novel 
modulators that mimic healthy lifespan. PGC-1α is one such novel modulator of 
PGC-1α in neurodegeneration and ageing 
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ageing that has been shown to extend lifespan in Drosophila. In this project, I 
identified dGABPα, as a downstream effector of PGC-1α and a novel modulator of 
ageing in the fly. I demonstrated that dGABPα extended lifespan via mechanisms 
beyond DR, with an associated reduction in IIS/mTOR signalling. Moreover, 
activation of dGABPα also improved healthy lifespan, including gut homeostasis and 
resistance to xenobiotic stress. Given the evolutionary conserved effects of reducing 
IIS/mTOR, this finding suggests that GABPα may prove to be an important modulator 
of mammalian ageing. 
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Chapter 1  Introduction 
1.1 Alzheimer’s disease 
1.1.1 Overview of Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common form of dementia in the ageing 
population, affecting millions of people worldwide. Clinical symptoms of AD include 
but are not limited to memory loss and cognitive decline, including temporal-spatial 
disorientation, impairment of judgment and problem solving, and deterioration of 
language abilities (Faber-Langendoen et al., 1988). Behavioral and personality 
changes may also be observed with disease progression. In the severe stages of the 
disease, movement abnormalities often develop, which along with dementia, leave 
patients often bedridden and dependent on caregivers.  
 
In 1907, Alois Alzheimer first described a dementing illness and identified senile 
plaques and neurofibrillary tangles (NFTs) in the post-mortem brain tissue 
(Alzheimer, 1907), the two neuropathogical hallmarks still utilized by 
neuropathologists today to make the histological diagnosis of AD. In 1927, Divry 
used Congo red staining to describe the senile plaques in the AD brain as extracellular 
aggregates of amyloid-β (Aβ) (Divry and Florkin, 1927), various species of which are 
derived from the amyloid precursor protein (APP) (Kang et al., 1987). NFTs, the 
other classic hallmark of AD pathology, are intracellular aggregates of paired helical 
filaments composed of hyperphosphorylated tau protein (Brion et al., 1985). NFTs are 
mainly found in the hippocampus, entorhinal cortex and neocortex (Hyman et al., 
1984). Since both Aβ and tau are normal proteins found in healthy neurons, there is a 
great deal of interest in understanding what triggers their conversion into the 
abnormal and aggregated forms found in AD.  
 
1.1.2 Molecular genetics of AD 
The majority of AD cases are sporadic, while only a small proportion of AD cases 
(<1%) result from the autosomal dominant inheritance of gene mutations. Since 
familial cases share similar symptoms and pathology with sporadic AD (Harvey et al., 
2003), the identification of the genes involved in these rare forms of AD provides a 
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powerful tool for the elucidation of disease pathogenesis and therapeutic strategy. 
Mutations in three genes cause autosomal dominant AD, including the amyloid 
precursor protein (APP) and the presenilin genes (PSEN1 and PSEN2) (Goate et al., 
1991, Levy-Lahad et al., 1995, Rogaev et al., 1995), all of which show altered Aβ 
production through APP processing (Figure 1.1) (Charier-Harlin, 1991, Citron et al., 
1992, Price and Sisodia, 1998, Suzuki et al., 1994). APP is a type I transmembrane 
protein with a large amino-terminal extracellular domain. To produce Aβ, the 
extracellular domain is first removed by β-secretase. The remaining carboxy-terminal 
fragment is then cleaved within the membrane by γ-secretase, which is composed of 
presenilin and other components (De Strooper et al., 1998, Edbauer et al., 2003). γ- 
secretase can cleave APP at different sites, producing Aβ peptides of 40 or 42 amino 
acids. APP gene mutations found in a Swedish family result in increased β-secretase 
cleavage and thus increased production of both Aβ40 and Aβ42. Among the different 
species of Aβ, Aβ42 is more prone to oligomerization and is believed to be more toxic 
than Aβ40 (McGowan et al., 2005). Mutations at the γ-secretase cleavage site found 
in the familial cases lead to production of more the toxic Aβ42 compared to Aβ40 
(Charier-Harlin, 1991, Price and Sisodia, 1998). Moreover, APP mutations found in 
the Dutch and Arctic families result in increased fibrillogenesis or resistance to 
proteolysis (Massi et al., 2002, Nilsberth et al., 2001). Identification of these mutants 
demonstrated a fundamental role of Aβ peptides, especially Aβ42, in the pathogenesis 
of AD. In addition to point mutations, multiplication in the APP gene can also cause 
early-onset AD (Cabrejo et al., 2006), indicating the importance of protein 
aggregation and mis-folding in disease progression. Other disease-related gene 
mutations have been identified in the presenilin genes, which encode the catalytic 
subunit of γ-secretase (Levy-Lahad et al., 1995, Rogaev et al., 1995). AD-associated 
presenilin mutations increase the Aβ42/Aβ40 ratio (Rogaev et al., 1995, Duff, 1997, 
Oyama et al., 1998), also indicating that Aβ42 is the more toxic species of the Aβ 
peptides. Taken together, genetic findings from familial AD have helped to establish a 
basic understanding of the aetiology of AD, in which increased levels of Aβ peptides, 
especially with an increased ratio of Aβ42/Aβ40 resulting from AD-related gene 
mutations or duplication, are the main cause of pathogenesis in AD.  
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Most cases of AD do not exhibit autosomal-dominant inheritance and are termed 
sporadic AD, in which genetic differences may act as risk factors. The best-known 
genetic risk factor for AD is the inheritance of the ε4 allele of the apolipoprotein E 
(APOE) (Strittmatter et al., 1993, Mahley et al., 2006).  The APOE4 allele increases 
the risk of the AD by three times in heterozygotes and by 15 times in homozygotes 
(Blennow et al., 2006). How the APOE proteins mediate their effect in AD is not fully 
elucidated, however the previous studies using APP transgenic mice model that 
harboured the human APOE genes suggest that APOE4 show reduced efficiency in 
the clearance of Aβ (Kim et al., 2009).  
 
 
Figure  1.1 Generation of Aβ from the amyloid precursor protein. 
The sites of  β- and γ-secretase–mediated cleavage are indicated with arrows, and the transmembrane 
domain of APP is highlighted in gray. γ-cleavage produces a pool of Aβ  fragments that vary in length 
and hydrophobicity. The mutations in the Aβ region of APP increase the total Aβ  production (in blue), 
alter Aβ  biophysical properties (in black), or affect the Aβ  spectrum in both quantitative and 
qualitative ways (in green). Taken from (Benilova et al., 2012).  
 
1.1.3 The amyloid cascade hypothesis 
The evidence from pathology, phenotypes mediated by genetic mutations in familiar 
cases and risk factors conferred by the APOE gene metioned above appears to 
facilitate Aβ in the central position of AD pathogenesis. The amyloid cascade 
hypothesis was first proposed in 1992 by Hardy and Higgins, who postulated that “Aβ 
peptides are the causative agent in AD pathology, and then give rise to a complex 
network of downstream events, including neurofibrillary tangles, cell loss, vascular 
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damage and dementia” (Hardy and Higgins, 1992). Although the majority of research 
data still supports a role for Aβ as the primary initiator of AD pathogenesis (Musiek 
and Holtzman, 2015), this hypothesis has subsequently been subject to some criticism. 
 
Firstly, it has become clear that the correlation between dementia or other cognitive 
alteration and the accumulation of amyloid plaques in the brain is not linear, neither in 
humans (Price et al., 2009) nor in mice (Games et al., 1995).  According to this 
observation, there is now increasing data to support the modified hypothesis that it is 
the soluble toxic oligomeric forms of the Aβ peptide that account for the neurotoxicity  
of Aβ peptide in AD, rather than the monomer or fibrillar aggregates. A variety of 
cytotoxic oligomeric Aβ species have been identified in AD brain lysates, with 
pathogenic effects in vitro and in vivo in animal models (Shankar et al., 2008, Walsh 
et al., 2002, Mucke and Selkoe, 2012). In humans, Aβ oligomers accumulate with 
age, and directly initiate tau phosphorylation in vitro and in vivo (Jin et al., 2011, 
Zhang et al., 2014). Mouse models displaying accumulation of Aβ oligomers 
developed synaptic damage, inflammation, glial activation, cognitive impairment and 
neuronal loss (Zhang et al., 2014, Tomiyama et al., 2010). Although the precise 
neurotoxicity of Aβ oligomers in vivo is still unknown, studies have revealed that Aβ 
can cause oxidative stress, lipid peroxidation, mitochondrial dysfunction and 
inflammation (Pratico et al., 2001, Benzing et al., 1999, Calkins et al., 2011). 
Interestingly, abnormal stress responses that can be induced by Aβ, such as oxidative 
stress (Guix et al., 2012), mitochondrial dysfunction (Kukreja et al., 2014) and 
inflammation (Liu et al., 2014), can also directly influence APP metabolism and Aβ 
accumulation, suggesting a confounding feed-forward mechanism to exacerbate Aβ 
production and toxicity. However, there is still little evidence in humans that genetic 
mutations that increase mitochondrial dysfunction, oxidative stress, or inflammation 
cause Aβ pathology. Since the aforementioned pathogenic markers are also seen in 
other neurological disease, it is likely that these risk factors influence the pathogenic 
mechanisms downstream of Aβ, but are not unique to AD (Musiek and Holtzman, 
2015). Factors that affect Aβ production or aggregation or suppress Aβ clearance can 
contribute to disease progression. The accumulation of Aβ oligomers is predicted to 
affect the ability of the brain to maintain proper protein quality control, including 
autophagy failure, imbalance in protein degradation and protein synthesis. This 
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eventually prompts further aggregation of Aβ, tau and other intracellular proteins in 
association with an exacerbation of neurotoxicity (Dasuri et al., 2013, Nixon and 
Yang, 2011). The sleep disturbance observed in AD patients may also increase 
neuronal Aβ release via an impaired sleep-wake cycle, thereby leading to abnormal 
oscillations of extracellular Aβ levels (Kang et al., 2009). Moreover, ageing is a major 
risk factor for AD. Since proteostatic and cytoprotective pathways in the central 
nervous system decline with age (Taylor and Dillin, 2011, Lu et al., 2014), age-related 
disturbances in proteostasis and neuronal stress response signalling pathways may 
also shift the balance of Aβ metabolism towards aggregation. In addition, age-related 
disorders such as vasculopathy and atherosclerosis, diabetes, head trauma, or sleep 
disruption may also affect Aβ accumulation and aggregation, exacerbating AD 
pathology and stimulating the onset of dementia (Kang et al., 2009, Musiek and 
Holtzman, 2015). A full understanding of the complex interplay between these 
processes and Aβ aggregation is still awaited, but it is likely that these cellular 
pathways may prove to be excellent therapeutic targets in the treatment of AD. 
 
 
Secondly, the relationship between Aβ plaques and neurofibrillary tangles of tau 
remains unclear and therefore has been of considerable debate for many years. 
Previous studies showed that tau pathology occurs first in the transentorhinal cortex, 
often in the absence of plaque pathology. Moreover, the patten of tau pathology is 
highly regular, whereas Aβ plaque pathology is much more varied (Braak and Braak, 
1991). In order population, there is significant increase in the presence of 
neurofibrillary tangles, but no association between age and Aβ plaque was observed 
(Price et al., 2009).  In addition, Gomes-Isla et al. measured the total number of 
neurons in AD braisn compared to age-matched controls, and found that there was a 
statistically significant correlation between the loss of neurons and the increased in 
the presence of neurofibrillary tangles with disease progression; however, no 
correlation was observed between Aβ load and either disease duration or neuronal 
loss (Gomez-Isla et al., 1997). All the evidence discussed above suggest that there is 
considerable gaps in our understanding of AD pathology, therefore to some extent 
debate amyloid hypothesis. The hypothesis that accommodates most of the known 
data is that Aβ aggregation and deposition triggers a process that leads to neuronal 
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loss via the formation of neurofibrillary tangles of tau, although the mechanisms are 
not fully understood. 
 
Thirdly, there are currently three main therapeutic interventions strategies amied at 
Aβ: reducing Aβ production, facilitating Aβ clearance and preventing Aβ aggregation. 
However, all of the Aβ-centric approaches that reached Phase III clinical trials have 
failed. For example, semagacestat, a well-characterzed γ-secretase inhititor, 
effectively reduced Aβ  deposition in both APP transgenic mouse model (Ness et al., 
2004) and human volunteers (Bateman et al., 2009). However, Phase III trails 
demonstrated that patients who were treated with semagacestat displayed an increased 
deterioration in cognition and daily activity compared to controls. This failure again 
challenged the amyloid hypothesis, and also remain questions unanswered: by how 
much should Aβ production be lowered, and at what stage of the disease process 
would an Aβ-directed therapeutic approach be likely to show clinical efficacy? 
Recently, aducanumab, a human monoclonal antibody that selectively targets 
aggregated forms of Aβ, was reported to reduce both soluble and insoluble Aβ in a 
transgenic mice model (Sevigny et al., 2016). In addition, AD patients in the early 
stages of disease injected with aducanumab showed reduced Aβ levels, which was 
accompanied by a slowing in clinical decline. These ongoing clinical trials, as well 
offering great promise for the future treatment of AD, also provide compelling 
support for the amyloid hypothesis. 
 
 
1.1.4 Animal models of Alzheimer’s disease 
A number of genetic models have been developed in the study of AD, including a 
large number of mouse models, many of which have failed to recapitulate all of the 
histopathological and behavioral features of AD. Transgenic mice harboring human 
APP mutations develop amyloid pathology and memory defects without neuronal loss 
(Mucke et al., 2000, Cheng et al., 2004). In order to isolate the effects of Aβ, 
transgenic Aβ mouse models were generated, but only amyloid pathology was 
observed (McGowan et al., 2005). Transgenic mice with mutant presenilin expression 
demonstrated increased Aβ42 levels, while no AD pathology or cognitive deficits 
developed (Holcomb et al., 1999, Dewachter et al., 2008). Moreover, a transgenic 
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mutant tau mouse model demonstrated hyperphosphorylated tau, neurofibrillary 
lesions and cell loss (Lewis et al., 2000, Andorfer et al., 2003).  
 
In addition, non-mammalian experimental models have been used to study the biology 
of AD. They are excellent genetic tools suited for drug screening and the study of 
toxic molecular cascades involved in disease progression. Furthermore they offer 
advantages over mammalian models with a quick generation time and low cost. The 
most commonly used invertebrate model organism in neurodegeneration is the fruit 
fly Drosophila melanogaster given their complex brains, short lifespan and relative 
ease of genetic manipulation. Several fly models already exist to study AD biology. 
Flies that over-express Drosophila or human tau have been developed that display 
several neuronal dysfunction phenotypes, including disrupted neuronal and synaptic 
function and climbing defects (Mershin et al., 2004, Wittmann et al., 2001, Ubhi et 
al., 2007). Fly models expressing Aβ peptides have also been developed that show 
neurodegeneration, reduced lifespan and amyloid deposition (Finelli et al., 2004, 
Crowther et al., 2005, Iijima et al., 2004). Although an APP orthologue exists in flies, 
the Aβ sequence is not conserved (Rosen et al., 1989). In keeping with this limitation, 
the only abnormal phenotypes seen in a fly model of APP over-expression were 
axonal transport phenotypes (Gunawardena and Goldstein, 2001). Therefore in 
summary, Drosophila models directly expressing Aβ allow investigation of Aβ 
toxicity in the absence of any endogenous amyloid production. It is a simple model to 
study the downstream effects of Aβ neurotoxicity and the potential mechanisms of Aβ 
degradation, independent of APP processing.  
 
1.1.5 Mitochondrial dysfunction and oxidative stress in Alzheimer’s 
disease 
Mitochondrial dysfunction and oxidative damage have been implicated in the 
pathogenesis of AD. Studies have shown that oxidative damage and lipid peroxidation 
occur early in the pathogenesis of AD brains and in an APP mouse model (Nunomura 
et al., 2001, Pratico et al., 2001). Moreover the genes responsible for mitochondrial 
metabolism and apoptosis were up-regulated in neurons undergoing oxidative stress, 
suggesting early cellular change before Aβ deposition (Reddy et al., 2004). 
Deficiency in cytochrome c oxidase and α-ketoglutarate dehydrogenase has been 
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observed in AD patients, suggesting the involvement of mitochondrial dysfunction in 
AD pathogenesis (Gibson et al., 1988, Parker et al., 1990). 
 
In addition, mitochondrial dysfunction and oxidative damage also contribute causally 
to AD-related pathology. Indeed treating neurons with hydrogen peroxide, a potent 
oxidizer, increases intracellular levels of Aβ (Ohyagi et al., 2000). Furthermore, 
treatment of astrocytes with the mitochondrial uncoupler CCCP (carbonylcyanide m-
chlorophenylhydrazone), an inhibitor of oxidative phosphorylation (OXPHOS), 
promotes amyloidogenic APP processing and intracellular Aβ accumulation 
(Busciglio et al., 2002). APP mouse models lacking the mitochondrial antioxidant 
enzyme, MnSOD, or treated with inhibitors of energy metabolism, have also shown 
dramatically increased levels of β-secretase, Aβ, and senile plaques (Li et al., 2004, 
Velliquette et al., 2005).  
 
Several studies have suggested that AD pathology can directly affect mitochondria 
and mitochondrial proteins. APP can directly target mitochondria, and clog the 
mitochondrial protein importation machinery, leading to mitochondrial dysfunction 
and metabolic defects (Anandatheerthavarada et al., 2003). Aβ can bind to a 
mitochondrial-matrix protein named ABAD (Aβ-binding alcohol dehydrogenase), 
leading to Aβ-induced apoptosis and free-radical generation in neurons (Lustbader et 
al., 2004). Moreover, Aβ can physically interact with mitochondria, inhibiting 
cytochrome c oxidase activity, impairing mitochondrial respiration, and increasing 
free radical generation and oxidative damage in AD neurons (Crouch et al., 2005, 
Manczak et al., 2006, Casley et al., 2002).  
 
Mitochondrial DNA (mtDNA) is particularly sensitive to free radical damage. 
Deletions and mutations in mtDNA have been observed in post mortem AD brains 
(Bender et al., 2008, Coskun et al., 2004), highlighting the likely role of 
mitochondrial dysfunction in AD pathogenesis. Moreover, oxidative stress has been 
implicated in AD pathology, with alterations in several signalling pathways identified 
in AD brain tissue. For example, oxidative damage can increase the levels of β-
secretase through activation of p38 mitogen-activated protein kinase (MAPK) and C-
Jun amino-terminal kinase (Tamagno et al., 2005), leading to excessive tau 
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hyperphosphorylation through the activation of glycogen synthase kinase 3 (GSK3) 
(Lovell et al., 2004).  
 
1.1.6 The unfolded protein response (UPR) in neurodegeneration 
Cells are faced with a variety of stressors throughout their lifetime, which leads to 
protein mis-folding and aggregation (Balch et al., 2008). Maintaining protein 
homeostasis (proteostasis) requires the appropriate coordination of efficient folding 
and assembly of proteins and protein quality control systems, in order to minimize the 
load of unfolded or mis-folded proteins, and to reduce abnormal protein aggregation. 
Protein folding and assembling occur mainly in the endoplasmic reticulum (ER), 
where chaperones are induced to ensure the proper folding of proteins. Mis-folded 
proteins are then recognized by the quality control mechanisms, triggering 
degradation by the ubiquitin-proteasome machinery or the lysosome-autophagy 
pathway. Under conditions of cellular stress or pathogenic conditions that alter the 
protein-folding process, accumulation of mis-folded protein in the ER lumen causes 
ER stress. In response to ER stress, the folding and degrading capacity of the ER is 
adjusted by induction of a complex signalling network, known as the unfolded protein 
response (UPRER).  
                                       
Whether the UPR restores proteostasis or induces apoptosis depends on the intensity 
and duration of the stress stimuli. Moderate accumulation of mis-folded proteins can 
activate the UPR to augment protein folding, quality control and protein degradation 
mechanisms (Hetz, 2012, Walter and Ron, 2011, Wang and Kaufman, 2012). Mis-
folded proteins can also be re-translocated to the cytosol, where they are cleared via 
the ER-associated protein degradation (ERAD) pathway, including ubiquitin-
proteosome mediated or lysosome-autophagy degradation. 
 
The UPR consists of two central components, a group of ER transmembrane sensors 
and downstream signalling cascades that enable adaptation to stress or the induction 
of apoptosis (Figure 1.2). Three well-characterized signalling branches mediate this 
response: PERK (protein kinase RNA-like ER kinase), inositol-requiring enzyme 1 
(IRE1), and transcription factor 6α (ATF6α) (Wu and Kaufman, 2006, Hetz and 
Mollereau, 2014). Under normal physiological conditions, these three trans-
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membrane signaling components are bound and inhibited by Grp78. During ER stress, 
mis-folded proteins titrate down Grp78, thus activating signaling cascades 
downstream of the UPR. PERK directly phosphorylates and inhibits ubiquitous 
eukaryotic translation initiation factor 2α (eIF2α), leading to a rapid and transient 
attenuation of translation. A reduction in global translation relieves the stress of mis-
folded proteins in the ER by reducing the total load of newly synthesized proteins in 
the ER lumen. Moreover, phosphorylated eIF2α selectively induces the translation of 
the mRNA encoding the transcription factor ATF4, which then translocates into 
nucleus and induces the expression of ER chaperones and genes involved in 
autophagy, redox control and amino acid metabolism (Walter and Ron, 2011). The 
most conserved UPR signalling branch is initiated by IRE1. Activated IRE1 catalyzes 
splicing of the mRNA encoding the transcription factor X-box binding protein 1 
(Xbp1), leading to a stable and active transcription factor that controls UPR target 
genes involved in protein folding, ERAD, lipid synthase, ER chaperones, and ER 
translation (Hetz et al., 2011). Upon ER stress, ATF6α is transported to the Golgi 
where it is processed to produce a cytosolic fragment, which operates as a 
transcription factor that regulates Xbp1, ER chaperones, and ERAD genes (Walter and 
Ron, 2011). 
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Figure 1.2 A schematic representation of the UPR 
The UPR is mediated by 3 trans-membrane signalling components. Under normal physiological 
conditions, these are bound and inhibited by Grp78. During ER stress, mis-folded proteins titrate down 
Grp78, thus activating signalling cascades downstream of the UPR. Taken from (Niccoli et al., 2016). 
 
Moreover, chronic or irreversible ER stress in neurodegenerative disease can trigger 
apoptosis via signalling mechanisms that overlap with those activated in the adaptive 
response (Figure 1.3). Sustained activation of PERK signalling triggers a series of 
transcriptional responses mediated by ATF4, which induce C/EBP-homologous 
protein (CHOP) and its downstream targets, leading to increased DNA damage-
inducible 34 (GADD34), BAX-and BAK-dependent caspases. In turn the survival 
protein BCL-1 is inhibited, leading to cells entering apoptosis (Tabas and Ron, 2011, 
Shore et al., 2011, Urra et al., 2013). Moreover, the IRE1 pathway also contributes to 
apoptosis and cell death by inducing the activity of JUN amino-terminal kinase (JNK) 
and the apoptotic signal-regulating kinase 1 (ASK1) (Urano et al., 2000). In addition, 
IRE1 can also degrade microRNAs (miRNAs), thereby negatively regulating the 
expression of ER chaperones (Urra et al., 2013).  In summary, the UPR is a complex 
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signalling network that coordinates adaptation to ER stress or elimination of damaged 
cells by apoptosis, depending on the intensity and temporal exposure to stress. 
 
 
Figure 1.3 The UPR signalling outputs in neurodegeneration 
Disease-related genes can trigger the mis-folding of a particular protein, which can then form different 
types of aggregates, ranging from small oligomeric species to inclusion bodies. This abnormal 
aggregation process results in ER stress. Prolonged ER stress overcomes the adaptive responses of the 
UPR and apoptosis is induced. Various apoptotic pathways have been described, including up-
regulation of CHOP through ATF4. This pathway also inhibits the expression of BCL-2 family 
members, and the up-regulation of BH3-only proteins results in BAK- and BAX-dependent apoptosis. 
CHOP also induces the expression of growth arrest and GADD34, which increases the levels of ROS 
and protein synthesis. IRE1α also induces activation of JNK and ASK1, which contributes to cell 
death. In addition, IRE1α can degrade miRNAs that negatively control the expression of caspases. UPR 
signalling events can also modulate the expression of various genes involved in the aetiology of 
disease. Taken from (Hetz and Mollereau, 2014). 
 
The UPR also contributes to ageing and age-related neurodegeneration. The ability of 
cells to ensure proteostasis by the UPR declines with age (Taylor and Dillin, 2011). 
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Damaged, mis-folded, and aggregated proteins progressively accumulate with age. At 
the same time ER chaperones are down-regulated, and activation of the UPRER and 
ER stress is limited during ageing, leading to an overall decline in the capacity of the 
cell to adapt and protect its proteome against age-related disease (Ben-Zvi et al., 
2009).  
 
Neurodegeneration is characterized by the accumulation of mis-folded pathological 
proteins in the central nervous system (CNS). For example, amyloid plaques and 
neurofibrillary tangles, the two hallmark pathological lesions in AD, and α-synuclein, 
the main component of Lewy Bodies (LB) in PD, all arise from protein mis-folding. 
The involvement of ER stress in neurodegenerative disease is well known but the role 
of the UPR in neurodegeneration is complex and yet to be fully determined. 
Activation of the UPR can either enhance or reduce neurodegeneration depending on 
the specific UPR-signalling mechanisms activated. In PD, chronic ER stress has been 
identified as a pathological event that contributes to dopaminergic neuronal loss 
(Hoozemans et al., 2007). However, activation of UPR components (ATF6) protects 
against PD-induced neurotoxicity in cells (Egawa et al., 2011), and up-regulation of 
GRP78 or eIF2α phosphorylation has shown neuroprotective effects in PD mouse 
models (Gorbatyuk et al., 2012, Boyce et al., 2005).  
 
In AD, neurons expressing phosphorylated tau show activated PERK signalling, 
suggesting up-regulation of the UPR (Hoozemans and Scheper, 2012). In addition, 
Xbp1, the downstream effector in the IRE1 branch of the UPR, has been found to be a 
risk factor in sporadic AD (Liu et al., 2013). Reduced levels of Xbp1 are also found in 
AD patients’ brains (Reinhardt et al., 2014), suggesting that elevating Xbp1 may 
represent an excellent therapeutic avenue. Indeed, over-expression of active Xbp1 
rescues the neurotoxic phenotypes in a Drosophila model of Aβ toxicity (Casas-Tinto 
et al., 2011). Moreover, a C. elegans model of AD confirmed that Xbp1 is critically 
important for maintaining ER homeostasis in the presence or absence of ER stress 
(Safra et al., 2013). Moreover, we recently demonstrated that down-regulation of 
glucose-regulated protein 78 (Grp78; also know as Bip-binding immunoglobulin 
protein) in fly neurons can ameliorate Aβ-induced neurotoxicity. In addition this 
correlated with increased activation of the UPR (Niccoli et al., 2016). Grp78 is the 
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master negative regulator of the UPR, and binds and inhibits the UPR trans-
membrane sensors under normal physiological conditions. Under ER stress, mis-
folded proteins titrate down Grp78, leading to activation of UPR sensors and their 
downstream targets. Our study therefore suggests that decreasing Grp78 protein 
levels, leading to activation of the UPR, may be neuroprotective in AD.  
 
In addition to the up-regulation of the adaptive response of the UPR in AD, the 
apoptosis phase of the UPR has been also implicated in AD pathogenesis. JNK3, the 
downstream effector of IRE1, which activates apoptosis, and eIF2α phosphorylation, 
the downstream effector in PERK activity, have both been shown to be up-regulated 
in AD brain and APP mouse models (Yoon et al., 2012, Ma et al., 2013). Activation 
of JNK3 increases Aβ levels by promoting APP processing, while suppression of 
eIF2α kinase ameliorates AD-related memory defects, suggesting that chronic or 
irreversible activation of the UPR could also exacerbate AD pathology. Indeed, down-
regulation of Grp78 in fly neurons ameliorates Aβ toxicity via activation of the UPR, 
to the extent that eIF2α phosphorylation is not detectable (Niccoli et al., 2016). This 
supports the hypothesis that moderate activation of the UPR may be beneficial in 
preventing AD pathology. In summary, the impact of the UPR on AD depends on the 
strength and duration of the stress stimulus. However, a better understanding of this 
pathway awaits more in vivo studies. 
 
1.2 Parkinson’s Disease 
1.2.1 Overview of Parkinson’s disease 
Parkinson disease (PD) is the commonest movement disorder and the second most 
prevalent neurodegenerative disease after AD. The typical clinical presentation of PD 
includes tremor, bradykinesia, rigidity, gait and balance impairment (Lees et al., 
2009). Although the cause of PD is not fully explored, it is believed to involve both 
genetic and environmental factors. There is an increased risk in people exposed to 
certain pesticides including rotenone and paraquat (Moretto and Colosio, 2013, 
Tanner et al., 2011). Moreover, MPTP is a pro-drug to the neurotoxin MPP+, which 
inhibits Complex 1 activity, leads to mitochondrial dysfunction and causes permanent 
symptoms of PD by destroying DA neurons in the SN of the brain (Langston et al., 
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1983). There is also a reduced risk in tobacco smokers and those who drink coffee 
(Kalia and Lang, 2015). The predominant pathological features of PD are the selective 
loss of dopaminergic neurons in the substantia nigra (SN) of the mid brain, in 
association with intraneuronal inclusions called Lewy bodies (LB), composed of 
insoluble aggregates of the presynaptic protein α-synuclein (Spillantini et al., 1997, 
Dickson et al., 2009). The finding of α-synuclein gene (SNCA) mutations in familial 
PD patients, together with the identification of SNCA as a genetic risk factor for 
sporadic PD in two genome-wide association studies (GWAS) and a meta-analysis, 
confirmed the fundamental role of α-synuclein in the pathogenesis of PD 
(Polymeropoulos et al., 1997, International Parkinson Disease Genomics et al., 2011, 
Simon-Sanchez et al., 2009, Satake et al., 2009, Martin et al., 2011).  
 
Over the past few years, a number of genes linked to Parkinsonism, known as the 
PARK genes, have been characterized. Currently 16 PARK loci have been identified, 
with autosomal dominant genes such as SNCA (PARK1), and leucine-rich repeat 
kinase 2 (LRRK2) (PARK8) (Paisan-Ruiz et al., 2004), and autosomal recessive genes 
such as parkin (PARK2) (Kitada et al., 1998), PTEN-induced putative kinase 1 
(PINK1) (PARK6) (Valente et al., 2004), DJ-1 (PARK7) (Bonifati et al., 2003),  
ATP13A2 (Ramirez et al., 2006) and PLA2G6 (PARK14) (Paisan-Ruiz et al., 2009). 
Unraveling the link between mutations in these genes and neurodegeneration has 
greatly aided our understanding of the pathogenic mechanisms underlying familial 
and sporadic PD pathology.  
 
1.2.2 Drosophila models of Parkinson’s disease 
Recent research has focused on the development of genetic animal models, including 
organisms as diverse as yeast, worms, Drosophila and mice, in order to model the 
cellular and phenotypic features of human PD. Such models allow the dissection of 
the critical events leading to α-synuclein accumulation and neurodegeneration in PD. 
Among these animal models, the fruit fly Drosophila melanogaster has produced 
some of the most significant advances in our understanding of the cellular pathways 
in PD.  
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Drosophila is a widely used genetic tool to study neurological and genetic disorders, 
including PD and AD. One of the greatest advantages of using Drosophila to model 
PD is that it can recapitulate some of the characteristic phenotypes of patients, such as 
inclusion-like formation and dopaminergic neuronal loss (Feany and Bender, 2000). 
Moreover, PD Drosophila models also show locomotor defects that parallel the motor 
disability of patients. In fact, the climbing phenotype has become one of the best 
approaches to evaluating neurodegeneration in flies. In addition, the other advantages 
of using the fruit fly as a model organism, is that it is fast breeding, has rapid growth 
and easy genetic manipulation, as well as substantial genetic stocks. In addition, 
approximately 60% of the genes in Drosophila overlap with those of human genes. 
Therefore, Drosophila has become an important organism for the study of 
neurodegeneration.  
 
1.2.2.1 Gain-of-function fly models of PD 
Drosophila models exist for the study of many of the genetic variants of PD. Of the 
classic genes involved in PD, SNCA is the only one not conserved in Drosophila. 
However, by over-expressing human SNCA in the fly neuronal tissue, it has been 
possible to model the neurotoxicity of α-synuclein in PD in Drosophila. The fly 
models display LB-like aggregates (Figure 1.4), movement phenotypes, and 
dopaminergic neuronal loss (Feany and Bender, 2000). Although work in cell and 
mouse models suggest that mutant α-synuclein leads to the development of LB-like 
inclusions, as well as mitochondrial dysfunction and increased oxidative stress 
(Conway et al., 2000, Greenbaum et al., 2005, Masliah et al., 2000), the precise 
mechanisms by which α-synuclein species result in neurotoxicity is still unclear 
(Cookson and van der Brug, 2008).  
 
 
Figure 1.4 Alpha-synuclein pathology 
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Left: aggregated α-synuclein in a LB-like inclusion in the brain of Drosophila.  Right: a human LB 
composed of α-synuclein. Images taken from (Feany and Bender, 2000). 
 
Work in Drosophila has shown that over-expression of both wild type and pathogenic 
forms of α-synuclein leads to dopaminergic neuronal loss and neurodegeneration 
(Feany and Bender, 2000, Karpinar et al., 2009, Chen and Feany, 2005, Periquet et 
al., 2007). Furthermore expression of mutant forms of α-synuclein, which increase the 
generation of oligomeric species, leads to greater toxicity, confirming the preferential 
toxicity of α-synuclein oligomers in vivo (Karpinar et al., 2009).  
 
However, so far all of these PD-like phenotypes are induced through the use of the 
UAS-GAL4 system in Drosophila, which results in the expression of α-synuclein 
throughout development as well as adulthood. One concern is that developmental 
effects may significantly alter brain physiology and neurodegeneration measured in 
adulthood. It is therefore impossible to disentangle developmental effects from 
secondary neurodegenerative effects in these models. Similar to other animal models 
such as rats or monkeys, specific over-expression of α-synuclein in adult neurons 
avoids any deleterious effects of developmental expression and the possibility of 
compensatory mechanisms (Waxman and Giasson, 2009). It is therefore necessary to 
model late-onset sporadic PD through the temporal expression of α-synuclein using 
the inducible GeneSwitch system. I have shown that over-expression of different 
variants of α-synuclein (Karpinar et al., 2009) in adult neurons do not shorten 
lifespan, and only cause climbing defects to a very limit extent (unpublished results). 
Moreover, I found that mutations that increase the generation of oligomeric species of 
α-synuclein increase the amount of total α-synuclein protein. It is therefore impossible 
to conclude whether the toxic phenotypes are due to increased oligomeric species or a 
greater total load of α-synuclein.  
 
1.2.2.2 Knockout fly models of PD 
Unlike SNCA, PARK2 is well conserved in Drosophila. Flies lacking parkin display a 
wide variety of phenotypes, including locomotor defects, DA neurodegeneration and 
muscle degeneration, in addition to clear mitochondrial phenotypes (Greene et al., 
2003, Cha et al., 2005). In addition, Drosophila PINK1 mutants show almost all of the 
phenotypes of parkin mutants, presenting with decreased climbing ability, flight 
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disability, flight muscle degeneration as well as DA neuronal loss (Park et al., 2006, 
Clark et al., 2006, Whitworth and Pallanck, 2009). Moreover, epistasis experiments 
using the fruit fly have shown that PINK1 and parkin are linked in a common 
pathway with parkin acting downstream of PINK1 (Park et al., 2006). The link 
between PINK1 and parkin and their role in mitochondrial disease will be described 
in detail in Chapter 4.  
 
Recently we generated the first PLA2G6 knockout fly model, which showed reduced 
survival, locomotor defects, increased sensitivity to oxidative stress, mitochondrial 
lipid peroxidation and mitochondrial defects (Kinghorn et al., 2015, Kinghorn et al., 
2016). Another known causative gene, DJ-1, is also conserved in Drosophila, and has 
been shown to mediate a protective role against oxidative stress. DJ-1 alpha and DJ-1 
beta double knockout flies have a normal lifespan, but exhibit locomotor defects and 
increased sensitivity to environmental stressors, including paraquat and rotenone, 
demonstrating the involvement of DJ-1 in stress response pathways (Menzies et al., 
2005, Meulener et al., 2005). All of these genetic fly models enable us to study the 
pathogenesis of PD, and also provide a useful platform for drug discovery. 
 
1.2.3 Mitochondrial dysfunction in PD 
Mitochondrial dysfunction was first implicated in the pathogenesis of PD more than 2 
decades ago. The first evidence came from a postmortem study, which described 
abnormalities of mitochondrial function in complex I and increased free radical 
mediated damage in the PD brains (Schapira et al., 1989). Since then a number of 
gene mutations causing familial PD have been identified. The study of how these 
genes cause dopaminergic neuronal loss has significantly aided our understanding of 
the mechanisms of pathogenesis of PD. Studies have shown that mitochondrial 
dysfunction and oxidative damage play an important role in PD pathology. Although 
proteostatic failure due to protein mis-folding and aggregation is undoubtedly crucial 
to PD pathogenesis, the importance of mitochondrial dysfunction has been 
specifically highlighted by work studying PD causing genes. Mutations in SNCA, 
PINK1, PARK2, and PLA2G6 have all been shown to cause alterations in 
mitochondrial function, further confirming the role of mitochondrial dysfunction in 
PD (Schapira and Gegg, 2011, Gadd et al., 2006, Singleton et al., 2003).  
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As mentioned above, α-synuclein is one of the major components of LB in PD and 
other synucleinopathies. The finding that point mutations or multiplications in the 
SNCA gene were associated with PD provided important insights into the role of α-
synuclein in neurodegeneration (Polymeropoulos et al., 1997, Kruger et al., 1998, 
Farrer et al., 2004, Zarranz et al., 2004, Spillantini et al., 1997). Although the majority 
of α-synuclein was found localized to the cytoplasm, a small part of the protein was 
identified localized to the membrane of mitochondria in a mouse brain (Li et al., 
2007a). Studies from cell and animal models demonstrated that α-synuclein could 
directly interact with the mitochondrial membrane to inhibit Complex I activity, 
reducing ATP synthase and the mitochondrial membrane potential, resulting in 
mitochondrial dysfunction (Liu et al., 2009, Devi et al., 2008, Nakamura et al., 2008, 
Banerjee et al., 2010, Kamp et al., 2010, Martin et al., 2006). In turn these 
mitochondrial abnormalities lead to increased oxidative stress, synaptic defects and 
eventual cell loss and neurodegeneration.   
 
Autosomal recessive mutations in the PINK1 gene can cause an early onset juvenile 
parkinsonism. The PINK1 protein, encoded by PINK1 gene, is a serine/threonine 
kinase possessing a mitochondrial targeting sequence at its N-terminus and has an 
intra-mitochondrial location (Valente et al., 2004). PINK1 pathology in humans and 
animal models includes mitochondrial dysfunction, defective oxidative 
phosphorylation (OXPHOS), and increased free radical damage (Hoepken et al., 
2007, Piccoli et al., 2008, Gautier et al., 2008, Gandhi et al., 2009, Gegg et al., 2009). 
Mutations found in PINK1 lead to the abnormal phosphorylation of PINK1-targeted 
mitochondrial proteins, which in turn leads to mitochondrial respiratory and metabolic 
defects, oxidative damage and neuronal death (Valente et al., 2004).  
 
PARK2 mutations are the commonest cause of autosomal recessive juvenile 
parkinsonism (ARJR), with an age of onset around 40 years. This form of PD displays 
a benign disease course and a good response to L-DOPA. Parkin-associated PD is 
associated with pure dopaminergic neuronal loss in the SN without LB formation, in 
contrast to PINK1-associated PD neuropathology in which LBs are seen (Kitada et al., 
1998, Farrer et al., 2001, Pramstaller et al., 2005). Parkin functions as an E3 ligase, 
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ubiquitinating proteins for degradation by the proteasome (Shimura et al., 2000, 
Zhang et al., 2000, Chin et al., 2010). Cell studies have revealed that parkin can 
translocate and associate with the mitochondrial outer membrane to regulate 
mitochondrial function (Darios et al., 2003). Human and animal model studies have 
identified reduced complex I and IV activities in parkin mutants, which lead to 
reduced ATP production, impaired electron transport chain (ETC) activity, and 
apoptotic neuronal death (Greene et al., 2003, Darios et al., 2003, Muftuoglu et al., 
2004, Mortiboys et al., 2008, Grunewald et al., 2010). Cell studies have demonstrated 
that PINK1, together with parkin, plays a crucial role in the turnover of mitochondria 
by autophagy (mitophagy), a mitochondrial quality control program that maintains 
mitochondrial dynamics and homeostasis (Zhang and Ney, 2010). Damaged 
mitochondria were firstly recognized by PINK1. PINK1 builds up on the outer 
membrane of the mitochondria and recruits parkin to target the damaged mitochondria 
for degradation by lysosomes-autophagy pathway (Zhang and Ney, 2010, Poole et al., 
2008, Narendra et al., 2008, Vives-Bauza et al., 2010).  
 
The PLA2G6 gene encodes an 85-kDa group VI calcium-independent phospholipase 
A2 beta enzyme. PLA2G6, at the PARK14 locus, has been characterized as the 
causative gene in a subgroup of patients with autosomal recessive early-onset 
dystonia-parkinsonism. Neuropathological examination of the post mortem brains of 
affected individuals revealed widespread LB pathology and the accumulation of 
hyperphosphorylated tau (Paisan-Ruiz et al., 2009, Paisan-Ruiz et al., 2012). PLA2G6 
localizes to the mitochondria, and is required for the remodeling of membrane 
phospholipids and calcium signalling (Gadd et al., 2006). Loss-of-function mutations 
lead to abnormalities in mitochondrial morphology and synaptic membranes (Beck et 
al., 2011). In addition, we recently showed that knockout of the Drosophila 
homologue of PLA2G6 leads to elevated mitochondrial lipid peroxidation and reactive 
oxygen species (ROS), mitochondrial respiratory chain dysfunction, reduced ATP 
synthesis and abnormal mitochondrial morphology (Kinghorn et al., 2015).  In 
summary, studies of the mechanisms of pathogenesis of the PARK genes in causing 
neurodegeneration highlight the central role of mitochondrial dysfunction in PD.  
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In conclusion, the mechanisms of pathogenesis of both AD and PD described above 
are tightly linked to mitochondrial dysfunction. Therefore, targeting mitochondrial 
biogenesis may potentially ameliorate neurotoxicity in these neurodegenerative 
conditions. In Chapters 3 and 4, I will focus on dissecting the role of PGC-1α, the key 
regulator of mitochondrial biogenesis, in the pathogenesis of AD and PD using 
Drosophila models.  
 
1.3 PGG-1α: an overview 
Transcription factors (TFs) regulate gene transcription in the control of the myriad of 
biological signalling pathways necessary for the effective functioning of our cells.  
Gene transcription must be temporally coordinated through the interplay of protein 
complexes including TFs, RNA polymerases and related factors. TFs are proteins that 
bind DNA around the 5’ end at the transcription start site in a sequence-specific 
manner. Transcriptional coactivators are proteins that can increase the rate of 
transcription by interacting with TFs, but do not themselves bind to DNA in a 
sequence-specific manner. Transcriptional coactivators coordinate RNA polymerase 
recruitment and orientation, and the unwinding of DNA to initiate transcriptional 
activity. The work in this thesis will focus on Peroxisome proliferator-activated 
receptor (PPAR)-γ coactivator-1α (PGC-1α), which is a well-know transcriptional 
coactivator involved in multiple biological processes in different tissues and 
physiological states.  
 
The PGC-1α gene is located on chromosome 4 in humans, and encodes a protein 
containing 798 amino acids. It is mainly located in the cell nucleus and expressed at a 
high level in metabolically active tissues, where mitochondria are abundant and 
oxidative metabolism is active, such as in skeletal muscle, brown adipose tissue 
(BAT), the heart, the brain and kidneys. It is involved in a wide variety of biological 
functions, including adaptive thermogenesis, mitochondrial biogenesis, glucose/fatty 
acid metabolism, fibre type switching in skeletal muscle, as well as in the 
development of the heart.  
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1.3.1 Adaptive thermogenesis 
PGC-1α was first discovered as a transcriptional coactivator in studies that 
distinguished white and brown fat pathways in adaptive thermogenesis. Adaptive 
thermogenesis involves the activation of a number of physiological mechanisms to 
increase heat production in response to environmental challenges such as cold, diet or 
infections, particularly in brown fat and muscle (Cannon et al., 1998, Rothwell and 
Stock, 1979). This process is important for energy homeostasis and metabolic defense 
against obesity. BAT, containing multiple small lipid droplets and a high number of 
mitochondria, is the main metabolic site for energy dissipation, in contrast to white 
adipose tissue (WAT), which primarily stores energy. Uncoupling protein-1 (UCP-1), 
which is exclusively expressed in BAT, is the main component in diet/cold-induced 
thermogenesis (Enerback et al., 1997), where its gene transcription is controlled by 
the transcription factors cAMP response element binding protein (CREB) (Kozak et 
al., 1994), thyroid hormone receptor (Cassard-Doulcier et al., 1994), and nuclear 
hormone receptor PPARγ (Sears et al., 1996). Interestingly, PGC-1α, whose mRNA 
levels are dramatically increased in response to cold stress, can elevate the 
transcriptional activity of PPARγ and the thyroid hormone receptor on the UCP-1 
promoter (Puigserver et al., 1998). Indeed, ectopic expression of PGC-1α in brown fat 
cells activates UCP-1 and the expression of a number of genes necessary for 
mitochondrial respiratory chain activity. It also leads to the up-regulation of 
mitochondrial density, and thus has a central role in adaptive thermogenesis and 
energy metabolism. 
 
1.3.2 Mitochondrial biogenesis 
Enhanced mitochondrial biogenesis in skeletal muscle, in which PGC-1α is highly 
expressed and up-regulated by cold, adrenergic stimuli and exercise, is an important 
component of adaptive thermogenesis (Figure 1.5). Ectopic expression of PGC-1α in 
myotubes results in elevated mitochondrial biogenesis, including increased respiration 
and mtDNA copy number, as well as increases in genes involved in OXPHOS (Wu et 
al., 1999). In a mouse model of amyotrophic lateral sclerosis (ALS), a disease 
characterized by loss of motor neurons, over-expression of PGC-1α maintained 
mitochondrial biogenesis and muscle function, and delayed muscle atrophy, in the 
absence of any effect on lifespan (Da Cruz et al., 2012). Scarpulla and collaborators 
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have identified two transcription factors, nuclear respiratory factor (NRF)-1 and -2, 
that can bind to the promoter regions of nuclear-encoded mitochondrial genes, 
including ATP synthase, cytochrome-c, cytochrome-c-oxidase subunit IV, and 
mitochondrial transcription factor A (mtTFA). It is of particular interest that mtTFA 
can translocate to the mitochondrion and activate mitochondrial DNA (mtDNA) 
replication and mtDNA-encoded mitochondrial protein expression (Virbasius et al., 
1993, Evans and Scarpulla, 1990). This suggests that the NRFs are key nuclear 
receptors for mitochondrial biogenesis and respiration. Interestingly, PGC-1α 
physically interacts with NRF-1, therefore co-regulating its transcriptional activity in 
mitochondrial biogenesis. In addition to NRF-1, transcription factors YY1 and ERRα 
were later also identified as being co-activated by PGC-1α in mitochondrial 
biogenesis (Scarpulla, 2008, Cunningham et al., 2007). Moreover, PGC-1α can 
dramatically induce gene expression of NRF-1 and -2, and ERRα, forming a double –
positive–feedback loop that drives the expression of many OXPHOS genes (Wu et al., 
1999, Mootha et al., 2004).  
 
 
Figure 1.5 Adaptive thermogenesis and mitochondrial biogenesis 
Mitochondrial biogenesis is highly induced by environmental stressors including cold, diet and 
infections in adaptive thermogenesis. PGC-1α, the key regulator in mitochondrial biogenesis is 
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activated by a cytokine signalling pathway through direct phosphorylation by p38 MAPK. In addition, 
the expression level of PGC-1α is directly controlled by the cAMP-CREB pathway. PGC-1α interacts 
with the transcription factors NRF-1 and NRF2 which in turn control the expression of genes for 
mitochondrial function. Taken from (Puigserver and Spiegelman, 2003). 
 
PGC-1α plays a central role in mitochondrial biogenesis, and itself is regulated by 
several signalling cascades. It is activated by the cytokine signalling pathway through 
direct phosphorylation by p38 mitogen-activated protein kinase (MAPK) (Puigserver 
et al., 2001). Moreover, CREB- a transcription factor activated by cAMP, directly 
activates the expression of PGC-1α by binding to its promoter in hepatic 
gluconeogenesis (Herzig et al., 2001). In addition, PGC-1α activity can also be 
directly regulated by insulin-stimulated AKT phosphorylation in hepatic metabolism 
(Li et al., 2007b).  
 
1.3.3 Hepatic gluconeogenesis 
The study of PGC-1α is increasingly an area of interest in diabetes. Blood glucose 
levels are normally tightly controlled by the balance between peripheral glucose 
uptake and hepatic gluconeogenesis. The exact role of PGC-1α in the control of 
glucose uptake and metabolism is controversial. Studies using cultured muscle cells 
suggest that PGC-1α regulates glucose uptake and metabolism by co-activating the 
muscle transcriptional regulator MEF2 (myocyte enhancer factor-2), up-regulating the 
endogenous level of the insulin-sensitive glucose transporter (Glut4), and increasing 
glucose uptake (Michael et al., 2001). However, another study reported that over-
expression of PGC-1α in skeletal muscle down-regulated Glut4 transcription and 
impaired the glycemic control after insulin administration (Miura et al., 2003). 
Indeed, it has been demonstrated that glucose uptake and metabolism do not 
necessarily reflect insulin sensitivity, which is most likely controlled by hepatic 
gluconeogenesis. 
 
The liver is the major producer of glucose, mainly through gluconeogenesis, which 
occurs during fasting and is aberrantly activated in diabetes mellitus. PGC-1α is 
highly induced in type I (insulin-deficient) and type II (profound insulin resistance 
with a relative lack of insulin) diabetic mouse models, suggesting a key role for 
insulin as a suppressor of PGC-1α expression in the liver. The diabetic state is also 
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associated with low insulin-stimulated cAMP-CREB signalling, which directly 
controls the gene expression of PGC-1α (Herzig et al., 2001, Yoon et al., 2001). 
Moreover, insulin can suppress PGC-1α activity directly through AKT 
phosphorylation. This prevents the recruitment of PGC-1α to the cognate promoters, 
impairing its ability to bind and co-activate the forkhead transcription factor FOXO1 
or the hepatocyte nuclear factor 4α (HNF-4α), to promote gluconeogenesis and fatty 
acid oxidation (Puigserver et al., 2003, Li et al., 2007b). Therefore, insulin inhibits 
PGC-1α activity, leads to a reduction in hepatic gluconeogenesis and reduced blood 
glucose levels. However, in type II diabetes, where patients exhibit high blood 
glucose levels, insulin resistance, and a low level of insulin, activation of PGC-1α and 
the associated up-regulation of hepatic gluconeogenesis lead to a further increase in 
glucose production and release. This phenomenon eventually leads to a further 
reduction in insulin sensitivity and exacerbates insulin resistance. 
 
1.3.4 The role of PGC-1α in neurodegeneration 
The physiological functions of PGC-1α have been studied in metabolically active 
tissues. However, there is an increasing interest in dissecting its role in 
neurodegeneration. PGC-1α null mice show hyperactivity and other movement 
disorders representative of basal ganglia pathology, such as stimulus-induced 
myoclonus, dystonic posturing and frequent limb clasping. They also develop 
spongiform lesions with axonal loss in the striatum, and exhibit neuronal cell death, 
suggesting a neuroprotective role for PGC-1α (Lin et al., 2004, Lucas et al., 2014, 
Leone et al., 2005). Moreover, PGC-1α plays a role in the defence against oxidative 
stress, a system that is known to contribute to neurodegeneration in ageing cells. 
Indeed, PGC-1α null mice display a more severe loss of dopaminergic neurons 
compared to controls when challenged with MPTP (1- methyl-4-phenyl-1, 2, 3, 6-
tetrahydropyridine), a complex I inhibitor that induces PD in humans and animal 
models (St-Pierre et al., 2006).  
 
PGC-1α has been shown to be a neuroprotective therapeutic target in animal models 
of several neurodegenerative diseases caused by abnormal protein aggregation, 
including Huntington’s disease (Cui et al., 2006, Weydt et al., 2006, Tsunemi et al., 
2012) and ALS (Zhao et al., 2011, Liang et al., 2011). Furthermore, amelioration of 
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neurotoxicity by PGC-1α activation is associated with the improvement in 
mitochondrial and lysosomal-autophagy function. Human studies have shown that 
PGC-1α activity negatively correlates with the age of onset of AD (Helisalmi et al., 
2008) and PD (Clark et al., 2011). Indeed, human post-mortem studies demonstrated 
that PGC-1α levels are remarkably decreased in AD and PD patients’ brains (Qin et 
al., 2009, Shin et al., 2011), suggesting that neuronal up-regulation of this factor may 
offer therapeutic benefits. However, the effects of elevating PGC-1α in AD animal 
models are elaborate (Sheng et al., 2012, Katsouri et al., 2011, Dumont et al., 2014), 
and its precise function in vivo in the pathogenesis of AD awaits further investigation. 
PGC-1α over-expression has been shown to rescue dopaminergic neuronal loss in 
primary neuronal cultures expressing mutant α-synuclein, in association with up-
regulation of mitochondrial respiratory chain complex genes (Zheng et al., 2010). The 
role of PGC-1α in PD in vivo, however, is yet to be studied.  In my thesis, I will focus 
on dissecting the role of PGC-1α in AD and PD using Drosophila models. A 
comprehensive review of what is already known with regards to the role of PGC-1α in 
AD and PD is provided in Chapters 3 and 4 respectively.  
 
1.3.5 The Drosophila homologue of the PGC-1 family 
Mammalian PGC-1α is a member of the PGC-1 family, which also includes the 
closely related homolog PGC-1ß (Lin et al., 2002), and PGC-1-related coactivator 
(PRC) (Andersson and Scarpulla, 2001). All of these proteins have significant 
functional overlap in mitochondrial biogenesis, and a high degree of homology in the 
transcriptional activation domain, RNA-binding motif, and serine-arginine-rich motif, 
which makes it difficult to tease apart their relative roles in vivo. Among invertebrate 
models, Drosophila carries a single PGC-1 homolog in its genome (Gershman et al., 
2007), whereas other invertebrate models such as yeast and C. elegans do not carry 
any PGC-1 homologous sequences (Lin et al., 2005). The Drosophila homologue of 
PGC-1α, spargel (CG9808), is the only homologue of the mammalian PGC-1 family, 
therefore providing a system in which PGC-1 function can be assessed without 
interference from redundancy. 
 
Drosophila larvae lacking dPGC-1 show that there is 44% of the nuclear encoded 
mitochondrial proteins have been reduced the expression compared to wild type 
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controls, together with mitochondrial respiratory chain defects, demonstrating that 
dPGC-1 is required for mitochondrial biogenesis in a similar manner to its 
mammalian counterpart (Tiefenböck et al., 2010). Moreover, dPGC-1 null flies show 
reduced lipid storage and glycogen levels in association with a lean body phenotype. 
These results confirm that the main metabolic functions of PGC-1α described in 
mammals, including mitochondrial biogenesis, fatty acid oxidation and energy 
metabolism, are all conserved in Drosophila.  
 
dPGC-1 has been reported to be a downstream target of the insulin/TOR signalling 
pathway involved in cellular growth, metabolism and nutrition (Tiefenböck et al., 
2010, Mukherjee and Duttaroy, 2013). Insufficiency of either insulin or TOR results 
in developmental growth defects due to low ATP levels. Reduced expression of 
dPGC-1 results in growth retardation with smaller body size and developmental 
delay, while dPGC-1 gain-of-function has no immediate effect on Drosophila growth 
(Rera et al., 2011, Mukherjee and Duttaroy, 2013). dPGC-1 acts to increase 
mitochondrial activity, cell growth and the transcription of target genes in response to 
insulin signalling, and over-expression of dPGC-1 can overcome insulin/TOR-
mediated cell growth defects. However, dPGC-1 does not mediate all of the effects of 
TOR, since dPGC-1 has been shown to have no effect on 4E-BP phosphorylation, the 
key regulator of mTOR-mediated mitochondrial activity and biogenesis (Morita et al., 
2013). In addition, epistasis analysis has shown that over-expression of dPGC-1 does 
not ameliorate the negative effects of over-expression of FOXO, the main IIS 
downstream effector responsible for cellular growth. This thus suggests that dPGC-1 
either works in parallel with FOXO or up-stream of FOXO. Therefore, the exact 
mechanisms linking dPGC-1-mediated cellular growth and mitochondrial function 
under the control of insulin/TOR are yet to be elucidated, though the overall effect of 
dPGC-1 on growth is positive, like other members of the insulin/TOR signalling 
pathway.  
 
An earlier study claimed that activation of insulin signalling is important for the 
transport of the dPGC-1 protein from the cytoplasm to the nucleus (Tiefenböck et al., 
2010). However, reduced insulin signalling by starvation failed to sequester the 
protein to the cytosol (Mukherjee et al., 2014), suggesting that the cellular localization 
PGC-1α in neurodegeneration and ageing 
 
 
 
53 
of dPGC-1 might occur independently of insulin signalling. Interestingly, dPGC-1 has 
also been found to form a negative feedback loop in the regulation of insulin 
signalling, suggesting a complex network between dPGC-1 and IIS (Tiefenböck et al., 
2010). In addition, a recent study suggested that dPGC-1 can be directly up-regulated 
by Mitf, the Drosophila homologue of the transcription factor EB (TFEB) (Bouche et 
al., 2016). Inhibition of mTORC1 induces Mitf translocation to the nucleus and 
regulates the expression of genes involved in lysosomal biogenesis and lipid 
metabolism. This therefore highlights a novel role of dPGC-1 in the mTOR-signalling 
pathway.  
 
Mammalian PGC-1α and its relationship with insulin/mTOR signalling have become 
more tissue-specific during the course of evolution. In the absence of insulin, PGC-1α 
expression is elevated in the liver and gluconeogenesis is subsequently initiated 
(Puigserver et al., 2003). Therefore, liver-specific knock down of PGC-1α in mice 
results in higher insulin sensitivity (Koo et al., 2004). Conversely, the absence of 
PGC-1α in skeletal muscles has no effect on insulin sensitivity (Zechner et al., 2010). 
In vivo studies have demonstrated the functions of dPGC-1 in several distinct fly 
tissues. Eye-specific knock down of dPGC-1 results in eye phenotypes, including 
abnormal ommatidia and bristle formation (Merzetti and Staveley, 2015), suggesting a 
role in neurodegeneration. Over-expression of dPGC-1α in Drosophila muscle tissue 
improved the climbing ability of the flies (Tinkerhess et al., 2012), although the 
precise mechanisms underlying these effects require further investigation. With 
respect to longevity, reduced IIS/mTOR signalling extends lifespan in different 
species (Fontana et al., 2010). The action of dPGC-1 on longevity is apparent as 
reduced dPGC-1 expression causes significant shortening of lifespan in Drosophila 
(Mukherjee et al., 2014). The most comprehensive study of dPGC-1 gain-of-function 
in vivo to date was that performed by Walker and colleagues. They demonstrated that 
over-expression of dPGC-1 in the fly gut improved gut homeostasis and extended 
lifespan (Rera et al., 2011). Improved mitochondrial function and reduced ROS 
production were cited as the two major underlying mediators of the lifespan 
extension, however this has yet to be fully proven.  
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Interestingly, over-expression of dPGC-1 in intestinal stem cells also prevented age-
related over-proliferation of cells in maintaining gut homeostasis (Rera et al., 2011). 
Although this mechanism is not fully elucidated, it is known that a moderate reduction 
in IIS/mTOR signalling can also reduce age-related cell proliferation (Biteau et al., 
2010). Previous studies have suggested that dPGC-1 forms a negative feedback loop 
in the regulation of insulin signalling (Tiefenböck et al., 2010), which potentially 
explains why dPGC-1 gain-of-function mimics reduced IIS/mTOR in regulating stem 
cell proliferation. Further work is required in this area to dissect the precise 
mechanisms of action of dPGC-1 in insulin/mTOR signalling. It is still controversial 
as to whether up-regulation of dPGC-1 in animal models is beneficial to lifespan 
(Tinkerhess et al., 2012), depending on the tissues and the experimental conditions. 
Research in Drosophila has significantly aided our understanding of the role of the 
PGC-1 group of proteins in ageing. Since both PGC-1α and IIS are involved in many 
physiological metabolic processes that contribute to obesity, diabetes, ageing and 
neurodegeneration, understanding how dPGC-1 modulates IIS is likely to provide 
new insights into our understanding of mammalian ageing and age-related diseases. It 
may also lead to the identification of novel biomarkers and therapeutic targets in the 
treatment of these diseases.   
 
1.4 The problem of ageing 
The need to understand the ageing process and to discover new strategies to improve 
healthy lifespan is becoming more urgent in light of the increasing ageing population 
and the higher prevalence of age-related diseases (Fontana and Partridge, 2015). By 
2050, the number of people over the age of 60 globally will triple (Figure 1.6) 
(Fontana et al., 2014). 
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Figure 1.6 The prevalence of the ageing population 
The prevalence of people over the age of 60 in developing and developed countries will dramatically 
increase by 2050. Taken from (Fontana et al., 2014). 
 
The majority of people over the age of 65 years already report suffering from one or 
more chronic disorders, such as diabetes, cancer, heart disease, stroke and 
neurodegeneration (Hung et al., 2011). With an ever-increasing aged population the 
prevalence of ageing-associated diseases has increased (Figure 1.7). These 
demographics are increasingly becoming a central issue for public health in developed 
countries, and bring considerable costs to the individuals as well at the population 
level. Moreover, studies using animal models suggest that delaying one age-related 
disease could potentially reduce the prevalence of others (Fontana et al., 2014), 
suggesting that ageing and age-related disorders are tightly linked. 
 
Figure 1.7 The incidence of age-related disease in 2006 
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(A) The incidence of cardiovascular disease in England. (B) The prevalence of dementia in European 
countries. (C) The UK cancer rate per 100,000 population. Taken from (Niccoli and Partridge, 2012). 
 
1.4.1 The theories of ageing                         
Ageing is a complex process, involving genetic and environmental factors. Many 
theories of ageing have been developed to explain why we age and how we age. The 
altruistic theory of ageing proposes that the existence of ageing is beneficial, since 
decreasing the burden of older individuals may benefit the young and healthy 
individuals when natural resources are limited (Kirkwood and Austad, 2000). 
However it does not explain why ageing exists in the first place.  
 
The evolutionary theory of ageing comes from the observation that the force of 
natural selection declines with age (Figure 1.8). The variation within the population 
exists, because random mutations will occur in the genome of individuals. Natural 
selection is the evolutionary mechanism that determines whether these mutations 
persist or are eliminated, depending on their contribution to reproductive capacity. If 
the mutations have a negative impact on development or reproductive ability, they 
would tend to be removed from the population and will not pass on to the next 
generation. However, the mutations that do not affect reproductive capacity will 
persist, and the offspring can inherit such mutations. In other words, harmful 
mutations that occur during childhood before the age of reproductive capacity are 
under strong natural selection, and thus are less likely to be passed on. However, the 
force of natural selection starts to decline after reproduction commences, which 
means that mutations that occur later will be under low or no natural selection, and 
will continue to accumulate. Accumulation of late-acting deleterious mutations over 
the course of the evolution of a population causes what we now understand as ageing, 
and this is called the mutation accumulation theory of ageing (Medawar, 1957).  
 
This can be better understood by a comparison between progeroid syndromes and 
Huntington’s disease (De Strooper et al.). Patients with progeroid show phenotypes in 
early life, limiting their reproductive capacity, giving rise to a low prevalence of this 
disorder in the population. Conversely, HD is a late-onset neurodegenerative disorder, 
which enables the defective gene to be passed on to the next generation, giving rise to 
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a higher prevalence (Rose, 1999, Haldane, 1941). This illustrates how deleterious 
disease-causing genes are not removed by natural selection. 
 
 
Figure 1.8 The force of natural selection declines with age 
Mutations arising during childhood before the onset of reproductive fitness are under strong natural 
selection. Mutations whose phenotypes manifest after sexual maturity are under less selective pressure. 
Therefore, late-manifesting mutations are able to pass on to the next generation. Taken from (Rose, 
1999).  
 
The evolutionary theory of ageing arising from the concept of natural selection has 
been further developed into several differential explanations. George Williams 
proposed that mutations that ensure reproductive capacity would be favored by 
natural selection even if they pose a disadvantage later in life, which is referred to as 
the antagonistic pleiotropic (AP) theory of ageing (Williams, 1957). The AP theory 
highlights the dual early benefit and late negative effect of such mutations, and 
provides guidance on translating developmental studies into ageing research. 
Researchers must bear in mind that genes that are required during development will 
affect reproductive fitness by natural selection, and their contribution to ageing will 
therefore remain unknown. Insulin and the mTOR signalling pathways provide good 
proofs of principle of the AP theory. These two pathways are very important for 
development and growth, as they promote energy metabolism and protein synthesis. 
Meanwhile, these pathways are now known to contribute to ageing, as down-
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regulation of the insulin/mTOR signalling pathways extends lifespan in diverse 
organisms (Fontana and Partridge, 2015), highlighting the pleiotropic functions of the 
insulin/mTOR pathways. They are also important for reproduction and therefore they 
persist after natural selection  
 
1.4.2 The study of ageing in model organisms  
To understand the biological processes that drive ageing, laboratory animal models 
have been used to investigate different pharmacologic or genetic interventions. In 
order to assess the effects of such interventions on lifespan, the median and maximum 
lifespan of groups of animals are often measured. Median lifespan refers to the time at 
which 50% of the population remains alive. Maximum lifespan refers to the time 
when the last individual dies. Each model organism has its advantages and 
disadvantages for studying ageing and age-related diseases. However, interventions in 
any specific cellular pathway have to be at least evolutionary conserved in order to 
effectively translate research findings from these animal model species to humans 
(Partridge, 2001). In mammalian models, the mouse is the preferred organism with an 
average lifespan of 3 years and the availability of well-characterised genetic tools. 
Although mice are costly and require considerable maintenance, especially for 
lifespan experiments requiring large population numbers (Swindell, 2012), their use is 
important when testing successful interventions discovered in less complex 
organisms.  
 
Simple model organisms like C. elegans and Drosophila melanogaster offer many 
advantages for ageing research, due to their relatively short lifespan and well-known 
genomes. Drosophila (the fruit fly) is a powerful genetic tool for studying genetic 
inheritance, development, behaviour, disease and ageing. Moreover, the distinct brain 
structure with cell types analogous to the human brain, and the presence of a blood 
brain barrier, make it an excellent model to study neurodegeneration (McGurk et al., 
2015, Fernandez-Funez et al., 2015). Drosophila has a short life cycle, which is 
approximately 10 days from egg laying to the eclosion of adult flies at 25°C (Figure 
1.9). Under laboratory conditions, Drosophila can live for around 3 months, and 
female flies live slightly longer than male flies. The Drosophila genome contains 4 
pairs of chromosomes: an X/Y pair, and three autosomes named 2, 3, and 4. 
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Determination of the sex in Drosophila depends on the ratio of X chromosomes to 
autosomes, which is different from that in humans. Moreover, 60% of the Drosophila 
genes are conserved in the human genome, and 75% of known human disease genes 
have a recognizable homologue in the Drosophila genome. Therefore, Drosophila has 
been successfully used as a genetic model for several human diseases including PD 
and AD, some of which I have utilized in my research.  
 
 
Figure 1.9 The Drosophila life cycle 
Fertilized females store sperm in storage organs, and fertilize their eggs just before laying the embryo 
(egg). The embryo completes its development within 24 hours and hatches as a first instar larva and 
progresses to a third instar larva. Just before pupariation the third instar larva crawls up the side of the 
housing bottle and undergoes metamorphosis inside the protective pupal case. During this four-day 
period most larval tissues are replaced with adult-like tissues. After flies emerge from their pupae, their 
wings expand, and their exoskeleton hardens and becomes pigmented. Taken from (Hartwell et al., 
2011). 
 
1.4.3 The molecular basis of the ageing process  
Ageing is the progressive loss of physiological integrity, leading to dysfunction and 
increased vulnerability to death. This deterioration is the main risk factor for human 
diseases, including cancer, diabetes and neurodegeneration. Ageing research has 
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achieved huge success during the past few decades, particularly with the discovery 
that ageing process can, to a certain extent, be delayed or ameliorated. The hallmarks 
of ageing include mitochondrial dysfunction, dysregulated nutrient sensing, 
proteostatic failure, alterations in epigenetics, telomere attrition, genomic instability, 
alterations in intercellular communication, stem cell exhaustion and cellular 
senescence (Figure 1.10) (Lopez-Otin et al., 2013). The ageing process is complex: 
not only do the individual components contribute to ageing, but also there is 
considerable crosslink between different components. Here I will describe the role of 
mitochondrial dysfunction and proteostatic failure in the ageing process. 
 
 
 
Figure 1.10 The hallmarks of ageing 
This diagram depicts the 9 hallmarks of ageing, including mitochondrial dysfunction, deregulated 
nutrient sensing, proteostatic failure, alterations in epigenetics, telomere attrition, genomic instability, 
alterations in intercellular communication, stem cell exhaustion and cellular senescence. Taken from 
(Lopez-Otin et al., 2013).  
 
1.4.4 Mitochondrial dysfunction in ageing  
The mitochondrion is the energy factory of living cells, playing an important role in 
maintaining intracellular homeostasis. The role of mitochondrial dysfunction in 
neurodegeneration has been addressed above. Its involvement in the ageing process, 
however, is complex and controversial. The physiological functions of mitochondria 
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include energy metabolism and respiration, which is essential for development and 
cell growth. The mitochondrial respiratory chain, as well aiding the production of 
ATP, is also the main site of ROS production. The mitochondrial free radical theory 
of ageing states that the accelerated mitochondrial dysfunction that occurs with age 
causes increased ETC leakage and production of ROS. In turn this accumulation of 
ROS results in free radical damage, including mtDNA mutations or deletions, 
increased lipid peroxidation, calcium deregulation, further mitochondrial deterioration 
and eventually cell death (Harman, 1965, Green et al., 2011). However, many studies 
have suggested that free radical damage and lifespan can be uncoupled. Mitochondrial 
ROS and oxidative damage in mice did not accelerate ageing (Zhang et al., 2009), 
while reduction of ROS by increasing antioxidant defence in mice failed to extend 
lifespan (Van Raamsdonk and Hekimi, 2009). Indeed, several studies showed that 
moderate increases in ROS can be beneficial and extend lifespan in yeast and C. 
elegans (Doonan et al., 2008, Mesquita et al., 2010, Van Raamsdonk and Hekimi, 
2009). Therefore, the role of ROS in ageing requires re-evaluation: rather than being a 
direct contributor to ageing, it is more likely a response modulator for stress-elicited 
survival signalling (Sena and Chandel, 2012).  
 
Mutations and deletions in aged mtDNA may also contribute to ageing (Park and 
Larsson, 2011). mtDNA is considerably vulnerable to ageing-associated stress and 
mutation due to the lack of protective histones and the limited efficiency of repair 
mechanisms (Linnane et al., 1989). Interestingly, most mtDNA mutations in aged 
cells appear to be caused by replication errors early in life rather than oxidative 
damage. These mutations may undergo polyclonal expansion and result in ETC 
dysfunction and mitochondrial ageing (Ameur et al., 2011, Payne et al., 2011). 
Moreover, mice lacking mitochondrial polymerase gamma showed accumulation of 
mtDNA mutations and deletions, impaired mitochondrial function, and shortened 
lifespan (Kujoth et al., 2005, Trifunovic et al., 2004, Vermulst et al., 2008). 
Therefore, it would be interesting to know whether genetic manipulations that 
decrease the load of mtDNA mutations can extend lifespan.  
 
PGC-1α, the captain of the mitochondrion, has dual effects in increasing 
mitochondrial mass and activity and defending against oxidative damage (St-Pierre et 
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al., 2006). A lack of PGC-1α leads to mitochondrial dysfunction and can cause 
premature ageing and age-related diseases. Recently a study showed that over-
expression of PGC-1 in Drosophila could extend lifespan, improve mitochondrial 
function, including increasing ETC activity and mitochondrial mass, as well as reduce 
ROS (Rera et al., 2011). Given the controversial roles of these effectors in ageing, 
further studies are warranted to investigate whether genetic manipulation of the above 
effectors can directly extend lifespan. 
 
1.4.5 Proteostatic failure in ageing  
A decline in proteome homeostasis (proteostasis) leads to ageing and age-related 
neurodegeneration (Hetz et al., 2011). Maintenance of proteostasis requires proper 
protein folding and assembly and protein quality control. To protect against 
proteotoxicity, cells have evolved several independent stress responses that result in 
the induction of chaperones and degradation machineries within selected organelles. 
Three well-characterized stress response pathways are the endoplasmic reticulum 
unfolded protein response (UPRER) (Ron and Walter, 2007), the mitochondrial 
unfolded protein response (UPRmt) (Haynes and Ron, 2010) and the heat shock 
response (HSR) (Akerfelt et al., 2010). The UPR is the stress response pathway that is 
activated by the accumulation of mis-folded proteins in the ER or mitochondria, in 
order to either re-establish proteostasis or induce apoptosis. However, the ability to 
maintain proteostasis by activating the UPRER declines with age (Casas-Tinto et al., 
2011). Activation of the UPRER by over-expression of an active Xbp1, the downstream 
effector of the IRE1 branch of the UPRER promotes ER stress resistance, and extends 
lifespan in C. elegans (Taylor and Dillin, 2013). The questions of whether activating 
the UPRER can extend lifespan in more complex organisms remains unanswered.  
 
In addition, deleterious mitochondrial stress caused by excessive ROS production 
may be detrimental to the maintenance of the mitochondrial proteome, with elevated 
mitochondrial lipid peroxidation (Kinghorn et al., 2015), calcium deregulation (Du et 
al., 2010), and eventually abnormal assembly of the ETC components (Tatsuta and 
Langer, 2008). Interestingly, mild mitochondrial stress has been shown to be 
beneficial in terms of lifespan (Merkwirth et al., 2016). The UPRmt is a stress-
response pathway that adapts and activates the folding capacity of the mitochondrial 
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matrix in response to mitochondrial dysfunction, leading to up-regulation of nuclear-
encoded, mitochondrial-localized chaperones. These in turn promote both protein 
folding and degradation to either restore mitochondrial proteostasis or to trigger 
apoptosis (Neupert and Herrmann, 2007, Haynes and Ron, 2010). In mammalian 
cells, activation of the UPRmt correlates with increased JNK2 signalling, leading to 
induction of the transcription factors CHOP and C/EBPβ, thus up-regulating the 
mitochondrial chaperone HSP60 (Aldridge et al., 2007, Zhao et al., 2002).  
 
 
Figure 1.11 A model of mitochondrial UPR signalling in C. elegans 
The mitochondrial UPR is initiated when mis-folded proteins in the mitochondrial matrix exceed the 
capacity of the mitochondrial chaperones. The ClpXP protease degrades the unfolded protein into 
peptides, which is then released to the cytosol by the HAF-1 transporter. This peptide efflux activates 
the translocation of the transcription factor ZC376.7 into the nucleus by unknown mechanisms. 
ZC376.7, together with UBL-5 and DVE-1, form a transcriptional complex to drive gene expression of 
nuclear-encoded but mitochondrial-localized chaperones. Transcriptional up-regulation of 
mitochondrial chaperones in turn relieves the stress and re-establishes homeostasis. Taken from 
(Haynes and Ron, 2010) 
 
In C. elegans (Figure 1.11), the protease ClpXP degrades mis-folded proteins into 
peptides, which are then exported into the cytosol through the HAF-1a transporter, 
leading to translocation of the transcription factor ZC376.7 into the nucleus. This 
leads to the up-regulation of the mitochondrial chaperones HSP60 and 
mtHSP70/Glucose regulated protein 75 (Grp75), thus relieving stress and re-
establishing homeostasis (Haynes et al., 2007, Yoneda et al., 2004). Recent studies 
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found that an early perturbation of mitochondria leads to remodelling and silencing of 
chromatin, and extends lifespan in C. elegans (Tian et al., 2016). Therefore, the role 
of UPRmt in ageing is complex and awaits further investigation. 
 
Another biological stress response pathway involved in ageing is the UPS (Ubiquitin 
proteasome system), which is also implicated in age-related neurodegenerative 
diseases such as AD and PD (Morimoto, 2008, Lopez-Otin et al., 2013). The UPS, 
together with the lysosome-autophagy system and chaperone network, acts to 
maintain cellular protein homeostasis by removing unwanted or damaged proteins that 
may become toxic to cells (Jung et al., 2009, Glickman and Ciechanover, 2002). UPS 
activity is ATP-dependent, which supports the hypothesis that improving energy 
metabolism may suppress the age-related decline in proteasome activity (Fontana and 
Partridge, 2015).  
 
1.4.6 Anti-ageing interventions 
Since ancient times individuals have been seeking ways to prolong youth and avoid 
the ageing process. The most successful findings in ageing research to date come from 
the discovery that ageing can be ameliorated by diet, genetic or pharmacological 
interventions in the nutrient-sensing pathway. Multiple molecular pathways appear to 
set the pace of physiological ageing. Interventions in these pathways prolong lifespan 
and healthy ageing in rodents and mammals. Reduced food/caloric intake, 
simultaneously avoiding malnutrition, can delay ageing and age-related disease in 
different organisms from yeast to humans (Fontana et al., 2010).  
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Figure 1.12 The role of DR in ageing 
DR improves healthy lifespan through multiple systemic, neuronal, and cellular mechanisms. Taken 
from (Fontana and Partridge, 2015).  
 
DR in mice and rats improves healthy lifespan, in association with a reduction in the 
prevalence of age-related pathologies (Fontana et al., 2010, Ikeno et al., 2006, Maeda 
et al., 1985). Young monkeys subjected to DR show improved metabolism and a 
lower prevalence of type-2 diabetes, cancer and cardiovascular disease (Colman et al., 
2014, Mattison et al., 2012). In humans, long-term DR results in similar metabolic 
and molecular changes to those seen in animals. DR improves several markers of 
health and reduces the risk of developing cardiovascular diseases, neurodegeneration, 
and cancer (Heilbronn et al., 2006, Cava and Fontana, 2013, Masoro, 2003). Due to 
its robustness and strong conservation across different species, the discovery of the 
molecular mechanisms involved in DR will provide useful insights into the 
mechanisms of ageing. The mechanisms by which DR improves healthy lifespan are 
not fully understood in any species. One of the best known mechanisms of DR that is 
evolutionarily conserved across species is that, under the conditions of nutrient 
limitation, there is an adaptive switch in metabolic state from reproduction and 
growth toward somatic maintenance to ensure survival (Holliday, 1989). DR also 
extends lifespan in many less-complex and shorter-lived organisms including S. 
cerevisiae, C. elegans and Drosophila. The wide use of yeast and invertebrates has 
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enabled researchers, through genetic and pharmacological interventions, to discover 
the evolutionarily conserved mechanisms that extend healthy lifespan.  
 
One of the molecular mediators of DR on longevity is the mTOR (mechanistic target 
of rapamycin), which is an evolutionarily conserved nutrient-sensing protein kinase 
that responds to amino acid levels. It thus regulates growth and metabolism in all 
eukaryotic cells (Johnson et al., 2013). mTOR functions in two distinct complexes: 
mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Rapamycin inhibits 
mTORC1 activity, extending lifespan across species from yeast to mammals. It 
mediates its longevity effects via mechanisms including reduced mRNA translation 
and induction of autophagy through at least two mTORC1 substrates, ribosomal 
protein S6 kinases (S6Ks) and eukaryotic translation initiation factor 4E-binding 
protein 1 (4E-BP1) (Bjedov et al., 2010, Powers et al., 2006, Robida-Stubbs et al., 
2012, Harrison et al., 2009, Medvedik et al., 2007, Miller et al., 2011). Moreover, 
inhibition of mTORC1 also improves proteostasis and enhances stem cell function 
(Kapahi et al., 2010, Johnson et al., 2013). mTORC2 is not sensitive to inhibition by 
rapamycin, and is usually considered not relevant in nutrient sensing. However it is 
necessary for the phosphorylation and activation of AKT downstream of the IIS 
(Guertin and Sabatini, 2009). In addition, mTORC1 extends lifespan in mechanisms 
overlapping with IIS. mTORC1 is activated by insulin through PI3K 
(phosphatidylinositide 3-kinases) and AKT kinase signalling, while mTORC1 
negatively regulates IIS though S6K, which inhibits insulin receptor substrate 1 (IRS 
1) (Laplante and Sabatini, 2012, Takano et al., 2001). Additional studies have 
indicated that the mTORC1 target 4E-BP is also a transcriptional target of FOXO in 
fruit flies (Tettweiler et al., 2005). mTORC1 has also been implicated in several 
ageing processes including inflammation and mitochondrial dysfunction (Johnson et 
al., 2013). Hyper-activation of mTOR is often associated with inflammation, and 
rapamycin has been shown to have anti-inflammatory effects via NF-kB (nuclear 
factor kappa-light-chain-enhancer of activated B cells) (Liu, 2006, Nuhrenberg et al., 
2005). The activity of NF-kB signalling increases with age (Ren et al., 2007, Libert et 
al., 2006), and imbalanced NF-kB signalling is a major risk factor underlying ageing 
and age-related disease (Chung et al., 2009). This highlights the potential therapeutic 
benefits of limiting NF-kB signalling to improve tissue homeostasis in ageing (Guo et 
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al., 2014). In addition, regulation of mitochondrial function by mTORC1 is complex. 
mTOR complex actively promotes mitochondrial biogenesis and metabolism through 
PGC-1α and YY1 (Cunningham et al., 2007). However, yeast and mouse studies have 
demonstrated that inhibition of mTORC1 results in a metabolic shift towards greater 
mitochondrial respiration, thereby increasing chronological longevity (Bonawitz et 
al., 2007, Polak et al., 2008). 
 
It has been shown in S. cerevisiae that decreased mTOR signalling mediates the pro-
longevity effects of DR (Kaeberlein et al., 2005). Moreover, the first C. elegans 
model to show a DR-like response with lifespan extension was that carrying an eat-2 
mutation, which directly causes pharyngeal pumping defects (Lakowski and Hekimi, 
1998). Several components in the mTOR signalling networks have been shown to 
mediate the lifespan extension of DR in C. elegans. Late-onset knockdown of mTOR 
using RNAi extends lifespan (Vellai et al., 2003), in a FOXO-independent manner. 
This suggests that mTOR mediates lifespan regulation through mechanisms other than 
reduced insulin signalling pathway activity (Vellai et al., 2003, Guarente and Kenyon, 
2000). Down-regulation of the components in the mTOR complex or the downstream 
effectors in the mTOR signalling pathway have been found to mediate lifespan 
extension by reducing bacterial food concentration in the diet, suggesting a DR-like 
mechanism (Chen et al., 2009b, Honjoh et al., 2009, Jia et al., 2004). Moreover, 
inhibition of the mTOR pathway in the DR mimetic eat-2 mutant background does 
not further extend lifespan, suggesting that mTOR signalling pathway inhibition and 
DR share overlapping mechanisms in regulating lifespan (Hansen et al., 2008, Chen et 
al., 2009b).  
 
DR also extends lifespan in Drosophila (Clancy et al., 2002, Mair et al., 2003, Rogina 
et al., 2002). In Drosophila, the method of restricting food intake is different from that 
in yeast or worms. The diet used in Drosophila usually contains a carbohydrate source 
(sucrose), yeast as a source of amino acids, vitamins, minerals, cholesterol and 
essential fatty acids. Previous studies showed that it was modulation of the yeast in 
the diet that mediated the DR-associated lifespan extension, rather than the 
carbohydrate content or water (Kapahi et al., 2004, Mair et al., 2005). Therefore, the 
diet in Drosophila DR studies is manipulated by reducing the yeast component 
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without changing the carbohydrate load. Therefore, the evaluation of DR on lifespan 
is usually performed by varying the amount of yeast from low to high, using at least 3 
different concentrations. With an increased gradient of yeast concentration, lifespan 
gradually increases to a maximum, after which the lifespan drops with any further 
increases in yeast concentration. When the values of the median or maximum lifespan 
are plotted against the concentration of yeast, the graph appears as a tent-shaped 
curve. The DR condition therefore refers to the yeast concentration that shows the 
highest lifespan (either median lifespan or maximum lifespan). Lower yeast 
concentrations limit lifespan by malnourishment, while higher concentration limits 
lifespan by over-nourishment (Bass et al., 2007, Grandison et al., 2009, Metaxakis 
and Partridge, 2013). The practical use of a DR-tent is to test the potential interactions 
between different interventions and diet on lifespan (Figure 1.13). When the 
intervention is truly a DR mimetic, the flies should behave as though they are already 
to some extent subjected to DR. They should therefore be more prone than controls to 
starvation at low levels of nutrition. At the food dilution that maximizes control 
lifespan, the flies with intervention would be malnourished and less long-lived. 
Lifespan of those flies should peak at a higher food concentration than that of controls 
dose, and at this and higher food concentrations, the flies with intervention should be 
longer lived than controls (Clancy et al., 2002) (Figure 1.13A). If the intervention is 
not a DR mimetic, lifespan extension will occur to a similar degree regardless of the 
yeast conditions (Figure 1.13B). In addition, if an intervention shares some 
mechanisms with DR, it might still further extend lifespan under DR conditions, 
however the response to different yeast conditions will differ and the maximum 
benefit for this intervention might be within full-feeding (Figure 1.13C). Cox 
proportional hazard (CPH) analysis makes this comparison much easier, and simply 
evaluates the effect of an intervention across all the different yeast levels. In other 
words, CPH will establish whether the shape of the DR-tent is different between 
interventions and related-controls. A significant interaction suggests that the 
intervention and DR share similar mechanisms. A non-significant difference suggests 
that the intervention is a non-DR mimetic or acts beyond DR.  
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Figure 1.13 Testing a genetic intervention that extends lifespan and its interaction with DR 
PGC-1α, the transcriptional coactivator in mitochondrial biogenesis, has previously been shown to 
extend lifespan in Drosophila (Rera et al., 2011). However its mechanisms of lifespan extension are 
not fully understood. (A) The DR-tent if over-expression of dPGC-1 is a true DR-mimetic. (B) The 
DR-tent if over-expressing dPGC-1 is partially overlapped with DR. (C) The DR-tent if dPGC-1 over-
expression extends lifespan beyond DR. Taken from (Castillo-Quan et al., 2015). 
 
Inhibition of mTOR signalling components extend lifespan in Drosophila, but not to a 
greater extent than that seen with DR, supporting the idea that mTOR mediates the 
lifespan extension by DR-related mechanisms (Kapahi et al., 2004). Moreover, 
feeding flies with rapamycin, which inhibits mTORC1 activity, extends lifespan in 
Drosophila (Bjedov et al., 2010). Rapamycin further increases the lifespan of 
Drosophila under different yeast concentrations. However, the responses to diet are 
different between controls and rapamycin-treated flies across the different food 
conditions, in which the largest increase in lifespan by rapamycin is under the full 
feeding. This result suggests that pharmacological inhibition of mTOR signalling by 
rapamycin shares overlapping mechanisms with DR in lifespan regulation. 
In addition, mTOR signalling also mediates mammalian longevity. The long-lived 
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Ames dwarf mice show reduced protein synthesis via inhibition of mTOR activity 
(Bartke and Brown-Borg, 2004, Sharp and Bartke, 2005). Moreover, administration of 
the mTORC1 inhibitor rapamycin extends lifespan in mice, further demonstrating the 
beneficial effect on lifespan of inhibiting mTOR signalling (Harrison et al., 2009, 
Chen et al., 2009a).      
Insulin/IGF-1-like signalling (IIS) also mediates the lifespan extension of DR, 
although comprehensive studies are very limited. Reduced insulin/IIS increases 
longevity in C. elegans, fruit flies and mice (Fontana et al., 2010, Kenyon, 2010). 
Lifespan extension and stress resistance resulting from reduced IIS is mediated by the 
FOXO family of transcription factors through PI3K and AKT kinase signalling 
(Laplante and Sabatini, 2012, Tullet et al., 2008). Inhibition of AKT activates FOXO, 
which then up-regulates several “longevity pathways” controlling DNA repair, 
autophagy, antioxidant activity, stress resistance and cell proliferation (Webb and 
Brunet, 2014, Wang et al., 2014). Reducing IIS via partial ablation of the insulin-like 
peptide-producing median neurosecretory cells (mNSCs) in the adult Drosophila 
brain, which produce three of the seven Drosophila insulin-like peptides (dilp2, 3 and 
5), reduces IIS signalling and extends lifespan (Broughton et al., 2010). Moreover, a 
study using chico1 mutants, a long-lived insulin mutant in Drosophila showed that 
reduced IIS and DR extended lifespan via overlapping mechanisms (Clancy et al., 
2002). Although the nature of the mechanisms by which chico1 acts like DR requires 
further analysis, reduced IIS and DR may interact in determination of lifespan 
because they both alter some common downstream process. Indeed, reduced IIS 
signalling can inhibit mTORC1 activity through AKT phosphorylation in Drosophila, 
suggesting that mTOR may be one of the common pathways downstream of both 
interventions.  
The other two nutrient sensors, AMPK (5' adenosine monophosphate-activated 
protein kinase) and sirtuins, act in the opposite direction to IIS and mTOR. They 
therefore sense nutrient scarcity and catabolism instead of nutrient abundance and 
anabolism (Lopez-Otin et al., 2013). In general, activation of AMPK and sirtuins 
promotes longevity. AMPK activation has multiple effects on metabolism. Activation 
of AMPK can down-regulate mTORC1 activity, therefore controlling cell growth, 
autophagy and translation (Alers et al., 2012). Activation of AMPK also activates 
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PGC-1α, antioxidant defences and fatty acid oxidation (Wu et al., 1999, St-Pierre et 
al., 2006). Moreover, AMPK mediates longevity induced by DR in C. elegans 
(Burkewitz et al., 2014, Greer et al., 2007). Administration of metformin to worms 
and mice show lifespan extension mediated by activation of AMPK (Anisimov et al., 
2011, Mair et al., 2011, Onken and Driscoll, 2010). In addition metformin does not 
further extend lifespan in Drosophila on DR food, further confirming the idea that it 
mimics the DR effect in lifespan extension (Slack et al., 2012).  
Over-expression of some sirtuins (i.e., SIRT1, 3, and 6) increases lifespan via 
mechanisms overlapping with DR (Guarente, 2013). Activation of SIRT increases 
genomic stability, reduces NF-kB signalling, and improves metabolic homeostasis 
through histone deacetylation (Mouchiroud et al., 2013, Guarente, 2013). Moreover, 
SIRT1 can deacetylate and activate PGC-1α to regulate glucose homeostasis (Rodgers 
et al., 2005), therefore sharing similar downstream effectors with AMPK. 
Another characterized effector mediating DR in mice is the transcription factor NF-
E2-related factor (NRF2), which is the key regulator in several enzymatic pathways 
involved in anti-oxidant responses (Martin-Montalvo et al., 2011). The beneficial 
effect of calorie restriction in mice is partially mediated by NRF2. In addition, we 
recently published research demonstrating that lithium, the most commonly 
prescribed drug for the treatment of bipolar disorder, extends lifespan in Drosophila 
through inhibition of GSK-3 and activation of NRF-2. Furthermore this lifespan 
extension was mediated at least partially through DR (Castillo-Quan et al., 2016).  
Heat shock factors (HSFs) have been also implicated in the effects of DR on health 
and longevity (Akerfelt et al., 2010). HSFs mediate the stress responses to 
environmental/pathological stressors by activating molecular chaperones such as 
HSP70 and stress proteins. These proteins are therefore essential for all organisms to 
survive exposure to acute stress. Furthermore the heat shock responses become 
impaired with age, in addition to numerous other cellular defense systems including 
the UPR and the removal of mis-folded proteins by the cellular degradation 
machinery, leading to cellular ageing and neurodegneration (Powers et al., 2009, Ben-
Zvi et al., 2009). Down-regulation of HSF in C. elegans leads to lifespan shortening 
and accelerated protein aggregation. On the other hand, reduced IIS can activate HSF, 
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improve proteostasis, and extend lifespan (Hsu et al., 2003, Morley and Morimoto, 
2004). In addition, age-related proteostatic failure can be ameliorated by over-
expression of HSF or daf-16 (FOXO), suggesting an important role of these stress-
responsive transcription factors in maintaining global proteome homeostasis (Ben-Zvi 
et al., 2009).  Moreover, HSF1 can be directly deacetylated by SIRT1, which then 
becomes activated for DNA binding. Indeed a decrease in SIRT1 levels during ageing 
is also associated with an inhibition of HSF1 DNA-binding activity (Westerheide et 
al., 2009). Furthermore, an age-related decrease in the HSF1 DNA-binding activity 
and reduced transcripts of HSP70 are reversed by caloric restriction (Heydari et al., 
1996). These results suggest that HSF1 and SIRT1 function together to protect cells 
from stress stimuli, thereby promoting survival and extending lifespan.  
In addition to reducing food intake, the timing of a meal also appears to be important. 
During evolution, animals and humans ate intermittently. For many invertebrates, 
long periods of starvation are normal and they have developed conserved responses 
against starvation (Fontana and Partridge, 2015). For example, intermittent fasting 
(IF), with 2 days of normal feeding followed by 2 days of fasting extends lifespan in 
C. elegans through reduced IIS/mTOR signalling (Honjoh et al., 2009). Chronic 
starvation even extends lifespan in C. elegans with shared mechanisms with IF that 
include reduced IIS/mTOR signalling and activation of FOXO family transcription 
factors (Kaeberlein et al., 2006, Lee et al., 2006, Uno et al., 2013, Honjoh et al., 
2009). Short-term every-other-day feeding/fasting mimics many positive outcomes of 
DR, improving the healthy lifespan by up to 30% in mice (Brown-Borg and Rakoczy, 
2013). However, the age of initiation of the fasting seems also to be crucial, as old-
aged mice are more sensitive to fasting than younger ones, suggesting they are more 
likely starvation-sensitive (Goodrick et al., 1990). In addition to its pro-longevity 
effects, IF may also prevent age-related chronic disorders, such as diabetes, 
neurodegeneration, obesity, cardiovascular disease and hypertension (Mattson et al., 
2014). Human trials on the effects of IF are ongoing and appear to show promising 
results, including reduced body weight, fat mass, serum concentrations of total and 
LDL cholesterol, triglycerides and arterial blood pressure. Biomarkers for cancer risk 
were reduced, but total and free IGF-1 did not change (Harvie et al., 2011). In rodents, 
several molecular changes appear to mediate the benefits of fasting, including a 
metabolic shift to fat metabolism and ketone production, enhanced adaptive cellular 
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and molecular stress responses that prevent and repair molecular damage, reduced 
inflammation and oxidative stress (Mattson et al., 2014). In addition, fasting can also 
improve mitochondrial function, elevate stress responses by increasing production of 
the chaperones HSP70 and Grp78. It also leads to the inhibition of the nutrient 
sensing network AKT/mTOR pathway, increases autophagy and stimulates the DNA 
repair pathway in different cell types (Brown-Borg and Rakoczy, 2013, Mattson et al., 
2014). Prolonged fasting in mice reduced circulating IGF-1, improved stem cell 
protection, self-renewal and regeneration (Cheng et al., 2014).  
However, the effect of IF in cancer or other cachexia disease states is controversial. 
One study reported that fasting could initiate and promote liver carcinogenesis in rats 
with increased production of TGF-beta1 (Tessitore and Bollito, 2006). Moreover, 
Drosophila models of tumours secreted ImpL2, the antagonist of insulin signalling, 
leading to a sustained and dramatic reduction of insulin activity and tissue loss, 
suggesting that excessive reduction of IIS/mTOR signalling pathway might be 
causative for the pathogenesis and progression of tumours (Figueroa-Clarevega and 
Bilder, 2015, Kwon et al., 2015). This cachexia mimics malnourishment and further 
reducing the insulin signalling by IF will deteriorate this situation. Wasting, 
starvation, IF, and DR therefore share similar molecular mechanisms in controlling 
the physiological and pathological state in response to nutrient limitation, although the 
levels of reduction and outcomes are varied.  
 
1.5 Thesis outline 
My PhD work was mainly focused on dissecting the role of PGC-1α in 
neurodegenerative diseases, including AD and PD, in Drosophila models. This work 
also involved the identification of the interaction partners of PGC-1α in regulating 
metabolic processes in disease states. Moreover, I also characterised the downstream 
effectors of PGC-1α in the regulation of ageing in the fly. This work provides 
significant insights into the role of PGC-1α and its interactors in both ageing and 
neurodegeneration. It also highlights a number of potential therapeutic strategies for 
promoting healthy ageing and preventing age-related diseases such as 
neurodegeneration.  
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Most of my PhD work is yet to be published. However, I have already been a co-
author on a number of publications and these can be found in the Appendix.  
 
A summary of each results chapter is detailed below.  
 
1.5.1 PGC-1 regulates the ER-unfolded protein response and 
ameliorates Aβ toxicity. (Chapter 3) 
AD is the most common neurodegenerative disorder affecting millions of people 
worldwide. Ageing is the greatest risk factor for developing AD (Niccoli and 
Partridge, 2012). Therefore there is an urgent need to develop therapeutic strategies 
for AD in the ever-increasing ageing world population. Mitochondrial dysfunction, 
oxidative stress, proteostatic failure, and circadian rhythm disruption have all been 
implicated in the pathogenesis of AD (Hetz and Mollereau, 2014, Bender et al., 2008, 
Nunomura et al., 2001, Harper et al., 2005), suggesting that these processes may 
provide excellent therapeutic targets for preventing AD. PGC-1α is a key regulator in 
many biological processes, including mitochondrial biogenesis, oxidative stress 
responses, circadian clock control, and protein quality control (Puigserver and 
Spiegelman, 2003, St-Pierre et al., 2006, Liu et al., 2007, Wu et al., 2011). It has also 
been found to be present at reduced levels in AD post mortem brains (Qin et al., 
2009), suggesting that elevating the levels of PGC-1α in neurons might be beneficial 
in AD. In Chapter 3, I demonstrated for the first time in vivo that up-regulation of 
PGC-1α in neurons can prevent the neurotoxic phenotypes in a Drosophila model of 
Aß toxicity. I then investigated the mechanisms by which activation of dPGC-1 in 
neurons ameliorates Aß induced neurotoxicity.  
 
To further explore the downstream effectors of dPGC-1 in ameliorating Aß 
neurotoxicity, I performed a small-scale screen of transcription factors previously 
reported to co-activate dPGC-1 in regulating many metabolic processes. We have 
previously shown that Aß neurotoxicity leads to an arrhythmic sleep pattern (Niccoli 
et al., 2016). I confirmed this by demonstrating that over-expression of Aß disrupts 
the circadian clock via increasing the period tau. I also demonstrated that over-
expression of dPGC-1 ameliorates this neurotoxic phenotype. Mammalian PGC-1α 
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has been implicated in a second feedback loop of circadian clock control by co-
activating a transcription factor RORα (Liu et al., 2007). However its role in the 
Drosophila in a similar loop is still unknown. In order to examine this further I 
investigated the Par Domain Protein 1ε (PDP1ε), the transcription factor involved in 
second feedback loop of the circadian clock in Drosophila (Cyran et al., 2003). I 
demonstrated that dPGC-1 and PDP1ε interact to form a complex by Fluorescence 
Resonance Energy Transfer. Using genetic manipulation, I further showed that over-
expression of Pdp1ε in neurons can ameliorate Aß neurotoxic phenotypes in flies.  
 
Activation of dPGC-1 or Pdp1ε in neurons can ameliorate Aß neurotoxicity through 
activation of the UPRER. Therefore compounds potentially targeting the UPRER may 
offer therapeutic avenues for the treatment of AD. I therefore tested three compounds 
in Aß-expressing fly models. In collaboration with Dr. Sofola-Adesakin, we found 
that lithium, the main drug used in the treatment of bipolar disorder, rescued the toxic 
phenotypes in Aß-expressing flies by reducing protein synthesis (Sofola-Adesakin et 
al., 2014). I also found that metformin, the drug for treating type-2 diabetes, could 
rescue the shortened lifespan of Aß-expressing flies. I then collaborated with Dr 
Niccoli to investigate the mechanisms of this amelioration, and found that metformin 
reduces Grp78 protein levels, leading to activation of the UPRER (Niccoli et al., 2016). 
Another drug I tested in collaboration with Dr. Castillo-Quan and Dr. Kinghorn is 
rifampicin, a well-known antibiotic used for the treatment of tuberculosis and leprosy. 
Previous studies have suggested that rifampicin can reduce Aß oligomerization and 
improve the memory defects in an APP mouse model via improved autophagy-
lysosomal function (Umeda et al., 2016). In keeping with this I describe the 
neuroprotective effects of rifampicin in Aß-expressing flies.  
 
1.5.2 The role of PGC-1α in Drosophila models of Parkinson’s disease 
(Chapter 4) 
One of the main aims of my PhD work was to investigate the role of PGC-1α in 
familial PD. This work followed on from extensive studies suggesting that PGC-1α 
and mitochondrial dysfunction might play a central role in PD pathogenesis 
(Whitworth and Pallanck, 2009, Shin et al., 2011). In Chapter 4, I describe my work 
assessing the role of PGC-1α in Drosophila null mutants of parkin and PINK1. 
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1.5.3 PGC-1α-GABPα modulates ageing in Drosophila. (Chapter 5) 
Drosophila models that over-express dPGC-1 in the intestinal system show extended 
lifespan with improved intestinal homeostasis and mitochondrial function (Rera et al., 
2011). However the mechanisms of lifespan extension by dPGC-1 have not been fully 
explored. Mammalian GABPα is induced by PGC-1α in the regulation of 
mitochondrial biogenesis in skeletal muscle (Yang et al., 2014, Mootha et al., 2004). 
Drosophila GABPα is required for proper mitochondrial gene expression together 
with dPGC-1 in a nutrient-sensing manner (Tiefenböck et al., 2010, Baltzer et al., 
2009), suggesting the Drosophila homologue may share a conserved molecular 
function with its mammalian counterpart. I hypothesised that dGABPα may be 
regulated by dPGC-1 and therefore responsible for dPGC-1-mediated lifespan 
extension. In Chapter 5, I describe my work investigating the role of dGABPα, the 
homologue of human GA-binding protein α subunit (also called Nuclear respiratory 
factor 2α, NRF2α), in regulating longevity and healthy lifespan. I used a genome-
wide unbiased approach to interrogate the transcriptomes in response to over-
expression of dGABPα, in order to aid our understanding of the molecular 
mechanisms underlying lifespan extension. I performed RNAseq analyses, to assess 
how the transcriptional response of dGABPα activation correlates with other 
interventions that promote longevity in Drosophila.  
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Chapter 2 General methodology 
2.1 Drosophila melanogaster: strains and genetics 
One of the major advantages of working with the fruit fly Drosophila melanogaster is 
that there is a huge wealth of different laboratory stains and mutants. The Partridge 
laboratory has a large inventory of genetic stocks allowing appropriate use of and 
generation of different crosses. All stocks were kept at 18°C, while experimental 
crosses and transgenic flies were kept at 25°C and 65% humidity on a 12:12 light: 
dark cycle using standard sugar/yeast (SY) medium. Flies were reared at standard 
larval density (around 300 flies per 200 mL bottles) and eclosing adults were 
collected over a 4-hour period after which they were mated for 48 hours, before 
collecting females or males for experiments (Bass et al., 2007). 
 
2.1.1 White Dahomey (wDah) 
The background control stock white Dahomey (wDah) has been maintained in large 
population cages with overlapping generations since 1970. The wDah stock was 
derived by the incorporation of the w1118 mutation into the outbred Dahomey 
background by backcrossing (Bass et al., 2007). The wDah strain is naturally infected 
by the intra-cytoplasmic bacterium Wolbachia, which modulates the lifespan effects 
of the IIS pathway (Gronke et al., 2010, Ikeya et al., 2009, Negri, 2011). 
 
2.1.2 White 1118 (w1118) 
The w1118 Drosophila stock is an inbred and isogenic strain often used for 
neurodegeneration studies. This strain is also often used as a control in ageing studies 
to demonstrate that pro-longevity effects found in the wDah strain are independent of 
genetic background (Bjedov et al., 2010). 
 
2.1.3 Backcrossing 
Backcrossing of the transgenic lines was necessary to ensure that any differences 
between mutant and control flies are due to the expression of the transgene alone, and 
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not due to confounding mutations or insertional mutagenic effects (Partridge and 
Gems, 2007). Previous studies have demonstrated that insufficient standardization of 
the genetic background, and inappropriate backcrossing or use of inappropriate 
controls, produces artificial lifespan extension (Burnett et al., 2011, Toivonen et al., 
2007). For this reason, before the transgenic stocks could be used for experiments, 
they were backcrossed at least 6 generations into the desired background strain. In the 
first cross, transgenic males were mated with wild type female virgins, which results 
in the wild type cytoplasmic content (including the mitochondrial genome) being pass 
to the offspring. The offspring then were selected either by their visible phenotype 
(eye colour for example) or by PCR analysis following transgene/construct-specific 
sequences. After this initial cross virgin females were collected and crossed to wild 
type males, and this cross was repeated at least another five times until six 
backcrossing events were completed. Transgenic lines were then made homozygous 
or balanced and kept as a stock for experiments. Transgenic lines were normally 
refreshed by three generations following a similar protocol before re-use after 
extended periods of time.  
 
2.1.4 The GAL4-UAS system 
The GAL4-UAS system is considered one of the most powerful genetic tools to study 
gene expression and function in the fruit fly (Brand and Perrimon, 1993). Its major 
advantage is that it can restrict the expression of genes of interest in a cellular or 
tissue-specific manner using native gene promoters. The system has two parts: the 
GAL4 gene, encoding the yeast Saccaromyces cervisiae transcriptional activator 
protein GAL4, and the UAS (Upstream Activation Sequence), an enhancer to which 
GAL4 specifically binds to activate gene transcription. The GAL4 transgene is placed 
under the control of a native gene promoter, or driver gene, which is then only 
expressed in cells where the driver gene is usually active. For example, the elav-GAL4 
fly line will express the GAL4 protein under the elav promoter. Elav encodes for 
embryonic lethal abnormal vision, a pan-neuronal protein and is therefore a neuronal 
driver. Therefore GAL4 should only activate gene transcription where a UAS has 
been introduced. For example, when green fluorescent protein (GFP) is placed under 
UAS control, i.e. UAS-GFP, and this line is crossed with an elav-GAL4 line, the 
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offspring genotype elavGAL4>UAS-GFP will express GFP only in neurons 
(Osterwalder et al., 2001). 
 
2.1.5 The gene-switch system 
The gene-switch (GS) system uses the GAL4/UAS system with the restriction that the 
transcriptional activity depends on the presence of a steroid hormone or a chemically 
related compound (Osterwalder et al., 2001, Ford et al., 2007, Roman et al., 2001). In 
the GAL4/UAS system, the binding of the transcription factor GAL4 to UAS, results 
in the transcription of the UAS-linked transgene (Brand and Perrimon, 1993). In the 
GS system, GAL4 is fused with the regulatory domain of the human progesterone 
receptor (Osterwalder et al., 2001, Ford et al., 2007, Roman et al., 2001, Poirier et al., 
2008). In the absence of the activator mifepristone (RU486), the GAL4 protein and 
UAS transgene can coexist in the fly with only leaky weak expression of the 
transgene under the control of UAS. Only when these flies are fed with RU486, the 
GAL4-GS is able to bind to the UAS and therefore the transgene is induced (Figure 
2.1) (Osterwalder et al., 2001, Roman et al., 2001). 
 
Figure 2.1 The GeneSwitch expression systems 
This diagram illustrates the cross between a gene-switch driver (elavGS) and a UAS construct linked to 
the SNCA gene (UAS-SNCA) to obtain a line carrying both the driver and UAS line, which results in the 
following line: elavGS/+>UAS-SNCA/+. Flies only express the α-synuclein protein in the nervous 
system following ingestion of medium supplemented with RU486 (RU+). Flies with the same 
genotypes, but not fed RU486 (RU-), are used as genetic controls.  
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2.2 Drosophila food medium 
2.2.1 Sugar-yeast medium (SY) 
Our standard laboratory medium (SY) was used for the development and maintenance 
of all flies, unless otherwise stated. The SY medium was made in the following way: 
15 g of agar were dissolved in 700 mL distilled water by heating until boiling. After 
this, 100 g of autolysed yeast powder and 50 g of sugar were added until boiling. 170 
mL of distilled water were added to the mixture and it was then left to cool down. 
When the temperature of the mixture was between 50-60°C, 30 mL of nipagin (100 
g/L) and 3 mL propionic acid (both anti-fungal preservatives) were added. The food 
was then dispensed (4 mL per vial) into plastic vials and allowed to set at room 
temperature before storing at 4°C (Bass et al., 2007).  
 
2.2.2 Grape juice medium 
Grape plates were used as a surface for egg laying and collection. Collected eggs were 
subsequently dispensed into bottles containing SY medium. Grape plates were made 
as follows: 25 g agar were dissolved in 500 mL distilled water and brought to the boil. 
To this, 300 mL of red grape juice were added and the medium was brought to the 
boil again. After adding an additional 50 mL of distilled water the medium was 
allowed to cool to below 60°C. As with the SY medium 21 mL of nipagin (100 g/L) 
were added. The medium was dispensed into plastic petri dishes and allowed to set at 
room temperature before storing at 4°C. 
 
2.2.3 Starvation medium 
The starvation medium was prepared by adding 15 g of agar to 700 mL of distilled 
water. This was brought to the boil and cooled down before dispensing into vials. No 
additional ingredients (including anti-fungal) were added to avoid any potential 
source of nutrients. 
 
2.2.4 Dietary restriction 
For DR experiments a yeast dilution protocol was established as detailed below:  
Recipe for SY preparation for DR tent (1 litre of medium) 
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1. Agar was added to the initial volume of water (ddH2O) just before heating. 
Stirring was continuous throughout the preparation process to prevent any of 
the ingredients sticking to the saucepan.   
2. Just after boiling, sucrose was added and the mixture was brought to the boil 
again.  
3. The yeast was added and the mixture was brought to the boil again. The 
saucepan was then removed from  the heating source and the additional ddH2O 
was added to cool down the medium.   
4. Only after the medium reached a temperature below 60°C (preferably between 
50 and 58°C),  nipagin and propionic acid were added.   
5. The medium was then ready for dispensing.   
 
2.3 Fly husbandry and culturing 
2.3.1 Male and female separation 
Some anti-ageing interventions that extend lifespan are sex-specific, and are often 
confined to females in both Drosophila (Clancy et al., 2001) and mice (Selman et al., 
2009). In other cases the responses show some dimorphism, with the response 
attenuated in males (Bjedov et al., 2010, Miller et al., 2014). Therefore, it is a 
common practice in ageing studies to test males and females separately (Partridge and 
Gems, 2007). Additionally, continuous mating can impact several physiological 
parameters, including survival (Barnes et al., 2008, Chapman and Partridge, 1996). 
Female and male flies can be distinguished very easily under a microscope whilst flies 
are anesthetized with CO2 (Greenspan, 2004). For most experiments only the female 
flies were used, though some phenotypes were also corroborated in males to ensure 
sex-independent effects. Female and male flies were sorted using a fine paintbrush 
while anesthetized. Flies were usually separated at day 2 post-eclosion after a 48-hour 
mating period. 
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2.3.2 Virgin collection 
To obtain the desired genotypes, it was often necessary to cross male and female flies 
of different genotypes. This ensured the transfer of at least one copy of the chosen 
transgene to the progeny. This was achieved by collecting unmated female flies (or 
virgins). Virgin collection was carried out for backcrossing and to obtain the desired 
genotypes for experiments. Female Drosophila flies do not respond to courting males 
during the first 6 hours after eclosion at 25°C (Greenspan, 2004). Therefore newly 
emerged female flies were collected within 6 hours after clearing rearing bottles.   
 
2.4 Drosophila handling and survival 
2.4.1 Lifespan assays  
An important determinant for ageing analysis is to ensure that the parents of the 
experimental flies were the same age at egg laying and reared under the same 
conditions. In this way the effects of parental age on lifespan were controlled (Priest 
et al., 2002). 'Egg squirt' protocols were undertaken to ensure that all flies in the 
experiment were raised at similar larval densities (~300 eggs per bottle containing 70 
mL of food), thereby avoiding any effects of larval density on lifespan (Priest et al., 
2002). Flies were allowed to lay eggs for less than 24 hours on grape medium plates, 
with live yeast paste to encourage mating. The eggs were then collected from the plate 
by washing with phosphate buffered saline (PBS) solution and collected into falcon 
tubes. The eggs were allowed to settle to the bottom of the tube. Using a 100 µL 
Gilson pipette, ~18-20 µL of egg suspension was dispensed into 200 mL glass bottles 
containing 70 mL SY medium. This equated to ~300 eggs per bottle.  
After 10 days of development flies emerged from their pupae and were then 
transferred into fresh bottles. The flies were then allowed to mate in these new bottles 
for 48 hours. After this flies were sorted using a paintbrush under CO2 anesthesia, and 
divided into vials (15 flies per vial). 
Flies were then transferred to fresh food vials three times a week throughout life. The 
number of dead flies found during each transfer was recorded. Accidental death and 
escapees were distinguished from deaths, and were censored from the experiment. 
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From these data, a survivorship graph was generated, making it possible to compare 
survival curves over time between different genotypes or experimental conditions. 
Lifespan curves were analyzed using a log-rank test. 
 
2.4.2 Stress assays 
For stress assays lifespan experiments were performed using different chemicals to 
induce cellular stress.  
2.4.2.1 Paraquat  
Flies were kept under pre-determined conditions similar to those in the lifespan assays 
for a fixed period of time, after which they were transferred onto food containing 
paraquat. 1 M paraquat containing food was prepared by dissolving N, N′-dimethyl-4, 
4′-bipyridinium dichloride (paraquat, Sigma 856177) into ddH2O. This was then was 
added to a 0.0 SY (agar/sugar) medium to achieve a final concentration of 10 mM. All 
stress assays were tested without yeast in the medium to avoid interaction between 
yeast and the stressor. The medium used has all the other components of the standard 
medium including sucrose. Flies were typically assayed with 15 flies per vial. Deaths 
were scored every 4 hours after the detection of the initial wave of death. Data was 
plotted as a survival curve and analysed using a log-rank test. 
2.4.2.2 Hydrogen Peroxide (H2O2) 
For the preparation of H2O2 containing medium, a 30% H2O2 stock solution from 
Sigma was diluted into a 0.0 SY medium to give a final concentration of 2.5% or 5%. 
Flies were typically assayed with 15 flies per vial. Deaths were scored at least 3 times 
per day, plotted as a survival curve and analyzed using a log-rank test.  
2.4.2.3 Phenobarbital  
Phenobarbital (Sigma P1636) was prepared by directly adding the salt to 0.0 SY 
medium to obtain a final concentration of 6%. 
2.4.2.4 Tunicamycin 
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Flies were tipped into vials containing 1% agar, 1.5% sucrose, and 10 mg/l of 
tunicamycin. Dead flies were scored at regular intervals, and lifespan curves were 
compared using a log-rank test.  
 
2.4.3 Mifepristone (RU486) 
As explained above the GeneSwitch system uses mifepristone (RU486) as an inducer 
of gene expression in the presence of the GeneSwitch driver (Osterwalder et al., 2001, 
Poirier et al., 2008). Our laboratory has optimised the dose of RU486 that produces 
effective transgene expression without impairing longevity, fecundity or metabolism. 
RU486 (Sigma, M8046) was dissolved in 100% ethanol and supplemented to standard 
SY medium before dispensing into vials. Food supplemented with RU486 was stored 
at 4°C until use. 
 
2.5 Behavioural investigations 
2.5.1 Fecundity assay  
Fecundity has historically been heavily linked to longevity (Partridge et al., 2005). 
Although this association has been uncoupled (Grandison et al., 2009), interventions 
to prolong lifespan without affecting fecundity are still limited. To assess fecundity 
female flies were allowed to lay eggs for a period of 24 hours in vials containing 
standard medium. Vials containing eggs were frozen and kept at -20°C for a short 
time until eggs were counted using a hand held counter. The total number of eggs laid 
was divided by the number of flies per vial and a t-test was used to determine 
statistical value.  
 
2.5.2 Climbing assay (negative geotaxis) 
Age-related decline in locomotor ability represents a behavioural measurement of 
neuronal health. It is an insightful measurement read-out of the functional capacity of 
flies that is also sensitive to some anti-ageing interventions (Gargano et al., 2005, 
Jones et al., 2009). The climbing assay involved the placement of 15 flies in a 35 cm 
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column (1.5 cm diameter) with a conic bottom end. Flies were tapped down and 
observed during a 45 second period. The column was separated into three areas: top, 
middle, and bottom by two lines: one was 10 cm from top and the other was 3 cm 
from bottom. After 45 seconds the flies located in each of these three sections were 
recorded. Each column was evaluated three times to minimized trial error and a 
minimum of three vials per genotype/condition was assessed. The numbers of flies in 
the top (ntop) and at the bottom (nbottom) were used to obtain a motor performance 
index (PI). This was calculated as ½ (ntot + ntop –nbottom /ntot). The PI was plotted 
against time per each genotype and condition. Statistical analysis was performed in R 
using ordinal logistical regression, using the individual heights for each fly as data 
points.  
 
2.6 Biochemistry and molecular biology methods 
2.6.1 DNA extraction and Single-Fly Polymerase Chain Reaction 
(PCR) 
To analyse single flies for specific mutations one fly was placed in a 1.5 mL 
eppendorf and squashed with a blue pestle. 50 µL of squish buffer (990 µL of squish 
buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA, 25 mM NaCl) + 10 µL of proteinase 
K) were then added. The liquid was transferred to a PCR tube and incubated for 1 
hour at 37°C and then at 95°C for 10 min. The sample was spun, after which it was 
either stored at 4°C or prepared for PCR.  
The PCR reaction consisted of (per fly) 2 µL of extracted DNA, 2.5 µL 10X PCR 
buffer (15 mM MgCl2), 0.5 µL dNTPs (10 mM), 0.5 µL of each primer (10 mM), 0.25 
µL TAQ polymerase and 18.75 µL of ddH2O. All reagents were obtained from 
Qiagen, UK. The PCR cycles were run using a thermal cycler (Eppendorf UK 
limited), with the following protocol: 1 cycle of 94 °C for 15 min (initial melting step 
to denature the hot-start TAQ polymerase), 30 to 35 cycles of 95 °C for 30 sec (for 
denaturing DNA), 50-60 °C for 30 sec (to anneal the primers), and 72 °C for 2 min 
(elongation step). Finally, 1 cycle of 72 °C for 10 min was performed for the final 
elongation phase. Samples were then either stored at 4 °C, -20 °C or run on an 
agarose gel.  
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2.6.2 Gel electrophoresis 
1 to 2 grams of agarose (Sigma, UK) were dissolved in 100 mL of TAE (Tris base, 
acetic acid, EDTA) buffer and heated in a microwave, until close to boiling, after 
which it was slowly cooled down. Once cooled 5 µL of ethidium bromide was added 
to the agar solution. The mixture was placed in a gel tray and a comb was added to 
create wells for the sample. The gel was allowed to set for 1 hour. A marker was 
added to the first well and samples were added in conjunction with 6X loading dye 
(40% glycerol, 6X TBE buffer, and 0.25% bromophenol blue) at a final volume of 20-
25 µL. Electrophoresis was performed between 70-100 V as necessary to separate the 
DNA bands. The samples were then visualized under the UV light using a UV trans-
illuminator.  
 
2.6.3 Quantitative Real Time PCR (qRT-PCR) 
Total RNA was extracted from 15 whole flies or 25 fly heads using TRIzol® 
(GIBCO) according to the manufacturer’s instructions. The concentration of total 
RNA purified for each sample was measured using Nano Drop2000 (Thermo 
Scientific). 5 µg of total RNA was then subjected to DNA digestion using DNAse I 
(Ambion), immediately followed by reverse transcription using the Superscript II 
system (Invitrogen) with oligo (dT) primers. Quantitative PCR was performed using 
the PRISM 7000 sequence-detection system (Applied Biosystems) and SYBR Green 
(Molecular Probes) by following the manufacturer’s instructions. Each sample was 
analyzed in duplicate with both target and reference (RP49) gene primers in parallel. 
The values are the mean of three or four independent biological repeats ± SEM.  
 
2.6.4 Western blotting 
10 female flies/15 fly heads were homogenized in 200 uL/40 uL of 2X SDS Laemmli 
loading sample buffer (120mM Tris-HCl pH6.8, 20% glycerol, 4% SDS) containing 
5% β-mercaptoethanol. Samples were heated at 95 °C for 5 minutes after which 
extracts were cleared by centrifugation. 10 µL of protein extract were loaded and 
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separated on pre-cast 4%-12% Invitrogen Bis-Tris gels (NP0322). After separation, 
the proteins were transferred to a nitrocellulose membrane in Tris-glycine buffer 
supplemented with 10% ethanol. Membranes were saturated in 5% milk in TBS-T 
(Tris-buffered saline with 0.05% Tween-20) for 1 hour at room temperature (RT) and 
then incubated with a selected primary antibody in saturation solution overnight. After 
5x washes in TBS-T, they were then incubated with an appropriate secondary 
antibody for 1 hour at RT. Bands were visualized with Luminata Forte (Millipore) and 
imaged with ImageQuant LAS4000 (GE Healthcare Life Sciences). Quantification 
was carried out with ImageJ.  
 
2.6.5 Protein Quantification 
The Bicinchoninic acid protein (BCA) assay from Thermo Sciencific (23225) was 
used to determine the protein concentration of biological samples. BSA albumin 
standards were diluted using the same diluent as the samples. The following standard 
concentrations were prepared: 2000, 1500, 1000, 750, 500, 250, 125, 25, 0 µg/mL. 
The working reagent (WR) was prepared by mixing 50 parts of BCA reagent A with 1 
part of BCA reagent B. 25 µL of each standard and sample was dispensed twice into a 
microplate well. To each well 200 µL of the WR was added by using a multi-channel 
pipette and mixed thoroughly on a plate shaker for 30 seconds. The plate was then 
covered and incubated at 37 °C for 30 mins. The plate was then allowed to cool to 
room temperature. The absorbance was then measured at 562 nm on a plate reader. 
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Chapter 3 PGC-1 regulates the ER-
unfolded protein response and 
ameliorates Aβ toxicity 
3.1 Summary 
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and is 
neuropathologically characterised by the extracellular deposition of aggregates of the 
Aβ protein. The misfolding of Aβ is associated with cellular defects in brain energy 
metabolism, hypersensitivity to stress and proteostatic failure (Musiek and Holtzman, 
2015). Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-
1α) is a transcriptional coactivator that regulates energy homeostasis within the cell, 
and is the master regulator of mitochondrial biogenesis (Puigserver and Spiegelman, 
2003).  The possible relevance of this gene in the pathogenesis of AD was identified 
with the demonstration that PGC-1α gene expression levels are decreased in the post-
mortem brain tissue of AD patients (Qin et al., 2009). Consistent with this I have 
shown that up-regulation of dPGC-1 in the neurons of a Drosophila model of Aβ 
toxicity rescues lifespan, behavioral phenotypes and circadian rhythm disruption. 
Moreover I demonstrated that the amelioration of Aβ toxicity is associated with 
improved mitochondrial homeostasis and activation of the unfolded protein response 
(UPR). Specifically, dPGC-1 increased electron transport chain (ETC) activity and 
ATP production. Moreover, expression of dPGC-1 also protected Aβ-expressing flies 
against oxidative stress and was shown to regulate the levels of mitochondrial 
chaperones in response to Aβ, thereby modulating mitochondrial UPR (UPRmt). In 
addition, over-expression of dPGC-1 negatively regulated Grp78 protein levels, 
indicative of increased endoplasmic reticulum UPR (UPRER). Therefore through UPR 
activation in the mitochondrial matrix and up-regulation of ER-mediated protein 
homeostasis and quality control, dPGC-1 over-expression ameliorated the Aβ 
associated neurotoxic phenotypes. Lastly I demonstrated that dPGC-1 physically 
interacted with Par Domain Protein 1ε (PDP1ε) in the Drosophila brain, and that 
genetic activation of Pdp1ε in neurons partially rescued the shortened lifespan of Aβ-
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expressing flies via activation of UPRER. In keeping with this, I demonstrated that 
rifampicin, a well-known antibiotic, also activated the UPRER and rescued 
neurotoxicity in Aβ flies. These findings suggest that either increasing intraneuronal 
PGC-1α levels, or oral administration of rifampicin, could offer therapeutic benefits in 
AD by increasing the UPRER. 
 
3.2 Introduction 
AD is a progressive neurological disorder characterized by memory loss, cognitive 
decline and neuronal death predominantly in the cerebral cortex and hippocampus. 
Typical neuropathology includes extracellular deposits of amyloid-ß aggregates and 
intracellular inclusions of hyper-phosphorylated tau aggregates (Crews and Masliah, 
2010). The disease progression is thought to be triggered by accumulation of Aß 
oligomer peptides, generated through the abnormal processing of the amyloid 
precursor protein (APP). This results in a neurotoxic cascade of events, including 
mitochondrial dysfunction, oxidative stress, proteostatic failure, circadian disruption, 
inflammation, tau hyper-phosphorylation, and eventual neuronal death. Some of these 
pathways also directly influence APP metabolism and Aß accumulation (Hardy and 
Higgins, 1992, Musiek and Holtzman, 2015). Whether these pathogenic processes are 
the main drivers of disease in AD is controversial, however, what is clear, is that they 
all represent possible therapeutic targets in the treatment of AD. Genetic or 
pharmacological interventions targeting these modulators may provide excellent 
therapeutic avenues.  
Neurodegenerative diseases are characterized by the neuronal accumulation of 
insoluble aggregates of mis-folded proteins in the endoplasmic reticulum (ER) (Hetz 
and Mollereau, 2014). Activation of the UPRER allows cells to either restore protein 
homeostasis or to enter apoptosis as a protective response. Three well-characterized 
UPR sensors mediate this response: PERK (protein kinase RNA-like ER kinase), 
inositol-requiring enzyme 1 (IRE1), and transcription factor 6α (ATF6α) (Wu and 
Kaufman, 2006, Hetz and Mollereau, 2014). Under normal physiological conditions, 
these trans-membrane signalling components are bound and inhibited by GRP78. 
During ER stress, mis-folded proteins titrate down the levels of Grp78, thus activating 
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the signalling cascades downstream of ATF6α, IRE1 and PERK. ATF6α is 
transported to the Golgi where it is processed to produce a cytosolic fragment, which 
operates as a transcription factor, regulating X-box binding protein 1 (Xbp1) and 
Grp78 mRNA levels. Active IRE1 induces the splicing of Xbp1 mRNA, leading to the 
expression of the active transcription factor Xbp1. PERK phosphorylates eukaryotic 
translation initiation factor 2α (elF2α), and induces the expression of ATF4. All of the 
above leads to the up-regulation of ER chaperones, ER-associated protein 
degradation, autophagy, redox reactions, and eventually apoptosis. 
Increasingly evidence has indicated that disruptions in brain energy metabolism are 
critically involved in the pathogenesis of AD (Kapogiannis and Mattson, 2011), 
including mitochondrial damage (Galindo et al., 2010, Wu et al., 1999, Calkins et al., 
2011), a decline in glucose metabolism (Mosconi et al., 2008), and oxidative damage 
(Siegel et al., 2007, Head et al., 2001). The PGC-1 family of transcriptional co-
activators, including the founding member PGC-1α (PPARγ co-activator 1), and its 
homologue PGC-1ß and PRC (PGC-1-related co-activator), are important for the 
normal functioning of mitochondrial biogenesis (Mootha et al., 2004, Scarpulla, 
2008), adaptive thermogenesis (Puigserver and Spiegelman, 2003), hepatic 
metabolism (Puigserver and Spiegelman, 2003, Li et al., 2007b), stress defence (Valle 
et al., 2005, St-Pierre et al., 2006), and circadian rhythms in metabolically active 
organs (Liu et al., 2007). Moreover, PGC-1α has been show to modulate ageing and 
diabetes, the two main risk factors for developing AD (Rogers et al., 2012, Willette et 
al., 2015). The PGC-1 family was reported in animal models as a novel modulator of 
lifespan (Rera et al., 2011). Furthermore, PGC-1α-responsive genes involved in 
oxidative phosphorylation have been shown to be reduced in the muscles of patients 
with type 2 diabetes mellitus (Mootha et al., 2003, Patti et al., 2003), suggesting its 
importance in ageing, human diabetes, and possibly in the development of AD. 
Indeed, the age-related decline in protein homeostasis and neuronal stress response 
signalling might contribute to AD progression (Taylor and Dillin, 2011, Hipp et al., 
2014), and PGC-1α, which has been implicated in the stress defence system, and in 
protein quality control (St-Pierre et al., 2006, Wu et al., 2011), might therefore 
represent a promising therapeutic target. 
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PGC-1α mutant mouse models display neurodegenerative pathology in the brain and 
behavioural abnormalities, highlighting its protective role in neurons (Leone et al., 
2005, Lin et al., 2004, Lucas et al., 2014, St-Pierre et al., 2006). Indeed, PGC-1α is 
neuroprotective in animal models of several neurodegenerative diseases characterised 
by abnormal protein aggregation, including Huntington’s disease (Cui et al., 2006, 
Weydt et al., 2006, Tsunemi et al., 2012) and amyotrophic lateral sclerosis (Zhao et 
al., 2011, Liang et al., 2011). Human studies report that PGC-1α activity negatively 
correlates with the age of onset of AD (Helisalmi et al., 2008) and PD (Clark et al., 
2011). In addition, PGC-1α and ATP are remarkably decreased in AD patient brains 
(Kapogiannis and Mattson, 2011, Hoyer, 1996, Qin et al., 2009). However, the effect 
of elevating PGC-1α in AD animal models is not well established, with some studies 
showing a protective role of PGC-1α in mitochondrial dysfunction (Sheng et al., 
2012) and Aß accumulation (Katsouri et al., 2011), while another study demonstrated 
opposite effects (Dumont et al., 2014). 
 
The question of whether reduced PGC-1α is causal in the neurodegeneration of AD is 
yet to be determined. A reduction in PGC-1α could contribute to disease progression 
in several ways. It may cause mitochondrial dysfunction and reduced ATP, as PGC-
1α is the master regulator of the electron transport chain to generate ATP synthesis. 
Reduced PGC-1α also leads to increased sensitivity to stressors by ROS, thereby 
impairing mitochondrial homeostasis (St-Pierre et al., 2006, Lu et al., 2014, Haynes 
and Ron, 2010). PGC-1α deficiency may also exacerbate age-related disturbances in 
proteostasis and neuronal stress response pathways (Taylor and Dillin, 2011, Hipp et 
al., 2014, Wu et al., 2011). Mammalian PGC-1α regulates the circadian clock and 
therefore a reduction in this transcription factor may contribute to circadian rhythm 
disruption (Liu et al., 2007). I therefore investigated these pathways to dissect the role 
of PGC-1α in the pathogenesis of AD.  
 
I studied the role of PGC-1α in the pathogenesis of AD, using a model of Aß toxicity 
in the fruit fly Drosophila melanogaster (Sofola et al., 2010). Drosophila is a 
powerful genetic tool to study neurodegeneration (McGurk et al., 2015, Fernandez-
Funez et al., 2015), with distinct brain structures and analogous cell types to those in 
the human brain, as well as a blood brain barrier. I utilised the fly AD model that 
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expresses pathogenic Arctic Aß1-42, which displays a shortened lifespan, behaviour 
defects as well as neurodegeneration (Sofola et al., 2010). Moreover, Drosophila 
possesses a single homologue of the mammalian PGC-1 family, Spargel (dPGC-1), 
(Tiefenböck et al., 2010), therefore providing a system in which PGC-1 function can 
be analysed in the absence of redundancy. 
 
In order to determine whether neuronal PGC-1 contributes to the pathogenic cascades 
downstream of toxic Aß, I genetically over-expressed dPGC-1 in the neurones of flies 
over-expressing Arctic Aß1-42 also in neuronal tissue. I demonstrated that dPGC-1 
over-expression partially rescued the Aß-induced neurotoxic phenotypes, including 
lifespan, climbing ability and circadian rhythm, without affecting the levels of Aß 
peptides. In addition, over-expression of dPGC-1 increased mitochondrial membrane 
potential and ATP levels, compensating for the mitochondrial defects mediated by 
Aß. Furthermore, activation of dPGC-1 ameliorated Aß-induced hypersensitivity to 
oxidative stress, and regulated mitochondrial chaperones in response to Aß, 
suggesting improved mitochondrial proteostasis. dPGC-1 also down-regulated the 
expression of Grp78, the negative master regulator of UPRER, suggesting activation of 
the UPRER, leading to improved proteostasis and restoration of ER function. In 
addition, I identified a novel transcriptional complex of PGC-1, the Par Domain 
Protein 1ε (PDP1ε), and demonstrated that they physically interact in fly brain using 
FRET (Fluorescence Resonance Energy Transfer). Activation of Pdp1ε ameliorated 
the shortened lifespan of Aß-expressing flies, likely through activation of the UPRER. 
Consistent with this, treatment of Aß flies with the antibiotic rifampicin, induced the 
UPRER by decreasing Grp78 levels, and rescued the toxic phenotypes associated with 
Aß in vivo. Taken together, our results highlight the potential therapeutic benefits of 
up-regulating the UPRER in AD, either via increasing intraneuronal PGC-1α or PDP1ε 
or via the use of pharmacological activators such as rifampicin.  
 
3.3 Results: 
3.3.1 dPGC-1 over-expression ameliorated Aβ42 toxicity 
To investigate the role of dPGC-1 in Aβ-mediated neurotoxicity I assessed the effect 
of over-expression of dPGC-1 on a number of Aβ-induced neurotoxic phenotypes. 
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Firstly I confirmed the over-expression of dPGC-1 in the heads of Aβ-expressing flies 
using qRT-PCR (Figure 3.1). In order to confirm that dPGC-1 was not mediating its 
effect through a change in Aβ load, I demonstrated that dPGC-1 over-expression did 
not affect Aβ protein or mRNA levels in fly heads (Figure 3.2 and 3.3) 
 
 
Figure 3.1 mRNA expression levels of dPGC-1 in Aß-expressing flies 
qRT-PCR analysis revealed that 30-day-old flies co-expressing Aβ + dPGC-1 in the neural tissue using 
the inducible elav-GS driver (Aβ; dPGC-1 RU+) displayed dPGC-1 mRNA levels (relative to a control 
endogenous gene, RP49) are significantly higher than in non-expressing Aβ + dPGC-1 flies (Aβ; 
dPGC-1 RU-) and induced and non-induced Aβ-expressing flies (Aβ; RU+ and Aβ RU-). The bars 
represent the mean ± SEM (n=4, ***p<0.001 by two-way ANOVA Newman-Keuls test).   
 
 
Figure 3.2 Aß protein levels were not significantly reduced by dPGC-1 over-expression 
dPGC-1 over-expression had no significant effect on Aß protein levels as measured by an ELISA assay 
on the heads of 30-day-old flies expressing Aß (Aß, red bar, RU+) compared with Aß + dPGC-1 co-
expressing flies (Aß; dPGC-1, green bar, RU+). Bars represent the means ±SEM (n=3, **p<0.01; 
***P<0.001 by two-way ANOVA Newman-Keuls test). 
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Figure 3.3 Over-expression of dPGC-1 did not affect Aß mRNA levels 
Over-expression of dPGC-1 did not alter Aß mRNA levels (relative to an internal control gene RP49) 
in the heads of 30-day-old flies compared to controls as measured by qRT-PCR. Bars represent the 
means ±SEM (n=3, ***p<0.001 by two-way ANOVA Newman-Keuls test).  
 
 
Over-expression of dPGC-1 in the neural tissue of adult flies using an inducible 
elavGS driver significantly extended the lifespan of both female and male Aβ-
expressing flies (Figure 3.4 A and B) (median lifespan was extended by 28% in 
females, p = 1.22354 x 10-17 and 8% in males, p<0.001). dPGC-1 over-expression 
also protected against Aβ-induced climbing defects, a behavioral measurement for 
neuronal health (Figure 3.5).  
 
Circadian rhythms, which have been found disrupted in AD patients and Drosophila 
Aβ-expressing models (Harper et al., 2005, Blake et al., 2015, Long et al., 2014), are 
directly controlled by neuronal activity. Circadian rhythm is a biological process that 
displays an endogenous, entrainable oscillation that completes one cycle (tau) in 24 
hours and is driven by the circadian clock located in the suprachiasmatic nucleus in 
humans. I demonstrated, in keeping with previous work (Long et al., 2014, Blake et 
al., 2015), that Aβ-expressing flies show an increase in the period tau compared to 
non-induced controls, suggesting an impaired circadian clock. Over-expression of 
dPGC-1, however, restored the period to control levels (Figure 3.6), suggesting an 
improved circadian clock. Taken together our results suggest that increasing dPGC-1 
in neurons ameliorates Aβ-induced toxicity. 
A 
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B 
     
Figure 3.4 Over-expression of dPGC-1 in neurons extended the lifespan of Aß-expressing flies. 
Survival curves of female (A) and male (B) flies expressing Aß or Aß + dPGC-1 in adult neurons 
(RU+) and non-induced controls (RU-) (p < 2 x 10-17 vs. Aß RU+ and Aß; dPGC-1 RU+ female flies by 
log-rank test; p < 0.001 vs. Aß RU+ and Aß; dPGC-1 RU+ male flies by log-rank test), n=150 flies per 
conditions. 
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Figure 3.5 Over-expression of dPGC-1 in Aß-expressing flies partially ameliorated the age-
dependent climbing defects. 
Co-expression of dPGC-1 in Aß-expressing female flies results in greater climbing ability than in non-
induced controls. (P < 2 x 10-16 Aß RU+ vs. Aß; dPGC-1 RU+ by ordinal logistic regression).  
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Figure 3.6 Over-expression of dPGC-1 in Aß-expressing flies rescued the defects in circadian 
rhythm 
(Above) Actograms for the locomotor activity rhythms of 21-day-old male flies expressing Aß or Aß + 
dPGC-1 in adult neurons (RU+) and un-induced controls (RU-). This data was recorded over 5 days 
under 12:12 LD conditions followed by 5 days in DD conditions in Trikinetics Drosophila Activity 
monitors. (Below) Mean free-running periods under DD conditions of the same flies were calculated 
using autocorrelation, plotted as means ±SEM (n=32, *p < 0.05, ***p < 0.001 by Two-way ANOVA 
Newman-Keuls test). This experiment was performed in collaboration with Dr Anna Tillman.  
 
 
To further explore the mechanisms by which dPGC-1 improves the health-span of 
Aβ-expressing flies, I measured the ATP concentrations in whole flies. I found 
reduced ATP levels in Aβ-expressing flies, with restoration towards control levels 
when dPGC-1 was co-expressed (Figure 3.7), suggesting an improvement in steady 
state of homeostasis.  
 
 
Figure 3.7 Over-expression of dPGC-1 in Aß-expressing flies ameliorated the reduction in ATP 
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ATP levels were reduced in 15-day-old whole flies expressing Aß in neurons using the elavGS driver 
(elavGS>UAS-Aß, red bar, RU+) compared with control non-induced flies (elavGS>UAS-Aß, black bar 
RU-). ATP levels measured in flies co-expressing Aß and dPGC-1 (elavGS>UAS-Aß/UAS-dPGC-1, 
green bar, RU+) in adult neurons demonstrated that dPGC-1 gain-of-function partially ameliorated the 
decreased ATP levels associated with Aß-expression. The bars are plotted as the means ±SEM (n=7), 
**p<0.01 by two-way ANOVA Newman-Keuls test. The genotypes used were: elavGS>UAS-Aß; 
elavGS>UAS-Aß/UAS-dPGC-1. 
 
 
3.3.2dPGC-1 extended the lifespan of Aβ flies beyond the maximum 
achieved by DR 
DR, an intervention involving the chronic reduction of food intake without 
malnourishment, is the most robust environmental method known to extend lifespan 
in a wide range of evolutionarily diverse organisms from yeast to mammals (Fontana 
et al., 2010, Katewa and Kapahi, 2010, Colman et al., 2009). In addition to its pro-
longevity effects, DR has also been shown to improve healthy lifespan in mice, 
monkeys and humans (Fontana et al., 2010, Ikeno et al., 2006, Maeda et al., 1985, 
Colman et al., 2014, Mattison et al., 2012). Long-term DR results in an improvement 
in several markers of health, and reduces the risk of developing age-related disorders 
such as neurodegeneration (Heilbronn et al., 2006, Cava and Fontana, 2013, Masoro, 
2003). As a result of the robust effects of DR, and its strong conservation across 
different species, unravelling the precise mechanisms linking this intervention to 
lifespan extension will provide useful insights into the mechanisms of ageing and age-
related neurodegeneration.  
 
I showed that over-expression of dPGC-1 in fly neurons extended lifespan in Aβ-
expressing flies (Figure 3.4). Other studies also suggested dPGC-1 is a modulator for 
longevity in Drosophila (Rera et al., 2011), however the mechanism has not been 
fully elucidated. To investigate whether lifespan extension mediated by dPGC-1 in 
Aβ-expressing flies involves a DR-like mechanism, I carried out a lifespan analysis 
using a DR-tent (varying concentrations of yeast in the food). If over-expression of 
dPGC-1 in Aβ expressing neurons extends lifespan like a true DR mimetic, the 
lifespan under the dietary conditions where lifespan has already been maximized will 
not be further extended or may even be shortened. If on the other hand dPGC-1 
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extends lifespan through overlapping mechanisms with DR, it might still further 
extend lifespan in the optimised DR condition, however, the maximum benefit on 
lifespan may occur with full feeding. Interestingly I found that over-expression of 
dPGC-1 in neurons extends both median and maximum lifespan in all yeast 
conditions compared to Aβ-expressing flies (Figure 3.8), suggesting that dPGC-1 
extends lifespan via an additive effect to DR. Interestingly, dPGC-1 over-expression 
achieved the maximum lifespan extension in full-feeding, indicating an overlapping 
mechanism with DR.  Taken together, dPGC-1 over-expression in neurons 
ameliorates the shortened lifespan of Aβ flies through mechanisms partially 
overlapping with those of DR.   
 
 
Figure 3.8 Over-expression of dPGC-1 increased the lifespan of Aβ flies irrespective of food 
concentration 
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Over-expression of dPGC-1 in neurons increased (A) the median and (B) the maximum lifespan in Aβ-
expressing female flies across different yeast concentrations in SY food. Plotted are median lifespan 
values for Aβ-expressing flies (blue line) and Aβ + dPGC-1 co-expressing flies (red line) against yeast 
concentration (0.1 x, 1.0 x, and 2.0 x yeast) in SY food supplemented with 200 µM RU.  Flies co-
expressing Aβ + dPGC-1 had significantly increased lifespan at each yeast concentration compared to 
Aβ-expressing flies (***p<0.001, log-rank test). For example, expression of dPGC-1 increased the 
median lifespan of Aβ-expressing flies by 17% and maximum lifespan by 24% in 1.0 x SY DR food, 
and increased median lifespan by 19% and maximum lifespan by 37% under 2 x SY full feeding food. 
The genotypes used were: elavGS>UAS-Aß; elavGS>UAS-Aß/UAS-dPGC-1. 
 
3.3.3 dPGC-1 over-expression improved mitochondrial function in Aβ 
flies 
PGC-1α affects many cellular processes, and therefore may rescue Aβ toxicity 
through a number of different mechanisms. Aβ toxicity has been linked to 
mitochondrial dysfunction, impaired energy metabolism and oxidative damage 
(Garcia-Escudero et al., 2013, Lustbader et al., 2004, Abramov et al., 2004). PGC-1α 
is the master regulator of mitochondrial biogenesis and oxidative phosphorylation 
through co-activation of nuclear receptors (Mootha et al., 2004, Tiefenböck et al., 
2010, Rera et al., 2011, Puigserver and Spiegelman, 2003). PGC-1 regulates 
mitochondrial density in mammalian primary neurons (Wareski et al., 2009), the fly 
fat body (Tiefenböck et al., 2010), and the fly gut (Rera et al., 2011). I therefore asked 
whether dPGC-1 induction increases mitochondrial biogenesis in fly neurons by 
measuring the amount of mitochondrial DNA (mtDNA) relative to that of nuclear 
DNA (nDNA). I demonstrated that Aβ expression lead to a significant reduction in 
mtDNA (Figure 3.9). This result parallels the observation of mtDNA deletions or 
mutations in AD patients’ brains (Bender et al., 2008, Coskun et al., 2004). Over-
expression of dPGC-1 in neurons did not rescue this phenotype (Figure 3.9).  
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Figure 3.9 Mitochondrial DNA was reduced in Aβ and dPGC-1 expressing flies 
Mitochondrial DNA (mtDNA), relative to the nuclear DNA (nDNA) amplicon was measured by qRT-
PCR in fly heads expressing Aß or Aß + dPGC-1 in adult neurons (RU+) and in un-induced controls 
(RU-) at 30-days of age. The bars represent the means ± SEM (n=4, *p<0.05 by ANOVA Newman-
Keuls test, two-way ANOVA shows p>0.05 when comparing Aß response to RU relative to Aß; 
dPGC-1 response to RU). The genotypes used were: elavGS>UAS-Aß; elavGS>UAS-Aß/UAS-dPGC-
1. 
 
Changes in mitochondrial DNA copy number do not necessarily reflect changes in the 
activity of the electron transport chain (ETC) (Tiefenböck et al., 2010). I therefore 
investigated whether up-regulation of dPGC-1 in neurons can increase ETC activity 
in Aβ-expressing flies. The ETC consists of a series of enzymes that transfer electrons 
from donors to acceptors via redox reactions, to create an electrochemical proton 
gradient, the mitochondrial membrane potential (ΔΨM), which is the driving force for 
the synthesis of adenosine triphosphate (ATP) by the F1F0-ATP synthase. To assess 
the mitochondrial membrane potential, I measured TMRM fluorescence in Aβ-
expressing fly brains, and found a significant increase in ΔΨM compared to controls 
(Figure 3.10). Hyperpolarization of mitochondria has previously been described in 
many neurodegenerative disorders, as a compensatory response to certain deficiencies 
in ETC enzymatic activity. For example, this has been observed in PD patient 
fibroblasts carrying a PINK1 mutation (Abramov et al., 2011) and in neurons carrying 
a severe mtDNA mutation, leading to defective complex I of the ETC (Abramov et 
al., 2010). In our study, mitochondria from Aβ-expressing flies display 
hyperpolarized mitochondrial membranes, likely in response to Aβ toxicity and 
reduced mtDNA, which encodes the subunits of the ETC components. Surprisingly, 
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dPGC-1 over-expression increased brain tissue TMRM fluorescent intensity even 
more than in flies expressing Aß alone (Figure 3.10), suggesting that dPGC-1 acts to 
rescue Aβ toxicity by increasing the hyperpolarising compensatory response.  
 
Figure 3.10 Both Aβ and dPGC-1 over-expression increased the mitochondrial membrane 
potential in the fly brain 
Aß-expressing fly brains displayed increased mitochondrial membrane potential at 30-day of age. 
dPGC-1 over-expression in Aß co-expressing flies lead to further hyperpolarization of the 
mitochondrial membrane. The ΔΨm is represented as arbitrary units of TMRM intensities. Data are 
shown as the mean ± SEM (n=11 for Aß RU-, n=10 for Aß RU+ and n=11 for Aß; dPCG-1 RU+; 
**p<0.01, ***p<0.001 by ANOVA Newman-Keuls test). In collaboration with Dr. Plamena R. 
Angelova. 
 
dPGC-1 is required for the proper expression of many mitochondrial ETC genes, 
including cytochrome c proximal  (cyt-c-p), which encodes one of the enzymes in 
PGC-1α in neurodegeneration and ageing 
 
 
 
103 
cytochrome c that participates in the creation of the mitochondrial membrane 
potential (Tiefenböck et al., 2010). Aβ has been shown to directly inhibit cytochrome 
c activity in vitro (Crouch et al., 2005, Casley et al., 2002), suggesting that elevating 
dPGC-1 in neurons might rescue toxicity be increasing expression of cyt-c-p. 
Therefore, I assessed the mRNA transcript levels of cyt-c-p in Aβ-expressing fly 
heads by qRT-PCR, and found that as predicted, mRNA levels of cyt-c-p were 
reduced in response to Aβ-expression, while co-expression with dPGC-1 significantly 
rescued this effect (Figure 3.11). These findings suggest that the induction of dPGC-1 
in fly neurons might lead to the elevation of ETC enzymes in association with 
mitochondrial membrane hyperpolarization.  
 
 
 
Figure 3.11 Aß and dPGC-1 had opposing effects on cyt-c-p transcription. 
qRT-PCR demonstrated that cyt-c-p mRNA levels (relative to RP49) in the heads of 30-day-old flies 
expressing Aß (RU+) were lower compared to controls (RU-). Co-expression of dPGC-1 in adult 
neurons had the opposite effect, increasing cyt-c-p mRNA levels. Bars represent means ± SEM (n=3, 
*p<0.05 by ANOVA Newman-Keuls test). The genotypes used were: elavGS>UAS-Aß; elavGS>UAS-
Aß/UAS-dPGC-1. 
  
To determine whether these changes in cyt-c-p had functional consequences, I 
measured ATP concentrations in fly heads and observed a significant increase in ATP 
levels in dPGC-1 flies (Figure 3.12). Although I observed a trend towards a reduction 
in ATP in response to Aβ, this did not reach statistical significance. Therefore, 
activation of dPGC-1 in neurons elevated ATP production by increasing the 
PGC-1α in neurodegeneration and ageing 
 
 
 
104 
membrane potential, through up-regulation of the genes responsible for ETC activity 
in Aβ-expressing flies. 
 
Taken together my results demonstrated that Aβ reduces mitochondrial DNA copy 
number and cytochrome c activity, in association with a compensatory increase in the 
mitochondrial membrane potential. In addition, dPGC-1 may partially ameliorate the 
Aβ–phenotypes through the compensatory increase in mitochondrial membrane 
potential, an increase in ATP production, as well as the up-regulation of ETC 
enzymes.   
 
 
Figure 3.12 dPGC-1 over-expression increased ATP levels in Aß-expressing fly heads 
dPGC-1 over-expression in Aß-expressing flies leads to an increase in ATP levels in adult neurons at 
30 days of age (genotypes: Aß RU-; Aß RU+; and Aß; dPGC-1 RU+). Bars represent the means ± SEM 
(n=5, *p<0.05 by ANOVA Newman-Keuls test). 
 
 
3.3.4 dPGC-1 over-expression regulated the mitochondrial stress 
response to Aβ toxicity and protected Aβ flies against oxidative stress 
Mitochondrial DNA depletion and increases in mitochondrial membrane potential can 
lead to excessive production of ROS and deleterious mitochondrial stress. This in turn 
is detrimental to the maintenance of the mitochondrial proteome and can lead to 
apoptosis (Haynes and Ron, 2010, Kinghorn et al., 2015). UPRmt is a stress-response 
pathway that adapts and activates the folding capacity of the mitochondrial matrix in 
response to mitochondrial dysfunction. It also leads to up-regulation of nuclear-
encoded mitochondrial-localized chaperones to promote both protein folding and 
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degradation, to either restore mitochondrial proteostasis or enter apoptosis (Neupert 
and Herrmann, 2007, Haynes and Ron, 2010).  
 
I next asked whether the amelioration of the neurotoxic phenotypes associated with 
Aß by dPGC-1 over-expression is accompanied by improved mitochondrial 
proteostasis.  Immunoblot analyses against mitochondrial chaperones HSP60 and 
Grp75 showed a significant reduction in response to Aβ (Figure 3.13 and 3.14), 
suggesting an impaired UPRmt and proteostastic failure. Interestingly, flies co-
expressing both dPGC-1 and Aβ in neurons returned the levels of HSP60 and Grp75 
to control levels seen in their un-induced counterparts. Since there was significantly 
different basal levels of mitochondrial chaperones in the corresponding transgenic 
control lines, we confirmed our findings by statistical analysis using a two-way 
ANOVA. This demonstrated a significant interaction between the induction of RU 
(indicative of gene expression) and the genotypes, suggesting that over-expression of 
neuronal dPGC-1 reverses the reduction in mitochondrial chaperones seen in Aβ-
expressing flies (Figure 3.13 and 3.14). These results suggest that over-expression of 
dPGC-1 leads to an increase in UPRmt activity, ameliorating Aβ toxicity.  
 
 
Figure 3.13 Aß-expressing flies displayed reduced levels of the HSP60 protein 
Western blot analysis on 22-day-old Aß-expressing fly heads (Aß RU+) showed reduced HSP60 
protein levels compared to controls (Aß RU-).  Co-expression of Aß + dPGC-1 in adult neurons (Aß; 
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dPGC-1 RU+) did not show significant difference in HSP60 protein levels compared to controls (Aß; 
dPGC-1 RU-). The HSP60 levels are shown normalized to ß-actin. Bars represent means ± SEM (n=4). 
The image is a representative gel from one biological repeat (**p<0.01, ***p<0.001 by ANOVA 
Newman-Keuls test. two-way ANOVA analysis shows **p<0.01 when comparing Aß response to RU 
relative to Aß; dPGC-1 response to RU). The genotypes used were: elavGS>UAS-Aß; elavGS>UAS-
Aß/UAS-dPGC-1. 
 
 
Figure 3.14 Aß-expressing flies displayed reduced levels of the Grp75 protein 
Aß-expressing fly heads display reduced levels of the Grp75 protein as assessed by Western blot 
analysis on the heads of 22-day-old flies. The Grp75 protein levels were normalized to ß-actin. Bars 
represent means ± SEM (n=3-4). The image is a representative gel from one biological repeat 
(**p<0.01 by ANOVA Newman-Keuls test, two-way analysis shows *p<0.05 when comparing Aß 
response to RU relative to Aß; dPGC-1 response to RU).  
 
Aß-induced mitochondrial stress is similar to that caused by exposure to the potent 
oxidizer paraquat (Cocheme and Murphy, 2008). I therefore determined the effect of 
dPGC-1 over-expression on the sensitivity of Aβ-expressing flies to paraquat. A 
single injection of the redox-cycler paraquat, which produces superoxide in part 
through the mitochondria (Cocheme and Murphy, 2008), caused a significant 
reduction in the survival of Aβ-expressing flies compared to controls (Figure 3.15). 
Interestingly, co-expression of Aβ with dPGC-1 restored survival to control levels 
(Figure 3.15), suggesting that activation of dPGC-1 in neurons protects Aβ-
PGC-1α in neurodegeneration and ageing 
 
 
 
107 
expressing flies from oxidative stress, likely through an improved mitochondrial 
stress response. 
 
 
 
Figure 3.15 Over-expression of dPGC-1 rescued the survival of Aß-expressing female flies 
injected with paraquat 
The survival curves of flies expressing Aß or Aß + dPGC-1 in adult neurons (RU+) and un-induced 
controls (RU-) demonstrated a rescuing effect of dPGC-1 on the survival of Aß-expressing flies when 
injected with paraquat (p<0.0001 when comparing Aß RU+ and Aß; dPGC-1 RU+ by log-rank test). 
This work was performed in collaboration with Dr. Anna Tillmann. 
 
Activation of dPGC-1 in neurons further increases the mitochondrial membrane 
potential in Aβ flies, which is assumed to increase the ETC leakage, the ROS 
production and the free radical damage (Green et al., 2011). However, the free radial 
damage and lifespan can be uncoupled (Zhang et al., 2009, Van Raamsdonk and 
Hekimi, 2009). Rather than a direct contributor to disease pathology, ROS is more 
likely a response modulator for mitochondrial stress-elicited survival signal (Sena and 
Chandel, 2012). Our findings suggest a model in which over-expression of Aß leads 
to mtDNA deletion, increased oxidative damage, and impaired mitochondrial stress 
response and proteostatic failure. However, over-expression of dPGC-1 in neurons 
switches on a compensatory mechanism involving the further increase in 
mitochondrial membrane potential to drive ATP synthase. In addition, dPGC-1 
protects Aß flies from mitochondrial stress likely through improvement in the UPRmt. 
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3.3.5 dPGC-1 regulated the UPRER in flies expressing Aβ 
PGC-1 activates the UPRER in mammalian skeletal muscle as an adaptive response to 
exercise, partially though co-activation of ATF6a (Wu et al., 2011). I therefore 
assessed whether dPGC-1 activation in neurons can protect Aβ flies from ER stress. 
The Grp78 protein is a negative master regulator of the UPR and binds and maintains 
the downstream cascades in an inactive state (Carrara et al., 2013, Bertolotti et al., 
2000, Gorbatyuk et al., 2012, Li et al., 2008), and increases in response to Aβ (Niccoli 
et al., 2016). Immunoblot analyses confirmed that the levels of the Grp78 protein 
were increased in Aβ-expressing flies, and that co-expression of dPGC-1 restored 
Grp78 expression back to control levels (Figure 3.16). In keeping with this we 
recently showed that genetic down-regulation of Grp78 protects flies from Aβ toxicity 
(Niccoli et al., 2016), suggesting that dPGC-1 could ameliorate Aβ toxicity by 
modulating the UPRER.  
 
 
 
Figure 3.16 The levels of the Grp78 protein were elevated in Aβ-expressing fly heads but 
returned towards control levels with co-expression of dPGC-1  
Western blot analysis of the protein levels of the ER chaperone Grp78 in the heads of 22-day-old flies 
expressing Aß or Aß + dPGC-1 in neurons (RU+) and un-induced controls (RU-). Protein levels were 
normalized to ß-actin and the bars represent the means ± SEM (n=4, *p<0.05, **p<0.01 by ANOVA 
Newman-Keuls test). The image is a representative gel of two biological repeats. 
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Low levels of Grp78 would be predicted to be associated with increased activation of 
the UPRER. To confirm this, I analysed the levels of Xbp1 splicing, a marker of IRE1 
activation. Over-expression of Aβ in the fly brain resulted in a trend towards an 
increase in Xbp1 splicing, but this did not reach significance. Other studies have 
however shown an increase in Xbp1 splicing in response to Aβ (Casas-Tinto et al., 
2011, Niccoli et al., 2016). As predicted, co-expression of Aβ with dPGC-1 increased 
the levels of spliced Xbp1 three-fold, suggesting over-expression of dPGC-1 in 
neurons increases IRE1 activity (Figure 3.17).  
 
 
 
Figure 3.17 The mRNA levels of Xbp1 splicing were increased in the heads of Aβ-expressing flies 
co-expressing dPGC-1  
Spliced Xbp1 mRNA levels in heads of 15-day-old flies expressing Aß or Aß + dPGC-1 in neurons 
(RU+) and un-induced controls (RU-), as measured by qRT-PCR (relative to RP49). The bars represent 
the means ± SEM (n=3, ** P<0.01, ***p<0.001 by ANOVA Newman-Keuls test). 
 
Similarly, Grp78 mRNA levels, a marker of ATF6a activation, increased in response 
to Aβ over-expression (Figure 3.18), and co-over-expression of dPGC-1 resulted in an 
even greater increase than that seen with Aβ alone (Figure 3.18). Grp78 protein levels 
are tightly controlled at the levels of translation (Gulow et al., 2002), and an increase 
in the mRNA, therefore, does not necessarily indicate higher protein levels, 
suggesting that dPGC-1 reduced either Grp78 translation or stability. Taken together, 
these findings suggest that Aβ activates the UPRER, and that dPGC-1 further activates 
it, by reducing the protein levels of Grp78 and hence activating the IRE1 and ATF6α  
pathways, resulting in the amelioration of Aß toxicity. 
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Figure 3.18 The mRNA levels of Grp78 were increased in Aβ-expressing fly heads and further 
increased by the co-expression of dPGC-1  
Grp78 mRNA levels in the heads of 15-day-old flies expressing Aß or Aß + dPGC-1 in neurons (RU+) 
and un-induced controls (RU-), measured by qRT-PCR (relative to RP49). The bars represent the 
means ± SEM (n=3, *p<0.05, **p<0.01, ***p<0.001 by ANOVA Newman-Keuls test). The genotypes 
used were: elavGS>UAS-Aß; elavGS>UAS-Aß /UAS-dPGC-1. 
 
As described above, I demonstrated that over-expression of dPGC-1 in neurons 
modulates the levels of chaperones in both the UPRER and the UPRmt in response to 
Aß toxicity. I therefore addressed the question of whether dPGC-1 regulates the basal 
levels of these chaperones in the absence of Aß.  Interestingly, activation of dPGC-1 
in neurons did not change the basal levels of Grp75 and Grp78, and even down-
regulated the level of HSP60 compared to non-RU treated young control flies (Figure 
3.19). This therefore demonstrated that the effect of dPGC-1 on the chaperones 
involved in the UPRER and the UPRmt is specific to Aß-mediated pathogenesis. It also 
highlights the potential therapeutic benefits of modulating these chaperones in the 
treatment of AD.    
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Figure 3.19 Over-expression of dPGC-1 in neurons did not change the basal levels of chaperones 
in young flies 
Western blot analysis of the protein levels of the mitochondrial chaperones HSP60, Grp75, and the ER 
chaperone Grp78 in the heads of 15-day-old flies over-expressing dPGC-1 (RU+) and un-induced 
controls (RU-). Protein levels were normalized to ß-actin. The bars are plotted below as the means ± 
SEM (n=4, *p<0.05 by t-test). The image is a representative gel from one biological repeat. 
 
 
3.3.6 Rifampicin ameliorated Aß neurotoxicity via activation of the 
UPRER 
Since dPGC-1 ameliorates Aβ toxicity through activation of UPRER, pharmacological 
targeting of the UPRER may represent a potential therapeutic avenue for the treatment 
of AD. Rifampicin, a well-known antibiotic used to treat tuberculosis and leprosy, is 
known to cross the blood brain barrier following oral administration (Umeda et al., 
2016). Interestingly it has been shown that leprosy patients treated with rifampicin 
show a lower incidence of dementia and a reduction in senile plaques compared to the 
general population (Mcgeer et al., 1992, Chui et al., 1994, Namba et al., 1992). 
Rifampicin has also been shown to have neuroprotective effects in a number of 
animal models of neurodegenerative diseases (Tomiyama et al., 1994, Umeda et al., 
2016, Oida et al., 2006, Kilic et al., 2004), but the mechanisms involved have not 
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been fully elucidated. Rifampicin reduced Aβ oligomerization and improved memory 
in an APP mice model through improved autophagy-lysosomal function (Umeda et 
al., 2016). It was also shown to activate the UPR and offer protection against 
rotenone-induced cytotoxicity in vitro (Jing et al., 2014).  
 
I therefore treated our Arctic Aβ over-expressing flies with rifampicin to determine 
whether it can protect against Aß neurotoxicity in vivo. Indeed, feeding Aβ flies with 
200 µM of rifampicin statistically extended lifespan (Figure 3.20, p=0.002 by log-
rank test), and improved climbing ability (Figure 3.22) without altering Aß levels 
(Figure 3.21). 200 µM of rifampicin did not improve either the lifespan (Figure 3.20, 
p=0.06 by log-rank test) or the climbing ability in non-induced control flies, 
suggesting that the effects of rifampicin are specific to AD pathology. Although 500 
µM rifampicin increased the lifespan of both Aβ-expressing flies and non-induced 
controls (Figure 3.20, p=0.0009 and p=0.0006 respectively), their climbing ability 
was not affected (Figure 3.22), suggesting that the effects on climbing ability and 
lifespan can be uncoupled. Cox proportional hazard analysis confirmed that there is 
no significant interaction between the response to RU and the response to rifampicin 
(500 µM) treatment (Table 1, p=0.89), suggesting that high dose (500 µM) rifampicin 
extends lifespan regardless of whether Aß is present or not. Rifampicin may therefore 
have broad-spectrum effects on lifespan when administrated at high concentrations, 
but a specific protective effect against Aß-induced neurotoxicity when administrated 
at lower concentrations. Rifampicin treatment, similar to dPGC-1 over-expression, 
also reversed the increase in Grp78 levels associated with Aβ-expression (Figure 
3.23), suggesting activation of the UPRER. Rifampicin is therefore a promising ready-
to-use medicine for the treatment of AD pathology, through its activation of the 
UPRER. 
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Figure 3.20 Rifampicin increased the lifespan of Aβ-expressing female flies  
Survival curves of flies expressing Aß in adult neurons (RU+) and un-induced controls (RU-) using 
inducible elavGS driver with or without rifampicin treatment at 200 µM (P=0.002 when comparing Aß 
RU+ Rifampicin 0 µM and Aß RU+ Rifampicin 200 µM by log-rank test; p=0.06 when comparing Aß 
RU- Rifampicin 0 µM and Aß RU- Rifampicin 200 µM by log-rank test) and 500 µM (P=0.0009 when 
comparing Aß RU+ 0 µM and Aß RU+ Rifampicin 500 µM by log-rank test; p=0.0006 when 
comparing Aß RU- Rifampicin 0 µM and Aß RU- Rifampicin 500 µM by log-rank test. N= 150 flies per 
conditions. This work was performed in collaboration with Dr. Jorge Iván Castillo-Quan.  
 
 
Table 1 CPH analysis of the survival of Aß-expressing flies on treatment with 500 µM rifampicin  
CPH analysis showed that there was no interaction between the response to RU and the response to 
rifampicin 500µM (p=0.89). This suggests that treatment with 500µM rifampicin extends lifespan 
regardless of whether Aß is present or not. 
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Figure 3.21 Rifampicin treatment had no effect on Aβ protein levels. 
Aß protein levels, measured by ELISA, in the heads of 15- or 30-day old Aß- expressing flies (+RU) 
and un-induced controls (-RU) treated with or without 200uM rifampicin. Bars represent the means 
±SEM (n=3, **p<0.01 by ANOVA Newman-Keuls test). 
 
 
 
Figure 3.22 Rifampicin rescued the locomotor ability of Aβ-expressing flies  
The climbing assay Performance Index (PI) of Aß-expressing flies in the absence and presence of 
rifampicin. P<0.001 when comparing the Aß response to RU relative to the Aß response to RU + 
rifampicin 200µM by ordinal logistic regression. There is no significant difference between Aß RU+ 
rifampicin 0 µM and Aß RU+ rifampicin 500 µM. 
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Figure 3.23 Rifampicin reduced the increased levels of the Grp78 protein in Aß-expressing fly 
heads 
Western blot of Grp78 in the heads of 15-day-old flies expressing Aß in neurons (RU+) and un-induced 
controls (RU-) with or without 200µM rifampicin treatment. The bars are plotted below as the means ± 
SEM (n=3, **p<0.01, ***p<0.001 ANOVA Newman-Keuls test). The image is a representative gel of 
one biological repeat. 
 
3.3.7 Over-expression of dGABPα or dYY1 did not rescue Aß toxicity 
PGC-1α is a transcriptional coactivator involved in mitochondrial biogenesis 
(Cunningham et al., 2007, Mootha et al., 2004) and the regulation of the circadian 
clock (Liu et al., 2007). To further explore the downstream effectors of dPGC-1 
involved in the amelioration of Aß neurotoxicity, I performed a small-scale screen of 
transcription factors previously reported to be required for the co-activation of dPGC-
1. I tested the transcription factor PDP1ϵ, which is involved in the regulation of the 
circadian clock (Cyran et al., 2003), and two other transcription factors, YY1 and 
GABPα, known to play a role in mitochondrial biogenesis. 
 
Mammalian PGC-1α has been shown to regulate mitochondrial oxidative 
phosphorylation by co-activating the transcription factor YY1 (Cunningham et al., 
2007). I therefore investigated whether dPGC-1 over-expression ameliorates Aß 
toxicity through YY1. Surprisingly, up-regulation of neuronal dYY1 (pho, CG17743) 
in neurons shortened the lifespan of the Aß-expressing flies (Figure 3.24). 
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Figure 3.24 The co-expression of dYY1 in the neurons of Aß-expressing flies lead to a decrease in 
lifespan 
The survival curves of female flies expressing Aß or Aß + dYY1 in adult neurons (RU+) and un-
induced controls (RU-). The genotypes used were: elavGS>UAS- Aß; elavGS>UAS- Aß/UAS-dYY1. 
 
Mammalian PGC-1α has been also shown to regulate mitochondrial biogenesis 
through the transcription factor GABPα (also known as Nuclear respiratory factor 2a, 
NRF2a) (Mootha et al., 2004, Virbasius et al., 1993). Animal models lacking GABPα 
exhibit mitochondrial dysfunction (Yang et al., 2014, Baltzer et al., 2009). I therefore 
considered whether dPGC-1 over-expression reduced Aß-mediated toxicity by acting 
through dGABPα. Up-regulation of dGABPα (delg, CG6338) in neurons was not 
sufficient to the extend lifespan of Aß-expressing flies (Figure 3.25), and therefore it 
does not appear to be an important downstream mediator of PGC-1α in extending 
lifespan. 
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Figure 3.25 Co-expression of dGABPα in neurons did not rescue the shortened lifespan of Aß-
expressing flies 
The survival curves of female flies expressing Aß or Aß + dGABPα in adult neurons (RU+) and un-
induced controls (RU-). The genotypes used were: elavGS>UAS- Aß; elavGS>UAS- Aß/UAS-dGABPα. 
 
 
3.3.8 PDP1ϵ ameliorated Aß neurotoxicity via activation of the 
UPRER 
We recently demonstrated that Aß-expressing flies display an arrhythmic sleep pattern 
(Niccoli et al., 2016). I confirmed the finding that over-expression of Aß can disrupt 
the circadian clock via increasing the period tau. In agreement with previous human 
and animal studies, our results suggest that Aβ-induced neurotoxicity might directly 
contribute to circadian rhythm disruption (Harper et al., 2005, Blake et al., 2015, 
Long et al., 2014). Moreover, metabolic defects and disturbance in redox state can 
lead to an alteration of circadian rhythm. This in turn has been found not only to occur 
as a consequence of AD pathology, but may also contribute to APP processing and 
Aβ accumulation (Kang et al., 2009, Xie et al., 2013, Musiek et al., 2013). Therefore, 
Aβ-induced defects in circadian rhythm might also lead to a further increase in 
disease progression.  
 
Circadian clocks coordinate physiological, neurological, and behavioral functions into 
approximately 24-hour rhythms, and the molecular mechanisms underlying circadian 
clock oscillation are conserved from Drosophila to humans. Drosophila have a well 
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studied circadian clock, consisting of two interlocked transcriptional feedback loops 
(Figure 3.26). In the first feedback loop, dCLOCK/CYCLE activates period 
expression, and the PERIOD protein then inhibits dCLOCK/CYCLE activity. In the 
second feedback loop, dCLOCK/CYCLE activates Pdp1ϵ and vri expression, and 
then PDP1ϵ activates dClock while VRI inhibits dClock expression (Cyran et al., 
2003). Flies lacking Pdp1ϵ have impaired circadian clocks, demonstrating that it is 
important for the rhythmic expression of dCLOCK. Moreover, flies lacking Pdp1ϵ 
also exhibit increased sensitivity to oxidative damage (Beaver et al., 2010), suggesting 
its role in maintaining the redox state and circadian rhythm. 
 
 
Figure 3.26 The circadian loop model for the Drosophila clock 
Two interconnected transcription feedback loops lie at the core of the Drosophila molecular clock. In 
one loop, dCLOCK and CYCLE directly activate the transcription of per and tim by binding their 
promoters. Inhibition of dCLOCK/CYCLE activity is mediated by TIM transporting PER into the 
nucleus. dCLOCK/CYCLE also directly activate vri and Pdp1ϵ transcription. dClock transcription is 
first repressed by VRI, and then activated by PDP1ϵ. Repression and activation of dClock are separated 
by the different phases of VRI and PDP1ϵ proteins.  
 
Mammalian PGC-1α has been found to co-activate the transcription factor RORα to 
activate Bmal/CLOCK gene expression. It is therefore involved in the second 
feedback loop of the circadian clock (Liu et al., 2007). Whether its Drosophila 
counterpart also controls circadian clock awaits investigation. Work in our research 
group has however shown that dPGC-1 is rhythmically expressed (unpublished data). 
Therefore, I hypothesised that dPGC-1 is a clock gene, regulating the circadian clock 
in Drosophila. As described above I have shown that over-expression of dPGC-1 in 
neurons ameliorates Aβ-induced circadian clock disruption, namely the increased 
period tau, suggesting that dPGC-1 might directly participate in the feedback loop. 
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Using FRET (Fluorescence Resonance Energy Transfer), a sensitive method to study 
protein interactions in vivo, I sought to determine whether dPGC-1 and PDP1ϵ 
physically interact in the fly brain. Briefly, FRET involves the non-radioactive 
transfer of energy from an excited state donor fluorophore to a nearby acceptor, which 
can be detected when two labelled molecules are separated by a distance of 2-10 nm. 
FRET acceptor photo bleaching is a method that measures the donor “de-quenching” 
in the presence of an acceptor by comparing donor fluorescence intensity in the same 
sample/region before and after destroying the acceptor by photobleaching. If FRET 
was initially present, a resultant increase in donor fluorescence will occur on 
photobleaching of the acceptor. FRET efficiency is considered positive when the 
fluorescence intensity of the donor after acceptor photobleaching (Dpost) > 
fluorescence intensity of the donor before acceptor photobleaching (Dpre). I generated 
transgenic flies carrying both GFP-tagged PDP1ϵ and HA-tagged dPGC-1 as a donor-
acceptor pair for FRET analysis (Figure 3.27). HA-tagged dPGC-1 protein were 
immune-stained and labelled with RFP as acceptor fluorophore. After acceptor 
photobleaching in region of interest (ROI), I observed an increase in Dpost compared 
to Dpre (Figure 3.28), suggesting the FRET efficiency was positive. It should be noted 
that this was a single experiment and more repeats are required to confirm this 
interaction. Therefore, I can conclude that dPGC-1 and PDP1ϵ may physically 
interact in the fly brain.  
 
 
Figure 3.27 A model for the FRET donor-acceptor pair 
Double mutant flies carried both GFP-tagged PDP1ϵ and HA-tagged dPGC-1. GFP labeled protein was 
excited at 488nm as the donor, and HA-labeled protein was stained and labeled by RFP and excited at 
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568nm as the acceptor. When two molecules are very close to each other (<10nm), then energy will 
transfer from the excited donor to the acceptor. The emission from the acceptor will include the part 
transferred from the donor. Acceptor photobleaching is used to stop the energy transfer from the 
excited donor and involves bleaching the acceptor. The emission of the donor will be increased after 
photobleaching as energy will no longer be transferred.  
 
 
Figure 3.28 Acceptor photobleaching within the regions of interest (ROI)  
FRET photobleaching was conducted using confocal microscopy. The mean fluorescence intensities in 
the same ROI (see boxes) in the brains before (36.7) and after (10.6) acceptor photobleaching with the 
555-nm laser line are shown. The mean fluorescence intensity of the donor after acceptor 
photobleaching (30.578) is higher than that before acceptor photobleaching (25.481), suggesting a 
positive FRET efficiency. Fluorescence intensity was measured using ImageJ. This demonstrates that 
dPGC-1 and PDP1ϵ may physically interact in the fly brain.  
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I then explored whether genetic manipulation of Pdp1ϵ may prevent Aβ neurotoxicity. 
Neuronal over-expression of Pdp1ϵ in adult flies using the inducible elavGS driver 
significantly extended the lifespan of Aβ-expressing flies (Figure 3.29), although the 
effects were much less than those seen with dPGC-1 over-expression. However, over-
expression of Pdp1ϵ in neurons was unable to rescue the climbing defects (Figure 
3.30).  
 
 
Figure 3.29 Over-expression of Pdp1ϵ in neurons extended the lifespan of Aß flies 
The survival curves of female flies expressing Aß or Aß + Pdp1ϵ in adult neurons (RU+) and un-
induced controls (RU-). P<0.01 when comparing the Aß response to RU relative to the Aß + Pdp1ϵ 
response to RU by Cox proportional hazard model using JMP and software R. The genotypes used 
were: elavGS>UAS-Aß; elavGS>UAS-Aß/UAS-Pdp1ϵ. This work was performed in collaboration with 
Miss. Nikoleta Vavouraki. 
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Figure 3.30 Co-expression of Pdp1ϵ did not rescue the locomotor ability of Aß-expressing flies  
The climbing ability shown as the PI of flies of the same genotypes. P>0.05 when comparing the Aß 
response to RU relative to the Aß; Pdp1ϵ response to RU, by ordinal logistics regression. This work 
was also performed in collaboration with Miss. Nikoleta Vavouraki. 
 
I confirmed that Pdp1ϵ over-expression was not modulating Aβ toxicity via a direct 
effect on Aβ levels, by demonstrating that total Aβ protein levels were not 
significantly different in flies co-expressing Aβ and Pdp1ϵ compared to those 
expressing Aβ alone (Figure 3.31). There was however a slight increase in Aβ mRNA 
levels in response to Pdp1ϵ over-expression (Figure 3.32), but since this was not 
correlated with increased protein expression, the significance of this is not clear. 
Therefore, I demonstrated that over-expression of Pdp1ϵ reduced the toxicity of Aβ, 
independently of Aβ protein levels.  
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Figure 3.31 Co-expression of Pdp1ϵ in Aß-expressing flies did not alter Aß protein levels 
Aß protein levels were measured by ELISA in the heads of 30-day-old flies expressing Aß or Aß + 
Pdp1ϵ in neurons (RU+) and un-induced controls (RU-). The bars are plotted as the means ±SEM (n=3, 
***P<0.001 by ANOVA Newman-Keuls test). This work was performed in collaboration with Miss. 
Nikoleta Vavouraki. 
 
 
 
Figure 3.32 The mRNA levels of Aß were increased by the co-expression of Pdp1ϵ in Aß-
expressing flies 
Aß mRNA levels (relative to the internal control gene RP49) in heads of 15-day-old flies were 
measured by qRT-PCR. The bars are plotted as the means ±SEM (n=4, ***p<0.001, ****p<0.0001 by 
ANOVA Newman-Keuls test). The genotypes used were: elavGS>UAS-Aß; elavGS>UAS-Aß/UAS- 
Pdp1ϵ. This work was performed in collaboration with Miss. Nikoleta Vavouraki. 
 
Previous studies demonstrated that Pdp1ϵ could regulate the expression of genes 
involved in the detoxification pathway (Beaver et al., 2010). Loss of Pdp1ϵ leads to 
reduced levels of cyp6a2 and DHR96, suggesting that over-expression of Pdp1ϵ might 
increase the expression of these genes. I therefore measured the transcript levels of 
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cyp6a2 and DHR96 in flies co-expressing Aβ and Pdp1ϵ, and found that over-
expression of Pdp1ϵ increased the mRNA levels of DHR96 compared to the non-
induced controls or flies expressing Aβ alone, confirming an increase in the activity 
of Pdp1ϵ (Figure 3.33). In addition, over-expression of Pdp1ϵ did not change the 
mRNA levels of cyp6a2. However cyp6a2 transcript levels were significantly reduced 
in response to Aβ, suggesting that Aβ may impair the detoxification pathway (Figure 
3.34). Our results confirm that Pdp1ϵ over-expression in flies activates the appropriate 
downstream molecular pathways.   
 
 
Figure 3.33 Over-expression of Pdp1ϵ in Aβ-expressing flies lead to increased DHR96 levels in fly 
heads 
DHR96 mRNA levels in the heads of 15-day-old flies expressing Aß or Aß + Pdp1ϵ in neurons (RU+) 
and un-induced controls (RU-), measured by qRT-PCR (relative to the internal control gene RP49). 
The bars represent the means ± SEM (n=4, *p<0.05 by ANOVA Newman-Keuls test). The genotypes 
used were: elavGS>UAS-Aß; elavGS>UAS-Aß/UAS-Pdp1ϵ. This work was performed in collaboration 
with Miss. Nikoleta Vavouraki. 
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Figure 3.34 Over-expression of Aβ, but not Pdp1ϵ, reduced cyp6a2 mRNA levels in fly heads 
cyp6a2 mRNA levels in the heads of 15-days-old flies expressing Aß or Aß + Pdp1ϵ in neurons (RU+) 
and un-induced controls (RU-), measured by qRT-PCR (relative to the internal control gene RP49). 
The bars represent the means ± SEM (n=4, *p<0.05, ** p<0.01 by ANOVA Newman-Keuls test). The 
genotypes used were: elavGS>UAS-Aß; elavGS>UAS-Aß/UAS- Pdp1ϵ. This study was performed in 
collaboration with Miss. Nikoleta Vavouraki. 
 
Since dPGC-1 ameliorates Aβ toxicity through activation of the UPRER, I assessed 
whether Pdp1ϵ activation in neurons can protect Aβ flies against ER stress. I first 
analysed the levels of Xbp1 splicing, a marker of IRE1 activation. Expression of Aβ 
significantly increased Xbp1 splicing in agreement with previous studies (Casas-Tinto 
et al., 2011, Niccoli et al., 2016). Co-expression with Pdp1ϵ lead to a trend towards an 
increase in Xbp1 splicing, but this did not reach statistical significance, suggesting 
that over-expression of Pdp1ϵ in neurons is not sufficient to increase IRE1 activity 
(Figure 3.35). I next assessed Grp78 mRNA levels, a marker of ATF6α activation, 
and found that in addition to their increase in response to Aβ, there was an even 
further increase in Pdp1ϵ-co-expressing flies (Figure 3.36), suggesting activation of 
the ATF6α branch of the UPRER. Taken together, over-expression of Pdp1ϵ activates 
the UPRER through activation of the ATF6α branch, in a similar manner to dPGC-1, 
therefore leading to re-establishment of ER homeostasis in Aβ-expressing flies. 
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Figure 3.35 mRNA levels of Xbp1 splicing were increased by the expression of Aβ and Pdp1ϵ in 
fly heads 
Spliced Xbp1 mRNA levels in heads of 15-day-old flies expressing Aß or Aß + Pdp1ϵ in neurons 
(RU+) and un-induced controls (RU-), measured by qRT-PCR (relative to RP49). Bars are plotted as 
the means ± SEM (n=3, *p<0.05, **p<0.01, ***p<0.001 by ANOVA Newman-Keuls test). This 
experiment was performed in collaboration with Miss. Nikoleta Vavouraki. 
 
 
 
 
Figure 3.36 mRNA levels of Grp78 were increased in flies expressing Aβ and Pdp1ϵ in their heads 
Grp78 mRNA levels in the heads of 15-day-old flies expressing Aß or Aß + Pdp1ϵ in neurons (RU+) 
and un-induced controls (R-U), measured by qRT-PCR (relative to the internal control gene RP49). 
The bars are plotted below as the means ± SEM (n=3, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
by ANOVA Newman-Keuls test). The genotypes used were: elavGS>UAS-Aß; elavGS>UAS-Aß/UAS- 
Pdp1ϵ. This work was performed in collaboration with Miss. Nikoleta Vavouraki. 
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3.4 Discussion 
AD, triggered by the accumulation of Aß oligomers or aggregates, causes a 
neurotoxic cascade including oxidative stress, mitochondrial dysfunction, proteostatic 
failure, and eventual cell death (Hardy and Higgins, 1992, Musiek and Holtzman, 
2015). Ageing-related disturbances in protein homeostasis, neuronal stress response 
pathways, and circadian rhythm also contribute and exacerbate disease progression 
(Musiek et al., 2013, Taylor and Dillin, 2011, Hipp et al., 2014). Therefore, genetic or 
pharmacological interventions targeting these modulators may provide excellent 
therapeutic avenues.  
 
PGC-1α has been implicated in AD pathology in both human and animal studies (Qin 
et al., 2009, Helisalmi et al., 2008). However the effects of elevating PGC-1α in 
animal models of AD are controversial (Sheng et al., 2012, Katsouri et al., 2011, 
Dumont et al., 2014). Acting as a transcriptional co-activator, PGC-1α has been 
broadly implicated in many cellular processes and it is therefore regarded as the 
master regulator of energy metabolism (Mootha et al., 2004, Scarpulla, 2008, 
Puigserver and Spiegelman, 2003, Li et al., 2007b). Here I demonstrated that neuronal 
activation of dPGC-1 can extend lifespan and ameliorate Aβ induced neurotoxicity, 
including climbing defects and circadian rhythm disruption. This improvement was 
associated with a compensatory mitochondrial response, namely increased ETC 
activity and ATP production, and improved mitochondrial proteostasis. Mitochondrial 
dysfunction plays a central role in disease progression, since it is the energy factory 
for cells. Damaged mitochondria lead to metabolic defects, including reduced glucose 
metabolism and ATP production in AD brains (Mosconi et al., 2008, Willette et al., 
2015, Winkler et al., 2015, Kapogiannis and Mattson, 2011). In our flies, Aβ over-
expression in neurons lead to a trend in ATP reduction. Conversely, dPGC-1 
activation in neurons increased the ATP levels in Aβ-expressing flies, suggesting an 
increase in steady-state homeostasis. 
 
In AD patients, mitochondrial dysfunction has been reported in association with 
mutations or deletions in mtDNA (Bender et al., 2008, Coskun et al., 2004). I showed 
that Aβ accumulation in the brain leads to the loss of mtDNA, and a compensatory 
response involving increased mitochondrial membrane potential. This is consistent 
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with the hyperpolarization of mitochondrial membranes seen in PD patient fibroblasts 
carrying PINK1 mutations (Abramov et al., 2011), and in neurons carrying a severe 
mtDNA mutation (Abramov et al., 2010). I demonstrated that dPGC-1 up-regulation 
potentiates this compensatory response via up-regulation of the cytochrome c, which 
leads to a further increase in mitochondrial membrane potential and ATP synthase.  
 
The ETC is the main site of premature electron leakage to oxygen, generating 
superoxide and reactive oxygen species (ROS). Inefficient electron transport chain 
activity of mitochondria also produces excessive ROS and mitochondrial-driven 
apoptosis, which both exacerbate AD pathology (Head et al., 2001, Siegel et al., 
2007). In keeping with this I demonstrated that flies over-expressing Aβ in neurons 
exhibit increased sensitivity to paraquat-induced oxidative stress. Over-expression of 
dPGC-1 in neurons protected Aβ –expressing flies against paraquat-induced oxidative 
stress. Our results are consistence with a previous study (St-Pierre et al., 2006), 
suggesting that PGC-1α suppresses ROS to prevent neurodegeneration.  
 
The mechanisms by which PGC-1α suppresses ROS and protects against oxidative 
damage have not been fully elucidated. However, it is already known that increased 
mitochondrial ROS and lifespan can be uncoupled (Zhang et al., 2009). Indeed, in the 
context of age-related pathology, ROS is likely a response modulator of stress-elicited 
survival signals (Sena and Chandel, 2012) and therefore has beneficial roles. Several 
studies have shown that a moderate increase in ROS or mitochondrial stress may be 
beneficial and extend lifespan in S. cerevisiae and C. elegans via modulation of stress 
response pathways, including up-regulation of mitochondrial chaperones and 
chromatin remodelling (Doonan et al., 2008, Mesquita et al., 2010, Van Raamsdonk 
and Hekimi, 2009, Merkwirth et al., 2016, Tian et al., 2016).  
 
Mitochondrial stress, similar to paraquat-induced oxidative stress (Cocheme and 
Murphy, 2008), activates the UPRmt. This is a stress signalling pathway designed to 
ensure mitochondrial homeostasis through up-regulation of mitochondrial chaperones 
(Merkwirth et al., 2016, Haynes et al., 2007). Recent studies demonstrated that early 
activation of the UPRmt, prior to mitochondrial dysfunction, can be beneficial for the 
organism and may extend lifespan in C. elegans (Merkwirth et al., 2016). This 
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suggests that a moderate increase in the UPRmt is essential for the maintenance of 
mitochondrial proteostasis. In our model, Aβ over-expression leads to a reduction in 
mitochondrial chaperones and therefore down-regulation of the UPRmt, leading to an 
imbalance in mitochondrial homeostasis. Co-expression of dPGC-1 blocked the 
down-regulation of mitochondrial chaperones, therefore improving mitochondrial 
proteostasis and neuronal health. This observation therefore explains why the 
mitochondrial hyperpolarisation associated with dPGC-1 activation resulted in overall 
beneficial effects in Aβ-over-expressing flies. Indeed it has been shown in fly muscle 
that over-expression of dPGC-1 increases the levels of the mitochondrial chaperone 
HSP60 and mitochondrial function (Rera et al., 2011). My work therefore supports 
the idea that neuronal up-regulation of dPGC-1 leads to an improved mitochondrial 
matrix environment, which can reverse the negative effects of Aβ toxicity. A previous 
study demonstrated that over-expression of dPGC-1 in the fly gut increased the basal 
levels of HSP60 (Rera et al., 2011). Conversely, I observed a reduction in the basal 
levels in HSP60 in young adult brains expressing dPGC-1 in the absence of Aβ, while 
the mechanisms are not fully understood. It would be interesting to know whether 
dPGC-1 modulates the basal levels of mitochondrial chaperones in fly brains during 
ageing. My work demonstrated that over-expression of dPGC-1 in neurons up-
regulated mitochondrial chaperones in response to Aβ-induced mitochondrial stress, 
re-establishing homeostasis and protecting against mitochondrial stress.  
 
Ageing-dependent failure in ER-related proteostasis also contributes to disease 
progression in AD (Taylor and Dillin, 2011, Hipp et al., 2014). The UPRER is 
activated early in AD disease pathogenesis (van der Harg et al., 2014), and both AD 
patients and animal model studies have shown increased UPRER components, 
including Grp78 and Xbp1 (Niccoli et al., 2016, Kondo et al., 2013). Interestingly, I 
demonstrated that the rescue of Aβ toxicity by dPGC-1 was associated with a 
reduction in Grp78 protein levels, leading to a further increase in UPRER and 
activation of the IRE1 and ATF6a branches. Indeed, it has been shown that down-
regulation of Grp78, the master negative regulator of the UPRER, leads to activation of 
the downstream cascades of the UPRER, to ameliorate Aβ toxicity (Niccoli et al., 
2016). Grp78 protein levels are tightly controlled at the levels of translation (Gulow et 
al., 2002), suggesting that dPGC-1 reduced either Grp78 translation or stability. 
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Moreover, over-expression of Xbp1 alone can ameliorate Aβ toxicity (Casas-Tinto et 
al., 2011), supporting the idea that up-regulation of UPRER components is beneficial 
in AD models. Grp78 is becoming an increasingly important therapeutic target for AD 
(Niccoli et al., 2016) and cancer, where its inhibition increases the cell’s susceptibility 
to stress (Lee et al., 2014). Although up-regulation of Grp78 showed detrimental 
effects in an animal model of Parkinson’s disease (Gorbatyuk et al., 2012), its 
function in other neurodegenerative disorders may depend on the precise experimental 
conditions. For example, a mild up-regulation of the UPRER in neurons may increase 
ER proteostasis in response to the increased burden of mis-folded proteins, whereas, a 
strong induction of the UPRER may lead to apoptosis and be detrimental to neurons 
(Hetz and Mollereau, 2014). 
 
Studies have shown that PGC-1α can modulate Grp78 levels. In skeletal muscle, in 
response to exercise, PGC-1α can increase the transcription of Grp78 and Xbp1 by co-
activating ATF6a (Wu et al., 2011). Already it has been shown that ablation of PGC-
1β, the homologue of PGC-1α, increases basal Grp78 levels and modulates the 
neuronal ER response in the mouse brain (Camacho et al., 2012), suggesting that 
PGC-1 might directly regulate Grp78 levels. I showed that activation of dPGC-1 in 
adult neurons does not change basal levels of Grp78 in young flies, but reduces Grp78 
levels and activates UPRER in the presence of Aβ. Since it has been shown that the 
UPRER and proteostasis decline with age in C. elegans (Ben-Zvi et al., 2009, Taylor 
and Dillin, 2013, Taylor and Dillin, 2011), it would therefore be interesting to know 
whether dPGC-1 affects the basal level of Grp78 levels to maintain proteostasis in old 
age.  
 
My work suggests a model where Aβ accumulation in the brain induces the UPRER, 
and activation of dPGC-1 in neurons blocks the negative feedback loop linked to 
Grp78 up-regulation, resulting in even further increased UPRER activity. In turn this 
allows neurons to re-establish the protein-folding environment and to restore protein 
homeostasis. This mechanism of action may be responsible for the benefits of PGC-
1α observed in models of other neurodegenerative disorders. PGC-1α displayed 
neuroprotective effects in a mouse model of HD with mechanisms including 
PGC-1α in neurodegeneration and ageing 
 
 
 
131 
attenuation of oxidative stress, activation of the lysosomal autophagy pathway and 
proteostasis (Tsunemi et al., 2012).  
 
Rifampicin, a well-known antibiotic widely in the treatment of tuberculosis and 
leprosy, has been proposed to be neuro-protective in PD and AD animal models (Jing 
et al., 2014, Umeda et al., 2016). Here I showed that treatment with rifampicin 
increased lifespan and improved locomotor ability in Aβ-expressing flies, in 
agreement with a previous APP mice model (Umeda et al., 2016). In accordance with 
previous observations in humans that rifampicin treatment reduced the risk of 
developing AD (Mcgeer et al., 1992), I also found that rifampicin treatment increased 
lifespan in wild type Drosophila, suggesting broad spectrum anti-ageing effects. A 
recent study suggested that rifampicin could reduce Aß oligomerization and improve 
the memory defects in an APP mouse model via improved autophagy-lysosomal 
function (Umeda et al., 2016). Here I confirmed that the amelioration of Aß-induced 
neurotoxic phenotypes by rifampicin are not due to a reduction in the level of Aß 
peptides, and therefore exclude an effect of rifampicin on APP processing. I found 
that rifampicin reduced Grp78 levels, suggesting that the rescue of Aβ toxicity is 
likely due to an increase in the UPRER. Our study points to a novel and unexplored 
role of rifampicin as a modulator of the UPRER in neurodegeneration downstream of 
Aβ accumulation. This may provide a useful therapeutic avenue in AD patients 
already displaying accumulation of Aβ peptides in the brain.  
 
Metabolic defects and disturbances in redox state can lead to alterations in circadian 
rhythm. In agreement with previous human and animal studies, I showed that Aβ 
disrupted the circadian rhythm (Harper et al., 2005, Niccoli et al., 2016, Blake et al., 
2015), leading to an increase in the period tau.  dPGC-1 activation has been shown to 
restore the period change in Aβ –expressing flies, which likely protects neurons from 
further deterioration (Kang et al., 2009). Moreover, a previous study found that 
knockout of the clock gene period did not further affect lifespan, climbing ability or 
neurodegeneration in an Aβ-expressing fly model that already exhibited circadian 
rhythm disruption (Long et al., 2014). Therefore, it would be interesting to know 
whether directly targeting the other clock gene could ameliorate Aβ neurotoxicity. 
Mammalian PGC-1α regulates the clock gene CLOCK expression by coactivating the 
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transcription factor RORα and is therefore involved in the second feedback loop (Liu 
et al., 2007). In the Drosophila second feedback loop, the transcription factor that 
induces the expression of clock gene dCLOCK is PDP1ϵ (Cyran et al., 2003). I first 
assessed the interplay between dPGC-1 and PDP1ϵ by FRET, and found these two 
molecules might physically interact in the fly brain. This suggests that the 
amelioration of circadian rhythm disruption by dPGC-1 over-expression in Aβ flies 
may be due to its direct interaction and co-activation with the transcription factor 
PDP1ϵ in the circadian clock. To evaluate this hypothesis, I over-expressed Pdp1ϵ in 
the neurons of Aβ-expressing flies, and found that this lead to a small but significant 
extension in lifespan without affecting Aβ levels. Over-expression of Pdp1ϵ did not 
rescue the climbing defects and therefore did not prevent Aβ-induced 
neurodegeneration. Similar to dPGC-1 gain-of-function, over-expression of Pdp1ϵ 
lead to a further increase in Grp78 transcription, and therefore activation of the 
UPRER. In keeping with this previous work has shown that flies lacking Pdp1ϵ are 
sensitive to oxidative damage, confirming its role in the maintenance of the redox 
state (Beaver et al., 2010). Here I also demonstrated that over-expression of Pdp1ϵ in 
neurons leads to increased expression of DHR96, suggesting a role in the 
detoxification pathway. Taken together, my results demonstrate that either genetic 
activation of dPGC-1 or Pdp1ϵ, or pharmacological treatment with rifampicin may 
provide novel therapeutic strategies in the prevention of AD. 
 
3.5 Materials and Methods 
3.5.1 Fly Husbandry and stocks 
All flies were reared at 25ºC on a 12:12 light: dark cycle at constant humidity and on 
standard sugar-yeast medium (15g/L agar, 50 g/L sugar, 100 g/L autolysed yeast). 
Adult-onset, neuron–specific expression of UAS constructs was achieved as 
previously described (Sofola et al., 2010). Briefly, 24-28 hours after eclosion female 
flies carrying a heterozygous copy of elavGS and at least one UAS-construct were fed 
SY medium supplemented with 200µM mifepristone (RU486) to induce transgene 
expression. Rifampicin was added to the SY medium food at a concentration of 
200µM or 500µM. The elavGS driver line was derived from the original elavGS 301.2 
line (Osterwalder et al., 2001) and obtained as generous gift from Dr H. Tricoire 
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(CNRS, France). The UAS-Aβ42Arc stock was a gift from Dr D. Crowther (University 
of Cambridge, UK). The UAS-spargel (UAS-dPGC-1) line was a gift from Dr. 
Christian Frei, and the UAS-Pdp1ϵ was obtained from FlyORF. All the lines were 
backcrossed 6 generations into the w1118 background. The UAS- Pdp1ϵ lines were 
backcrossed over 6 generations into the wDah background. All experiments were 
carried out on mated females, unless otherwise stated.  
 
3.5.2 Lifespan analyses 
Flies were raised at a standard density in 200mL bottles. After eclosion, flies were 
allowed to mate for 24-48 hours in the bottles. Mated females were then split into 
vials containing SYA medium with or without drugs, with 15 flies in each vial. 
Approximately 150 females flies were used for each condition in the lifespan 
experiments. Deaths were scored throughout the lifespan and flies tipped onto fresh 
food 3 times a week. Data were presented as cumulative survival curves, and survival 
rates were compared using log-rank tests. All procedures for lifespan experiments 
were performed at 25ºC unless otherwise stated. 
 
3.5.3 Climbing assays 
The climbing assay was performed as previously described (Kinghorn et al., 2015). 
Briefly, 15 flies were placed in a 25cm pipette, tapped to the bottom and allowed to 
climb for 45 seconds. The number of flies in the top 5cm, middle, and bottom 3cm 
was scored. A performance index was calculated for each time-point and plotted. 
Statistical analysis was performed in R using ordinal logistics regression, using the 
individual heights for each fly as data points.  
 
3.5.4 Circadian rhythm 
Individual, 21-day-old male flies were placed in 65 x 5 mm glass tubes containing 
standard 1xSYA, and their activity was recorded using the DAM system (Drosophila 
Activity Monitoring System, TriKinetics, Waltham, MA) as described previously 
(Veleri et al., 2007). Flies were entrained to a 12:12 hour LD cycle at 25°C and 65% 
humidity 24-36 hours before recording. 5 days of 12:12 hours LD were recorded 
followed by 5 days of 12:12 hours DD. Analysis of locomotor activity was performed 
using the fly toolbox and MATLAB software (MathWorks, Natick, MA) as described 
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previously (Levine et al., 2002). The circadian period was calculated using 
autocorrelation as described previously (Levine et al., 2002), and was presented by 
the mean values with their SEM. 
 
3.5.5 The DR protocol 
The specific preparation of the DR media has been described in Chapter 2. Work in 
this chapter used a DR-tent with 0.1SY, 1.0SY, and 2.0SY. RU486 was supplemented 
into the food to give a final concentration of 200µM. 
 
3.5.6 Paraquat injection 
Paraquat (Sigma 856177) was delivered at a dose of 50ng/mg as previously described 
(Bjedov et al., 2010). To deliver the compound, injection pipettes were prepared from 
10mm glass capillaries using the Flaming-Brown micropipette puller (Programme 2). 
A home-built microinjection machine was used for injections. In parallel flies were 
also injected with control Ringer’s solution. Both injected solutions contained blue 
dye for visualization of the injection (FD&C Blue No.1). 
 
3.5.7 Rifampicin treatment 
After eclosion flies were split into vials containing standard SY food supplemented 
with and without 200µM mifepristone (RU486), and with and without 200µM or 
500µM Rifampicin (Sigma R3501). Deaths were scored throughout the lifespan and 
flies tipped onto fresh food 3 times a week. Data were presented as the cumulative 
survival curves, and survival rates were compared using log-rank tests. 
 
3.5.8 Fly brain imaging using FRET acceptor photobleaching 
The following primary antibodies were used: the anti-HA (Abcam, #ab18181, 1:1000) 
and the anti-GFP (Invitrogen, A21311, 1µg/mL) antibodies. The goat anti-mouse IgG 
antibody (H+L) (Life technologies, A11019, 1µg/mL) was used as the secondary 
antibody. Brains were dissected in ice cold PBS and immediately fixed in 4% 
formaldehyde for 20*mins. Brains were then washed in 0.2% Triton-X/PBS, blocked 
in 5% bovine serum albumin/PBS, incubated in primary antibody overnight at 4°C 
and in secondary for 2*hours at RT. Brains were mounted in mounting medium 
containing DAPI (Vectastain). The method for FRET photobleaching was as 
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described previously (Broussard et al., 2013). Briefly, the system was set up to use the 
488 nm and the 555 nm lines of the laser as an excitation source for the GFP-based 
donor and RFP acceptor flurophores. 10% of the laser power was sufficient for the 
488 nm and 3% for the 555 nm. The image size was set to 512*512 pixel, with a line 
averaging of 2. GFP emission was measured from 454 to 505 nm, and the RFP 
emission from 530 to 590 nm. Photobleaching of the RFP was achieved within the 
ROI using the 555nm laser line. 100% power was sufficient. Images were captured 
with a Zeiss (UK) LSM 700*confocal laser-scanning microscope using a 60x oil-
immersion objective.  
 
3.5.9 Live cell imaging of the mitochondrial membrane potential 
For measurements of mitochondrial membrane potential, the dissected brains were 
loaded for 40*mins at room temperature with 25*nM tetramethylrhodamine 
methylester (TMRM) in HBSS (156*mM NaCl, 3*mM KCl, 2*mM MgSO4, 1.25*mM 
KH2PO4, 2*mM CaCl2 10*mM glucose and 10*mM HEPES at pH*7.35). TMRM was 
present in the imaging media throughout the experiment and was used in the quench 
mode to assess Δψm. Hence a reduction in TMRM intensity represents mitochondrial 
depolarization. Confocal images were obtained using a Zeiss 710 CLSM equipped 
with a ×40 oil immersion objective. Illumination intensity was kept to a minimum (at 
0.1–0.2% of laser output) to avoid phototoxicity. Fluorescence was quantified in 
individual mitochondria by exciting TMRM using the 561*nm laser line of a confocal 
microscope. Excitation and emission were measured above 580*nm. 4–5 fields per 
brain were acquired, and the mean maximal fluorescence intensity was measured for 
each group. The differences in Δψm were expressed as intensity units, arb.U, of 
TMRM. 
 
3.5.10 mtDNA measurement 
Genomic DNA and mitochondrial DNA from 20 fly heads were isolated using the 
Qiagen blood and tissue kit according to the manufacturer’s instruction. Quantitative 
PCR was performed suing the PRISM 7000 sequence-detection system (Applied 
Biosystem) and SYBR® Green (Molecular Probes) by following the manufacturer’s 
instructions. mtDNA in each sample were presented as a ratio of mitochondrial 
DNA/genomic DNA. Each sample was analysed in duplicate and values were 
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expressed as the mean of the 4 independent biological repeats +/- SEM. Primers used 
for genomic DNA were as follows: 
GAPDH:   
For: GACGAAATCAAGGCTAAGGTCG  
Rev: AATGGGTGTCGCTGAAGAAGTC 
For mitochondrial DNA the primers were as follows:  
COX I:  
For: GAATTAGGACATCCTGGAGC   
Rev: GCACTAATCAATTTCCAAATCC 
 
3.5.11 Quantitative PCR 
Total RNA was extracted from 20-25 fly heads per sample using TRIzol® (GIBCO) 
according to the manufacturer’s instructions. The concentration of total RNA purified 
for each sample was measured using the Nano Drop. 5µg of total RNA was then 
subjected to DNA digestion using DNase I (Ambion), immediately followed by 
reverse transcription using the SuperScript® II system (Invitrogen) with oligo(dT) 
primers. Quantitative PCR was performed suing the PRISM 7000 sequence-detection 
system (Applied Biosystem) and SYBR® Green (Molecular Probes) as per the 
manufacturer’s instructions. Each sample was analysed in duplicate and the values 
were presented as the means of 3-4 independent biological repeats +/- SEM. The 
primers used were: 
dPGC-1  
For; TCGGCGAGGATTTTTTGATC   
Rev: CGATTCGCCGCTCTTCA 
Aß42  
For: CGATCCTTCTCCTGCTAACC  
Rev: CACCATCAAGCCAATAATCG 
Grp78  
For: TCTTGTACACACCAACGCAGG 
Rev: CAAGGAGCTGGGCACAGTGA 
Spliced Xbp1 
For: CCGAACTGAAGCAGCAACAGC  
Rev: GTATACCCTGCGGCAGATCC  
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RP49  
For: ATCGGTTACGGATCGAACAA   
Rev: GACAATCTCCTTGCGCTTCT   
Cyt-c-p  
For: TAACGCGCGCTCGTCAT  
Rev: TTAACACGGACTCGAATTGAACAC 
DHR96 
For: CAAAGAGAGCATATTTAGGATACCAAG 
Rev: CACAGAACCCACGCTTCCAAG 
Cyp6a2  
For: GCGCAACGAGATCCAAAC  
Rev: TGTAGAGCCTCAGGGTTTCTG 
 
3.5.12 ATP assay 
ATP concentrations were determined using Roche ATP Bioluminesence Assay Kit 
HS II (Roche, West Sussex, UK). Briefly, 2 whole flies or 8 fly heads were 
decapitated and homogenized in 100 µl ice-cold lysis buffer using a Kontes pellet 
pestle. The lysate was then boiled for 5 min and centrifuged at 20,000g for 1 min. 
Cleared lysate was then diluted 1 in 200 in dilution buffer and ready to load with 10 
µL luciferase. The luminescence was immediately measured using a Tecan Infinite 
M2000 microplate reader and Magellan V6.5 software. Total proteins were measured 
using the Thermo Scientific BCA assay. ATP levels in each sample were expressed as 
a ratio of the total protein content. Data were expressed as the mean+/-SEM and 
obtained from 5-6 biological repeats for each genotype.  
 
3.5.13 Western blot analysis 
15 fly heads in each sample were prepared by homogenising in 2xSDS Laemmli 
sample buffer (4% SDS, 20% glycerol, 120 mM Tris-HCl pH6.8, 200 mM DTT with 
bromophenol blue) and boiled at 95ºC for 5 minutes. Samples were separated on pre-
cast 4-12% Invitrogen Bis-Tris gels (NP0322) and blotted onto nitrocellulose paper in 
Tris-glycine buffer supplemented with 10% ethanol. Membranes were blocked in 5% 
milk in TBST (TBS with 0.05% Tween-20) for 1 hour at RT and then incubated with 
the primary antibody in blocking solution. The primary antibody dilutions used were 
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anti-Grp78 (novusbio NBP1-06274, 1:1000) in 1% milk, 5% BSA in TBST for 1 hour 
at RT, anti-β actin (Abcam, #ab8224, 1:5000), anti-HSP60 (Cayman chemical, 
10011429, 1:1000) and anti-Grp75 (Abcam, #ab82591, 1:1000). The membranes were 
incubated in primary antibody in 5% BSA in TBS-T at 4ºC overnight unless 
otherwise stated. Secondary antibodies used were anti-rabbit and anti-mouse (Abcam 
#ab6721 and Abcam #ab6789 respectively) at 1:5000 dilutions for 1 hour at RT. 
Bands were visualized with Luminata Forte (Millipore) and imaged with ImageQuant 
LAS4000 (GE Healthcare Life Science). Quantification was carried out with ImageJ. 
 
3.5.14 Quantification of Aß42 
Five fly heads were homogenized in 50 ml GnHCl extraction buffer (5 M 
Guanidinium HCl, 50 mM Hepes pH 7.3, protease inhibitor cocktail (Sigma, P8340) 
and 5mM EDTA), centrifuged at 21,000g for 5 min at 4oC, and cleared supernatant 
was retained. Aß42 was measured with an ELISA kit (Millipore, EZHS42), according 
to the manufacturer’s instructions. The protein concentrations of the samples were 
measured using a Bradford assay (Bio-Rad protein assay reagent; Bio-Rad 
laboratories Ltd (UK) and the amount of Aß42 in each sample expressed as a ratio of 
the total protein content (pg/µg total protein). Data are expressed as the means +/- 
SEM and were obtained from three biological repeats for each genotype. 
 
3.5.15 Statistics 
Survival experiments were analyzed using a log rank test. The interactions between 
interventions in lifespan were analyzed using the Cox Proportional Hazard in a 
survival package developed from Terry M Therneau and Thomas Lumley 
(https://cran.r-project.org/web/packages/survival/survival.pdf) in R. Climbing assays 
were analyzed using ordinal logistics regression in R. Circadian rhythm data were 
analyzed using METLAB. Other data are presented as the means*±*SEM obtained 
from at least 3 independent experiments, and single comparisons were analysed using 
the Student’s t-test. Other data were tested by either one-way analyses of variance 
(Casali et al.) for three conditions or two-way ANOVA for four conditions with 
induction and genotype as main effects, and planned comparisons of means were 
made using Newman-Keuls test. Statistical analyses were performed using GraphPad 
Prism.  
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Chapter 4 The role of PGC-1α in a 
Drosophila model of Parkinson’s disease  
4.1 Summary 
Mitochondrial dysfunction has been implicated in the pathogenesis of PD. PGC-1α is 
the key regulator of mitochondrial biogenesis, and the possible link to PD arose from 
studies demonstrating decreased PGC-1α levels in human postmortem brain tissue, as 
well as in PD mouse models. Moreover, a genome-wide expression meta-analysis 
demonstrated that a number of genes downstream of PGC-1α are down-regulated in 
sporadic PD, suggesting that elevation of PGC-1α may offer a potential therapeutic 
strategy in PD. Here I found that over-expression of dPGC-1 did not rescue the toxic 
phenotypes of flies lacking PINK1 or parkin. Moreover, activation of dPGC-1 further 
increased the sensitivity to oxidative stress in PINK1 and parkin null mutants. This 
work demonstrates that the neuroprotective effects of dPGC-1 seen in the AD fly 
model are just not effective in these PD models. Further studies using different PD fly 
models and alternative organisms will be required to fully assess the role of dPGC-1 
in PD.  
 
4.2 Introduction 
Parkinson’s disease (PD) is the most common movement disorder. Studies on PD 
related genes have demonstrated that mitochondrial dysfunction plays a central role in 
the pathogenesis of PD. One of the most significant contributions of Drosophila 
models to the understanding of PD came from the elegant experiments in which the 
biology of PINK1 and parkin were elucidated (Greene et al., 2003, Whitworth and 
Pallanck, 2009, Whitworth et al., 2005, Park et al., 2009, Clark et al., 2006, Yang et 
al., 2006). Two genes related to autosomal recessive parkinsonism are PINK1 and 
PARK2. The Drosophila homologue of the PINK1 gene (also called CG4523) encodes 
a polypeptide of 721 amino acids with a molecular mass of about 80kDa. Similar to 
human PINK1, the structural analysis of the Drosophila PINK1 (dPINK1) protein also 
revealed 2 characteristic motifs: a mitochondrial targeting motif and a 
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serine/threonine kinase domain, which exhibited 60% similarity (42% identity) to that 
of human PINK1. Consistent with the localization of human PINK1, Drosophila 
PINK1 was also found localized to mitochondria (Park et al., 2006). Loss of dPINK1 
leads to a number of toxic phenotypes, including reduced longevity, indirect flight 
muscle and dopaminergic neuronal degeneration, accompanied by locomotor defects, 
increased sensitivity to oxidative stress, wing and thorax abnormalities and defective 
mitochondrial morphology and function (Park et al., 2006). 
Parkin functions as an E3 ligase in the ubiquitin protein degradation pathway. The 
Drosophila homologue of parkin (CG10523) encodes a polypeptide of 482 amino 
acid exhibiting 42% identity and 59% similarity overall with that of human parkin. 
Loss of the Drosophila homologue of parkin led to similar phenotypes to those of 
PINK1 knockdown, including reduced lifespan, locomotor defects and male sterility 
(Greene et al 2003). The locomotor defects derive from apoptotic cell death of muscle 
fibres, whereas the male sterile phenotype derives from a spermatid individualization 
defect at a late stage of spermatogenesis. Mitochondrial pathology is the earliest 
manifestation of muscle degeneration and a prominent characteristic of 
individualizing spermatids in parkin mutants (Greene et al., 2003). This study 
supported the concept that the tissue-specific phenotypes observed in Drosophila 
parkin mutants result from mitochondrial impairment, which is likely a main trigger 
to neurodegeneration in autosomal recessive juvenile Parkinsonism (ARJP). Further 
studies have shown that Drosophila parkin mutants display degeneration of a subset 
of dopaminergic neurons in the brain, mimicking the dopaminergic neuronal loss 
observed in sporadic PD (Whitworth et al., 2005). Moreover, these parkin mutant flies 
have increased oxidative stress and an impaired immune response, suggesting that 
these processes play a role in the pathogenesis of ARJP.  
Interestingly, it has also been demonstrated that over-expression of parkin ameliorates 
the loss-of-function phenotypes of PINK1, suggesting that parkin acts downstream of 
PINK1 (Park et al., 2006, Clark et al., 2006). Moreover, PINK1 kinase activity is 
required for its function in mitochondria, where PINK1 recruits parkin to localize to 
the mitochondria in a kinase-activity-dependent manner. This work in Drosophila has 
provided significant insights into the essential role of the PINK1-parkin pathway in 
regulating mitochondrial function, and highlights the importance of mitochondrial 
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dysfunction in the pathogenesis of PD. Furthermore, it has stimulated considerable 
research into the precise mechanisms linking loss-of-function of these two genes with 
mitochondrial dysfunction and neurotoxicity (Whitworth and Pallanck, 2009). In the 
normal state, PINK1 recruits parkin to translocate from the cytosol to the 
mitochondria in response to a fall in mitochondrial membrane potential, when 
mitochondria are under stress or become damaged (Zhang and Ney, 2010, Poole et al., 
2008, Narendra et al., 2008, Vives-Bauza et al., 2010, Kim et al., 2008). This 
physiological process terminates with a specialized form of autophagy, known as 
mitophagy, in which damaged mitochondria are engulfed in a double membrane and 
targeted to the lysosome for degradation (Deas et al., 2011, Youle and Narendra, 
2011). When either PINK1 or parkin function is lost (i.e. if the PINK1 or PARK2 
genes are mutated), this process cannot proceed and damaged mitochondria are 
retained within the cytoplasm. In turn, damaged mitochondria act as a source of 
oxidative stress that leads to DNA and cellular damage, ultimately causing neuronal 
death or muscle degeneration (Deas et al., 2011, Youle and Narendra, 2011, Green et 
al., 2011).  
As previously described, most of the physiological functions of PGC-1α have been 
studies in more details in metabolic tissues such as adipose tissue, liver and muscle. 
However, there have been only a few studies on the importance of PGC-1α in the 
brain. PGC-1α null mice show hyperactivity and other movement disorders that 
represent ganglia pathology, such as stimulus-induced myoclonus, dystonic posturing 
and frequent limb clasping. They also develop spongiform lesions in the striatum with 
axonal loss (Lin et al., 2004). In addition, PGC-1α has been demonstrated to play a 
role in the stress defense system. PGC-1α null mice display a severe loss of 
dopaminergic neurons compared to controls when challenged with MPTP (1- methyl-
4-phenyl-1, 2, 3, 6-tetrahydropyridine), an oxidative stressor that induces PD in 
human and animal models (St-Pierre et al., 2006). Flies over-expressing dPGC-1 
show increased resistance to paraquat, a potent oxidizer, highlighting its protective 
role in response to oxidative stress. In the previous Chapter, I demonstrated the 
neuroprotective effects of dPGC-1 in a Drosophila model of Aβ toxicity. Over-
expression of dPGC-1 ameliorated the shortened lifespan and neuronal phenotypes, 
including climbing defects and circadian rhythm disruption. This amelioration was 
associated with improved mitochondrial function and up-regulation of the UPR.  
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As described above, mitochondrial dysfunction is a predominant pathogenic feature in 
both familial and sporadic PD. A recent study demonstrated that parkin plays an 
important role in regulating mitochondrial biogenesis (Shin et al., 2011). It was shown 
that parkin physiologically ubiquitinates and thus regulates the proteasomal 
degradation of the genetic repressor PARIS. In turn, PARIS functions as a major 
genetic repressor of PGC-1α expression. Therefore, parkin loss-of-function leads to 
increased PARIS and reduced PGC-1α levels. The conditional knockout of parkin in 
adult mice leads to the progressive loss of dopaminergic neurons in a PARIS-
dependent manner, and this is reversed by over-expression of PGC-1α. This work 
therefore highlights the importance of PGC-1α in PD, and the potential therapeutic 
benefits of augmenting PGC-1α, especially in parkin-associated familial PD (Figure 
4.1). 
 
Figure 4.1 The PINK1-parkin pathway regulates mitochondrial function via PARIS and PGC-
1α. 
Under physiological conditions PINK1 recruits parkin to damaged mitochondria to induce mitophagy 
Parkin ubiquitinates PARIS, targeting it to degradation by the ubiquitin proteasome system. Reduced 
levels of PARIS lead to accumulation of PGC-1α, which in turn leads to increased mitochondrial 
biogenesis. If the parkin gene is mutated and there is loss-of-function of parkin, then it cannot be 
recruited to the damaged mitochondria to promote mitophagy. This therefore leads to increased 
production of ROS and mitochondrial damage. As a result of parkin loss-of-function PARIS 
accumulates and suppresses PGC-1α activity, leading to a reduction in mitochondrial biogenesis. As a 
result there is an increase in the number of damaged mitochondria and reduced mitochondrial 
biogenesis, leading to increased oxidative stress and neuronal death.  
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Moreover, the role of PGC-1α is not confined to patients with parkin mutations, but is 
also implicated in those with sporadic PD. Human postmortem brain tissue analysis 
revealed that sporadic PD patients displayed increased levels of PARIS and reduced 
expression of PGC-1α (Shin et al., 2011). In addition, a genome-wide expression 
meta-analysis independently demonstrated that 10 genes, which are known 
downstream targets of PGC-1α, were down-regulated in the SN of PD patients (Zheng 
et al., 2010). These genes mostly function in mitochondrial the ETC activity, glucose 
utilization, and glucose sensing, indicating that defects in energy metabolism 
mediated by PGC-1α occur early in the disease pathogenesis. PD pathology thus 
causes a reduction in PGC-1α and its downstream factors, leading to worsening of the 
disease pathology. Interestingly, over-expression of PGC-1α rescues dopaminergic 
neuronal loss in primary neuronal cultures expressing mutant α-synuclein, in 
association with up-regulation of genes in the mitochondrial ETC (Zheng et al., 
2010). Taken together, this work suggests that elevating PGC-1α may be a useful 
therapeutic target for treating PD.   
The question of whether reduced PGC-1α is a causal factor in the pathogenesis of PD 
is yet to be resolved. The reduction in PGC-1α seen in PD brains may contribute to 
the disease progression. Indeed it has been shown that a reduction in PGC-1α leads to 
increased sensitivity to stressors by elevating ROS, thereby impairing mitochondrial 
proteostasis, eventually leading to neuronal death (St-Pierre et al., 2006, Lu et al., 
2014, Haynes and Ron, 2010). I therefore studied the role of PGC-1α in PD 
pathogenesis, using a model of PINK1 and parkin loss-of-function in Drosophila 
melanogaster, which display shortened lifespans, behavioural defects and 
neurodegeneration (Clark et al., 2006, Greene et al., 2003).  
In order to determine whether PGC-1α contributes to the pathogenic cascades 
downstream of PINK1 and parkin loss-of-function, I genetically over-expressed 
dPGC-1 in PINK1 and parkin null mutant flies. I first demonstrated that the transcript 
levels of dPGC-1 were up-regulated in both PINK1 null mutants and parkin null 
mutants. dPGC-1 over-expression did not rescue the toxic phenotypes in either parkin 
or PINK1 null mutants in either males or females. Interestingly, PINK1 or parkin null 
mutants over-expressing of dPGC-1 were more sensitive to H2O2 or paraquat-induced 
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oxidative stress. Taken together, our results showed that elevation of dPGC-1 does 
not provide a beneficial effect in PD fly models lacking PINK1 and parkin.  
 
4.3 Results: 
4.3.1 Over-expression of dPGC-1 did not rescue the toxic phenotypes 
of PINK1 null mutants 
To investigate the role of dPGC-1 in PINK1 loss-of-function, I over-expressed dPGC-
1 in PINK1B9 null mutants, which have been previously characterized (Clark et al., 
2006). PINK1 is on the X chromosome and null mutant PINK1 males are sterile. I 
therefore only used male progeny for experiments. qRT-PCR analysis demonstrated 
that the transcript levels of dPGC-1 were increased in response to PINK1 loss-of-
function (Figure 4.2). I then assessed whether over-expression of dPGC-1 can 
ameliorate the neurotoxic phenotypes induced by PINK1 loss-of-function. I confirmed 
the over-expression of dPGC-1 using the UAS-dPGC-1 construct driven ubiquitously 
by the ActGS driver using qRT-PCR (Figure 4.3). Ubiquitous over-expression of 
dPGC-1 throughout development using the DaGAL4 driver neither extended lifespan 
nor improved the climbing defects in PINK1B9 null mutants (Figure 4.4 and 4.5), 
suggesting that elevation of dPGC-1 does not rescue the toxic phenotypes induced by 
PINK1 loss-of-function. 
 
 
Figure 4.2 The mRNA expression levels of dPGC-1 were increased in PINK1 loss-of-function flies 
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The dPGC-1 mRNA levels (relative to actin) in male PINK1B9 null mutant flies at 15-day-old were 
increased compared to control flies. This was measured using qRT-PCR and the bars represent the 
means ± SEM (n=4, ***p<0.001 by t test). The genotypes used were: w1118 and PINK B9. 
 
 
 
Figure 4.3 The mRNA expression levels of dPGC-1 were raised in dPGC-1-over-expressing flies 
The dPGC-1 mRNA levels (relative to RP49) were increased in 15-day-old flies ubiquitously over-
expressing dPGC-1, as measured by qRT-PCR. The bars represent the means ± SEM (n=4, ***p<0.001 
by t test). The genotypes used were: ActGS> UAS-dPGC-1. 
 
 
 
Figure 4.4 Ubiquitous over-expression of dPGC-1 did not extend the lifespan of PINK1 null 
mutant male flies 
Male flies lacking PINK1 show reduced survival compared to wild type flies (p=4.5 x 10-19 when 
comparing DaGAL4/+ with PINK1B9>DaGAL4/+). The survival curves demonstrated that ubiquitous 
over-expression of dPGC-1 did not rescue the shortened lifespan of PINK1B9 males. P=0.04 when 
comparing PINK1B9> Da-GAL4/+ with PINK1B9> Da-GAL4/UAS-dPGC-1. P=0.93 when comparing 
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PINK1B9> UAS-dPGC-1/+ with PINK1B9> Da-GAL4/UAS-dPGC-1 by log-rank test. The genotypes 
used were: Da-GAL4/+; UAS-dPGC-1/+; Da-GAL4/UAS-dPGC-1; PINK1B9> Da-GAL4/+; PINK1B9> 
UAS-dPGC-1/+; PINK1B9> Da-GAL4/UAS-dPGC-1. 
 
 
Figure 4.5 The over-expression of dPGC-1 in PINK1B9 null mutant male flies did not rescue the 
climbing defects 
The ubiquitous over-expression of dPGC-1 using the Da-GAL4 driver did not rescue the locomotor 
ability of PINK1B9 null mutant male flies using the negative geotaxis climbing assay. The bars are 
plotted as the means ± SEM, n=3, 15 flies per condition. **P<0.01, *p<0.05 by ANOVA analysis.  
 
 
4.3.2 Over-expression of dPGC-1 did not rescue the toxic phenotypes 
of parkin null mutants 
To investigate the role of dPGC-1 in neurotoxicity mediated by the loss of parkin, I 
first measured the levels of dPGC-1 in park25 null mutants, which have been 
previously characterized (Greene et al., 2003). qRT-PCR showed that the mRNA 
levels of dPGC-1 were increased in response to loss of parkin (Figure 4.6). I then 
assessed whether over-expression of dPGC-1 could ameliorate the neurotoxic 
phenotypes induced by parkin loss-of-function. Ubiquitous over-expression of dPGC-
1 throughout development using the ActGAL4 driver extended lifespan in both male 
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and female parkin null mutants (Figure 4.7 and 4.8), and improved the climbing 
defects in female parkin null mutants (Figure 4.9). However, the lifespan extension 
was not consistent and repeatable (Figure 4.10 and 4.11). These results therefore 
suggest that over-expression of dPGC-1 does not rescue the toxic phenotypes induced 
by parkin loss-of-function.  
 
 
Figure 4.6 The expression of dPGC-1 was increased in park25 null mutant flies 
dPGC-1 mRNA levels (relative to actin) in female park25 null flies at 15-day-old, measured by qRT-
PCR. The bars were plotted as the means ± SEM (n=4, *p<0.05 by t test). The genotypes used were: 
w1118 and park25. 
 
 
 
Figure 4.7 Ubiquitous over-expression of dPGC-1 extended the lifespan of park25 null mutant 
female flies  
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The survival curves of park25 female flies ubiquitously over-expressing dPGC-1. P=3.3 x 10-8 when 
comparing ActGAL4>+; park25 with ActGAL4>UAS-dPGC-1; park25. P=0.01 when comparing UAS-
dPGC-1>+; park25 with ActGAL4>UAS-dPGC-1; park25 by log-rank test. The genotypes used were: 
ActGAL4>+; park25, ActGAL4>UAS-dPGC-1; park25, UAS-dPGC-1>+; park25. 
 
 
 
Figure 4.8 Ubiquitous over-expression of dPGC-1 extended the lifespan of park25 null mutant 
male flies 
Ubiquitous over-expression of dPGC-1 in park25 null mutant male flies (ActGAL4>UAS-dPGC-
1;park25 (red line)) extended lifespan. P=0.03 when comparing ActGAL4>+; park25 with 
ActGAL4>UAS-dPGC-1; park25, P=1.7 x 10-6 when comparing UAS-dPGC-1>+; park25 with 
ActGAL4>UAS-dPGC-1; park25 by log-rank test. The genotypes used were: ActGAL4>+; park25, 
UAS-dPGC-1>+; park25, ActGAL4>UAS-dPGC-1; park25. 
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Figure 4.9 Ubiquitous over-expression of dPGC-1 in park25 null mutant female flies partially 
ameliorated the climbing defects 
Ubiquitous over-expression of dPGC-1 using the ActGAL4 driver rescued the climbing ability of park25 
null mutant female flies. The bars represent the means ± SEM, n=3, 15 flies per condition. **P<0.01, 
*p<0.05 by ANOVA. 
 
 
 
Figure 4.10 Ubiquitous over-expression of dPGC-1 did not extend the lifespan of park25 null 
mutant female flies 
Female flies lacking parkin show reduced survival compared to wild type flies (p=4.3 x 10-42 when 
comparing DaGAL4/+ with PINK1B9>DaGAL4/+).  Ubiquitous over-expression of dPGC-1 in park25 
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null mutant female flies did not recue the lifespan phenotype. P=1.6 x 10-6 when comparing 
ActGAL4>+; park25 with ActGAL4>UAS-dPGC-1; park25. P=0.03 when comparing UAS-dPGC-1>+; 
park25 with ActGAL4>UAS-dPGC-1; park25 by log-rank test. The genotypes used were: w1118, 
ActGAL4>+; park25, UAS-dPGC-1>+; park25, ActGAL4>UAS-dPGC-1; park25. 
 
 
 
Figure 4.11 Ubiquitous over-expression of dPGC-1 did not extend the lifespan of park25 null 
mutant male flies 
The survival curves of park25 male flies ubiquitously over-expresses dPGC-1. P=0.97 when comparing 
ActGAL4>+; park25 with ActGAL4>UAS-dPGC-1; park25, P=0.005 when comparing UAS-dPGC-
1>+; park25 with ActGAL4>UAS-dPGC-1; park25 by log-rank test. The genotypes used were: 
ActGAL4>+; park25, UAS-dPGC-1>+; park25, ActGAL4>UAS-dPGC-1; park25. 
 
 
4.3.3 Over-expression of dPGC-1 increased the sensitivity to oxidative 
stress of park25 null mutant male flies 
To assess whether flies over-expressing dPGC-1 are resistant to oxidative stress I 
assessed the survival of park25 null mutant flies treated with H2O2, a potent oxidizer, 
and with paraquat, a redox cycler. I demonstrated that both male and female flies 
lacking parkin had significantly reduced survival upon exposure to H2O2 (Figures 
4.12 and 4.13) and paraquat (Figures 4.14 and 4.15). Surprisingly ubiquitous over-
expression of dPGC-1 (ActGAL4>dPGC-1; park25) even further increased the 
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sensitivity of park25 null mutant male flies to oxidative stress, while further increased 
the sensitivity of park25 null mutant female flies to oxidative stress compared to one 
the control lines (UAS-dPGC-1>+; park25) but not the others (ActGAL4>+; park25).  
 
 
Figure 4.12 Ubiquitous over-expression of dPGC-1 did not alter the sensitivity to H2O2 of park25 
null mutant female flies 
Female flies lacking parkin (ActGAL4>+; park25) show increased sensitivity to 2.5% H2O2 compared 
to wild type flies (p=3.1 x 10-41). Ubiquitous over-expression of dPGC-1 using the ActGAL4 driver did 
not alter the sensitivity of park25 null mutant female flies on exposure to 2.5% H2O2 at 15-days of age. 
P=0.24 when comparing ActGAL4>+; park25 with ActGAL4>UAS-dPGC-1; park25. P=0.01 when 
comparing UAS-dPGC-1>+; park25 with ActGAL4>UAS-dPGC-1; park25 by log-rank test. The 
genotypes used were: w1118, ActGAL4>+; park25, UAS-dPGC-1>+; park25, ActGAL4>UAS-dPGC-1; 
park25. 
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Figure 4.13 Ubiquitous over-expression of dPGC-1 increased the sensitivity of park25 null mutant 
male flies to oxidative stress with H2O2 
Male flies lacking parkin (ActGAL4>+; park25) show increased sensitivity to 2.5% H2O2 compared to 
wild type flies (p=7.1 x 10-9). Ubiquitous over-expression of dPGC-1 in park25 null mutant flies 
(ActGAL4>UAS-dPGC-1;park25) reduced the survival on exposure to 2.5% H2O2 at 15-days of age. 
P=0.005 when comparing ActGAL4>+; park25 with ActGAL4>UAS-dPGC-1; park25, P=0.0003 when 
comparing UAS-dPGC-1>+; park25 with ActGAL4>UAS-dPGC-1; park25 by log-rank test. The 
genotype used were: w1118, ActGAL4>+; park25, UAS-dPGC-1>+; park25, ActGAL4>UAS-dPGC-1; 
park25. 
 
 
Figure 4.14 Ubiquitous over-expression of dPGC-1 did not alter the sensitivity of park25 female 
flies to paraquat 
Female flies lacking parkin (UAS-dPGC-1>+; park25) show increased sensitivity to 2.5% H2O2 
compared to wild type flies (p=5.5 x 10-6). Ubiquitous over-expression of dPGC-1 in park25 null 
mutant flies did not alter the sensitivity to treatment with 10mM paraquat at 15-days of age. P=0.5 
when comparing ActGAL4>+; park25 with ActGAL4>UAS-dPGC-1; park25. P=3.2 x 10-5 when 
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comparing UAS-dPGC-1>+; park25 with ActGAL4>UAS-dPGC-1; park25 by log-rank test. The 
genotypes used were: w1118, ActGAL4>+; park25, UAS-dPGC-1>+; park25, ActGAL4>UAS-dPGC-1; 
park25. 
 
 
 
Figure 4.15 Ubiquitous over-expression of dPGC-1 increased the sensitivity to oxidative stress on 
exposure to paraquat in park25 null mutant male flies 
Male flies lacking parkin (UAS-dPGC-1>+; park25) show increased sensitivity to 2.5% H2O2 compared 
to wild type flies (p=3.0 x 10-17). The survival curves of park25 null mutant male flies over-expressing 
dPGC-1 (ActGAL4>UAS-dPGC-1; park25) compared to flies lacking parkin only (ActGAL4>+; park25 
and UAS-dPGC-1>+; park25) on exposure to 10mM paraquat at 15-days of age. P=2.2 x 10-5 when 
comparing ActGAL4>+; park25 with ActGAL4>UAS-dPGC-1; park25. P=3.1 x 10-5 when comparing 
UAS-dPGC-1>+; park25 with ActGAL4>UAS-dPGC-1; park25 by log-rank test. The genotypes used 
were: w1118, ActGAL4>+; park25, UAS-dPGC-1>+; park25, ActGAL4>UAS-dPGC-1; park25. 
 
4.4 Discussion 
I demonstrated that the gene expression levels of dPGC-1 were up-regulated in 
PINK1 or parkin null mutant flies. This is opposite to what has been shown in human 
and mouse models, displaying reduced levels of PGC-1α in familial and sporadic PD 
(Shin et al., 2011, Zheng et al., 2010). The up-regulation of dPGC-1 that I see in the 
fly models of familial PD may represent a compensatory response to the 
mitochondrial dysfunction induced by PINK1 and parkin loss-of-function. Since flies 
do not have a homologue of PARIS, the transcriptional repressor of PGC-1α, this 
transcriptional regulation may not be conserved in Drosophila. To dissect the role of 
dPGC-1 in PINK1 and parkin loss-of-function, I further assessed the lifespan and 
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behavioral phenotypes in the corresponding null mutants over-expressing dPGC-1. I 
found that over-expression of dPGC-1 did not extend the lifespan of either PINK1 or 
parkin null mutant flies. Moreover, dPGC-1 over-expression did not improve the 
climbing phenotypes of PINK1 or parkin null mutants. These results suggest that 
elevation of dPGC-1 is not neuroprotective in PD fly models.  
 
 
4.5 Experimental procedures 
4.5.1 Fly strains and backcrossing 
The PINK1B9 line (w* PINK1B9/FM7i) was obtained from the Bloomington 
Drosophila Stock Centre (Park et al., 2006, Park et al., 2009) and contains a deletion 
of PINK1 on chromosome X. The park25 line (w; park25/TM6B. GFP) and the PINK1 
genomic rescue line were kind gifts from Dr. Alex Whitworth (University of 
Cambridge). All of the lines were backcrossed into the w1118 strain for at least 6 
generations before they were used in experiments. The PINKB9 and park25 lines have 
no visible phenotypes to follow for backcrossing. Therefore, the progeny from every 
generation of backcrossing were identified by PCR analysis with primers designed to 
detect the presence of the transgenic construct. This was performed as follows: a 
single cross was set up in an individual vial (one virgin female was crossed with one 
wild type male). They were then left for several days to mate and lay eggs. Female 
flies were then individually taken from each vial and used for PCR analysis. Only the 
progeny from female flies that were PCR-positive were selected for the next 
backcrossing. The PCR primers were designed using the Primer3 software. The PCR 
primers for PINK1B9 were: FOR: CCAAATGATTCGAGTCCACA+ REV: 
TCCAGTTCATCCTCCTTGCT. The size of the PCR product for PINK1B9 null flies 
was 721bp, while the size of the full PINK1 construct was 1291bp. For park25 the 
primers used were: FOR: CAGGAGTTTGTTTGTGGCACTGG+ REV:  
GCCATTACCTACCGAAACTTTACA. The PCR product size of the mutant flies 
was 500bp, while wild type flies had a 1.8kb PCR product size. The PINK1B9 null 
males are sterile, and females are balanced with FM7 on chromosome X. In order to 
pass the cytoplasmic content from w1118 virgin females to the progeny, I made double 
transgenic lines carrying both PINK1B9 and the PINK1 genomic rescue construct, so 
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that males were fertile and able to mate with w1118 virgin females. Once the initial 
cross was complete, the PINK1 genomic construct was removed by excluding orange 
eye color in the following generation. After 6 back-crosses the park25 null mutant 
lines were balanced twice with w1118; Cyo/Sp; TM6B/MKRS to create a stable stock. 
The PINK1B9 lines were balanced with FM6 to create a stable stock.  
 
4.5.2 qRT-PCR 
RNA extraction and cDNA synthesis have been previously described. The primers for 
qRT-PCR were: 
Actin: For: TTGTCTGGGCAAGAGGATCAG 
REV: ACCACTCGCACTTGCACTTTC  
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Chapter 5  PGC-1α-GABPα modulates 
ageing in Drosophila 
5.1 Summary 
Dietary restriction is an evolutionarily conserved intervention that extends healthy 
lifespan across different species. Our understanding of the molecular mechanisms 
downstream of the nutrient-sensing network has improved significantly over the last 
30 years, but is still not fully understood. PGC-1α is a key transcriptional co-activator 
in energy metabolism, and has recently been identified as a novel modulator of fly 
ageing, however the mechanism is not completely understood. Here I identified the 
transcription factor GA-binding protein (dGABPα), downstream of PGC-1α, as a key 
modulator of fly ageing. dGABPα gain-of-function extended female lifespan beyond 
dietary restriction (DR), with an associated reduction in IIS/mTOR signalling. Over-
expression of dGABPα improved gut homeostasis by delaying age-related over-
proliferation in intestinal stem cells. Additionally, dGABPα gain-of-function flies 
displayed resistance to xenobiotic stress. Finally, I demonstrated that dGABPα up-
regulates ImpL2, encoding the insulin ligand binding protein, which down-regulates 
IIS and extends lifespan. Given the evolutionarily conserved effects of reduced 
IIS/mTOR, the findings suggest that GABPα may be an effective modulator of 
mammalian ageing. 
 
5.2 Introduction 
An increasing ageing population coupled with the rising prevalence of age-related 
diseases, highlights the need for effective strategies to improve healthy ageing. 
Ageing is a complex process that includes genetic and environmental factors. The 
most successful insights into ageing came from the discovery that ageing could be 
ameliorated by dietary, genetic, or pharmacological interventions. DR, an intervention 
that chronically reduces food intake without malnourishment, is the most robust 
environmental method to extend longevity in a wide range of evolutionarily diverse 
organisms, from yeast to mammals (Fontana et al., 2010, Colman et al., 2009, Katewa 
and Kapahi, 2010). DR can also improve healthy lifespan and reduce the prevalence 
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of age-related diseases in humans and mammalian models (Colman et al., 2014, 
Mattison et al., 2012, Ikeno et al., 2006, Maeda et al., 1985, Cava and Fontana, 2013, 
Heilbronn et al., 2006, Masoro, 2003). The mechanisms by which DR improves 
healthy lifespan have not been fully elucidated. However, the wide use of shorter-
lived organisms including, C. elegans and Drosophila, has facilitated the 
experimental discovery of genetic and pharmacological interventions that extend 
healthy lifespan. The molecular mediators of the effects of DR on longevity include 
the mTOR (Kaeberlein et al., 2005, Chen et al., 2009b, Honjoh et al., 2009, Jia et al., 
2004, Hansen et al., 2008), insulin/IGF-1-like signalling (IIS) (Broughton et al., 2010, 
Laplante and Sabatini, 2012, Takano et al., 2001), the energy sensor 5’ adenosine 
monophosphate-activated protein kinase (AMPK) (Burkewitz et al., 2014, Greer et 
al., 2007, Slack et al., 2012), sirtuins (Guarente, 2013), NF-E2-related factor (NRF2) 
(Castillo-Quan et al., 2016) and heat shock factors (HSFs) (Heydari et al., 1996).  
 
In addition to reducing food intake, the timing of the meal has also emerged as an 
important determinant of ageing. Intermittent fasting (IF) or chronic starvation 
extends lifespan in C. elegans through mechanisms that include reduced IIS/mTOR 
signalling (Honjoh et al., 2009, Kaeberlein et al., 2006, Lee et al., 2006, Uno et al., 
2013). Moreover, short term fasting in human or mammalian models results in an 
improved healthy lifespan and the reduced prevalence of age-related chronic 
disorders. This involves mechanisms such as induction of the chaperone HSP70 and 
inhibition of the IIS/mTOR signalling network (Brown-Borg and Rakoczy, 2013, 
Mattson et al., 2014, Cheng et al., 2014). However, the effect of fasting or starvation 
on cachexia, such as in cancer, may be detrimental, leading to organ wasting and loss 
of body mass. Fasting in rats increased the production of TGF-beta1, leading to the 
initiation and promotion of liver carcinogenesis (Tessitore and Bollito, 2006). In a 
Drosophila tumour model, resulting from activation of the oncogene Yorkie in 
intestinal stem cells, there was organ-wasting associated with a sustained and 
dramatic reduction in systemic IIS signalling, via increased levels of the secreted 
insulin antagonist ImpL2 (Kwon et al., 2015, Figueroa-Clarevega and Bilder, 2015). 
Interestingly, over-expression of ImpL2 extends lifespan in Drosophila via 
mechanisms consistent with reduced IIS signalling, suggesting a possible involvement 
in mammalian ageing (Alic et al., 2011b). Therefore, wasting, starvation, IF, and DR 
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might share similar molecular mechanisms, including reduced IIS signalling, in 
response to nutritional limitation. However, the outcomes are varied depending on 
multiple factors, including the levels of signalling reduction, nutrient availability and 
the sensitivity of the host.  
 
The functions of the insulin/IGF-1-like signalling (IIS) pathway include regulation of 
growth, development, reproduction, stress resistance and metabolic homeostasis. 
Insulin-like ligands mediate cell-to-cell signalling by activating an insulin-like 
receptor, leading to the activation of PI3K (Phosphatidylinositide 3-kinase), AKT, 
mTOR, and ERK (extracellular signal-regulated kinases) intracellular signalling 
pathways (Tatar et al., 2003, Piper et al., 2008, Slack et al., 2015). Reduced IIS 
increases longevity in nematodes, fruit flies and mice (Fontana et al., 2010, Kenyon, 
2010), highlighting the relevance of IIS in human ageing. Lifespan extension and 
stress resistance resulting from down-regulation of IIS are mediated by the FOXO 
family of transcription factors through PI3K and AKT kinase signalling (Laplante and 
Sabatini, 2012). Inhibition of AKT activates FOXO, which in turn up-regulates 
several “longevity genes” controlling DNA repair, autophagy, antioxidant activity, 
stress resistance, as well as cell proliferation (Wang et al., 2014, Webb and Brunet, 
2014). 
 
The evolutionarily conserved mTOR signalling pathway responds to growth factors 
and amino acids to regulate the growth and metabolism of all eukaryotic cells. mTOR 
functions via two distinct multiprotein complexes: mTOR complex 1 (mTORC1) and 
mTOR complex 2 (mTORC2) (Johnson et al., 2013). mTORC1 regulates growth 
through phosphorylation of the downstream effectors ribosomal protein S6 kinases 
(S6Ks). Under favourable conditions, such as an amino acid-rich diet, phosphorylated 
S6K promotes cellular growth and alters metabolism (Um et al., 2006). mTORC1-
dependent phosphorylation of the eukaryotic translation initiation factor 4E-binding 
protein 1 (4E-BP1) disrupts its association with the translation initiation factor 4E 
(elF4E), allowing the latter to promote cap-dependent translation (Sonenberg and 
Hinnebusch, 2009). Rapamycin, a natural macrolide compound isolated from bacteria, 
inhibits mTORC1 activity, extending the lifespan across species from yeast to 
mammals. Rapamycin acts by reducing mRNA translation and by inducing autophagy 
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through at least two mTORC1 substrates, S6K and 4E-BP1 (Bjedov et al., 2010, 
Powers et al., 2006, Robida-Stubbs et al., 2012, Harrison et al., 2009, Medvedik et al., 
2007, Miller et al., 2011). Moreover, inhibition of mTORC1 also improves 
proteostasis and enhances stem cell function (Kapahi et al., 2010, Johnson et al., 
2013). mTORC2 is not sensitive to inhibition by rapamycin, and is usually considered 
not relevant to nutrient sensing. However it can positively regulate the IIS pathway by 
activating phosphorylation of AKT, the main kinase in the IIS pathway (Guertin and 
Sabatini, 2009). In addition, AKT kinase can then phosphorylate and inactivate 
mTORC1, while S6K negatively regulates the insulin receptor substrate 1 (Laplante 
and Sabatini, 2012, Takano et al., 2001, Um et al., 2006). It has also been shown that 
the mTORC1 substrate 4E-BP is a transcriptional target of FOXO in fruit flies 
(Tettweiler et al., 2005).  
 
PGC-1α is the master regulator of many biological processes, including adaptive 
thermogenesis (Puigserver et al., 1998), mitochondrial biogenesis (Wu et al., 1999), 
glucose metabolism (Miura et al., 2003), hepatic gluconeogenesis, fatty acid oxidation 
(Li et al., 2007b, Puigserver et al., 2003), circadian rhythmicity (Liu et al., 2007) as 
well as stress response systems (St-Pierre et al., 2006). PGC-1α is directly regulated 
by insulin-stimulated AKT phosphorylation in hepatic metabolism (Li et al., 2007b). 
Phosphorylation and inhibition prevent the recruitment of PGC-1α to its cognate 
promoters, impairing its ability to bind and co-activate FOXO1 or HNF4 (hepatocyte 
nuclear factor) to promote gluconeogenesis and fatty acid oxidation (Puigserver et al., 
2003, Li et al., 2007b). Moreover, PGC-1α can also be regulated by FOXO1 in the 
control of mitochondrial biogenesis in response to insulin signalling (Cheng et al., 
2009). Drosophila PGC-1 (dPGC-1), the only homologue of the mammalian PGC-1 
family, regulates mitochondrial activity, cellular growth and metabolism in response 
to insulin signalling in parallel with FOXO, the main IIS downstream effector 
responsible for cellular growth (Mukherjee and Duttaroy, 2013, Tiefenböck et al., 
2010). Interestingly, dPGC-1 can also negatively regulate insulin signalling, although 
the precise mechanisms involved are not known (Tiefenböck et al., 2010).  
 
dPGC-1 is also a terminal target of the mTOR signalling pathway in regulating 
cellular growth and metabolism (Mukherjee and Duttaroy, 2013, Tiefenböck et al., 
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2010). It may be regulated in a number of different ways. Inhibition of mTOR1 by 
rapamycin reduces the transcript levels of PGC-1α (Cunningham et al., 2007), and 
inhibition of mTORC1 induces Mitf, the Drosophila homologue of the transcription 
factor EB (TFEB). This translocates to the nucleus and directly up-regulates the 
transcript levels of dPGC-1 (Bouche et al., 2016). Moreover, the mTOR signalling 
pathway is associated with human longevity (Passtoors et al., 2013), and over-
expressing dPGC-1 in the intestinal system of the fruit fly extends lifespan with 
improved gut homeostasis and increased mitochondrial biogenesis, suggesting PGC-
1a might be a modulator for mammalian ageing. However, the direct contribution of 
mitochondrial function in regulating longevity has not been investigated (Rera et al., 
2011). Therefore, whether mitochondrial function is the major determinant of PGC-
1α-mediated lifespan extension in response to reduced mTOR signalling is yet to be 
proven. Some studies have however demonstrated that inhibition of mTORC1, or up-
regulation of 4E-BP, results in a metabolic shift towards greater mitochondrial 
respiration and increased lifespan across species from yeast to mice (Bonawitz et al., 
2007, Polak et al., 2008, Morita et al., 2013, Zid et al., 2009). In addition, mild 
inhibition of mitochondrial respiration extends lifespan of many organisms including 
worms, flies and mice (Feng et al., 2001, Dillin et al., 2002, Lee et al., 2003, Lee et 
al., 2010, Liu et al., 2005, Dell'agnello et al., 2007, Copeland et al., 2009). I therefore 
hypothesised that PGC-1α, being-downstream of IIS/mTOR signalling, may regulate 
longevity partially through a mitochondrial-independent manner.  
 
In order to address this hypothesis, I first investigated whether genetic activation of 
the transcription factors required by PGC-1α in regulating mitochondrial biogenesis 
and respiration can affect lifespan. PGC-1α co-activates a number of different 
transcription factors, including NRF1, GABPα, YY1 and ERRα (Puigserver and 
Spiegelman, 2003, Scarpulla, 2008, Cunningham et al., 2007). GABPα is the alpha 
subunit of the GA binding protein complex, which is a mammalian E26 
transformation-specific (ETS) transcription factor required for mitochondrial 
biogenesis (Yang et al., 2014). In addition, GABPα can be induced and co-activated 
by PGC-1α in skeletal muscle, forming a double-positive-feedback loop that drives 
the expression of many genes in OXPHOS and during neuromuscular junction (NMJ) 
programming (Handschin et al., 2007, Mootha et al., 2004, Wu et al., 1999). In 
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Drosophila, PGC-1α and GABPα work by overlapping mechanisms required for 
mitochondrial abundance and gene expression for OXPHOS (Baltzer et al., 2009), 
suggesting a conserved function with their mammalian counterparts (Mootha et al., 
2004, Yang et al., 2014). I hypothesised that if PGC-1α extends lifespan partially 
through GABPα, then over-expression of GABPα might be enough to extend lifespan.  
 
As described in this Chapter, I first re-examined the effect of dPGC-1 over-expression 
on the lifespan of Drosophila, and found that both ubiquitous and CNS specific over-
expression of dPGC-1 extends lifespan. In keeping with its human counterpart, 
dPGC-1 over-expression also up-regulated the transcription of dGABPα. Either 
ubiquitous or tissue-specific (brain or gut and fat body) over-expression of dGABPα 
was sufficient to extend lifespan via mechanisms beyond DR. It also improved 
measures of health, including increased resistance to xenobiotic stress and improved 
gut homeostasis. Surprisingly I found that dGABPα up-regulated the levels of ImpL2, 
the secreted insulin antagonist and an important negative regulator of IIS. This 
suggests that up-regulation of dGABPα may therefore modulate insulin sensitivity. To 
assess this further I performed both lifespan and bioinformatics analyses, and 
confirmed that over-expression of dGABPα extends lifespan through overlapping 
mechanisms with reduced IIS. In addition, over-expression of dGABPα also reduced 
mTORC1 activity, therefore extending lifespan in a similar manner to rapamycin. My 
results point to the possibility that GABPα, or a related protein, may be an effective 
modulator of mammalian ageing and age-related diseases. Further work is now 
required to study the effects of up-regulating GABPα in specific disease models, such 
as the AD and PD fly models. 
 
5.3 Results 
5.3.1 Over-expression of dPGC-1 extended the lifespan of female 
Drosophila  
Previous studies demonstrated that over-expression of dPGC-1 specifically in the 
intestine extends lifespan (Rera et al., 2011). I then asked whether over-expression of 
dPGC-1 throughout the fly is also sufficient to extend lifespan.  Ubiquitous over-
expression of dPGC-1, either throughout development using the ActGAL4 driver, or 
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in adulthood using the Actin-GeneSwitch (ActGS) driver, significantly increased the 
median lifespan of female flies by 9% (Figure 5.1, p=3.28 x 10-18; Figure 5.3, p=3.54 
x 10-6) but not in males (Figure 5.2, p=0.1). Additionally, over-expression of dPGC-1 
delayed the age-related decline in climbing ability (Figure 5.4), a behavioural 
measurement of neuromuscular health. My results therefore confirm that dPGC-1 is 
indeed a modulator for healthy ageing.  
 
 
 
Figure 5.1 Ubiquitous over-expression of dPGC-1 extended the lifespan of female flies 
Ubiquitous over-expression of dPGC-1 throughout development and adulthood using the ActGAL4 
driver (ActGAL>UAS-dPGC-1, green line) extended the lifespan of female flies (the median lifespan 
was extended by 9%, p=3.28 x 10-18 when comparing ActGAL4>UAS-dPGC-1 and +>UAS-dPGC-1; 
p=2.2 x 10-8 when comparing ActGAL4/UAS-dPGC-1 and ActGAL4/+ by log-rank test). The genotypes 
used were: ActGAL4/UAS-dPGC-1, ActGAL4>+, +>UAS-dPGC-1. 
PGC-1α in neurodegeneration and ageing 
 
 
 
163 
 
Figure 5.2 Ubiquitous over-expression of dPGC-1 during development and in adulthood did not 
extend the lifespan of male flies 
Ubiquitous expression of dPGC-1 throughout development and in adulthood using the ActGAL4 driver 
(ActGAL4>UAS-dPGC-1, green line) did not extend the lifespan of male flies. P=0.1 when comparing 
ActGAL4>UAS-dPGC-1 and ActGAL4>+ by log-rank test. The genotypes used were: ActGAL4>UAS-
dPGC-1, ActGAL4>+, +>UAS-dPGC-1. 
 
 
Figure 5.3 Ubiquitous over-expression of dPGC-1 only in adulthood extended the lifespan of 
female flies 
Ubiquitous over-expression of dPGC-1 in adulthood only using the ActGS driver in the presence of RU 
(ActGS>UAS-dPGC-1, RU+, red line) extended the lifespan of flies compared to un-induced (RU-) 
controls (the median lifespan  was extended by 8.7%, p=3.54 x 10-6 by log-rank test). The genotypes 
used were: ActGS>UAS-dPGC-1. 
PGC-1α in neurodegeneration and ageing 
 
 
 
164 
 
Figure 5.4 Ubiquitous over-expression of dPGC-1 partially ameliorated the locomotor 
abnormalities of flies 
Ubiquitous over-expression of dPGC-1 using the ActGAL4 driver (ActGAL4>UAS-dPGC-1, black 
bars) partially rescued the age-dependent climbing defects of control flies.  ***P<0.001 when 
comparing the dPGC-1 over-expressing flies to age-matched control flies response by two-way 
ANOVA analysis. For example, ****p<0.0001 when comparing ActGAL4>UAS-dPGC-1 over-
expressing flies and +>UAS-dPGC-1 flies at day 22 by Tukey’s multiple comparisons test. The 
genotypes used were: ActGAL4>UAS-dPGC-1, ActGAL4>+, +>UAS-dPGC-1. 
 
I previously demonstrated that over-expression of dPGC-1 extends lifespan in AD 
flies expressing Aβ (Chapter 3). I hence asked whether longevity would be affected if 
dPGC-1 is over-expressed in neurons in the absence of Aβ. Interestingly, over-
expression of dPGC-1 in adult neurons using the elavGS driver was sufficient to 
extend lifespan (Figure 5.5, the median lifespan was extended by 6%, p<0.0001), 
suggesting a broad-spectrum effect of neuronal dPGC-1 on lifespan regulation. 
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Figure 5.5 Over-expression of dPGC-1 in adult neurons extended lifespan 
Over-expression of dPGC-1 in adult neurons using the elavGS driver induced in the presence of RU 
(elavGS>UAS-dPGC-1, RU+, red line) extended the lifespan of flies compared to the un-induced 
control (RU-, black line). The median lifespan was increased by 6%, P<7 x 10-5 by log-rank test. The 
genotypes used were: elavGS>UAS-dPGC-1. 
 
Interventions that extend the lifespan of flies are often associated with resistance to 
various stressors (Castillo-Quan et al., 2016, Broughton et al., 2005, Afschar et al., 
2016). Ablation of PGC-1α in cultured cells down-regulates antioxidants including 
SOD1 and 2, resulting in hypersensitivity to hydrogen peroxide (H2O2)-induced 
oxidative stress. Conversely, over-expression of PGC-1α in muscles up-regulates the 
same genes, suggesting that PGC-1α regulates the antioxidant defence system as well 
as mitochondrial ROS (St-Pierre et al., 2006). Tissue-specific over-expression of 
dPGC-1 has been reported to suppress ROS in the gut of flies (Rera et al., 2011), and 
even when dPGC-1 is ubiquitously over-expressed there is resistance to paraquat-
induced oxidative stress. However the levels of SOD1 and SOD2 are not changed in 
response to dPGC-1 (Mukherjee et al., 2014). I therefore investigated the survival of 
flies over-expressing dPGC-1 under exposure to H2O2, a potent oxidizer, or paraquat, 
a redox cycler, which produces superoxide in part through the mitochondria 
(Cocheme and Murphy, 2008). I found that ubiquitous over-expression of dPGC-1 
increased the sensitivity of flies to H2O2-induced oxidative stress (Figure 5.6, p=3 x 
10-21). Moreover, dPGC-1 activation did not change the survival of flies exposed to 
paraquat (Figure 5.7, p=8.5). These results therefore do not support previous findings 
PGC-1α in neurodegeneration and ageing 
 
 
 
166 
(Mukherjee et al., 2014), and suggest  an increased sensitivity to oxidative stress in 
response to dPGC-1 over-expression.  
 
 
 
Figure 5.6 Ubiquitous over-expression of dPGC-1 increased the sensitivity of female flies to H2O2 
Ubiquitous over-expression of dPGC-1 throughout development and in adulthood using the ActGAL4 
driver (ActGAL4>UAS-dPGC-1, red line) decreased the survival of females flies on food containing 
2.5% H2O2. P=1.61x 10-18 when comparing ActGAL4>UAS-dPGC-1 and +>UAS-dPGC-1. P=3 x 10-21 
when comparing ActGAL4>UAS-dPGC-1 and ActGAL4>+ by log-rank test. The genotypes used were: 
ActGAL4>UAS-dPGC-1, ActGAL4>+, +>UAS-dPGC-1. 
 
 
 
Figure 5.7 Ubiquitous over-expression of dPGC-1 did not significantly affect the lifespan of flies 
exposed to paraquat. 
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Ubiquitous over-expression of dPGC-1 using the ActGAL4 driver (ActGAL4>UAS-dPGC-1; red line, 
RU+) did not significantly alter the survival of female flies exposed to 10mM paraquat. P=0.85 when 
comparing ActGAL4>UAS-dPGC-1 and ActGAL4>+. P=0.04 when comparing ActGAL4>UAS-dPGC-
1 and +>UAS-dPGC-1 by log-rank test). The genotypes used were: ActGAL4>UAS-dPGC-1, 
ActGAL4>+, +>UAS-dPGC-1. 
 
5.3.2 Over-expression of dYY1 extended lifespan in female flies 
To investigate whether downstream TFs mediate the lifespan extension of dPGC-1 
over-expression, the effects of YY1 (Cunningham et al., 2007), PDP1ε (Cyran et al., 
2003), and GABPα (Mootha et al., 2004, Baltzer et al., 2009) on survival were tested. 
Mammalian YY1 regulates mitochondrial biogenesis by co-activation with PGC-1α in 
response to mTOR signalling. However the effect of the Drosophila homologue of 
YY1 (pho, CG17743) on mitochondrial function and lifespan is not yet known. Here I 
show that ubiquitous over-expression of dYY1 extended the median lifespan by 6% 
and maximum lifespan by 12% in female flies (Figure 5.8).  
 
 
Figure 5.8 Ubiquitous over-expression of dYY1 in adulthood extended the lifespan of female flies 
Ubiquitous over-expression of dYY1 in adulthood using the daGS driver and inducing expression with 
RU (daGS>UAS-dYY1, red line, RU+) increased the lifespan of female flies compared with un-induced 
controls (black line, RU-). The median lifespan extension was 6%, the maximum lifespan extension 
was 12%, p=0.003 by log-rank test. The genotypes used were: daGS>UAS-dYY1. 
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PDP1ε is a transcription factor involved in the second feedback loop of the circadian 
clock and positively regulates the transcription levels of dCLOCK. Conversely VRI is 
the transcription factor that negatively regulates dCLOCK (Cyran et al., 2003). Flies 
lacking Pdp1ε display hypersensitivity to oxidative stress (Beaver et al., 2010), 
whereas over-expression of Pdp1ε increases the transcription levels of genes involved 
in the stress-response pathway such as DHR96, Xbp1 and Grp78 (Figure 3.34, 3.36, 
and 3.37). Disturbances in circadian rhythm and the stress response pathway 
contribute to ageing (Harper et al., 2005, Taylor and Dillin, 2013, Hipp et al., 2014, 
Musiek et al., 2013), suggesting that PDP1ε and VRI may be significant modulators 
of fly ageing. I previously showed that dPGC-1 and PDP1ε may physically interact in 
the fly brain. I therefore investigated whether over-expression of Pdp1ε modulates 
longevity. I found that ubiquitous over-expression of Pdp1ε did not extend the 
lifespan of flies (Figure 5.9, p=0.9). Similarly, ubiquitous over-expression of vri 
shortened the lifespan of flies (Figure 5.10, p=0.008). These results therefore suggest 
that activation of the circadian genes involved in the second feedback loop in 
Drosophila does not extend lifespan.  
 
 
Figure 5.9 Ubiquitous over-expression of Pdp1ε in adulthood does not extend lifespan in female 
flies 
Ubiquitous over-expression of Pdp1ε in adulthood using the daGS driver induced by the presence of 
RU (daGS>UAS-Pdp1, red line, RU+) did not affect the lifespan compared to non-induced controls 
(black line, RU-). P=0.9 by log-rank test. The genotypes used were: daGS>UAS- Pdp1ε. 
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Figure 5.10 Ubiquitous over-expression of vri shortened the lifespan of female flies 
Ubiquitous over-expression of vri in adulthood using the daGS driver induced by RU (daGS>UAS-vri, 
blue unbroken line, RU+) shortened the lifespan compared to un-induced female flies (blue broken 
line, RU-). P=0.008 by log-rank test. The genotypes used were: daGS>UAS-vri. 
 
 
5.3.3 Adult-onset over-expression of dGABPα extended lifespan. 
I then assessed whether direct activation of dGABPα was sufficient to extend lifespan. 
Adult ubiquitous over-expression of dGABPα resulted in a modest but significant 
lifespan extension in female flies (Figure 5.11), with an increase in median survival of 
8.9% (p=1.93 x 10-8). qRT-PCR confirmed the increase in transcript level of dGABPα 
following induction with RU486 administration (Figure 5.13). In addition, ubiquitous 
knockdown of dGABPα using RNAi significantly shortened lifespan in female flies 
(Figure 5.12, p=3.6 x 10-20), and qRT-PCR confirmed the reduced transcript levels of 
dGABPα by ~20% in these flies (Figure 5.13). Interventions that extend fly lifespan 
are often associated with reduced fecundity (Bjedov et al., 2010, Alic et al., 2011b, 
Broughton et al., 2010, Slack et al., 2015). I therefore assessed whether dGABPα 
over-expression affects reproductive ability. Although there was a trend towards a 
reduction in egg laying in response to dGABPα over-expression, this did not reach 
statistical significance (Figure 5.14). Therefore, our results show that dGABPα is a 
modulator of longevity.  
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Figure 5.11 Over-expression of dGABPα in adulthood extended the lifespan in female flies. 
Ubiquitous over-expression of dGABPα in adulthood using the daGS driver induced by RU 
(daGS>UAS-dGABPa, red line, RU+) extended lifespan compared with non-induced controls (black 
line, RU-). The median lifespan was extended by 9 % p=1.93 x 10-8 by log-rank test. The genotypes 
used were: daGS>UAS-dGABPa. 
 
 
 
Figure 5.12 Knockdown of dGABPα in adulthood using RNAi shortened the lifespan of female 
flies 
Knockdown of dGABPα in adulthood using RNAi (daGS>UAS-dGABPαRNAi, red line, RU+) resulted in 
a decrease in lifespan compared with the un-induced control flies (black line, RU-). The median 
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lifespan was shortened by 13% p=3.6 x 10-20 by log-rank test. The genotypes used were: daGS>UAS-
dGABPαRNAi. 
 
Figure 5.13 dGABPα expression levels in flies either over-expressing dGABPα or expressing the 
RNAi construct against dGABPα 
(A, B) The mRNA levels of dGABPα, GstD2, and cyp6a8 were determined by qRT-PCR and 
normalized to a control gene (RP49). The bars are plotted as the means ± SEM, n=4. ***P<0.001, 
**p<0.01, *p<0.05 by t-test. The genotypes used were: (A) daGS>UAS-dGABPα and  (B) daGS>UAS-
dGABPαRNAi. 
 
 
 
Figure 5.14 Ubiquitous over-expression of dGABPα did not affect fecundity 
Ubiquitous over-expression of dGABPα in adulthood using the daGS driver (daGS>UAS-dGABPα, 
RU+) did not alter the average number of eggs laid per female over 24 hours compared to that of un-
induced control flies (-RU) at 12-days of age. The bars represent the means ± SEM, p>0.05 by t-test. 
The genotypes used were: daGS>UAS-dGABPα. 
 
I then asked whether dGABPα, similar to its mammalian counterpart, is itself 
downstream of dPGC-1 (Mootha et al., 2004). Indeed I showed that over-expression 
of dPGC-1 significantly increased the transcript levels of dGABPa (Figure 5.15, 
p<0.01), suggesting that dGABPa is activated downstream of dPGC-1.  
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Figure 5.15 Over-expression of dPGC-1 up-regulated dGABPα 
Ubiquitous over-expression of dPGC-1 in adulthood using the ActGS driver by induction with RU 
(ActGS>UAS-dPGC-1, red bar, RU+) resulted in an up-regulation of dGABPa gene expression. The 
mRNA levels of dGABPα were determined by qRT-PCR and normalized to the control gene (RP49). 
The bars are representative of the means ± SEM, n=4.  **P<0.01, by t-test. The genotypes used were: 
ActGS>UAS-dPGC-1. 
 
5.3.4 The tissue-specific over-expression of dGABPα extended 
lifespan 
The Drosophila brain, gut, and fat body, the latter functionally being equivalent to the 
mammalian liver and adipose tissue, have an evolutionarily conserved function in 
ageing (Fontana et al., 2010). I therefore examined whether confining dGABPα over-
expression to these organs is sufficient to extend lifespan. Using the inducible, pan-
neuronal elavGS driver or the gut- and fat body-specific S1106 driver, I over-
expressed dGABPα specifically within these tissues. In each case, induction of 
expression with RU486 resulted in a significant extension of lifespan (Figures 5.16 
and 5.17, median lifespan extensions were 6% and 3%, p=4.8 x 10-8, p=0.002, 
respectively). Taken together, these data clearly show that over-expression of 
dGABPα in the brain as well as in the gut and fat body is sufficient to extend lifespan. 
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Figure 5.16 Over-expression of dGABPα in adult neurons extended the lifespan in female flies 
Neuronal expression of dGABPa in adulthood using the elavGS driver induced by RU (elavGS>UAS-
dGABPa, red line, RU+) extended the lifespan compared to non-induced control flies (black line, RU-). 
The median lifespan was extended by 6%, p=4.8 x 10-8 by log-rank test. The genotypes used were: 
elavGS>UAS-dGABPα. 
 
 
 
Figure 5.17 Over-expression of dGABPα in the adult gut and fat body extended the lifespan in 
female flies 
Over-expression of dGABPα in the adult gut and fat body using the S1106GS driver induced by RU 
(S1106GS>UAS-dGABPα, red line, RU+) extended the lifespan compared with un-induced female flies 
(black line, RU-). The median lifespan was extended by 3% p=0.003 by log-rank test. The genotype 
used was: S1106GS>UAS-dGABPα.  
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5.3.5 Energy production was uncoupled from energy consumption in 
dGABPa-over-expressing flies  
Long-lived invertebrate mutants often display a reduction in the rate of cellular 
functions, with a slowing in energy metabolism, and a lower accumulation of age-
related stress. This manifests in resistance to various stressors, including oxidative 
stress and xenobiotic stress (Castillo-Quan et al., 2016, Broughton et al., 2005, 
Afschar et al., 2016, Braeckman et al., 1999, Lakowski and Hekimi, 1996). Animal 
models lacking dGABPα exhibit mitochondrial dysfunction (Baltzer et al., 2009, Yang 
et al., 2014). It is therefore interesting to assess whether dGABPα gain-of-function 
leads to an improvement in mitochondrial function. To test this hypothesis, I 
determined whether up-regulation of dGABPα increased mitochondrial activity by 
measuring four independent mitochondrial markers: ATP production, mitochondrial 
mass, mitochondrial protein synthesis and oxygen consumption. Firstly, I found that 
over-expression of dGABPα significantly increased ATP production by approximately 
50% (Figure 5.18), suggesting an increased steady state of mitochondrial homeostasis. 
I then measured the amount of mtDNA, relative to the amount of the nuclear DNA 
(nDNA) amplicon, in heads and thoraxes of young and old flies expressing dGABPα. 
Interestingly, there was no significant difference in mitochondrial mass between 
dGABPα-over-expressing flies and wild type controls at either young or old age. 
There was however a significant increase in aged dGABPα-over-expressing flies 
compared to their younger counterparts (Figure 5.19). In addition, immunoblots with 
antibodies against NDUFS3, one of the complex I subunits of the ETC, did not show 
any significant difference between flies over-expressing dGABPα and un-induced 
controls (Figure 5.20).  
 
 
Figure 5.18 ATP levels were increased in dGABPα-over-expressing flies. 
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Ubiquitous over-expression of dGABPα using the daGS driver induced with RU (daGS>UAS-
dGABPα, blue bar, RU+) resulted in increased ATP levels compared to un-induced control female flies 
(red bar, RU-). ATP levels were measured in 40-day-old whole fly lysates with the ovaries removed. 
The bars represent the means ± SEM (n=6), *p<0.05 by t-test. The genotype used was: daGS>UAS-
dGABPα. 
 
 
 
Figure 5.19 Over-expression of dGABPα did not alter the mitochondrial mass in young or older 
flies 
Mitochondrial DNA (mtDNA), relative to the nuclear DNA (nDNA) amplicon, was measured by qRT-
PCR in the heads and thoraxes of flies over-expressing dGABPα (+RU) and un-induced controls (-RU) 
at 12 or 40 days of age. A significant increase was observed in old flies over-expressing dGABPα 
(daGS>UAS-dGABPα, blue bar, RU+) compared to young flies over-expressing dGABPα (red bar). 
The bars represent the means ± SEM (n=4, *p<0.05 by ANOVA). The genotype used was: 
daGS>UAS-dGABPα. 
 
 
 
Figure 5.20 Over-expression of dGABPα did not alter NDUFS3 protein levels  
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Western blot analysis of NDUFS3 in 14-day-old flies demonstrated that ubiquitous over-expression of 
dGABPα using the daGS driver induced by RU486 (daGS>UAS-dGABPα, red bar, RU+) did not alter 
the protein levels of NDUFS3 compared to un-induced controls (black bar RU-). The protein levels 
were normalized to β-actin. The bars represent the means ± SEM (n=3). The image is a representative 
gel from one biological repeat. The genotype used was: daGS>UAS-dGABPα. 
 
Finally, I sought to analyse the effect of elevated dGABPα expression on 
mitochondrial respiratory chain activity. The rate of oxygen consumption was 
measured using the Oroboros Oxygraph-2k on fly heads rather than whole fly lysates, 
enabling a more defined and tissue-specific signal. The steps in respiration were 
compared in mitochondria separated from dGABPα-over-expressing fly head 
homogenates and controls by using substrates, uncouplers, and inhibitors specific to 
individual respiratory complexes. In doing so, I observed there was no significant 
difference in the oxygen consumption rate (OCR) for Complex I-, and II-dependent 
respiration (Figure 5.21). Moreover, there was no significant difference in OCR in 
state 2, state 3, or in the maximum uncoupled state between flies over-expressing 
dGABPα and controls (Figure 5.21). This is consistent with the observations of 
mitochondrial mass and mitochondrial-related protein levels, suggesting that over-
expression of dGABPα does not change energy consumption. Taken together, these 
data suggest that over-expression of dGABPα increases ATP production, but this is 
uncoupled from mitochondrial respiration rates. 
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Figure 5.21 Oxygen consumption rates were not altered in dGABPα-over-expressing fly heads 
Oxygen consumption rate (OCR) were measured in the heads of flies over-expressing dGABPα (RU+) 
and un-induced controls (RU-) at day 14. There was no significant difference in OCR in state 2, state 3, 
and in the maximum uncoupled state, or for Complex I- and II-dependent respiration. The values are 
plotted as the means ± SEM, n=5, p>0.05 by t-test. The genotype used was: elavGS>UAS-dGABPα. 
These experiments were performed in collaboration with Dr.Vassilios N Kotiadis. 
 
 
5.3.6 Over-expression of dGABPα increased the resistance to 
phenobarbital stress 
I then assessed whether the long-lived flies over-expressing dGABPα were resistant to 
different stressors. I tested the survival of dGABPα-over-expressing flies under 
starvation conditions and on exposure to oxidative stress with H2O2 and paraquat, and 
phenobarbital. Here we show that dGABPα over-expression did not significantly 
affect survival compared to controls under starvation conditions or when challenged 
with H2O2 (Figure 5.22, p=0.3, p=0.7 respectively). However, flies over-expressing 
dGABPα exhibited a small but significant increase in sensitivity to paraquat (Figure 
5.22, p<0.05). In addition, flies over-expressing dGABPα were significantly resistant 
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to phenobarbital stress (Figure 5.22, p=1.75 x 10-11). Taken together these results 
suggest that dGABPα may extend lifespan through increased detoxification of 
endobiotic and xenobiotic compounds.  
 
 
 
Figure 5.22 The effect of ubiquitous over-expression of dGABPα in adulthood on exposure to 
various stressors in female flies 
The survival curves of flies over-expressing dGABPα in adulthood (RU+) or un-induced control flies 
(RU-) using the inducible daGS driver. Flies were pre-treated with RU for 14 days and then transferred 
to either agar-only food for starvation assays (p=0.7), or to sugar/agar food supplemented with paraquat 
(p=0.04), H2O2 (p=0.33) or phenobarbital (p=1.75 x 10-11 by log-rank test). The genotype was: 
daGS>UAS-dGABPα. 
 
Increased resistance to phenobarbital stress in dGABPα over-expressing flies may rely 
on the UPS (Ubiquitin-Proteasome System), the lysosomal-autophagy pathway, and 
the chaperone network, acting to maintain cellular protein homeostasis by removing 
unwanted or damaged proteins that could become toxic to cells (Jung et al., 2009, 
Glickman and Ciechanover, 2002, Ross et al., 2015, Lopez-Otin et al., 2013). I 
therefore investigated whether over-expression of dGABPα affects proteasomal 
activity and autophagy. Here I show that the 26S proteasomal activity was 
significantly increased in flies over-expressing dGABPα compared to controls (Figure 
5.23). Immunoblots with antibodies against the alpha subunit of the 26S proteasome 
complexes demonstrated that levels of the 26S were not altered in flies over-
expressing dGABPα compared to controls (Figure 5.24). This suggests that over-
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expression of dGABPα may increase the assembly of the proteasome and therefore its 
activity, rather than the total load of the proteasomal machinery. In addition, western 
blot analysis with an antibody against the fly LC-3 orthologue, Atg8, demonstrated no 
significant change in Atg8-I levels or Atg8-II levels in response to dGABPα over-
expression (Figure 5.25). Even the ratio of Atg8-II/Atg8-I was not changed, indicating 
no change in autophagasome formation (Figure 5.25). Taken together, over-
expression of dGABPα increased proteasome activity but not autophagy. 
 
 
Figure 5.23 Over-expression of dGABPα increased proteasome activity 
Proteasome activity, as measured using the fluorogenic peptide substrate LLVY-AMC, was increased 
in flies over-expressing dGABPα (daGS>UAS-dGABPα, red bar, +RU) compared to non-RU induced 
controls (blue bar, RU-). The bars are plotted as the means of activity (pmol/min/mg protein) ± SEM. 
*p<0.05, n=6 by t-test. The genotype used was: daGS>UAS-dGABPα. 
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Figure 5.24 Ubiquitous over-expression of dGABPα in adulthood did not alter the protein levels 
of the 26S proteasome 
Western blot analysis with an antibody against the alpha subunit of the 26S proteasome demonstrated 
no significant change in the amount of the alpha subunit protein in dGABPα-over-expressing flies 
(daGS>UAS-dGABPα, red bar, +RU) compared with age-matched non-RU induced control flies (blue 
bar, RU-). The bars represent the means ± SEM, n=3 by t-test. The genotype used was: daGS>UAS-
dGABPα.  
 
 
 
Figure 5.25 Flies over-expressing dGABPα did not show any change in autophagy 
Western blot analysis with an antibody against the fly LC-3 orthologue, Atg8, demonstrated no 
significant change in Atg8-I levels (normalized to β-actin levels), Atg8-II levels or the Atg8-II/Atg8-I 
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ratio in flies over-expressing dGABPα (daGS>UAS-dGABPα, red bars, RU+) compared with age-
matched non-RU induced control flies (green bars, RU-) at day 14. The bars represent the means ± 
SEM, n=3 by t-test. The genotype used was: daGS>UAS-dGABPα. 
 
 
5.3.7 Over-expression of dGABPα extended the lifespan via 
mechanisms beyond those of DR 
To explore the mechanisms of lifespan extension by dGABPα activation, I first 
investigated whether over-expression of dGABPα was acting as a DR mimetic. DR is 
a well-established anti-ageing intervention that extends healthy lifespan in diverse 
species (Fontana and Partridge, 2015, de Cabo et al., 2014), and some genetic 
interventions that extend lifespan have features of DR mimetics (Ingram and Roth, 
2015, de Cabo et al., 2014). To determine whether dGABPα and DR extend lifespan 
by similar mechanisms, I assessed whether dGABPα can extend lifespan beyond the 
maximum achievable by DR. To maximize lifespan under DR, the yeast 
concentrations were varied in the food, while maintaining a constant concentration of 
sucrose (Bass et al., 2007), resulting in a typical tent-shaped response, with a peak 
median lifespan with food containing a 1.0 yeast concentration (Figure 5.26 A and B). 
If dGABPα activation and DR share overlapping pathways, then activation of 
dGABPα would not be able to further extend lifespan already maximized by DR 
(Castillo-Quan et al., 2016, Gems et al., 2002, Broughton et al., 2010, Bjedov et al., 
2010). Activation of dGABPα significantly extended median lifespan in the yeast 
condition that maximized lifespan (1.0 yeast; p=1.93 x 10-8), in full feeding (2.0 yeast; 
p=3.9 x 10-5), and under reduced yeast concentrations (0.5 yeast; p=2.94 x 10-7), with 
the greatest extension of median lifespan seen using 2.0 SY food (Figures 5.26 A and 
B). Cox proportional hazards (CPH) analysis confirmed that the response to RU was 
not significantly different across the different yeast concentrations on the right side of 
the DR-tent (Table 3, p=0.11), suggesting that over-expression of dGABPα extended 
the lifespan via mechanisms independent to those of DR and beyond DR. 
Interestingly, dGABPα over-expression significantly reduced lifespan (Figure 5.26 A 
and B, p=3.27 x 10-14) on the ‘starvation-inducing’ yeast concentration of 0.1 SY 
food. CPH analysis confirmed that the response to RU was modulated by food on the 
‘starvation side’ of the DR tent (Table 2, p=0.02), suggesting that the effect of over-
expression of dGABPα on lifespan is dependent on nutrient-availability.  
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B 
 
Figure 5.26 Ubiquitous over-expression of dGABPα extended the lifespan via mechanisms 
independent of those of DR 
(A) The survival curves of female flies ubiquitously over-expressing dGABPα in adulthood using the 
daGS driver induced by RU (daGS>UAS-dGABPα, RU+, full lines) compared to non-induced controls 
(RU-, dash lines). The RU was supplemented into food containing different yeast concentrations (0.1x, 
0.5x, 1.0x, and 2.0x yeast concentrations). (B) The median lifespans are plotted at four different yeast 
concentrations: over-expression of dGABPα extended lifespan under the 0.5x, 1.0x, and 2.0x dietary 
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conditions tested. Over-expression of dGABPα significantly shortened the lifespan on the 0.1x yeast 
containing diet. ***P<0.001 by log-rank test; n=145 flies per condition. The genotype used was: 
daGS>UAS-dGABPα. 
 
 
Table 2 CPH analysis of the survival of flies over-expressing dGABPα on different yeast 
concentrations of food 
CPH analysis showed that there is an interaction between the response to different diets and the 
response to over-expression of dGABPα (p=0.02). This means that the response to RU (absence or 
presence of dGABPα over-expression) is modulated by diet. Flies fed with ‘starvation-inducing’ low 
yeast food (0.1SY) were shorter lived in response to dGABPα over-expression, while flies fed with any 
other diets were longer lived in response to dGABPα over-expression. Therefore the responses to RU 
across all the diets are not in same direction (p=0.15).  
 
 
 
Table 3 CPH analysis of the survival of flies over-expressing dGABPα on DR and full-feeding 
food 
CPH analysis showed that there is no interaction between the response to different diets (DR food and 
full-feeding food) and the response to over-expression of dGABPα (p=0.11). This means that the 
response to RU is not modulated by food. Therefore over-expression of dGABPα extends lifespan 
independently of DR and beyond DR. 
 
 
5.3.8 Next-generation Transcriptome profiling  
In order to determine the molecular mechanisms by which dGABPα over-expression 
mediates its pro-longevity effects, I undertook next generation sequencing to analyse 
the transcript profile in flies over-expressing dGABPα. RNAseq analysis was 
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performed at the Glasgow Polyomics Unit, and the bioinformatics analysis was 
performed in collaboration with Dr. Dobril Ivanov. Given that the brain specific over-
expression of dGABPα using the inducible elavGS driver significantly extended 
lifespan (Figure 5.16), I sought to investigate the brain specific transcriptional 
response to dGABPα over-expression.  Fly heads over-expressing dGABPα for 10 
days were subjected to RNAseq analysis and compared to non-RU induced controls, 
and 4 replicates each condition were used. According to FDR correction for multiple 
hypothesis testing, which is an acronym for adjusted p-value, there is around 50 
differentially expressed genes in response to dGABPα over-expression, including 
genes involved in memory, learning, synaptic formation and in the perception of 
sound and pain (Figure 5.27). For example, SIFaR (SIFamide receptor) was up-
regulated in response to dGABPα over-expression. This is a G-protein coupled 
peptide receptor involved in both neuropeptide and the G-protein coupled receptor 
signalling pathways. It is required for the sensory perception of pain and is involved 
in sexual behaviour and the determination of lifespan (Figueroa-Clarevega and Bilder, 
2015, Paik et al., 2012). In addition, dGABPα regulated several genes involved in 
insulin signalling pathway, including up-regulated nord, daw, ImpL2, and down-
regulated Glt, tobi, and Gnmt, suggesting that over-expression of dGABPα might 
regulate IIS.  
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Figure 5.27 Heat-map of the genes differentially expressed in fly heads over-expressing dGABPα 
Heat-map showing genes that were significantly up-regulated (red colour) or down-regulated (blue 
colour) in  fly heads over-expressing dGABPα (RU+) compared to non-induced controls (RU-). The 
intensity of the color represents the statistical significance. N=4 per condition, P<0.05 for statistically 
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significant changes according to multiple hypothesis testing. Genotypes used were: elavGS>UAS-
dGABPα. 
 
I then sought to look at the gene ontology (GO) annotations using Catmap analysis 
(Breslin et al., 2004). GO categories include three classes: Biological Process 
ontology, Cellular Component ontology and Molecular Function ontology. The 
Biological Process ontology includes terms that represent collections of processes as 
well as terms that represent a specific, entire process that the gene product is involved 
in. The Cellular Component ontology describes locations, at the levels of subcellular 
structures and macromolecular complexes. The Molecular Functions of a gene 
product are the functions that it performs or the "properties" that it has. These may 
include transporting molecules around, binding to molecules, holding molecules 
together and changing one molecule into another. This is different from the Biological 
Processes, which involve more than one activity. Down-regulated GOs mean that the 
results represent GO categories are significantly enriched in genes that are mainly 
down-regulated, while up-regulated GO categories are enriched in genes that are 
predominantly up-regulated. For GO analysis, all genes were used along with p-
values (not-adjusted for multiple hypothesis testing), and the statistical significance of 
the GO categories is calculated using p-value-adjusted FDR correction for multiple 
hypothesis testing. Here I have listed the top 10 GO categories in each class (Figure 
5.28). For example, over-expression of dGAPBα up-regulated biological processes 
including ‘development’, ‘regulation of signalling pathway’, and ‘regulation of 
response to stimulus’while down-regulated biological processes including ‘nitrogen 
compound metabolic process (cellular amino acid metabolic process)’, ‘translation’, 
and ‘oxidation-reduction process’. In terms of molecular function, over-expression of 
dGAPBα up-regulated ‘transcription factor activity’ and ‘protein kinase activity’, 
while down-regulated ‘ribosome’, ‘translation activity’, and ‘electron carrier activity’. 
In addition, over-expression of dGAPBα up-regulated cellular components mainly 
involved in membrane, neurons, synapses and axon, while down-regulated GO terms 
involved in mitochondrion, respiratory chain complex, lipid particle and ribosome.  
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Figure 5.28 GO categories of fly heads over-expressing dGAPBα 
The graphs showthe top 10 GO categories that significantly enriched in genes that are mainly up-
regulated (left side) or down-regulated (righ side) in response to dGAPBα over-expression in fly heads 
using inducible elavGS driver (RU+) compared to non-induced control (RU-). GO terms are classified 
into 3 different groups, including Biological Process (blue colour), Molecular Function (orange colour) 
and Cellular Components (green colour). GO annotations have been analyzed using Catmap, and 
calculated using p-value-adjusted FDR correction for multiple hypothesis testing. N=4 per condition, 
p<0.05 for statistically significance. Genotypes used were: elavGS>UAS-dGABPα. 
 
5.3.9 Over-expression of dGABPα extended lifespan in overlapped 
mechanisms with reduced IIS likely through up-regulation of ImpL2  
As described above, overexpression of dGAPBα regulates several genes involved in 
insulin signalling pathway. Among those differentially expressed genes that were up-
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regulated in response to dGABPα over-expression, ImpL2 is particularly interesting. 
ImpL2 (Imaginal morphogenesis Protein-late 2), the ortholog of the mammalian 
insulin-like growth factor-binding protein 7 (IFGBP7), resembles IGFBP7 in 
sequence and acts as a negative regulator of IIS during development, regulating 
growth cell-non-autonomously (Sloth Andersen et al., 2000, Alic and Partridge, 2008, 
Honegger et al., 2008). ImpL2 is a secreted protein belonging to the immunoglobulin 
superfamily that forms a protein complex with the circulating dilps, and inhibits their 
ability to bind the insulin receptor, thus reducing IIS (Sloth Andersen et al., 2000, 
Alic et al., 2011b). In addition, a modest over-expression of ImpL2 extends lifespan in 
association with reduced IIS (Alic et al., 2011b, Paik et al., 2012). Therefore, I 
hypothesised that over-expression of dGABPα may mediate lifespan extension 
through mechanisms that up-regulate ImpL2 to down-regulate IIS. Although the direct 
evidence showing that ImpL2 mediates the lifespan extension of dGABPα over-
expression is still lacking, it is possible that activation of dGABPα may reduce insulin 
signalling and therefore affect IIS-related traits. 
 
It is known that down-regulation of IIS extends lifespan in diverse organisms (Piper et 
al., 2008). To further assess whether dGABPα activation extends lifespan through 
reduced IIS, I investigated whether dGABPα over-expression can further extend the 
lifespan of flies that already have reduced IIS. To do this I tested the lifespan effect of 
dGABPα over-expression on flies co-expressing the INRDN (Slack et al., 2011). Adult-
onset, ubiquitous over-expression of either dGABPα or the INRDN significantly 
extended lifespan (Figure 5.29, the median lifespans were increased by 7% and 9.8%, 
p=3.04 x 10-7 and p=0.0001, respectively). In addition, co-expressing dGABPα and 
INRDN also extended lifespan (Figure 5.29, the median lifespan extension was 9.7%, 
p= 3 x 10-8). To compare the extent of lifespan extension between the two 
interventions, CPH analysis was used. The lifespan extension observed in the INRDN 
flies was not significantly different to that in the dGABPα over-expressing flies in the 
response to RU486 (Table 4, RU486 by genotype interaction, p=0.76). CPH analysis 
also confirmed that there was no significant difference between the lifespan extension 
in INRDN expressing flies and dGABPα-INRDN co-expressing flies (Table 4, RU486 by 
genotype interaction, p=0.43), suggesting that dGABPα over-expression and reduced 
IIS signalling may mediate lifespan extension via overlapping mechanisms.  
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Figure 5.29 Female flies over-expressing INRDN and dGABPα mediated lifespan extension 
The survival curves of flies over-expressing either the dominant negative form of the insulin receptor 
(INRDN, black line), or dGABPα (red line), or both INRDN and dGABPα (green line, +RU) and non-RU 
induced controls (broken lines, -RU) are shown. Ubiquitous over-expression of dGABPα extended 
lifespan (p=3.04 x10-7). Ubiquitous over-expression of a dominant negative form of INR also extended 
lifespan (p=0.0001), and co-expression of both dGABPα and the INRDN also extended lifespan (p= 3 x 
10-8). The lifespans were analyzed by the log-rank test. N=130 flies per condition. The genotypes used 
were: daGS>UAS-INRDN, daGS>UAS-dGABPα, daGS> UAS-INRDN; UAS-dGABPα. 
 
 
Table 4 CPH analysis of the survival of flies co-expressing dGABPα and INRDN 
CPH analysis demonstrated that three genotypes (daGS>UAS-INRDN, daGS>UAS-dGABPα, daGS> 
UAS-INRDN; UAS-dGABPα) responded to RU in the same way (p=2.24 x 10-5). There was no 
significant difference between the genotypes daGS>UAS-INRDN and daGS>UAS-dGABPα (p=0.414). 
There was a significant difference between the genotypes daGS>UAS-INRDN and daGS> UAS-INRDN; 
UAS-dGABPα (p=1.47 x 10-5). There was no significant difference between the genotypes daGS>UAS-
INRDN and daGS>UAS-dGABPα in response to RU (P=0.762). There was also no significant difference 
between daGS>UAS-INRDN and daGS> UAS-INRDN; UAS-dGABPα in response to RU (P=0.428). This 
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means that the three genotypes are responsive to RU in a similar way, suggesting that over-expression 
of dGABPα and over-expression of INRDN extended lifespan via similar mechanisms. 
 
 
5.3.10 dGABPα over-expression and reduced IIS in flies shared 
overlapping transcriptional responses  
I next investigated whether the transcriptional response to dGABPα over-expression is 
similar to that observed when IIS is genetically down-regulated. I used a recently 
published microarray analysis performed on whole flies over-expressing the dominant 
negative form of the insulin receptor, INRDN, as a means of reducing IIS (Alic et al., 
2011a). I compared the overlap of genes elicited by both interventions, and detected 
statistical significance for down-regulated genes (Figure 5.30 A, p=0.004). By 
comparing the overlap of GO categories elicited by both interventions, I found the 
two most significant overlapping enriched GO terms in both interventions are either 
up-regulated or down-regulated (Figure 5.30 B, p=6.5 x 10-87 and p=1.5 x 10-12 
respectively), suggesting that these two interventions share highly overlapped 
transcriptional response in same direction. There was also a significant overlap 
between GOs down-regulated by lowering IIS and those up-regulated by over-
expressing dGABPα (Figure 5.30 B, p=8.54 x 10-11), suggesting that they may 
regulate some of the transcriptional responses in opposite ways.  
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Figure 5.30 Comparative analyses of the transcriptional response of IIS down-regulation and 
dGABPα over-expression. 
 (A) Venn diagrams showing overlap between genes regulated by IIS down-regulation via the over-
expression of a dominant negative version of InR (Blue color), and the transcriptional response to 
dGABPα over-expression (red color). P<0.05. The heat map shows genes that were overlapped between 
the two interventions.  
(B) Venn diagrams demonstrating overlapping enriched GO categories regulated by IIS down-
regulation (yellow color) and dGABPα over-expression (green color). P<0.05. The bioinformatics 
analysis was performed by Dr. Dobril Ivanov.  
 
5.3.11 dGABPα over-expression mediated the lifespan extension of 
reduced IIS signalling in flies  
The long-term beneficial effect of modest reductions in IIS on lifespan is largely 
dependent on the fine-tuning of the IIS down-regulation and the potential tissue and 
systemic adaptation.  However, when dGABPα is genetically knocked-down, ImpL2 
maybe down-regulated, which would reduce binding to the circulating dilps, leading 
to increased binding to the insulin receptor. Continuous ligand stimulation of the 
insulin receptor and the resulting increase in IIS activity can be harmful, because it 
eventually leads to tissue insensitivity to the ligand, which is referred to insulin 
resistance. I previous showed that down-regulation of dGABPα increased the early 
mortality, which mechanisms might be associated with a constant insulin receptor 
stimulation and resulting “insulin resistance”. Down-regulation of IIS through the co-
expression of a dominant negative form of the insulin receptor may further exacerbate 
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the dGABPα-mediated insulin resistance, accelerating mortality. In keeping with this, 
I showed that adult-onset ubiquitous over-expression of the INRDN significantly 
extended lifespan (Figure 5.31, p=0.002), and RNAi-mediated ubiquitous knockdown 
of dGABPα shortened lifespan (Figure 5.31, p=0.005). Co-expression of dGABPαRNAi 
in flies expressing INRDN shortened lifespan (Figure 5.31, p=4.8 x 10-7) even further 
than flies expressing dGABPαRNAi alone (p=0.01). This result suggested that dGABPα 
is at least partially required for the lifespan extension of reduced IIS, and that 
reduction of the insulin receptor, and hence IIS signalling, further exacerbates the 
negative effect of knocking down of dGABPα.  
 
Figure 5.31 dGABPα mediated the lifespan extension of reduced IIS 
The survival curves of flies over-expressing either INRDN (black line, RU+) or dGABPαRNAi (green line, 
RU+), or both INRDN and dGABPαRNAi (red line, +RU) and non-RU induced controls (broken lines, RU-
). Ubiquitous RNAi-mediated down-regulation of dGABPα using the daGS driver shortened the 
lifespan (p=0.005), and abolished the lifespan extension mediated by over-expression of a dominant 
negative form of INR (p=4.8 x 10-7). Over-expression of the dominant negative form of the INR 
extended lifespan (p=0.002), but further shortened the lifespan when dGABPα was knocked-down 
using RNAi (p=0.01). The lifespans were analyzed by using the log-rank test. N=150 flies per 
condition. The genotypes used were: daGS>UAS-INRDN, daGS>UAS-dGABPαRNAi, daGS>UAS-INRDN; 
UAS-dGABPαRNAi.  
 
 
5.3.12 Over-expression of dGABPα reduced AKT signalling  
Reducing IIS inhibits the PI3K-PDK1-AKT signalling pathway and activates FOXO, 
a transcription factor that up-regulates several “longevity pathways” (Webb and 
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Brunet, 2014, Wang et al., 2014). To examine whether over-expression of dGABPα 
reduces systemic insulin signalling, I firstly measured the levels of phosphorylated 
AKT (p-AKT), a downstream target of the insulin receptor, by western blot analysis. 
Given the lack of an antibody recognizing the PDK1 phospho-site on AKT, I 
evaluated the phosphorylation status at the S505 site, which is phosphorylated by 
mTORC2 (Guertin and Sabatini, 2009). Previous studies have used this antibodies as 
a readout of insulin activity (Palu and Thummel, 2016). This analysis demonstrated 
that over-expression of dGABPα caused a modest but significant reduction in the 
levels of phosphorylated AKT normalized to total AKT (Figure 5.32, p=0.03), 
suggesting reduced activity of the IIS pathway. 
 
 
Figure 5.32 Over-expression of dGABPα reduced systemic insulin signalling 
Whole fly lysates from flies over-expressing dGABPα (red bar, +RU), and non-induced controls (black 
bar, RU-) were analysed by western blot analysis using antibodies directed against phosphorylated 
AKT (p-AKT), total AKT, and tubulin as a loading control. Flies were 2-weeks old. The same samples 
were loaded onto separate gels for blotting either p-AKT or total AKT. The levels of p-AKT and t-
AKT were measured using ImageJ, and normalized to same-gel loading control. The ratio of p-AKT 
levels to total AKT levels were then calculated, and plotted as the means ± SEM, n=4. *P=0.03 using 
the t-test. A representative gel is shown for the loading control, tubulin, and was derived from the p-
AKT gel. The genotype was used: daGS>UAS-dGABPα. 
 
 
 
 
5.3.13 dGABPα over-expression inhibited mTORC1 and mimicked 
the effect of rapamycin on lifespan 
The transcriptional profiling showed that over-expression of dGABPα significantly 
down-regulated the biological functions including amino acid metabolism and 
translation, which both are tightly linked with reduced mTOR signalling pathway. 
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The mTOR signalling pathway regulates ageing by mechanisms that overlap with IIS 
(Johnson et al., 2013). mTORC1 is activated by insulin through PI(Powers et al.)K 
and AKT kinase signalling (Laplante and Sabatini, 2012).  I demonstrated above that 
over-expression of dGABPα inhibited AKT kinase activity. I therefore assessed 
whether mTORC1 activity is altered by dGABPα activation. To do this I measured the 
phosphorylation levels of S6K, a well-described downstream target of TORC1, using 
western blot analysis with the phospho-Thr398-dependent S6K antibody. I observed a 
significant reduction in phospho-T398-S6K levels in response to dGABPα over-
expression (Figure 5.33), confirming that dGABPα inhibits mTORC1 activity in vivo.  
 
 
Figure 5.33 The ubiquitous over-expression of dGABPα reduced the phosphorylation levels of 
S6K 
Whole fly lysates from flies over-expressing dGABPα ubiquitously in adulthood (daGS>UAS-
dGABPα, red bar, +RU) demonstrated reduced levels of S6K phosphorylation compared to non-
induced controls (blue bar, RU-). Western blots were performed using antibodies directed against 
phosphorylated S6K (p-S6K), total S6K and β-actin as a loading control. Animals were collected at two 
weeks of age. The same samples were loaded onto separate gels for blotting either p-S6K or total S6K. 
The levels of p-S6K and t-S6K were measured using ImageJ and normalized to same-gel loading 
control. The ratio of p-S6K levels to total S6K levels was then calculated. Bars represent the means ± 
SEM, n=3. **P=0.004 using the t-test. A representative gel is shown for the loading control β-actin, 
which was derived from the p-S6K gel. The genotype used was: daGS>UAS-dGABPα. 
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I next investigated whether the lifespan extension of dGABPα is mediated by 
mTORC1 signalling. Rapamycin inhibits mTORC1 activity and extends lifespan by 
mechanisms that include reduced mRNA translation and autophagy induction (Bjedov 
et al., 2010). I therefore assessed whether the lifespan extension mediated by dGABPα 
over-expression mimics the effects of reduced mTOC1 activity. To do this I observed 
whether dGABPα over-expression can further extend the lifespan extension mediated 
by rapamycin treatment. I first confirmed that induction of dGABPα with RU 
extended the lifespan compared to un-induced controls (Figure 5.34, the median 
lifespan was extended by 6%, p=0.03). I then used two concentrations of rapamycin, 
50 and 200µM, both of which have been shown to mediate lifespan extension through 
a dose-dependent reduction of S6K activity, the most effective dose being 200µM 
(Bjedov et al., 2010). I showed that both 50 and 200µM of rapamycin extended 
lifespan in a dose-dependent manner (Figure 5.34, the median lifespan was extended 
by 16%, and 25%, p= 2.29 x 10-14, p= 1.52 x 10-28 respectively by log-rank test). 
However no further extension occurred when the rapamycin-flies over-expressed 
dGABPα (for rapamycin 50µM: p=0.24 and for rapamycin 200µM: p=0.67 by log-
rank test), suggesting that dGABPα acts in a similar manner to rapamycin. Indeed, 
200µM rapamycin-treated flies over-expresssing dGABPα showed reduced survival 
compared to 200µM rapamycin-treated controls (the median lifespan was shortened 
by 5%, p=0.046 by Wilcoxon test), suggesting a toxic effect likely due to the 
excessive inhibition of mTOR that is detrimental to the lifespan of the flies. 
Surprisingly, the CPH analysis failed to detect any significant interaction between the 
response to RU and the response to rapamycin 50µM (Table 5, p=0.47), likely due to 
the limitation of the test.  Taken together, these results demonstrated that over-
expression of dGABPα may act via similar mechanisms of action with 
rapamycin/mTORC1 in regulating of lifespan, likely through inhibition of S6K.  
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Figure 5.34 The survival of flies over-expressing dGABPα in response to rapamycin treatment 
Ubiquitous over-expression of dGABPα extended lifespan (p=0.03 by log-rank test). Rapamycin 
treatment (50µM) also extended lifespan compared to non-treated controls (p=2.29 x 10-14), and no 
further extension occurred with the over-expression of dGABPα (p=0.24 by log-rank test). Treatment 
with a higher dose of rapamycin (200µM) extended lifespan, to a greater extent than 50µM, compared 
to non-treated controls (p= 1.52 x 10-28), but the lifespan was shortened when dGABPα was over-
expressed in the rapamycin-treated flies (p=0.67 by log-rank test and p=0.046 by Wilcoxon test). 
N=140 flies per condition. The lifespans were analyzed using the log-rank test or Wilcoxon test. The 
genotype used was: daGS>UAS-dGABPα. 
 
 
 
Table 5 The CPH analysis of the survival of rapamycin-treated flies co-expressing dGABPα 
CPH analysis showed that there was no significant interaction between the response to dGABPα over-
expression and the response to 50µM rapamycin treatment, p=0.4773.  
 
 
5.3.14 dGABPα modulated intestinal homeostasis 
The Drosophila intestine is an accessible model system to study tissue homeostasis in 
ageing (Biteau et al., 2010). Intestinal stem cells (ISCs) in the gut drive cell division 
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in response to environmental stress (Choi et al., 2008, Biteau et al., 2008, Jiang et al., 
2009, Cronin et al., 2009, Buchon et al., 2009, Amcheslavsky et al., 2009). However, 
age-related over-proliferation of ISCs has deleterious consequences with 
accumulation of mis-differentiated cells ultimately contributing to the disruption of 
epithelial integrity and to the increased mortality of ageing flies (Choi et al., 2008, 
Biteau et al., 2008). Previous studies have shown that limiting cell proliferation rates 
by moderately reducing IIS/mTOR signalling in stem cells, is sufficient to delay 
intestinal dysplasia, improving metabolic health and extending lifespan (Biteau et al., 
2010, Regan et al., 2016). Since over-expression of dGABPα extends female lifespan 
in the mechanisms associated with a reduction in IIS/mTOR signalling, I hypothesised 
that improvements in gut homeostasis may be responsible for some of the beneficial 
effects of dGABPα over-expression. Therefore, I assessed whether over-expression of 
dGABPα improves the proliferative homeostasis in the ageing fly gut. I therefore 
over-expressed dGABPα using the gut-specific driver TIGs-Geneswitch-GAL4 (TIGs-
GS), to direct intestinal-specific expression in adulthood. Female flies over-expressing 
dGABPα showed a moderate, but significant, reduction in the number of actively 
dividing (pH3+) cells at 45-days of age (Figure 5.35, p=0.02). This suggests that over-
expression of dGABPα modulates intestinal homeostasis by preventing over-
proliferation of stem cells with age, likely through a reduction in IIS/mTOR 
signalling. 
 
 
Figure 5.35 Over-expression of dGABPα in gut prevented the over-proliferation of stem cells 
Quantification of pH3+ cells per gut demonstrated that over-expression of dGABPα specifically in the 
fly gut, using the TIGs-GS driver (TIGs-GS>UAS-dGABPα, red bar, RU+) showed a reduced number 
of mitoses compared with non-induced controls (black bar, RU-) at 45 days. N>16 per condition; 
p=0.02 using the t-test. The genotype used was: TIGs-GS>UAS-dGABPα. The gut dissection was 
performed in collaboration with Dr. Mobina Khericha and Dr. Jennifer C Regan. 
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5.3.15 Over-expression of dGABPα extended lifespan via mechanisms 
independent of those of lithium treatment 
Over-expression of dGABPα increases resistance to phenobarbital stress (Figure 
5.22). The responses to xenobiotics in Drosophila are not only regulated by the 
transcription factors dFOXO and DHR96 (Salih and Brunet, 2008, Sykiotis and 
Bohmann, 2010, Hoffmann and Partridge, 2015), which mediate the xenobiotic stress 
response in insulin mutants (Afschar et al., 2016), but also by the transcription factor 
CncC (Sykiotis and Bohmann, 2010). We recently showed that CncC-induced 
xenobiotic resistance and longevity can be achieved through the administration of 
lithium (Castillo-Quan et al., 2016). I therefore assessed whether the lifespan 
extension mediated by dGABPα over-expression mimics the effect of lithium 
treatment. To test this, I investigated whether dGABPα over-expression could further 
extend the lifespan of lithium-treated flies. Flies treated with 10mM lithium displayed 
a significant lifespan extension (Figure 5.36, p= 5.3 x 10-5), consistent with previously 
reported observations (Castillo-Quan et al., 2016), and further extension occurred 
when the lithium-flies over-expressed dGABPα (p=0.001). Induction of dGABPα by 
RU486 extended the lifespan of wild type flies (Figure 5.36, p=0.007), and further 
extension occurred when dGABPα-over-expressing flies were treated with 10mM 
lithium (p=0.01). CPH analysis also confirmed that there was no significant 
interaction between the response to RU and the response to lithium treatment (Table 
6, p=0.7), suggesting that over-expression of dGABPα extends lifespan via 
mechanisms independent of those of lithium treatment. 
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Figure 5.36 Ubiquitous over-expression of dGABPα extended the lifespan of lithium-treated flies 
The survival curves of flies over-expressing dGABPα with the daGS driver (RU+) and non-RU induced 
controls (RU+) with and without lithium treatment. Ubiquitous over-expression of dGABPα extended 
lifespan in wild types flies (p=0.007), and a further extension occurred in dGABPα-over-expressing 
flies treated with 10mM lithium (p=0.01). 10mM lithium extended lifespan in wild type flies (p= 5.3 x 
10-5), and a further extension occurred when the lithium-flies over-expressed dGABPα (p=0.001). The 
lifespans were analyzed using the log-rank test. N=150 flies per condition. The genotype used was: 
daGS>UAS-dGABPα. 
 
 
 
Table 6 CPH analysis of the survival of flies over-expressing dGABPα with and without lithium 
treatment 
The CPH showed that there is no significant interaction between the response to RU and the response 
to lithium treatment (p=0.7). This means that lithium extended lifespan regardless of whether dGABPα 
is over-expressed. This suggests that over-expression of dGABPα extends lifespan via mechanisms 
independent of those of lithium treatment. 
 
I then assessed whether the transcriptional response mediated by dGABPα over-
expression was similar to that observed in lithium treatment. I used our recently 
published microarray data for whole flies treated with 10mM lithium (Castillo-Quan 
et al., 2016). By comparing the overlap of GO categories elicited by both 
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interventions, I detected statistical significance in GO terms of those that are up-
regulated or down-regulated in both interventions (Figure 5.37), suggesting that the 
transcriptional response changed in the same directions.  
 
Lithium protects flies from xenobiotic stress by up-regulating the genes involved in 
the detoxification pathway (Castillo-Quan et al., 2016). The RNAseq data suggested 
that over-expression of dGABPα does not change the transcript levels of GstD2, and 
down-regulates the levels of cyp6a8, two genes involved in the detoxification 
pathway. I further confirmed these findings by qRT-PCR analysis of whole flies over-
expressing or lacking dGABPα (Figure 5.13). Since the direct contribution of 
individual detoxification proteins to the xenobiotic stress and lifespan regulation is as 
yet unexplored, it will be interesting to further study whether any of these proteins 
mediate the effects of dGABPα on xenobiotic stress resistance and lifespan extension. 
 
 
Figure 5.37 Comparative analyses of the transcriptional response of lithium and dGABPα over-
expression 
Venn diagrams showing the overlap between the GO terms enriched by 10mM lithium treatment 
(yellow color) and those enriched by dGABPα over-expression (green color). P<0.05. Bioinformatics 
analysis was performed by Dr.Dobril Ivanov. 
 
 
PGC-1α in neurodegeneration and ageing 
 
 
 
201 
5.3.16 Ubiquitous knockdown of AKT increased ER stress resistance 
We previously demonstrated the importance of nutrient sensing pathway in regulation 
of the lifespan, although the molecular mechanisms of the improvement of healthy 
ageing are not fully elucidated. Age-related proteostatic failure contributes to ageing 
and age-related diseases (Taylor and Dillin, 2011, Hetz, 2012). Direct up-regulation 
of the components of the UPRER delays ageing in C. elegans (Taylor and Dillin, 
2013). Whether the UPRER plays an important role in fly ageing has not yet been 
determined. I therefore asked whether long-lived mutants mediate their effects via 
modulation of the UPRER. To test this, I genetically knocked down AKT, the main 
kinase in the nutrient-sensing pathway that has been previously reported to extend 
lifespan (Biteau et al., 2010). RNAi knockdown of AKT in flies dramatically 
increased the resistance to tunicamycin, a well-known ER stress inducer (Figure 
5.38), suggesting up-regulation of the UPRER. Given the central position of AKT in 
the nutrient-sensing pathway, this result suggests that the UPRER, being downstream 
of the nutrient-sensing pathway, may play an important role in lifespan regulation.  
 
 
Figure 5.38 Flies lacking AKT are more resistant to the ER stressor tunicamycin 
The survival curves of flies over-expressing AKTRNAi in adulthood using the inducible daGS driver 
(daGS>UAS-AKTRNAi, dark blue line, RU+) and un-induced controls (red line, RU-). Flies were pre-
treated with RU486 for 14 days and then transferred to sugar/agar food supplemented with 
tunicamycin. P=1.52 x 10-11 using the log-rank test. The genotype used was: daGS>UAS-AKTRNAi. 
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5.4 Discussion 
PGC-1α is a key transcriptional co-activator in energy metabolism, regulating growth 
and mitochondrial biogenesis in response to IIS/mTOR signalling (Mukherjee and 
Duttaroy, 2013, Tiefenböck et al., 2010). Recent studies highlight its importance for 
longevity in Drosophila melanogaster (Rera et al., 2011), suggesting an evolutionary 
conserved function in lifespan regulation. Here I showed that ubiquitous over-
expression of dPGC-1 extends lifespan and improves behavioural phenotypes in 
Drosophila, confirming it is indeed a modulator for healthy longevity. Interestingly, 
over-expression of dPGC-1 only extended female lifespan, and not the lifespan of 
males, suggesting that sex difference may mediate the effects of dPGC-1 on lifespan 
regulation. Indeed, interventions that down-regulate the nutrient-sensing pathway 
extend fly lifespan mostly in female flies, and furthermore the sex differences in the 
ageing-gut have been identified as mediators of this response (Regan et al., 2016). 
This highlights the intricate link between gut homeostasis, the nutrient sensing 
pathway and female lifespan. dPGC-1 has been shown to improve gut homeostasis 
(Rera et al., 2011) and therefore improving gut health and homeostasis during the 
ageing process may be an important determinant of healthy ageing. The link between 
dPGC-1 and reduced nutrient-sensing pathway signalling in ageing has been 
highlighted in a developmental study, showing that dPGC-1 forms a negative 
feedback loop to fine-tune the insulin signalling. However the mechanisms mediating 
this are yet to be fully elucidated (Mukherjee and Duttaroy, 2013, Tiefenböck et al., 
2010).  
 
To identify the mechanisms involved in the regulation of lifespan by dPGC-1, I 
assessed the effect of downstream TFs on longevity. I identified that ubiquitous over-
expression of the Drosophila homologue of human GA-binding protein α subunit 
(also known as nuclear respiratory factor 2α) extended lifespan. Moreover, tissue 
specific dGABPα gain-of-function in the central nervous system or in the gut and fat 
body was sufficient to extend lifespan, suggesting its broad beneficial effects in 
different tissues. In addition, dGABPα was up-regulated followed by dPGC-1 over-
expression, consistent with human data suggesting that GABPα is induced by PGC-1α 
(Mootha et al., 2004).  
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Consistent with their mammalian counterparts, dPGC-1 and dGABPα are required for 
the appropriate expression of genes in mitochondrial OXPHOS (Tiefenböck et al., 
2010, Mootha et al., 2004). Previous work has already shown that dPGC-1 gain-of-
function correlates with increased mitochondrial oxygen consumption, mitochondrial 
mass, and ATP production (Rera et al., 2011). However, the transcriptional profiling 
suggested that over-expression of dGABPα in CNS down-regulated the cellular 
components involved in respiratory chain complex and mitochondrial part, suggesting 
mitochondrial-related functions might be repressed in response to dGABPα over-
expression. I found that over-expression of dGABPα increased ATP production, but 
not oxygen consumption and mitochondrial mass, suggesting that energy production 
and consumption are uncoupled. Indeed this has been observed in long-lived worms 
showing elevated ATP but not respiration rate (Braeckman et al., 1999). In addition, 
the contribution of mitochondrial function to longevity is controversial, and whether 
direct up-regulation of mitochondrial components extend lifespan is yet to be 
unequivocally answered. It is already known that mild inhibition of mitochondrial 
respiration extends lifespan in diverse organisms, including worms, flies and mice 
(Feng et al., 2001, Dillin et al., 2002, Lee et al., 2003, Lee et al., 2010, Liu et al., 
2005, Dell'agnello et al., 2007, Copeland et al., 2009). The role of mitochondrial 
function in the coordination of the ageing process is therefore very complex and yet to 
be fully elucidated.   
 
The ETC is the major site of ROS production. PGC-1α, the “captain” of the 
mitochondrion, has dual effects, not only regulating mitochondrial biogenesis, but 
also controlling mitochondrial ROS, by regulating the antioxidant defence system (St-
Pierre et al., 2006). Although Drosophila PGC-1 gain-of-function results in resistance 
to paraquat-induced oxidative stress, the studies have failed to detect any changes in 
the main antioxidant enzymes, including SOD1, and SOD2 (Mukherjee et al., 2014). 
Here I demonstrated that the long-lived flies over-expressing dPGC-1 does not show 
increased resistance to paraquat-induced oxidative stress, and shows hypersensitivity 
to H2O2-induced oxidative stress. The difference in the two studies may be 
attributable to the background strains used to over-express dPGC-1, possibly with 
different expression levels of dPGC-1. In addition, the contribution of ROS to the 
ageing process is still a controversial area, since ROS production and lifespan can be 
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uncoupled (Copeland et al., 2009). Increasing ROS and oxidative damage in mice 
does not lead to increased ageing (Zhang et al., 2009), and reducing ROS via 
activation of the antioxidant defence system in mice does not extend lifespan (Van 
Raamsdonk and Hekimi, 2009). There is increasing evidence that a moderately 
inducing ROS may be beneficial and leads to lifespan extension in yeast and worms 
(Doonan et al., 2008, Mesquita et al., 2010, Van Raamsdonk and Hekimi, 2009). Here 
I demonstrated that dGABPα gain-of-function does not change sensitivity to either 
H2O2- or paraquat-induced oxidative stress, therefore excluding the possibility that 
oxidative stress is the driving force behind the lifespan prolonging effects of dGABPα.  
 
To investigate the mechanisms by which dGABPα over-expression extends lifespan, I 
first assessed whether dGABPα acts like a DR-mimetic. DR is the most established 
anti-ageing intervention that extends lifespan in diverse species, by shifting 
metabolism from reproduction and growth to somatic maintenance (Fontana and 
Partridge, 2015, de Cabo et al., 2014, Holliday, 1989). By comparing the effects of 
dGABPα gain-of-function and DR on lifespan, I found that dGABPα gain of function: 
1) further extended lifespan beyond that already maximized by DR; 2) extended 
lifespan via mechanisms independent of DR; and 3) shortened lifespan in starvation-
like low yeast food.  
 
To further explore the molecular mechanisms involved in these effects, I performed 
transcript profiling to assess the transcriptional response to dGABPα gain-of-function. 
This also enabled me to compare the data with the available sequencing data from 
previous studies. I showed that dGABPα regulates several genes involved in insulin 
signalling, in which over-expression of dGABPα up-regulates ImpL2, the secreted 
antagonist of insulin signalling (Sloth Andersen et al., 2000, Alic and Partridge, 2008, 
Honegger et al., 2008), thereby reducing insulin signalling. I showed that dGABPα 
gain-of-function shares similar transcriptional response with reduced IIS. In addition, 
over-expression of dGABPα extends lifespan via overlapping mechanism with 
reduced IIS. This finding supports the negative feedback loop of dPGC-1 on IIS that 
has been proposed (Tiefenböck et al., 2010), involving up-regulation of dGABPα and 
ImpL2. It will be interesting to determine whether the dGABPα-IIS link is conserved 
across species. 
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It is known that a modest reduction in insulin signalling extends lifespan in diverse 
species (Piper et al., 2008), likely due to a beneficial effect of increased insulin 
sensation in later life. Here I showed that down-regulation of dGABPα increased the 
early mortality, which is likely an outcome secondary of reduced ImpL2, leading to 
increased binding of dilps to the insulin receptor, with a reduction in the insulin 
sensitivity. Insulin resistance in type-2 diabetes and leptin resistance in obesity are 
common clinical examples (Chiu et al., 2007, Pan et al., 2014). In both of these 
conditions, cells fail to respond normally to the hormone. Type-2 diabetes is a chronic 
metabolic disease that normally develops over several years. Under physiological 
conditions, insulin is secreted from the pancreas in response to increased blood 
glucose levels after a meal, and binds to the insulin receptor on the cell surface of 
tissue-sensitive organs, triggering a series of downstream cascades including glucose 
uptake and metabolism. However, a long-term high-fat diet/high-calorie diet causes a 
constant stimulus to the insulin-insulin receptor interaction, which in turn leads to a 
reduction in sensitivity of the insulin receptor to insulin. This is referred to as insulin 
resistance. Patients with insulin resistance, or leptin resistance in obesity, normally 
show increased levels of circulating insulin or leptin, with a lower tissue sensitivity to 
these hormones. In keeping with this, I demonstrated that down-regulation of 
dGABPα shortens lifespan and knockdown of the insulin receptor further accelerates 
ageing, resulting in down-regulation of IIS beyond beneficial levels. Thus dGABPα is 
required for reduced IIS, in order to maintain the insulin sensitivity necessary for 
lifespan extension.  
 
I further showed that flies over-expressing dGABPα displayed reduced 
phosphorylation of AKT, the main enzyme in the IIS/mTOR signalling pathway, 
suggesting a reduction in IIS/mTOR signalling activity (Webb and Brunet, 2014, 
Wang et al., 2014, Guertin and Sabatini, 2009, Palu and Thummel, 2016, Laplante 
and Sabatini, 2012). Interestingly, the transcriptional profiling showed that over-
expression of dGABPα significantly down-regulated the biological functions 
including amino acid metabolism and translation, which both are tightly linked with 
reduced mTOR signalling pathway. Indeed, dGABPα gain-of-function inhibited 
mTORC1 activity, as evident from the reduction in S6K phosphorylation levels (Um 
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et al., 2006). In addition, dGABPα gain-of-function extended the lifespan via 
overlapping mechanisms with rapamycin, the mTORC1 inhibitor, likely through 
inhibition of S6K (Bjedov et al., 2010). Taken together, dGABPα gain-of-function 
extends lifespan via overlapping mechanisms with that of reduced IIS/mTOR 
signalling. dFOXO is one of the main transcription factors responsible for many 
metabolic traits of reduced IIS/mTOR signalling (Alic et al., 2011a, Slack et al., 
2011).  
 
I then looked at whether dGABPα gain of function improved healthy lifespan. Here I 
found that over-expression of dGABPα reduced the age-related over-proliferation of 
intestinal stem cells, preventing the disruption of epithelial integrity, and reducing the 
mortality of ageing flies (Choi et al., 2008, Biteau et al., 2008). Our results are 
consistence with previous findings showing that dPGC-1 gain-of-function and 
reduced IIS/mTOR signalling, all contribute to improved gut homeostasis via similar 
mechanisms (Rera et al., 2011). Since all of the above effectors extend only female 
lifespan, this indicates that the gut differences between the sexes may mediate the 
lifespan extension from reduced nutrient sensing pathway.   
 
Interestingly, I observed that, unlike many other genetic and pharmacological 
interventions (eg. DR, reduced IIS, rapamycin, or trametinib treatment), dGABPα 
gain-of-function did not reduce fecundity (Slack et al., 2011, Slack et al., 2015, 
Bjedov et al., 2010). It therefore promotes healthy lifespan in adult Drosophila with 
limited side effects. Indeed, extended longevity is not consistently correlated with 
reduced fertility (Copeland et al., 2009) and in our recently published work, we 
pointed out that flies treated with lithium show extended lifespan without a reduction 
in fecundity (Castillo-Quan et al., 2016). Lithium induces lifespan-extension and 
protection against xenobiotic via GSK3/NRF2-dependent mechanisms. Here I show 
that dGABPα gain-of-function shares overlapped transcriptional responses with those 
of lithium, suggesting they might share similar mechanisms in meditating lifespan 
regulation. However, over-expression of dGABPα does further extend lifespan in flies 
treated with lithium, suggesting that over-expression of dGABPα also extends lifespan 
via mechanisms independent of lithium treatment. In addition, flies over-expressing 
dGABPα show increased resistance to phenobarbital stress, indicating that it improves 
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healthy lifespan through up-regulation of the detoxification pathway. Since both 
lithium and NRF-2 and reduced IIS are involved in the detoxification pathway (Salih 
and Brunet, 2008, Sykiotis and Bohmann, 2010, Hoffmann and Partridge, 2015, 
Afschar et al., 2016, Castillo-Quan et al., 2016), it will be interesting to know which 
mediator is particularly responsible for this effect of dGABPα over-expression in flies.  
 
My work has thus shown that dGABPα gain-of-function extends lifespan via similar 
mechanisms to those of reduced IIS and rapamycin treatment, all of which further 
extend lifespan beyond the maximum achieved by DR in Drosophila (Bjedov et al., 
2010, Broughton et al., 2010). This suggests that dGABPα may be one of the main 
molecular modulators of lifespan extension beyond DR. In addition, dGAPBa gain-of-
function up-regulates the chaperones HSP70, together with inhibition of IIS/mTOR 
signalling pathway, which both mediate the beneficial effects in short-term fasting in 
humans or mammalian models (Brown-Borg and Rakoczy, 2013, Mattson et al., 2014, 
Cheng et al., 2014, Hine et al., 2015). This therefore highly suggests that GABPα may 
be the central mediator of the benefits of short term fasting in mammalian ageing and 
chronic diseases. Moreover, dGABPα up-regulates HSP70, which is known to 
improve proteostasis in IF and short-term fasting (Brown-Borg and Rakoczy, 2013). 
Whether direct over-expression of dGABPα improves protesostasis is yet to be 
determined. Furthermore I demonstrated here that down-regulation of AKT, the key 
enzyme in the nutrient-sensing pathway, increased the resistance to ER stress in flies, 
suggesting activation of the UPRER. These results therefore indicate that up-regulation 
of UPRER may be beneficial for fly ageing. 
 
Finally, the effects of both genetic interventions that down-regulate the IIS/mTOR 
signalling pathway, and the environmental interventions that alter meal timing, are 
dependent on the levels of the signal reduction and nutrient availability. Under normal 
conditions, GABPα activation may be beneficial for mammalian ageing through the 
use of mechanisms that mimic IF. However, in cachexic states, such as in cancer and 
type-2 diabetes, activation of GABPα maybe harmful. A previous study suggested 
that under adverse nutritional conditions, ImpL2 is up-regulated in the fat body and 
represses systemic IIS activity (Honegger et al., 2008). Indeed, starvation or fasting in 
cachexic states, as seen in Drosophila tumour models (Kwon et al., 2015, Figueroa-
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Clarevega and Bilder, 2015), lead to organ wasting and loss of body mass (Tessitore 
and Bollito, 2006). This is associated with a sustained and dramatic reduction in 
systemic IIS signalling via increased levels of secreted ImpL2, suggesting that 
sustained activation of the ImpL2/IIS pathway under malnutrition accelerates ageing.  
Here I show that under low-yeast food conditions, flies over-expressing dGABPα are 
more sensitive than non-induced controls to malnutrition, through activation of ImpL2 
and repression of IIS. In type-2 diabetes (high-insulin but profound insulin 
resistance), hepatic gluconeogenesis is highly induced, through both up-regulation of 
PGC-1α mRNA levels via either the cAMP-CREB pathway (Herzig et al., 2001), or 
through co-activation with the transcription factor HNF4 (Rhee et al., 2003). This 
leads to increased blood glucose levels and exacerbates insulin resistance. Therefore 
in conclusion up-regulation of PGC-1α or GABPα activity may prove to be a useful 
therapeutic strategy in modulating human ageing and age-related diseases. However, 
activation of these genes will require careful optimisation, especially in the 
established disease state.  
 
 
5.5Experimental procedures 
5.5.1 Fly strains 
The UAS-dPGC-1 and UAS-dGABPα lines were gifts from Dr. Christian Frei and Dr. 
Hugo Stocker (Tiefenböck et al., 2010, Baltzer et al., 2009). The AKTRNAi and 
dGABPαRNAi lines were obtained from the VDRC. Actin-GAL4 (ActGal4) and UAS-
INRDN (K1409A) stocks were obtained from the Bloomington Drosophila Stock 
Centre. The S1106-GeneSwitch (S1106GS) driver was a kind gift from the R. Davis lab 
(Roman et al., 2001). The Daughterless-GeneSwitch (daGS) driver line was kindly 
provided by Dr. Veronique Monnier (Tricoire et al., 2009). The ActGS driver line was 
kindly provided by Dr. Laurent Seroude (Poirier et al., 2008). All of the lines were 
backcrossed over 6 generations into the whiteDahomey (wDah) stock, which was 
maintained in population cages. wDah was derived by backcrossing the w1118 into the 
outbred wild-type Dahomey background. Flies were raised and maintained on 
standard sugar/yeast medium (Bass et al., 2007). Experiments were conducted at 25°C 
in a 12:12 hours light/dark cycle at constant humidity.  
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5.5.2 Dietary restriction protocol 
The specific preparation of the DR media has been described in Chapter 2. In this 
chapter, I used 0.1SY, 0.5SY, 1.0SY and 2.0SY. RU486 was supplemented into the 
SY food to give a final concentration of 200 µM.  
 
5.5.3 Rapamycin preparation and delivery 
Rapamycin (LC Laboratories #R-500) was dissolved in 100% ethanol at a 
concentration of 50mM and then added to the fly medium to give the final 
concentration. 
 
5.5.4 Lithium preparation and delivery 
Lithium chloride (LiCl; Sigma L0505) was dissolved in ddH2O to give a stock 
concentration of 5M and then supplemented into 1.0 SY medium to give the final 
concentration. Food was then dispensed into plastic vials and stored at 4 °C. Cold 
refrigerated vials were placed at 25 °C for a minimum of 2 hours before use. 
 
5.5.5 Stress experiments 
Flies were reared and housed as for lifespan experiments until 14 days of age, and 
then flies were transferred onto the specific foods containing the various stress 
reagents. The preparation and delivery of the various stress assay foods has been 
described in Chapter 2.  
 
5.5.6 Fecundity assays 
For fecundity measurement, eggs were collected over a 24-hour period and counted. 
Data was reported as the mean number of eggs laid per female ± SEM over this 24-
hour period. 
 
5.5.7 Oxygen consumption 
The mitochondrial Oxygen Consumption Rate (OCR) was analyzed using an 
Oroboros Oxygraph-2k (O2k). Drosophila heads (30-40 heads per run) were collected 
and placed in ice-cold homogenization buffer (pH 7.4, Sucrose 320 mM, Tris-HCl 10 
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mM, K+EDTA 1 mM, BSA essentially fatty acid free 2.5 g/L), homogenized with a 
Teflon homogenizer over ice, spun down and re-suspended in ice-cold 
homogenization buffer without BSA. The homogenate was added to the MiR05 buffer 
(pH 7.1, EGTA 0.5 mM, MgCl2.6H2O 3 mM, Lactobionic Acid 60 mM, Taurine 20 
mM, KH2PO4 10 mM, HEPES 20 mM, D-Sucrose 110 mM, BSA essentially fatty 
acid free 1 g/L) for OCR recordings. The experimental temperature of the O2k was 
set at 30°C and electrodes were calibrated according to the manufacturer’s protocol. 
Acquisition and analysis of the OCR was done through the Oroboros Datlab software. 
Substrates, uncouplers and inhibitors were added in the following order and final 
concentrations: 2 mM malate, 10 mM glutamate, 2.5 mM ADP, 10 µM cytochrome c, 
10 mM succinate, 0.25 µM titrations with the protonophore uncoupler Carbonyl 
cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) until maximal uncoupled 
respiration was reached, 0.5 µM rotenone, and finally 2.5 µM antimycin A. State 2 
respiration was obtained after the additions of malate and glutamate, State 3 after 
ADP, and maximal uncoupling after FCCP. The OCR was normalized to total protein 
levels obtained from the homogenate and units of activity are presented as pmol 
O2/mg*s. All reagents were from Sigma, unless stated otherwise 
 
5.5.8 Immunohistochemistry 
The following antibodies were used for cell division analyses: the primary antibody 
rabbit anti-PH3 (Cell Signaling (Danvers, MA) 9701) 1:500, and the secondary 
antibody Alexa Fluor 594*donkey anti-rabbit (A21207) Thermo Fisher Scientific, 
Waltham, MA) 1:1000. Guts were dissected in ice cold PBS and immediately fixed in 
4% formaldehyde for 15*mins. They were then serially dehydrated in MeOH, stored at 
-20°C and subsequently stained. For staining guts were defrosted and washed in 0.2% 
Triton-X/PBS, blocked in 5% bovine serum albumin/PBS, incubated in primary 
antibody overnight at 4°C and in secondary for 2*hour at RT. At least 16*guts per 
condition were mounted in mounting medium containing DAPI (Vectastain). Scoring 
was performed under the Zeiss (UK) fluorescence microscope using a 40X oil-
immersion objective. 
 
PGC-1α in neurodegeneration and ageing 
 
 
 
211 
5.5.9 Quantitative RT-PCR 
Total RNA was isolated from 10 whole adult flies using standard TRIZOL 
(Invitrogen) protocols and converted to cDNA using oligo d(T)s, primers and 
Superscript II reverse transcriptase (Invitrogen). Quantitative RT-PCR was performed 
using the Power SYBR Green PCR Master Mix (ABI), and relative quantities of 
transcripts were determined using the relative standard curve method normalized to 
the internal control gene RP49. 
The following primers sequences were used for the qRT-PCR: 
dGABPα: 
FOR: GCAACATCTTCTGGACCCAC 
REV: CCGCATAATCCGCTGTTCAA 
Cyp6a8: 
FOR: CAAGATAAGGTTCGGGCTGA 
REV: TGGTGTACAGTCGCAGAGTTTC 
GstD2: 
FOR: CGGACATTGCCATCCTGT 
REV: TGCTGAAGTCGAACTCACTAACTT 
4EBP: 
FOR: CACTCCTGGAGGCACCA 
REV: GAGTTCCCCTCAGCAAGCAA 
RP49: 
FOR: ATCGGTTACGGATCGAACAA 
REV: GACGGTCTCCTTGCGCTTCT 
ImpL2: 
FOR: CCTCATTAAGTACGGGATAC 
REV: CTTCTGATCTCCGAGATCAAG 
 
5.5.10 Immunoblot analyses 
Protein extraction and western blot techniques were described in Chapter 2. Primary 
antibodies used in this work were: pSer505-AKT (Cell Signalling Technologies 
#4054, 1:1000), total-AKT (Cell Signalling Technologies #9272, 1:1000), pThr398-
S6K (Cell Signalling Technologies #9209, 1:1000), custom made total-S6K (kindly 
provided by Dr. Cathy Slack, 1:1000), β-actin (Abcam #ab8224, 1:5000), tubulin 
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(Sigma-aldrich T6199, 1:5000), NDUFS3 (Abcam #ab14711, 1:1000), and custom 
made Atg8 (kindly provided by Dr. Ivana Bjedov, 1:1000). Secondary antibodies used 
in this work were: anti-rabbit and anti-mouse (Abcam #ab6721 and Abcam #ab6789) 
at 1:5000 dilutions. 
 
5.5.11 Proteasome activity 
Two whole flies were homogenized in 25mM Tris, pH 7.5 and the protein content was 
determined using a BCA assay. Chymotrypsin-like peptidase activity of the 
proteasome was assayed by using the fluorogenic peptide substrate Succinyl-Leu-
Leu-Val-Tyr-amidomethylcoumarin (LLVY-AMC), based on a previously published 
protocol (Bulteau et al., 2002, Rogers et al., 2012). 20 µg of crude fly homogenate 
total protein was incubated at 37°C with 25uM LLVY-AMC in a final volume of 200 
µLs. Enzymatic kinetics were measured in a temperature-controlled microplate 
fluorimeter (Tecan Infinite M200), at excitation/emission wavelengths of 360/460 nm, 
measuring fluorescence every 2 min for 1 h. Proteasome activity was determined as 
the slope of AMC accumulation over time per mg of total protein (pmoles/min/mg). 
 
5.5.12 RNA sequencing 
RNA was extracted using Trizol (Invitrogen) from four biological repeats of 25 heads 
of 10-day-old flies of the following genotypes: elavGS>UAS-dGABPα (+RU) and 
non-RU treated controls. The RNA was purified with the RNeasy columns (Qiagen) 
and its quality and concentration were determined using a NanoDrop.  The RNA was 
further processed for RNAseq analysis at the Glasgow Polyomics Unit, University of 
Glasgow. The differentially expressed genes were measured for multiple hypothesis 
testing. The raw data were analysed by Dr. Dobril Ivanov, University of Cambridge. 
 
5.5.13 Gene-Ontology (Catmap analysis) 
For the functional analysis of all the expressed genes, I used the Wilcoxon rank sum 
test available in Catmap (Breslin et al., 2004). Ranks of genes were based on the 
Bayes t-statistic for differential expression and for a given functional category. The 
significance of the rank sum for all genes in the category was calculated analytically 
based on a random gene-rank distribution. Catmap analysis was performed by Dr. 
Dobril Ivanov.  
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5.5.14 Statistical analysis 
Survival experiments were analysed using log-rank test or wilcoxon test. Cox 
Proportional Hazards analysis was performed in R to compare interactions for 
survivals. Other statistical analyses were performed using Excel and Prism 
(GraphPad, La Jolla, CA), have been indicated in the figure legends.  
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Chapter 6 General Discussion and 
future plan 
PGC-1α is the key transcriptional co-activator in energy metabolism, regulating many 
biological processes, including growth, mitochondrial biogenesis, stress defence 
system, circadian rhythm and proteostasis. In my thesis, I focused on dissecting the 
role of PGC-1α in ageing and age-related neurodegeneration. I have found that 
genetic activation of PGC-1α in the central nervous system could ameliorate the 
neurotoxic phenotypes in a Drosophila model of Aβ toxicity. The improvements were 
associated with an improved mitochondrial homeostasis and the activation of UPRER. 
In keeping with this, I found that both rifampicin, the antibiotic used in the treatment 
of tuberculosis and leprosy, and metformin, the drug used in the treatment of type-2 
diabetes, activated the UPRER and rescued the neurotoxicity in Aβ-expressing flies. 
These findings suggested that the pharmacological interventions that activating 
UPRER, or elevating PGC-1α may offer significant therapeutic benefits in AD. My 
findings are significant in the field. Although both mitochondrial dysfunction and ER-
related proteostastic failure have been implicated in the disease progression in AD, in-
vivo studies using animal models targeting above effectors are still limited. It would 
be interesting to investigate in future studies whether directly targeting components of 
UPRmt or UPRER could provide beneficial effects in animal models. This knowledge 
could eventually be translated into drug discovery for human use. 
 
There is urgent need for effective strategies to improve healthy ageing, with facts that 
the increasing ageing population coupled with the rising prevalence of age-related 
neurodegeneration. PGC-1α has also been implicated in fly ageing, however the 
mechanisms are not fully elucidated. Previous studies suggested that over-expression 
of PGC-1α in intestine extends lifespan associated with improved stress-defence 
system. However, I found that the long-lived flies were not resistant to different 
oxidative stressors, therefore excluding the possibility that oxidative stress is the 
driving force behind the lifespan prolonging effects of PGC-1α. There are three clues 
as to the mechanisms underlying the anti-ageing effects of PGC-1α over-expression. 
Over-expression of PGC-1α: 1) extended lifespan only in females but not males; 2) 
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formed an un-defined negative feedback loop on IIS/mTOR signalling pathway; 3) 
improved gut homeostasis. The sex difference in gut pathology in modulating lifespan 
prolonging effects has previously been observed in interventions involving down-
regulation of nutrient-sensing pathways. To investigate the link between PGC-1α and 
nutrient-sensing pathways, I identified that transcription factor GABPα being 
downstream of PGC-1α, extended fly lifespan, through mechanisms associated with 
reduced IIS/mTOR signalling pathway. This finding supports the negative feedback 
loop of dPGC-1 on IIS that has been proposed (Tiefenböck et al., 2010), involving 
up-regulation of dGABPα and ImpL2. It will be interesting to determine whether the 
dGABPα-IIS link is conserved in mammalian systems. Moreover, over-expression of 
GABPα improved gut homeostasis by delaying age-related over-proliferation in 
intestinal stem cells. My findings are novel and important in the ageing field. Given 
the evolutionarily conserved effects of reduced IIS/mTOR, the findings suggest that 
GABPα may be an effective modulator of mammalian ageing. 
 
Moreover, I have demonstrated that lifespan could be uncoupled from oxidative 
stress, mitochondrial function, and fecundity. Xenobiotic stress seems to play an 
important role in the lifespan pro-longing effects of GABPα over-expression. It would 
be interesting in future studies to target this pathway genetically or pharmacologically 
for healthy ageing.  
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The greatest risk factor for Alzheimer’s disease (AD) is age, and changes in the ageing
nervous system are likely contributors to AD pathology. Amyloid beta (Aβ) accumulation,
which occurs as a result of the amyloidogenic processing of amyloid precursor protein
(APP), is thought to initiate the pathogenesis of AD, eventually leading to neuronal
cell death. Previously, we developed an adult-onset Drosophila model of AD. Mutant
Aβ42 accumulation led to increased mortality and neuronal dysfunction in the adult
flies. Furthermore, we showed that lithium reduced Aβ42 protein, but not mRNA, and
was able to rescue Aβ42-induced toxicity. In the current study, we investigated the
mechanism/s by which lithium modulates Aβ42 protein levels and Aβ42 induced toxicity
in the fly model. We found that lithium caused a reduction in protein synthesis in
Drosophila and hence the level of Aβ42. At both the low and high doses tested, lithium
rescued the locomotory defects induced by Aβ42, but it rescued lifespan only at lower
doses, suggesting that long-term, high-dose lithium treatment may have induced toxicity.
Lithium also down-regulated translation in the fission yeast Schizosaccharomyces pombe
associated with increased chronological lifespan. Our data highlight a role for lithium and
reduced protein synthesis as potential therapeutic targets for AD pathogenesis.
Keywords: lithium, Drosophila, Alzheimer’s disease, translation, lifespan
INTRODUCTION
Alzheimer’s disease (AD) is the most common form of demen-
tia in the ageing population. The proportion of deaths due
to heart disease and stroke decreased by 13 and 20% respec-
tively between 2000 and 2008, while those due to AD increased
by a staggering 66% (Alzheimer’s Association, 2012). AD is
a neurodegenerative disorder characterized by the presence
of amyloid beta (Aβ) deposits and neurofibrillary, hyper-
phosphorylated tau tangles in the brain (Spires and Hyman,
2005). Age is the major risk factor for AD, and the fruit fly
Drosophila has been used to demonstrate experimentally that
the neurons of older adult flies are intrinsically more suscep-
tible to Aβ toxicity (Rogers et al., 2012). The ageing process
could contribute to increased vulnerability to protein toxic-
ity through several routes, including reduced protein turnover
through inefficient proteasome- and autophagy-mediated clear-
ance mechanisms (Rubinsztein et al., 2011; Rogers et al., 2012).
Interestingly, Aβ accumulation has been linked to several pro-
cesses affected by ageing. For instance, in a Drosophila model
of AD, Aβ increased the appearance of abnormal autophagic
vesicles, which lost their structural integrity and function
with age, and thus influenced neuronal integrity (Ling et al.,
2009).
In a previous study, we developed an adult-onset Drosophila
model of AD, using an inducible gene expression system to
express Arctic mutant Aβ42 specifically in adult neurons (Sofola
et al., 2010). Aβ42 accumulated in these flies and they dis-
played increased mortality together with progressive neuronal
dysfunction. We also demonstrated that, if we treated the adult
flies expressing Aβ chronically with lithium, we rescued toxicity
caused by Aβ. Furthermore, we found that Aβ protein, but not
mRNA levels were reduced upon lithium treatment (Sofola et al.,
2010).
Lithium has been used to treat psychiatric conditions such
as bipolar disorder, and it also has interesting neuroprotective
effects (Rybakowski, 2011). Lithium is able to promote neuro-
genesis, and increase the levels of neurotrophins such as brain-
derived neurotrophic factor (BDNF), and to inhibit glycogen
synthase kinase-3 (GSK-3), which is involved in AD (Machado-
Vieira et al., 2009; Rybakowski, 2011). Lithium also reduces
amyloid production by affecting APP processing/cleavage in
cells and mice, presumably by down regulating the levels of
phosphorylated APP (Phiel et al., 2003; Rockenstein et al., 2007).
Lithium can also influence various ageing-regulated pro-
cesses that could interfere with protein turnover and conse-
quently affect neurological function. For instance, lithium has
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been shown to induce autophagy (Sarkar et al., 2005), pro-
mote proteasome-mediated degradation (Jing et al., 2013), and
influence components of the translational machinery (Bosetti
et al., 2002; Karyo et al., 2010). Also, inhibiting GSK-3 in
HCC1806 cells by a GSK-3 inhibitor or knockdown of GSK-3β
has been reported to significantly decrease polysome assem-
bly, and thus affect translation (Shin et al., 2014). GSK-3 was
shown in these cells to partially exert its effects on transla-
tion via eIF4E-binding protein 1 (4E-BP1). Knocking down
4E-BP1 only partially restored the cap-dependent translation
suppressed by GSK-3 inhibition, suggesting that GSK-3βmay reg-
ulate other components involved in protein synthesis (Shin et al.,
2014).
In this study, we investigated underlying mechanism/s by
which lithium can reduce Aβ protein levels and thus pathol-
ogy in the adult-onset, Drosophila model of AD. Aβ peptide
is directly expressed in this model, and therefore, any effect of
lithium on Aβ levels is not due to its ability to alter APP process-
ing, but rather a consequence of its role in protein synthesis or
degradation.
MATERIALS AND METHODS
FLY STOCKS AND MAINTENANCE
All fly stocks were maintained at 25◦C on a 12:12-h light:dark
cycle at constant humidity on a standard sugar-yeast (SY)
medium (15 gl−1 agar, 50 gl−1 sugar, 100 gl−1 autolyzed yeast,
100 gl−1 nipagin and 3ml l−1 propionic acid). Adult-onset,
neuronal-specific expression of Arctic mutant Aβ42 peptide was
achieved by using the elav GeneSwitch (elavGS)-UAS system
[GAL4-dependent upstream activator sequence; (Osterwalder
et al., 2001)]. ElavGS was derived from the original elavGS
301.2 line (Osterwalder et al., 2001) and obtained as a
generous gift from Dr H. Tricoire (CNRS, France). UAS-
ArcAβ42 were obtained from Crowther et al. (2005). elavGS
and UAS-lines used in all experiments were backcrossed six
times into the w1118 genetic background. For the fly AD
model, flies carrying homozygous UAS-ArcAβ42;elavGS con-
structs were out-crossed to either w1118 flies, or flies express-
ing EGFP in a w1118 background; and adult-onset neuronal
expression was induced in the female progeny by treatment
with mifepristone (RU486; 200µM) added to the standard SY
medium.
LITHIUM TREATMENT PROTOCOL
Lithium chloride solution was made at 10M concentration
and added to 200µM RU486 standard SY medium for final
concentrations of lithium.
LIFESPAN ANALYSES
For all experiments, flies were raised at a standard density on
standard SY medium in 200mL bottles. Two days after eclosion
once-mated females were transferred to experimental vials con-
taining SY medium with or without RU486 (200µM) at a density
of 15 flies per vial. Deaths were scored almost every other day and
flies were transferred to fresh food. Data are presented as survival
curves and statistical analysis was performed using log-rank tests
to compare survival of groups.
NEGATIVE GEOTAXIS ASSAYS
Climbing assays were performed at 25◦C according to previously
published methods (Sofola et al., 2010). Climbing was analyzed
every 2–3 days post-RU486 treatment. Fifteen adult flies were
placed in a vertical column (25 cm long, 1.5 cm diameter) with
a conic bottom end, tapped to the bottom of the column, then
their climb to the top of the column was analyzed. Flies reach-
ing the top and flies remaining at the bottom of the column after
a 45 s period were counted separately, and three trials were per-
formed at 1min intervals for each experiment. Scores recorded
were the mean number of flies at the top (ntop), the mean num-
ber of flies at the bottom (nbottom) and the total number of flies
assessed (ntot). A performance index (PI) defined as½(ntot + ntop
- nbottom)/ ntot) was calculated. Data are presented as the mean
PI ± s.e.m. obtained in three independent experiments for each
group, and analyses of variances (ANOVA) were performed using
JMP 10.0 software.
QUANTIFICATION OF Aβ42 PEPTIDE
To extract total Aβ42, five Drosophila heads were homoge-
nized in 50µl GnHCl extraction buffer (5M Guanidine HCl,
50mM Hepes pH 7.3, protease inhibitor cocktail (Sigma, P8340)
and 5mM EDTA), centrifuged at 21,000 g for 5min at 4◦C,
and cleared supernatant retained as the total fly Aβ42 sample.
Aβ42 content was measured in Arctic mutant Aβ42 flies and
controls using the hAmyloid β42 ELISA kit (HS) (Millipore).
Samples were diluted in sample/standard dilution buffer and
the ELISA performed according to the manufacturers’ instruc-
tions. Protein extracts were quantified using the Bradford pro-
tein assay (Bio-Rad protein assay reagent; Bio-Rad laboratories
(UK) Ltd) and the amount of Aβ42 in each sample expressed
as a ratio of the total protein content (pmol/g total pro-
tein). Data are expressed as the mean ± s.e.m. obtained in
three independent experiments for each genotype. ANOVAs and
Tukey’s-HSD post-hoc analyses were performed using JMP 7.0
software.
WESTERN BLOTTING
The same number of Drosophila heads for each sample
were homogenized in Laemmli sample buffer containing β-
mercaptoethanol and boiled for 10min. Proteins were separated
on SDS polyacrylamide gels and blotted onto nitrocellulose
membranes. Membranes were incubated in a blocking solution
containing 5% milk proteins in TBST for 1 hr at room temper-
ature, then probed with primary antibodies diluted in TBST +
5% BSA overnight at 4◦C. Antibodies were from Cell Signaling
unless specified. GFP antibody was used at 1 in 1000 dilution
(2955), phospho eIF2B and total eIF2B at 1 in 1000 (Ab4775 and
Ab32713), phospho and total eEF2 at 1 in 500 (2331 and 2332),
and phospho S6K (9206), total S6K at 1 in 1000 [made from pre-
viously published sequence (Pearson et al., 1995)]. Appropriate
secondary antibodies were used at a dilution of 1 in 10,000.
PROTEASOME ACTIVITY
Fly heads were homogenized in 25mM Tris, pH 7.5 and
protein content determined by Bradford assay. Chymotrypsin-
like peptidase activity of the proteasome was assayed the
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using fluorogenic peptide substrate Succinyl-Leu-Leu-Val-Tyr-
amidomethylcoumarin (LLVY-AMC), based on a previously pub-
lished protocol (Bulteau et al., 2002; Rogers et al., 2012). 20µg of
crude fly head homogenate total protein was incubated at 37◦C
with 25µM LLVY-AMC in a final volume of 200µLs. Enzymatic
kinetics were measured in a temperature-controlled microplate
fluorimeter (Tecan Infinite M200), at excitation/emission wave-
lengths of 360/460 nm, measuring fluorescence every 2min
for 1 h. Proteasome activity was determined as the slope
of AMC accumulation over time permg of total protein
(pmoles/min/mg).
35S-METHIONINE INCORPORATION
Protein translation was measured in fly heads using a method
adapted from Bjedov et al. (2010). Standard SY medium was
first supplemented with 100µCi 35S methionine/mL of food
(American Radiolabeled Chemicals 1mCi/37MBq ARS0104A). 15
flies were transferred to each vial containing 1mL radioactive SY
medium. After three-hours of feeding, flies were transferred to
non-radioactive SY for 30min in order to purge any undigested
radioactive food from the intestines. Flies that were in contact
with the radioactive food for 1min were used as a background
control. Flies were then decapitated using liquid nitrogen and the
heads and bodies homogenized in 1% SDS and heated for 5min
at 95◦C. Samples were centrifuged twice for 5min at 16,000 g.
Proteins were precipitated by the addition of the same volume
of 20% cold TCA (10% TCA final concentration) and incubated
for 15min on ice. Samples were then centrifuged at 16,000 g for
15min, the pellet washed twice with acetone and re-suspended in
200µl of 4M guanidine-HCl.
Samples (100µl) were mixed with 3mL of Fluoran-Safe 2,
BDH and radioactivity counted in a liquid scintillation analyzer
(TriCarb 2800TR, Perkin Elmer), with appropriate quench cor-
rections. SDS-homogenates, prior to TCA precipitation, were also
sampled and analyzed as a measure of the total radioactivity
(incorporated and un-incorporated) present. Total protein for
each sample was determined by Bradford assay and a translation
index was calculated as follows: (TCA protein cpm/total cpm)/µg
protein per sample.
CHRONOLOGICAL LIFESPAN ASSAYS IN FISSION YEAST
Standard S. pombe laboratory strain 972 h− cells were grown in
EMM2 as previously described (Rallis et al., 2013). When cultures
reached a stable maximal density, cells were harvested, serially
diluted and plated on YES plates. The measurement of Colony
Forming Units (CFUs) was taken as time-point 0 at the beginning
of CLS curve (i.e., 100% cell survival). Measurements of CFUs
were conducted on the following days. Error bars represent stan-
dard deviation calculated from three independent cultures, with
each culture measured three times at each time-point. Statistical
significance (t-test) was determined at the time-point when
medial lifespan (50% cells dead) was reached for the untreated
cells.
POLYSOME PROFILING IN FISSION YEAST
Translational profiles were acquired as previously described
(Rallis et al., 2013). Briefly, S. pombe cells were treated with
100µM Cycloheximide for 5min. Cells were then collected by
centrifugation at 3500 rpm for 5min and diluted in 20mM
Tris-HCl pH 7.5, 50mM KCL, 10mM MgCl supplemented
with protease (PMSF), 100µM cycloheximide, 1mM DTT and
200 ng/mL Heparin. Cells were lysed in a Fastprep-24 machine
using glass beads. Sucrose gradients (10–50%) were generated
using a Biocomp Gradient Master, and protein preparations were
loaded and centrifuged at 35,000 rpm for 2 h 40min. Polysome
gradients were then loaded to the fractionator to obtain the
translational profiles.
POLYSOME PROFILING IN DROSOPHILA
Polysome profiles were generated as previously described with
minor modifications (Dinkova et al., 2005). Heads (300) were
homogenized on ice in 1200µl polysome extraction buffer
(300mMNaCl, 50mM Tris-HCL (pH 8.0), 10mMMgCl2, 1mM
EGTA, 200mg heparin/ml, 400 U RNAsin/ml, 1.0mM phenyl-
methylsulfonyl fluoride, 0.2mg cycloheximide/ml, 1% Triton X-
100, 0.1% Sodium Deoxycholate). Lysates were mixed gently and
placed on ice for 10min. Debris was the removed by spinning
at 20,000 g (4◦C) for 10min and the supernatant was layered
onto a 10–50% sucrose gradient in high salt resolving buffer
(140mM NaCl, 25mM Tris-HCL (pH 8.0), 10mM MgCl2).
Using a Beckman SW41Ti rotor (38,000 rpm at 90min, 4◦C)
polysomes and ribosomal subunits were separated before the gra-
dients were fractionated. Profiles were continuously monitored
(Ab 252 nm) using a Teledyne density gradient fractionator.
STATISTICAL ANALYSES
Data are presented as means ± s.e.m. obtained in at least three
independent experiments. JMP (version 10.0) software (SAS
Institute, Cary, NC, USA) was used for data analyses.
RESULTS
LITHIUM REDUCED Aβ LOAD IN ARCTIC Aβ42 EXPRESSING FLIES
THROUGH PROTEIN CLEARANCE/DEGRADATION-INDEPENDENT
MECHANISMS
To understand the mechanism/s by which lithium reduces Aβ42
protein level, we first investigated the speed of Aβ42 accumula-
tion after induction of expression, in the presence and absence
of lithium. We measured total Aβ protein in the flies express-
ing Arctic mutant Aβ42 specifically in adult neurons (elav gene
switch system was used to induce Aβ expression with the acti-
vator mifepistrone, RU486/RU) (Sofola et al., 2010) at a very
early time-point, 2 days post Aβ induction. We found by ELISA
analysis that even at this early time point, UAS-ArcAβ42/UAS-
gfp;elavGS/+ +RU +Li flies that were fed either 25 or 100mM
lithium showed a major reduction in total Aβ burden in compari-
son to UAS-ArcAβ42/UAS-gfp;elavGS/++RU controls, P < 0.01
and P < 0.001 respectively (Figure 1A). These data suggest that
lithium may affect synthesis rather than degradation of Aβ,
because a reduction in Aβ levels was already present at such an
early time point.
Next, we directly assessed the effects of lithium on degradation
of Aβ42. We induced Aβ expression for 6 days in the presence
of lithium (UAS-ArcAβ42/UAS-gfp;elavGS/+ +RU +Li), then
stopped Aβ induction and divided the flies randomly into two
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FIGURE 1 | Lithium reduced the level of Aβ42 peptide in the adult
Drosophila nervous system. (A) Lithium reduced amyloid levels of Arctic
Aβ42 flies at a very early time-point. Protein levels of UAS-ArcAβ42/
UAS-gfp;elavGS/+ flies on +RU486 SY medium, and UAS-ArcAβ42/
UAS-gfp;elavGS/+ flies on +RU +lithium (LiCl), were measured by ELISA
at 2 days post-induction (see Materials and Methods). Data were compared
using One-Way ANOVA, number of independent tests (n) = 4. ∗P < 0.01
and ∗P < 0.001 when comparing UAS-ArcAβ42/UAS-gfp;elavGS/+ +RU to
UAS-ArcAβ42/UAS-gfp;elavGS/+ +RU +LiCl 25 or 100mM respectively.
(B) Protein levels of UAS-ArcAβ42/UAS-gfp;elavGS/+ flies on RU +
100mM LiCl medium at 6 days post induction, and then switched to –RU
LiCl for 5 days were not significantly different from ArcAβ42/UAS-gfp;
elavGS/+ flies on RU + 100mM LiCl medium for 6 days, P = 0.6, nor
were UAS-ArcAβ42/UAS-gfp;elavGS/+ flies on +RU 6 days post induction
different in comparison to UAS-ArcAβ42/UAS-gfp;elavGS/+ flies on +RU
–LiCl for 6 days switched on to –RU + LiCl for 5 days, P = 0.7. Data were
compared using One-Way ANOVA, number of independent tests (n) = 4.
(C) Proteasome activity, as measured using the fluorogenic peptide
substrate LLVY-AMC, was not changed in flies over-expressing Arctic Aβ42
with or without LiCl treatment. Data are presented as mean activities
(pmol/min/mg protein) ± s.e.m., P = 0.72 and 0.82 for 10 and 100mM Li
(n = 5).
groups, in one of which lithium treatment was continued for a
further 5 days (UAS-ArcAβ42/UAS-gfp;elavGS/+ -RU+Li), while
no lithium was added to the food of the control group (UAS-
ArcAβ42/UAS-gfp;elavGS/+ -RU -Li). Thus, if lithium promoted
degradation of Aβ, then the level of Aβ at the end of the treatment
period should have been lower in the flies with continued lithium
treatment. Aβ levels at the end of the 11-day period did not differ
significantly between the two groups (Figure 1B), indicating that
lithium treatment did not enhance degradation of Aβ. To confirm
this finding, we again induced Aβ expression for 6 days, but in
the absence of lithium (UAS-ArcAβ42/UAS-gfp;elavGS/+ +RU -
Li), then stopped Aβ induction and divided the flies randomly
into two groups, one of which was frozen immediately, while
in the other, lithium treatment was administered for 5 days
(UAS-ArcAβ42/UAS-gfp;elavGS/+ -RU+Li). Aβ levels at the end
of the 5-day lithium treatment period did not differ significantly
from levels in the untreated, 6-day old flies (Figure 1B). These
data suggest that lithium does not promote Aβ degradation or
clearance, and point instead to a role in Aβ protein synthesis.
We also tested if lithium modulated proteasome activity in Aβ
expressing flies (2 days post Aβ induction) and found that at
10 and 100mM doses it did not (Figure 1C), consistent with
our finding that lithium does not appear to affect Aβ protein
degradation.
LITHIUM DOWN-REGULATED TRANSLATION
To determine whether the effect of lithium on Aβ protein
level was specific to Aβ, we investigated whether it affected
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the level of green fluorescent protein (GFP), a protein that
is irrelevant to AD pathology. Surprisingly, we found that
100mM lithium significantly reduced levels of GFP in the
neurons of adult flies (UAS-egfp/+;elavGS/+ +RU), P = 0.01
(Figure 2A). These data suggest that lithium affects protein syn-
thesis through a mechanism that is not specific to Aβ. To
determine whether overall level of translation was reduced by
lithium, we carried out S-methionine radioactive tracer exper-
iments in UAS-egfp/+;elavGS/+ flies. Interestingly, we found
lower 35S-methionine incorporation into protein in the bodies
of flies treated with lithium (pooled data of 10 and 100mM
lithium) in comparison to untreated control flies (Figure 2B),
P < 0.05. Based on this finding, we measured the effect of
lithium on polysome profiles of Aβ flies, as an indication
of activity of the translation machinery. There was a signif-
icant reduction in the ratio of high (polysomes >4) to low
(monosome/polysome 1-2-3) fraction in flies treated with lithium
(10mM) (UAS-ArcAβ42/+;elavGS/+ +RU +Li) in comparison
to untreated controls (UAS-ArcAβ42/+;elavGS/+ +RU flies),
0.34 vs. 0.40, P < 0.001 (Figure 2C), again demonstrating that
lithium reduced activity of the translation machinery, possibly
through a stall in translation initiation.
We next determined whether lithium exerted its effect on
translation through an effect on the activity of the mechanis-
tic target of rapamyicin (mTOR) pathway, which is involved
in control of translation. S6K is a phosphorylation tar-
get of mTOR kinase in the mTORC1 complex (Bjedov and
Partridge, 2011); interestingly, both phosphorylated S6K and
total S6K were reduced in Aβ flies treated with lithium (UAS-
ArcAβ42/+;elavGS/+ +RU +Li) in comparison to untreated
flies (UAS-ArcAβ42/+;elavGS/+ +RU) (Figure 3A). However,
the ratio of phosphorylated S6K to total S6K was not significantly
FIGURE 2 | Lithium reduced overall protein synthesis/translation. (A)
Protein levels of UAS-egfp/+;elavGS/+ flies on +RU486 SY medium, and
UAS-egfp/+;elavGS/+ flies on +RU +100mM LiCl were measured by
Western blot analyses at 7 days post-induction (see Materials and Methods).
GFP levels were significantly reduced when comparing UAS-egfp/+;elavGS/+
+RU to UAS-egfp/+;elavGS/+ +RU +LiCl 100mM, ∗P < 0.001. Data were
compared using One-Way ANOVA, number of independent tests (n) = 6. (B)
Protein synthesis was reduced in pooled UAS-egfp/+;elavGS/+ +RU +LiCl
10mM and Li 100mM treated flies in comparison to UAS-egfp/+;elavGS/+
+RU flies measured by 35S-methionine incorporation, ∗P < 0.05. Data were
analyzed by One-Way ANOVA (n = 7 for +RU and n = 13 for +RU +LiCl
treated flies). (C) Polysome profiles showed a reduction in translation in
lithium treated Aβ expressing flies, measured by calculating the area under
the different fractions, and their ratios (area under the first 3 peaks for low
fraction, and >4 for high, ratio >4/1-2-3) P < 0.001. Data were analyzed by
paired t-test (n = 5). One representative figure is shown.
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FIGURE 3 | (A) Lithium reduced protein levels of phosphorylated and total
S6K. There was no change in the ratio of phosphorylated S6K to total S6K
protein levels when UAS-ArcAβ42/+;elavGS/+ +RU +LiCl 100mM flies are
compared to UAS-ArcAβ42/+;elavGS/+ +RU controls, P = 0.2 (n = 3) (B)
Rapamycin did not reduce Aβ levels in UAS-ArcAβ42/+;elavGS/+ +RU
+50µM flies in comparison to UAS-ArcAβ42/+;elavGS/+ +RU untreated
flies, P = 0.8 (n = 3).
different between the two groups (Figure 3A). In these blots,
because of the possibility that total protein content of the flies
could have been altered by lithium, samples derived from a
fixed number of fly heads were used. Interestingly, actin levels
did not seem to be affected by lithium and were used as an
additional loading control. This finding suggests that either the
turnover rate of actin is very low, or there is a subset of proteins
that is not down-regulated by lithium. Treatment of Aβ express-
ing flies (UAS-ArcAβ42/+;elavGS/+ +RU) with rapamycin, an
inhibitor of mTOR that inhibits translation and extends lifespan
in Drosophila (Bjedov et al., 2010) also did not reduce the levels
of Aβ in the Aβ-expressing flies (Figure 3B), and nor did it ame-
liorate the Aβ-induced toxicity (Supplemental Figure 1A). These
data suggest that lithium did not act through the mTOR path-
way to reduce translation in the Aβ-expressing flies, and that the
reduced levels of total and phosphorylated S6K were instead a
consequence of a general reduction in translation.
Lithium has been shown to regulate the translation initiation
factor eIF2B in rats (Bosetti et al., 2002) and the elongation factor,
eEF-2 in SH-SY5Y cells and mice (Karyo et al., 2010). We inves-
tigated whether lithium reduced protein synthesis by regulating
one or both of these factors. Again, we observed a reduction in
both the phosphorylated and total forms of eIF2B-epsilon and
eEF-2 in Aβ expressing flies treated with 100mM lithium (UAS-
ArcAβ42/+;elavGS/++RU+Li) in comparison to untreated flies
(UAS-ArcAβ42/+;elavGS/+ +RU), but the ratio of phosphory-
lated to total eIF2B-epsilon or eEF-2 was not significantly affected
(Figures 4A,B). These data again demonstrate that lithium down-
regulated protein levels, but they do not point to a specific role for
eIF2B-epsilon or eEF-2.
Indeed, a clear-cut explanation of the effects of lithium may
be elusive, since translation of many proteins involved in the
protein synthesis machinery is presumably inhibited by lithium.
Furthermore, we used a high dose of lithium (100mM) to max-
imize our chances of identifying these downstream factors that
are responsible for the effect of lithium on translation, and were
unable to identify a specific role for the proteins we tested; and
thus did not test lower concentrations of lithium. Overall, the
data suggest that the reduction in Aβ levels we observe upon
lithium treatment is as a consequence of reduction in protein
synthesis, probably because of reduced expression of multiple
proteins involved in initiation of translation, but do not identify
the specific targets responsible.
LITHIUM ALSO INHIBITS PROTEIN SYNTHESIS IN FISSION YEAST
Reduction in protein synthesis has been frequently linked to
increased lifespan, possibly attributable to both a reduction in
energy consumption, because translation requires a significant
amount of the energy budget, and a reduction in mis-translated
polypeptides (Browne and Proud, 2002; Proud, 2002; Hansen
et al., 2007; Hipkiss, 2007). Additionally, lithium has been shown
to cause significant lifespan-extension in the nematode worm
C. elegans and in Drosophila (McColl et al., 2008; Kasuya et al.,
2009; Zarse et al., 2011). Therefore, we decided to turn into
a simpler system to determine whether lithium has an evolu-
tionarily conserved effect on translation, and whether it has an
associated effect on lifespan. Unicellular yeasts have been piv-
otal in the advancement of understanding of mechanisms of
ageing (Kaeberlein et al., 2005; Rallis et al., 2013). Fast-growing
fission yeast cells in mid-log phase were treated with 0.1mM
lithium chloride for 1 h and their translational profiles were com-
pared to those of untreated (control) cells. Following lithium
treatment, translation was reduced: high (polysomes >4) to low
(monosome/polysome 1-2-3) ratios were lower (0.51) in lithium
treated yeast cells in comparison to control cells (0.63), P < 0.001
(Figure 5A). Interestingly, the same dose of lithium extended the
chronological lifespan of fission yeast, P = 0.001 (Figure 5B).
Yeast is hence an ideal model organism in which to perform
a genetic screen to identify the relevant targets of lithium for
reduced protein synthesis and increased lifespan.
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FIGURE 4 | (A,B) Lithium reduced protein levels of phosphorylated and
total eIF2Be and eEF-2. There was no change in the ratio of
phosphorylated eIF2Be or eEF-2 to total protein levels of eIF2Be or eEF-2
in UAS-ArcAβ42/+;elavGS/+ +RU +LiCl 100mM flies in comparison to
UAS-ArcAβ42/+;elavGS/+ +RU controls, P = 0.6 and 0.7 respectively
(n = 3).
LITHIUM EXTENDED LIFESPAN OF FLIES EXPRESSING Aβ
Since we observed an association between reduced global protein
synthesis and increased longevity in fission yeast, we determined
whether lithium could also extend the survival of Aβ express-
ing flies. We measured lifespan of flies expressing Arctic Aβ42
(UAS-ArcAβ42/+;elavGS/+ +RU) and treated chronically with
different concentrations of lithium from two days post-eclosion.
Flies expressing Arctic Aβ42 in adult neurons had a shortened
median and maximum lifespan as previously reported (Sofola
et al., 2010), which could be extended with 10, 25, and 50mM
(P < 0.001 for all doses), but not with 1 or 100mM lithium
(Figure 5C). The data suggest that above a certain a thresh-
old, somewhere between 50 and 100mM, lithium no longer
rescued the shortened lifespan of flies expressing Aβ, possi-
bly because it became toxic. However, this toxicity with a high
lithium dose was only evident when taken long term and/or
in older flies, since both 10mM (Supplemental Figure 1B) and
100mM lithium previously published (Sofola et al., 2010)
were able to protect against the Aβ-induced locomotor dys-
function measured after shorter term treatment and earlier
in life.
DISCUSSION
Human life expectancy continues to increase at a steady rate
in most countries worldwide, and has done so by almost 3
months per year in the last 160 years (Oeppen and Vaupel, 2002).
Therefore, it is of great importance to tackle ageing-related dis-
eases such as AD, because they are becoming increasingly preva-
lent. Because age is the biggest risk factor for AD, interventions
that promote general increases in health during ageing could also
be important and beneficial in AD.
Lithium is becoming increasingly implicated as a drug that can
ameliorate ageing and neurodegenerative diseases. Several groups
have shown that it extends lifespan in model organisms such as
the nematode worm C. elegans and Drosophila (McColl et al.,
2008; Kasuya et al., 2009; Zarse et al., 2011). Here, we showed that
it also extends lifespan in fission yeast Schizosaccharomyces pombe,
highlighting that this effect is conserved over large evolutionary
distances. Fission yeast is an ideal organism for genetic screens,
and future work should identify the molecular targets of lithium
both for control of protein synthesis and of lifespan. Furthermore,
slightly higher levels of lithium present in the drinking water have
been reported as associated with reduced mortality in a Japanese
human population (Zarse et al., 2011).
A substantial body of work has demonstrated that several
neurodegenerative diseases and neurological disorders, including
but not confined to stroke, schizophrenia, Fragile X syndrome,
Huntington’s disease and Parkinson’s disease, benefit from the
therapeutic properties of lithium (Chiu et al., 2011). In addition,
several studies have investigated whether lithium has a beneficial
effect in AD pathogenesis. Clinical trials conducted with lithium
have yielded conflicting results; some have found benefits, whilst
others have not (Nunes et al., 2007; Macdonald and Briggs, 2008;
Hampel et al., 2009). Interestingly, a correlative study conducted
in patients with bipolar disorder, suggested that patients that had
been on chronic lithium treatment showed a reduced incidence
of AD in comparison to patients that had not been on treatment
(Nunes et al., 2007). And amore recent small-scale clinical trial on
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FIGURE 5 | Lithium reduced overall protein synthesis/translation and
extended lifespan in fission yeast. (A) Polysome profiles showed a
reduction in translation in lithium treated fission yeast cells. The area under
the different fractions and their ratios were calculated (area under the first 3
peaks for low fraction, and >4 for high, fraction, ratio >4/1-2-3). Data were
analyzed by paired t-test (n = 3), P < 0.001. (B) 0.1mM LiCl increased the
chronological median lifespan of fission yeast (paired t-test comparing
triplicates of lifespan values at 50% survival/medial lifespan, P = 0.001). (C)
Survival curves of flies expressing Arctic Aβ42 with or without lithium
treatment are depicted, data were compared using the log-rank test,
comparing UAS-ArcAβ42/+;elavGS/+ +RU +LiCl 1, 10, 25, 50 or 100mM
flies to UAS-ArcAβ42/+;elavGS/+ +RU controls. No significant difference
was seen between UAS-ArcAβ42/+;elavGS/+ +RU controls and
UAS-ArcAβ42/+;elavGS/+ +RU +LiCl 1 or 100mM, P = 0.24 and 0.17
respectively, a significant difference was observed with 10, 25, and 50mM
LiCl, P < 0.001.
mild cognitive impaired (MCI) patients found that low doses of
lithium slowed cognitive decline (Forlenza et al., 2011). The inves-
tigators suggested that a reason for the previous conflicting data
on the efficacy of lithium was probably attributable to the patho-
logical states/stages at which the patients were given lithium. It is
becoming increasingly evident that drug trials are most likely to
yield positive effects when initiated early, at the MCI stage.
Our results add to existing data suggesting that lithium could
be beneficial in ameliorating Aβ toxicity, and should be consid-
ered for a potential large-scale trial on MCI patients. It has the
added advantage of being an already approved drug, used to treat
bipolar patients. It does have side-effects, but these are mini-
mal at the low doses used in the recent small-scale clinical study
(Forlenza et al., 2011). We also found that there are limits to
the beneficial/therapeutic benefits of lithium in fission yeast in
chronological lifespan—lithium was unable to increase chrono-
logical lifespan at higher doses (data not shown) as well as in
the Drosophila AD model. Previously, we showed in Sofola et al.
(2010) that administering both 30 and 100mM lithium into the
fly food are effective in modulating Aβ neuronal toxicity as evi-
denced by the improved locomotor function in young flies (Sofola
et al., 2010). These lithium concentrations were initially chosen
based on the paper by Dokucu et al. (2005)—they showed that
lithium concentrations ranging from 10 to 100mM lithium in
the fly food translates to roughly 0.05–0.4mM in the fly tissue
(Dokucu et al., 2005), so well below the toxic levels in patients
and mice (Wood et al., 1986; Schou, 2001; Can et al., 2011). In
this paper, we show that both 25 and 100mM lithium reduce Aβ
levels in a dose dependent manner at an early time point. We also
find that lower doses of Lithium (10 and 25mM) rescue the short-
ened longevity of the Aβ flies, but 100mM lithium was unable
to extend lifespan when given to the flies throughout adulthood.
It will be important to determine the therapeutic thresholds for
lithium in patients that could offer therapeutic benefits without
overt side effects.
Similar to the published data on the role of GSK-3 inhibi-
tion in down-regulating translation in HCC1806 cells (Shin et al.,
2014), we find that lithium is able to reduce translation in fis-
sion yeast and flies, suggesting that perhaps some of the effect of
lithium on translation down-regulation is via GSK-3 inhibition.
However, this is correlative and future work will involve carry-
ing out epistasis interactions between lithium and GSK-3, and
identifying molecular targets of GSK-3 and lithium for control
of protein synthesis.
Nonetheless, our study highlights the potential benefits of
lithium through down-regulation of translation, associated with
extension of lifespan in very distantly related organisms. By
reducing protein synthesis, lithium may reduce the increased
proteostatic burden in ageing, a recognized hallmark of ageing
(López-Otín et al., 2013). Lithium is also of specific benefit in
AD, because of its ability to down-regulate translation, and hence
levels of proteins involved in promoting the presence of toxic Aβ.
The mutant Arctic Aβ42 protein present in the transgenic flies
used in this study has a propensity to aggregate faster than wild
type Aβ (Spires and Hyman, 2005). However, we have observed
both soluble and insoluble Aβ in the Arctic Aβ42 flies [(Rogers
et al., 2012), and data not shown]; and the ability of lithium to
reduce translation of the Aβ peptide without affecting its clear-
ance may lower the level of soluble Aβ. In a wider context, lithium
might be beneficial in ameliorating toxicity of AD by lowering
expression of APP and of proteins that are involved in the genera-
tion of Aβ from APP. Our model does not express full length APP,
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and may therefore not include other potential/additional bene-
fits of lithium on Aβ toxicity. As well as the increased ratio of
Aβ42 to Aβ40 peptide observed in familial AD cases with APP
mutations (De Jonghe et al., 2001), increased levels of APP could
also contribute to AD pathogenesis. Indeed, patients with Down
syndrome have a high risk of developing AD possibly due to tri-
somy of the APP gene which leads to increased APP expression
(Wiseman et al., 2009). Also, several mutations in the APP pro-
moter region were found to significantly increase APP expression
in SH-SY5Y cells, and were associated with risk for AD (Theuns
et al., 2006).
The ability of lithium to down-regulate translation could
therefore be beneficial at several stages in AD pathogenesis.
Lithium might also have therapeutic benefits for other neu-
rodegenerative disorders that are caused by over-expression of
wild type or mutant forms of proteins such as α-synuclein in
Parkinson’s disease. Lithium could also reduce the production
of mis-translated polypeptides, and free proteases or/and chap-
erones that can then participate in cellular proteostasis (Proud,
2002; Singleton et al., 2003). Furthermore, diseases where protein
turnover is compromised by loss of function of the degrada-
tion machinery could also benefit from lowering the burden of
protein production hence reducing cellular stress. This could be
particularly important in lysosomal storage diseases, where the
intrinsic function of the degradative machinery is compromised
(Kinghorn, 2011; Sarkar et al., 2013). Moreover, induction of
autophagy in some cases increases the load of an already dysfunc-
tional lysosome, worsening the cellular proteostatic stress (Wong
and Cuervo, 2010; Nixon and Yang, 2011). Hence lowering the
production of proteins could again be a viable mechanism to
restore proteostasis. Other neurodegenerative models where the
role of lithium in lowering protein translation could be ben-
eficial are, for example, the Drosophila models of Pink1 and
Parkin, which do not include the over-expression of toxic proteins
(Whitworth et al., 2006; Castillo-Quan, 2011). Flies lacking either
of these proteins accumulate unfolded proteins in mitochondria,
resulting in mitochondria impairment (Pimenta de Castro et al.,
2012). It would be interesting to study whether lithium could
ameliorate mitochondrial stress by reducing the production of the
proteins accumulating in the mitochondria of the Pink1 or parkin
null flies. Lithium could hence be a useful drug with an overall
benefit for health during ageing and protection against AD and
other neurodegenerative diseases.
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SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://www.frontiersin.org/journal/10.3389/fnagi.
2014.00190/abstract
Supplemental Figure 1 | (A) Rapamycin did not rescue the climbing
phenotype of UAS-ArcAβ42/+;elavGS/+ flies on +RU486 +200µM
rapamycin, P = 0.83 (B) Lithium suppressed the locomotor dysfunction
phenotype, P < 0.05. Climbing ability of UAS-ArcAβ42/UAS-gfp;elavGS/
+ +RU486 and UAS-ArcAβ42/+;elavGS/+ flies on +RU486 +LiCl 10mM
SY medium or +Rapamycin 200µM was assessed at the indicated
time-points (see Materials and Methods). Data are presented as the
percentage climbing performance of flies ± s.e.m. [Two-Way ANOVA,
number of independent tests (n) = 3].
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Loss of PLA2G6 leads to elevated mitochondrial
lipid peroxidation and mitochondrial
dysfunction
Kerri J. Kinghorn,1,2 Jorge Iva´n Castillo-Quan,1,2,3 Fernando Bartolome,2
Plamena R. Angelova,2 Li Li,1,2 Simon Pope,4 Helena M. Cocheme´,1,3 Shabana Khan,1
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The PLA2G6 gene encodes a group VIA calcium-independent phospholipase A2 beta enzyme that selectively hydrolyses
glycerophospholipids to release free fatty acids. Mutations in PLA2G6 have been associated with disorders such as infantile
neuroaxonal dystrophy, neurodegeneration with brain iron accumulation type II and Karak syndrome. More recently, PLA2G6
was identified as the causative gene in a subgroup of patients with autosomal recessive early-onset dystonia-parkinsonism.
Neuropathological examination revealed widespread Lewy body pathology and the accumulation of hyperphosphorylated tau,
supporting a link between PLA2G6 mutations and parkinsonian disorders. Here we show that knockout of the Drosophila
homologue of the PLA2G6 gene, iPLA2-VIA, results in reduced survival, locomotor deficits and organismal hypersensitivity to
oxidative stress. Furthermore, we demonstrate that loss of iPLA2-VIA function leads to a number of mitochondrial abnormalities,
including mitochondrial respiratory chain dysfunction, reduced ATP synthesis and abnormal mitochondrial morphology.
Moreover, we show that loss of iPLA2-VIA is strongly associated with increased lipid peroxidation levels. We confirmed our
findings using cultured fibroblasts taken from two patients with mutations in the PLA2G6 gene. Similar abnormalities were seen
including elevated mitochondrial lipid peroxidation and mitochondrial membrane defects, as well as raised levels of cytoplasmic
and mitochondrial reactive oxygen species. Finally, we demonstrated that deuterated polyunsaturated fatty acids, which inhibit
lipid peroxidation, were able to partially rescue the locomotor abnormalities seen in aged flies lacking iPLA2-VIA gene function,
and restore mitochondrial membrane potential in fibroblasts from patients with PLA2G6 mutations. Taken together, our findings
demonstrate that loss of normal PLA2G6 gene activity leads to lipid peroxidation, mitochondrial dysfunction and subsequent
mitochondrial membrane abnormalities. Furthermore we show that the iPLA2-VIA knockout fly model provides a useful platform
for the further study of PLA2G6-associated neurodegeneration.
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Introduction
The PLA2G6 gene encodes an 85-kDa group VI calcium-
independent phospholipase A2 beta (PLA2G6). This
enzyme hydrolyses the sn-2 acyl chain of glycerophospho-
lipids to release free fatty acids and lysophospholipids
(Wolf and Gross, 1996; Ma and Turk, 2001). PLA2G6
localizes to the mitochondria, and has proposed roles in
the remodelling of membrane phospholipids, signal trans-
duction and calcium signalling, cell proliferation and apop-
tosis (Gadd et al., 2006; Seleznev et al., 2006; Strokin
et al., 2012).
Humans with PLA2G6 mutations can show progressive
cognitive and motor skill regression, as displayed in
disorders such as infantile neuroaxonal dystrophy, neurode-
generation with brain iron accumulation type II and Karak
syndrome (Khateeb et al., 2006; Morgan et al., 2006).
Infantile neuroaxonal dystrophy is a neurodegenerative
disease with onset in infancy and fatality in the teenage
years or in early adulthood. It is characterized neuropatho-
logically by axonal swelling and the presence of spheroid
bodies in the central and peripheral nervous systems in add-
ition to hallmark cerebellar atrophy. Neurodegeneration
with brain iron accumulation comprises a clinically and gen-
etically heterogeneous group of disorders with a progressive
extrapyramidal syndrome and high basal ganglia iron, and
includes pantothenate kinase-associated neurodegeneration
caused by mutations in PANK2 (neurodegeneration with
brain iron accumulation type I). Post-mortem examination
of the brain of a patient with neurodegeneration with brain
iron accumulation associated with homozygous PLA2G6
mutations demonstrated both Parkinson’s and Alzheimer’s
disease pathology with widespread Lewy bodies, dystrophic
neurites and cortical neuronal neurofibrillary tangles
(Gregory et al., 2008).
Furthermore, PLA2G6 has also been implicated in a
number of other brain diseases including Alzheimer’s
disease (Schaeffer and Gattaz, 2008) and bipolar disorder
(Xu et al., 2013). More recently, PLA2G6, at the PARK14
locus, has also been characterized as the causative gene in a
subgroup of patients with autosomal recessive early-onset
dystonia-parkinsonism. Interestingly these patients did not
display cerebellar atrophy or basal ganglia iron on
MRI (Paisan-Ruiz et al., 2009), and neuropathological
examination revealed widespread Lewy body pathology
and the accumulation of hyperphosphorylated tau
(Paisan-Ruiz et al., 2012). These clinical and neuropatho-
logical features further support a link between PLA2G6
mutations and parkinsonian disorders, and demonstrate
the clinical heterogeneity in PLA2G6-associated
neurodegeneration.
It is not known how mutations in PLA2G6 cause neuro-
pathology. However, it has been suggested that the loss of
normal PLA2G6 activity in neurodegenerative disease
involves structural abnormalities of cell or mitochondrial
membranes and disturbances in lipid homeostasis and
lipid metabolism. Indeed, a study in a mouse Pla2g6
knockout model demonstrated ultrastructural abnormalities
in mitochondrial and synaptic membranes (Beck et al.,
2011). As well as possible mitochondrial defects, it is
thought that changes in the composition of the plasma
membrane and other intracellular membranes may in turn
affect the normal processes responsible for the movement
of membranes within axons and dendrites, subsequently
leading to accumulation of membranes as so-called
spheroids.
Support for a loss-of-function of PLA2G6 enzyme activ-
ity in causing disease comes from a recent study on recom-
binant wild-type and mutant human PLA2G6 proteins.
This demonstrated that mutations in PLA2G6 associated
with infantile neuroaxonal dystrophy or neurodegeneration
with brain iron accumulation resulted in encoded proteins
that exhibited 520% of control levels of phospholipase
and lysophospholipase activities. Conversely, mutations
associated with dystonia-parkinsonism did not impair
catalytic activity. The differential enzymatic activities asso-
ciated with PLA2G6 mutations in infantile neuroaxonal
dystrophy/neurodegeneration with brain iron accumulation
and dystonia-parkinsonism may explain the relatively later
onset and milder phenotype seen in the latter. Furthermore,
the preserved enzymatic function of dystonia-parkinsonism
causing mutations must be interpreted with caution as there
may be differences in PLA2G6 activity in vivo that are not
detected by these in vitro assays. For example, there may be
alternative mechanisms that alter the regulation of PLA2G6
activity, such as changes in the binding to calmodulin or
other proteins (Engel et al., 2010). Further support for the
loss of enzymatic function hypothesis comes from a recent
study of a Chinese population with Parkinson’s disease,
which identified novel PLA2G6 mutations occurring in
the heterozygous state, associated with an inhibition
in the phospholipid-hydrolysing functions of PLA2G6
(Gui et al., 2013). Moreover Gregory et al. (2008) found
a genotype–phenotype correlation in patients with infantile
neuroaxonal dystrophy and neurodegeneration with brain
iron accumulation: mutations that are predicted to lead to
an absence of protein were associated with more severe
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infantile neuroaxonal dystrophy-type clinical phenotypes,
while those with compound heterozygous missense muta-
tions correlated with the less severe phenotype of neurode-
generation with brain iron accumulation and are
predicted to result in protein with some residual enzyme
function.
Genetic ablation of Pla2g6 in mice is associated with an
in vivo disturbance of brain phospholipid metabolism
(Cheon et al., 2012), mitochondrial membrane degener-
ation (Beck et al., 2011) and marked cerebellar atrophy
(Zhao et al., 2011). Furthermore, in vitro experiments
demonstrated a disturbance in calcium signalling in astro-
cytes from PLA2G6-deficient mice (Strokin et al., 2012).
However, despite these studies, the precise molecular mech-
anisms linking loss of PLA2G6 activity to mitochondrial
morphological abnormalities and neurodegeneration
remain unclear and further studies are required.
The fruit fly Drosophila melanogaster has proven to be
an excellent model system for studying neurodegenerative
diseases, especially the role of mitochondrial activity in
Parkinson’s disease (Clark et al., 2006; Park et al., 2006).
Once a faithful model is established, the fly has the advan-
tage over mouse models in that it can be used to perform
high-throughput screening to identify genetic modifiers and
novel therapeutic targets. Here we show that iPLA2-VIA,
the Drosophila homologue of PLA2G6, plays an essential
role in maintaining normal mitochondrial function.
We demonstrate that knockout of the iPLA2-VIA gene
activity in the fly results in reduced survival, locomotor
deficits and organismal hypersensitivity to oxidative stress.
Furthermore, loss of iPLA2-VIA function leads to a
number of mitochondrial abnormalities, including reduced
mitochondrial membrane potential, mitochondrial respira-
tory chain dysfunction and reduced ATP synthesis. We also
show that levels of lipid peroxidation are significantly
elevated in the brains of flies lacking iPLA2-VIA. In add-
ition, we examined cultured fibroblasts taken from two
patients with known PLA2G6 mutations and found similar
abnormalities to those seen in the fly, including mitochon-
drial membrane abnormalities and raised levels of cytoplas-
mic and mitochondrial reactive oxygen species. Moreover,
lipid peroxidation levels, especially in the mitochondria,
were elevated in the PLA2G6 mutant human fibroblasts
compared to controls. Taken together, our findings suggest
that loss of normal PLA2G6 gene activity leads to mito-
chondrial lipid peroxidation, mitochondrial dysfunction
and mitochondrial membrane abnormalities. Finally we
demonstrate that reduction of lipid peroxidation, by treat-
ment with deuterated polyunsaturated fatty acids
(D-PUFAs), is able to recover the mitochondrial
membrane potential of PLA2G6 mutant human fibroblasts
and partially rescue the locomotor deficits in iPLA2-
VIA knockout flies. We have therefore shown that
the iPLA2-VIA knockout fly appears to be a useful
model organism for studying PLA2G6-associated
neurodegeneration.
Materials and methods
Fly stocks and husbandry
The fly stocks y[1] w[67c23]; P{w[ +mC]
y[ +mDint2]=EPgy2}iPLA2-VIA[EY05103], actin-5C-GAL4,
elav-GAL4c155 were obtained from the Bloomington
Drosophila Stock Centre. The iPLA2-VIA RNAi
(HMS01544) line was provided by the TRiP at Harvard
Medical School. All fly strains used were backcrossed at least
six generations into the w1118 background to obtain isogenic
lines. All fly stocks were maintained at 25!C on a 12:12 hour
light: dark cycle at constant humidity on a standard
sugar-yeast (SY) medium (15 g/l agar, 50 g/l sugar, 100 g/l
autolysed yeast, 100 g/l nipagin and 3ml l/ propionic acid).
For all experiments, flies were raised at a standard density
on standard SY medium in 200ml bottles unless otherwise
stated. Tissue-specific expression of iPLA2-VIA RNAi
constructs was achieved by using the GAL4-UAS system
[GAL4-dependant upstream activator sequence (Brand and
Perrimon, 1993)].
Lifespan analyses
The survival assays were performed using newly eclosed flies
that were allowed to mature and mate for 24 h before the
females and males were separated and collected. One hundred
and fifty flies were housed in groups of 15 and the flies were
transferred every 2 to 3 days onto fresh food and the number
of dead flies recorded. Data are presented as cumulative
survival curves, and survival rates were compared using log-
rank tests.
Climbing assays
The climbing assay was performed using a negative geotaxis
assay according to previously published methods (Rival et al.,
2004). Briefly, 15 adult flies were placed in a vertical column
(25ml tissue culture pipette), and allowed to climb for 45 s
before the number of flies at the top and bottom was deter-
mined. A performance index (PI) defined as 0.5(n(total) +
n(top) " n(bottom)/ n(total)) was calculated. The experiment
was repeated three times for each time point.
Fertility tests
For female fecundity tests, female flies were housed with males
for 48 h post-eclosion and then separated into vials at a density
of 10 females per vial. Eggs were collected over a 24-h period
at different time points. The number of eggs laid per vial at
each time point was counted.
Quantitative RT-PCR
Total RNA was extracted from 15 flies per sample using
TRIzol! (GIBCO) according to the manufacturer’s instruc-
tions. The concentration of total RNA purified for each
sample was measured using an Eppendorf biophotometer.
One microgram of total RNA was then subjected to DNA
digestion using DNase I (Ambion), immediately followed by
reverse transcription using the SuperScript! II system
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(Invitrogen) with oligo(dT) primers. Quantitative PCR was
performed using the PRISM 7000 sequence-detection system
(Applied Biosystems), SYBR! Green (Molecular Probes),
ROX Reference Dye (Invitrogen), and HotStarTaq (Qiagen)
by following the manufacturer’s instructions. Each sample
was analysed in triplicate with both target gene (iPLA2-VIA)
and reference gene (RP49) primers in parallel. The end
products of the RT-PCR reactions were also visualized by
staining with ethidium bromide following separation with
agarose-gel electrophoresis. The primers for the Drosophila
iPLA2-VIA used in the RT-PCR of the EY05103 fly line
were as follows: forward 5’-TACTGGAATTGTGCGATAA
GG-‘3 and reverse 5’-GATGTGGTATTGGAATCCGAG-‘3.
The primers used for the RT-PCR performed on the
iPLA2-VIA RNAi (HMS01544) fly line were as follows:
forward 5’- AACtriacylglycerolTAGTGCCGATCGTCCAA-‘3
and reverse 5’-GAACCAGTATCCTTGCAGCG-‘3. The refer-
ence gene primers were as follows: forward 5’-ATGACCAT
CCGCCCAGCATCAGG-‘3 and reverse 5’-
ATCTCGCCGCAGTAAACG-‘3.
Stress experiments
For all stress assays, flies were reared and housed as for life-
span experiments. For oxidative stress assays, 7-day or 15-day
old flies were transferred onto 5% sucrose/agar containing 5%
hydrogen peroxide (Sigma) or 20mM paraquat (Sigma). For
starvation and osmotic stress experiments, 7-day or 15-day old
flies were transferred to 1% agar or 500mM NaCl respect-
ively. For hypoxia experiments 15-day old flies were trans-
ferred to a hypoxia chamber with oxygen levels of 7%.
After 15 h the flies were removed from the chamber and the
number of dead flies was counted.
Triacylglyceride and ATP assays
Levels of triacylglyceride in adult females were measured using
the Triglyceride Infinity Reagent (ThermoScientific) and nor-
malized to total body protein using a BCA assay (Sigma). The
ATP concentration of whole female flies was determined using
the Roche ATP Bioluminescence Assay Kit HS II (Roche).
Briefly, two live whole flies or eight fly heads were homoge-
nized in 100ml ice-cold lysis buffer (provided in the kit) for
1min using a Kontes pellet pestle. The lysate was then boiled
for 5min and centrifuged at 20 000g for 1min. 2.5 ml of
cleared lysate was added to 187.5 ml dilution buffer and
10 ml luciferase and the luminescence was immediately mea-
sured using a Tecan Infinite M2000 microplate reader and
Magellan V6.5 software. Each reading was converted to the
amount of ATP per fly based on the standard curve generated
with ATP standards. At least three measurements were made
for each genotype and the experiment was repeated three
times.
Isolation of Drosophila mitochondria
Fly mitochondria were isolated by differential centrifugation,
essentially as described in Miwa et al. (2003). Briefly, adult
flies (n = 500 for each time point) were chilled on ice and
gently pressed using a pre-chilled pestle and mortar.
Importantly, the pestle was moved in a vertical motion (with
no horizontal motion) until the shape of the flies was no longer
visible. The flies were then washed in STE + BSA buffer
[250mM sucrose, 5mM Tris, 2mM EGTA, pH 7.4 (4!C),
1% bovine serum albumin]. The flies were then pressed further
in 5ml of STE + BSA buffer. The squashed flies were then
passed through double-layered muslin cloth. The collected
pulp was then spun for 3min at 4!C at 1500 rpm to remove
debris. The supernatant was then passed through a single layer
of muslin into a clean centrifuge tube and spun for 10min at
4!C and 10 000 rpm to collect the mitochondria. The mito-
chondrial pellet was then suspended in 250ml STE + BSA
buffer and stored on ice. A BCA assay (Sigma) was used to
determine the protein concentration of the mitochondrial prep-
arations. The isolated mitochondria were kept on ice and used
immediately for experiments.
Drosophila mitochondrial respiration
measurement
Oxygen consumption was measured using a Clark-type oxygen
electrode thermostatically maintained at 25!C. Glutamate
(5mM) and malate (5mM) or pyruvate (5mM) were added
to measure Complex I-linked respiration, and succinate
(5mM) with rotenone (5 mM) were added to measure
Complex II-linked respiration. All data were obtained using
an Oxygraph Plus system with Chart recording software.
Light and electron microscopy of fly
brains
Flies were decapitated and the proboscis was removed to allow
penetration of the fixative. The heads were perfused with 3%
glutaraldehyde in phosphate buffer overnight. Brains were then
treated with 1% osmium tetroxide for 3 h at 4!C and
embedded in Araldite! CY212 resin. Thin sections were
stained with toluidine blue and the brain visualized with the
light microscope. Ultrathin sections (70 mm) were stained with
lead citrate and uranyl acetate and digital images taken on a
Phillips CM10 electron microscope with a Megaview III digital
camera (Olympus).
Human fibroblast collection and
culture
The p.R747W PLA2G6 fibroblasts were generated from a
4mm skin punch biopsy taken under local anaesthetic.
Biopsies were dissected into "1mm pieces and cultured in
5 cm petri dishes in Dulbecco’s modified Eagle’s medium
(DMEM), 10% foetal bovine serum, 1% L-glutamine until
fibroblasts were seen to grow out from the explants. When
fibroblasts reached confluency, they were detached from cul-
ture dishes using TrypleETM (Invitrogen) and transferred to
larger culture vessels for further expansion and cryopreserva-
tion. This sample was collected with the written consent of the
participant and formal ethical approval from the National
Hospital for Neurology and Neurosurgery–Institute of
Neurology Joint Research Ethics Committee (London, UK).
The GM11529 mutant PLA2G6 human fibroblast cell cultures
were obtained from the Coriell Cell Repositories. This line was
sampled from a patient with infantile neuroaxonal dystrophy.
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Fibroblasts were seeded at a density of 4 ! 104 cells/cm2,
grown to 75–80% confluence and maintained at 37"C and
5% CO2 in DMEM supplemented with 10% (v/v) foetal
bovine serum, 2mM L-glutamine and 1% (v/v) penicillin/
streptomycin.
Measurement of mitochondrial
membrane potential and cytosolic
and mitochondrial reactive oxygen
species
For measurements of mitochondrial membrane potential
(!"m), dissected fly brains or cells were loaded with 25 nM
tetramethylrhodamine methylester (TMRM) for 30min at
room temperature and the dye was present for the duration
of the experiment. TMRM is used in the redistribution mode
to assess !"m, and therefore a reduction in TMRM fluores-
cence represents depolarization.
Confocal microscopy of
mitochondrial membranes in fly
brains and human fibroblasts
Confocal images were obtained using a Zeiss 710 VIS CLSM
equipped with a META detection system and a !40 oil
immersion objective. Illumination intensity was kept to a
minimum (at 0.1–0.2% of laser output) to avoid phototoxicity
and the pinhole set to give an optical slice of #2mm.
TMRM was excited using the 560 nm laser line and fluores-
cence measured above 580 nm. All data presented were
obtained from at least five coverslips and two to three
different cell preparations for cell experiments, and
six coverslips and at least six counts for fly brain
experiments. The same anatomical area of the fly brain was
used each time.
Measurement of reactive oxygen
species levels in human fibroblasts
For measurement of mitochondrial reactive oxygen species
production, cells were preincubated with 5mM MitoSOXTM
(Molecular Probes) for 10min at room temperature.
Cytosolic reactive oxygen species generation was measured
with 2mM dihydroethidium with the dye present in all solu-
tions throughout the duration of the experiment.
Fluorescence images were obtained on an epifluoresence
inverted microscope equipped with a !20 fluorite objective
(Cairn Research). Ratiometric dihydroethidium and
MitoSOX fluorescence was recorded with an excitation light
at 380 and 530nm and emission at 440 and 630nm,
respectively.
Measurement of lipid peroxidation in
fly brains and human fibroblasts
C11-BODIPY581/591 (Molecular Probes) is a sensitive fluor-
escent probe for indexing lipid peroxidation in model mem-
brane systems and living cells undergoing a shift from red to
green fluorescence emission upon oxidation, even under
physiological oxidation (Vaarmann et al., 2010). Fly brains
were dissected in phosphate-buffered saline and placed into
Hank’s balanced salt solution (HBSS). C11-BODIPY581/591
(5 mM) was loaded for 15min at 20"C. Coverslips were
washed once and resuspended in 1ml of HBSS. Ratiometric
measurements of probe oxidation were taken over a 12min
time course. Fluorescence excitation was at 488 nm, green
fluorescence was detected at 530 nm and red fluorescence at
670 nm.
Cardiolipin analysis by mass
spectrometry
Cardiolipin and oxidized cardiolipin were measured by mass
spectrometry essentially as described previously (Pope et al.,
2008; Heather et al., 2010; Rodriguez-Cuenca et al., 2010)
with some minor modifications to make the analysis specific
for Drosophila cardiolipin species. In brief, 500 flies of each
genotype were homogenized in NaPi buffer (50mM NaPi,
1mM EDTA, 100mM DTPA, pH 7.5) using a Kontes pellet
pestle. The homogenates were then spun for 2min at
13 000 rpm to remove fly debris. Lipids were extracted using
a modified Folch extraction and the combined organic layers
were evaporated to dryness under nitrogen. Before analysis,
samples were resuspended in 1ml of a 1:1 mix of buffers
A and B (buffer A, 15% water, 85% methanol containing
1ml of 250ml/l aqueous ammonia per litre; buffer B, 97%
chloroform, 3% methanol containing 0.1ml of 250ml/l aque-
ous ammonia per litre). 1 nmol of (C14:0)4-cardiolipin (Avanti
Polar Lipids) was used as an internal standard and was added
to Drosophila head homogenates.
The LC/MS/MS system (Waters 2795 separation unit and a
Quattro Micro API triple quadrupole mass spectrometer) and
parameters were as described previously (Heather et al., 2010;
Rodriguez-Cuenca et al., 2010) except that the multiple
reaction monitoring (MRM) transitions were specific for
Drosophila cardiolipin. Mass spectra from retention times
5.5–6.0min were combined to generate cardiolipin spectra.
Cardiolipin species were identified in MRM mode with the
collision gas at 0.25 Pa and collision energy at 35 eV.
Cardiolipin species were analysed as their dianions
[CL–2H]2$. In these samples, the dominant form of
cardiolipin was (C16:1)4-cardiolipin (m/z 671), which was
therefore selected for analysis based on its fragmentation to
a C16:1 fatty acid (m/z 253) by monitoring the
6714253 transition. Similarly, other cardiolpin species
(C18:2)1(C16:1)3-cardiolipin (m/z 684) and (C18:2)2
(C16:1)2-cardiolipin (m/z 697) were analysed by assessing
transitions of 6844253 and 6974253, respectively.
Oxidized cardiolipin was analysed by the transitions
6784253 and 6914253 transition. The internal standard
(C14:0)4-cardiolipin (m/z 619) was analysed by its fragmenta-
tion to a C14:0 fatty acid (m/z 227) using the transition
6194227. Data were analysed with QuanLynx software
(Waters). Total cardiolipin content was expressed as peak
area relative to that of the internal standard. The amounts
of each cardiolipin and oxidized cardiolipin were expressed
relative to the total amount of cardiolipin in the sample,
giving dimensionless ratios.
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Deuterated polyunsaturated fatty
acids
Deuterated polyunsaturated fatty acids (D-PUFAs)
11,11-D2-linoleic acid (D2-linoleic acid) and 11,11,14,
14-D4-!-linolenic acid (D4-linoleic acid) were kindly provided
by Dr Mikhail S. Shchepinov (Retrotope, Inc), and their
synthesis has been previously described (Hill et al., 2012).
Hydrogenated polyunsaturated fatty acids (H-PUFAs) were ob-
tained from Sigma–Aldrich (99%). Cells were preincubated
with 10 mM H- or D-PUFA (D4-linoleic acid) in the culture
media for 24 h and then washed with HBSS before experi-
ments. For the fly experiments, D2-linoleic acid was diluted
in water and added to the standard fly medium to give a
final concentration of 10 or 100 mM.
Statistics
Data were expressed as means ! standard error of the mean
(SEM). Significant differences were evaluated by unpaired two-
tailed Student’s t-test and significance levels are described in
individual figure legends. Climbing assays were analysed using
a two-way ANOVA or a one-way ANOVA with Bonferroni
correction.
Results
Drosophila lacking iPLA2-VIA activity
display age-dependent locomotor
deficits and reduced lifespan
A null mutant fly stock completely lacking the Drosophila
orthologue of the PLA2G6 gene, iPLA2-VIA, was obtained
from the Bloomington Drosophila Stock Centre. We will
refer to null mutant flies lacking both iPLA2-VIA genes
as iPLA2-VIA" /" henceforth. This fly strain carries a
P-element insertion (EY05103) in the iPLA2-VIA gene
(Fig. 1A). As previously shown, RT-PCR analysis con-
firmed that there was complete knockout of iPLA2-VIA
gene expression in this strain with no detectable SYBR
green signal produced. The end products of the RT-PCR
reactions were also visualized on agarose gel electrophor-
esis, which confirmed the complete absence of iPLA2-VIA
gene expression in the iPLA2-VIA" /" flies (Fig. 1B)
(Malhotra et al., 2009). Knockout of iPLA2-VIA activity
in the fly did not produce any gross changes in body size or
obvious differences in morphology (data not shown).
iPLA2-VIA is expressed throughout the adult fly body,
including the brain and eye. The iPLA2-VIA gene displays
good homology with the human PLA2G6 gene, with a
51% identity and 67% positivity (FlyBase).
The iPLA2-VIA" /" flies displayed progressive locomotor
deficits, with the climbing ability of iPLA2-VIA" /" flies in
response to light tapping progressively falling below that
of w1118 controls from #20 days of age (Fig. 1C).
Accompanying this climbing defect the iPLA2-VIA" /"
flies also showed an #50% reduction in lifespan, in both
females (Fig. 1D) and males (Supplementary Fig. 1A).
Furthermore, flies heterozygous for the EY05103 P-element
insertion (iPLA2-VIA), with presumed 50% gene activity
only, did not display reduced survival (Fig. 1D and
Supplementary Fig. 1A). To ensure that the reduced life-
span was, indeed, due to the EY05103 P-element insertion,
we generated flies with precise excisions of the P-element,
by introducing a transposase in an appropriate cross, and
found that this restored a normal lifespan (Supplementary
Fig. 1B).
To confirm the effect of iPLA2-VIA deficiency in the fly,
we also inhibited iPLA2-VIA gene expression by transgenic
RNA interference (RNAi) technology, using the GAL4/UAS
system (Brand and Perrimon, 1993). Ubiquitous expression
of iPLA2-VIA dsRNAi (UAS-iPLA2-VIA-RNAi) with the
actin-GAL4 driver resulted in a #40% reduction in whole
body iPLA2-VIA gene expression using RT-PCR analysis
(Supplementary Fig. 1C). This reduction was associated
with an age-dependent decrease in climbing ability
(Fig. 1E) and a shortened lifespan (Fig. 1F). It can therefore
be robustly concluded that genetic inactivation of iPLA2-
VIA activity results in progressive locomotor deficits and a
reduction in lifespan in Drosophila. To determine whether
these phenotypes were specific to loss of iPLA2-VIA
activity in the brain, we knocked down iPLA2-VIA in fly
neural tissue using UAS-iPLA2-VIA-RNAi driven by the
elavc155-Gal4 driver. We observed a significant reduction
in lifespan in these flies (Fig. 1G), confirming the brain-
specific effects of iPLA2-VIA deficiency.
We also assessed the fecundity of iPLA2-VIA" /" female
flies. The number of eggs laid per female significantly
declined with age compared with age-matched w1118 con-
trol flies, and by Day 25 the null mutant flies were almost
completely infertile (Supplementary Fig. 1D).
Brains lacking iPLA2-VIA display
severe, widespread neurodegeneration
and mitochondrial degeneration
Light microscopic examination of thin paraffin sections of
iPLA2-VIA" /" fly brain revealed normal brain architecture
in young Day 2 flies that was indistinguishable from w1118
controls (Fig. 2A and B). However, by Day 32 there was
significant widespread vacuolation in the iPLA2-VIA" /" fly
brains that was not present in w1118 control flies (Fig. 2C
and D). Ultrastructural examination using electron micros-
copy revealed that the mitochondria were grossly abnormal
and swollen with fragmented cristae in aged Day
32 iPLA2-VIA" /" fly brains as compared to the mitochon-
dria in age-matched w1118 control brains (Fig. 2E–H) or
younger Day 2 iPLA2-VIA" /" flies (data not shown),
which were both filled with densely packed cristae.
Furthermore, examination of the fly eye using electron mi-
croscopy revealed abnormal retinal structure in the aged
Day 32 iPLA2-VIA" /" flies compared with age-matched
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control flies, with grossly abnormal ommatidial structure
(Supplementary Fig. 2A and B).
Loss of iPLA2-VIA resulted in reduced
mitochondrial membrane potential
and abnormal mitochondrial
respiratory chain activity
Given the abnormal mitochondrial membrane morphology
in older iPLA2-VIA! /! flies, we investigated whether loss
of iPLA2-VIA affected mitochondrial membrane potential
(!"m), an indicator of mitochondrial health and function.
Mitochondrial membrane potential was assessed in the
brains of 25-day-old flies using TMRM fluorescence and
imaging with confocal microscopy. This revealed a signifi-
cant reduction in mitochondrial membrane potential in
iPLA2-VIA! /! fly brains compared to controls (Fig. 3A).
We next isolated mitochondria from iPLA2-VIA! /! flies
and assessed respiratory chain activity by measuring
oxygen consumption using a Clark-type oxygen electrode.
The steps in respiration were compared in mitochondria
isolated from iPLA2-VIA! /! flies and control w1118 flies
with substrates and inhibitors specific to individual respira-
tory complexes. We found that knockout of iPLA2-VIA
activity conferred a decrease in complex I and II-dependent
respiration (Fig. 3B), manifested as significantly decreased
oxygen consumption in state 3 respiration, whether using
substrates for complex I (5mM glutamate and 5mM
malate) or for complex II (5mM succinate in the presence
of rotenone) (Fig. 3B). The respiratory control ratio is
the ratio of state 3 respiration (ADP stimulated) to state
4 respiration (no ADP present), and is considered an indi-
cation of the degree of coupling of mitochondrial respira-
tory chain activity to oxidative phosphorylation (Chance
and Williams, 1955). The respiratory control ratio was sig-
nificantly lower in iPLA2-VIA! /! mitochondria compared
with age-matched control w1118 flies (Fig. 3C), because of
Figure 1 Lack of iPLA2-VIA gene activity leads to reduced survival and locomotor deficits. (A) Schematic of the Drosophila iPLA2-VIA
gene, showing the position of the P-element insertion (arrowhead). The iPLA2-VIA gene has four main transcripts: iPLA2-VIA-RB, iPLA2-VIA-RC, iPLA2-
VIA-RD and iPLA2-VIA-RA (FlyBase). The position of the primers has been previously shown (Malhotra et al., 2009). (B) RT-PCR analysis of iPLA2-
VIA! /! flies shows that there is no mRNA expression of the iPLA2-VIA gene compared with w1118 control flies. The end products of the RT-PCR
reaction were run on an agarose gel. RP49 is an internal control gene and is expressed in both the iPLA2-VIA! /! and control w1118 flies. (C) iPLA2-
VIA! /! flies display an age-dependent reduction in climbing ability compared with w1118 controls (n = 45 flies per genotype, three repeats per
genotype, P5 0.05). Climbing ability is expressed as a perfomance index (PI) over time in days (d). (D) Female flies lacking both iPLA2-VIA genes
(iPLA2-VIA! /!) have a significantly reduced lifespan compared with w1118 control flies (P5 0.0001). Furthermore female flies lacking only one
iPLA2-VIA gene (iPLA2-VIA+ /!; n = 150 flies per genotype) do not display a reduction in lifespan. (E) Ubiquitous downregulation of iPLA2-VIA
activity using sRNAi (UAS-iPLA2-VIA-RNAi) driven by Act5c-Gal4 (Act5c-Gal44UAS-iPLA2-VIA-RNAi) results in an age-dependent reduction in
climbing ability compared with control UAS-iPLA2-VIA-RNAi flies (P5 0.05; n = 45 flies per genotype, three repeats each). (F) Knockdown of
iPLA2-VIA activity using iPLA2-VIA sRNAi (UAS-iPLA2-VIA-RNAi) driven ubiquitously by Act5c-Gal4 (Act5c-Gal44UAS-iPLA2-VIA-RNAi) results in a
decrease in lifespan compared with control non-expressing UAS-iPLA2-VIA-RNAi flies (P5 0.0001) or driver Act5c-Gal4 flies (P5 0.0001), similar to
that seen with the null mutant flies (iPLA2-VIA! /!; n = 150 flies per genotype). (G) Knockdown of iPLA2-VIA activity using sRNAi (UAS-iPLA2-
VIA-RNAi) driven in the fly nervous system using the elav-Gal4 driver results in a decrease in lifespan compared with control non-expressing
UAS-iPLA2-VIA-RNAi flies (P5 0.0001), or driver elav-Gal4 (P5 0.0001; n = 150 flies per genotype), similar to that seen with the null mutant flies
(iPLA2-VIA! /!).
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Figure 2 Fly brains lacking iPLA2-VIA display severe mitochondrial degeneration at the ultrastructural level. (A) Light microsopic examin-
ation of Day 2 w1118 control (scale bar = 20mm) and (B) iPLA2-VIA! /! fly brains (scale bar = 30mm). (C) At Day 32 w1118 control fly brains display healthy
brain tissue compared with (D) iPLA2-VIA! /! flies brains, which display widespread vacuolation (arrows) ("60 magnification; scale bars 20 = mm). (E and F)
Ultrastructural examination of aged Day 32 w1118 control fly brains ("2500; scale bar = 0.6mm and " 5300; scale bar = 0.2 mm) revealed normal mito-
chondrial morphology, which is in contrast to (G and H) Day 32 iPLA2-VIA! /! fly brains, which display significant degeneration of the mitochondrial cristae
("3100; scale bar = 0.5 mm and " 5300; scale bar = 0.2 mm). Images representative of six fly brains examined for each genotype. No abnormal mitochondria
were seen in the w1118 control fly brains.
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the inhibition of state 3 respiration. Furthermore, the re-
spiratory control ratio of iPLA2-VIA! /! flies in the pres-
ence of glutamate/malate was dependent on the age of the
flies: older flies having lower respiratory control ratio
values (Fig. 3C). Thus, loss of iPLA2-VIA activity reduces
mitochondrial membrane potential as a result of mitochon-
drial uncoupling, which increases with age in the iPLA2-
VIA! /! flies.
Loss of iPLA2-VIA activity results in
reduced ATP levels and increased
sensitivity to oxidative stress
In keeping with the mitochondrial dysfunction caused by
loss of iPLA2-VIA activity, we also demonstrated that ATP
levels in aged, Day 25, iPLA2-VIA! /! fly heads were
reduced by 40% compared with control flies (Fig. 4A).
Levels were also reduced in whole iPLA2-VIA! /! flies
compared with controls (Supplementary Fig. 3A).
Mitochondrial dysfunction can lead to decreased resist-
ance to reactive oxygen species, which has been implicated
in many neurodegenerative diseases. To explore the role of
iPLA2-VIA in resistance to oxidative stress, we examined
the survival of iPLA2-VIA! /! flies after exposure to the
potent oxidizer hydrogen peroxide and paraquat, a free
radical generator. Consistent with the structural mitochon-
drial abnormalities in aged flies, iPLA2-VIA! /! flies
showed an age-dependent, mild sensitivity at Day 15 to
hydrogen peroxide and, more so, to paraquat (Fig. 4B
and C) that was not consistently present in younger
7-day-old flies (data not shown). Both young Day 7 and
older Day 15 iPLA2-VIA! /! flies were also sensitive to
osmotic stress and showed reduced survival compared to
w1118 control flies when fed 500mM NaCl (Supplementary
Fig. 3B). Day 15 iPLA2-VIA! /! flies also displayed
increased sensitivity to hypoxic and xenobiotic (dichlorodi-
phenyltrichloroethane, DDT) stresses (Supplementary Fig.
3C and D).
Loss of iPLA2-VIA was not associated
with changes in cardiolipin
composition
Given that mitochondrial membrane morphology appeared
to be abnormal in the iPLA2-VIA! /! flies, we performed
mass spectroscopic analysis of cardiolipin, one of the major
phospholipids in mitochondrial membranes. It has been
hypothesized that PLA2G6 is critical for the normal
repair and remodelling of damage to cardiolipin caused
by mitochondrial reactive oxygen species, and that loss of
PLA2G6 activity may lead to cardiolipin oxidation and
pathogenic downstream events such as induction of apop-
tosis. To test this hypothesis, we performed mass spectro-
scopic analysis on iPLA2-VIA! /! fly heads to compare the
cardiolipin composition with that in w1118 control flies.
We found no significant differences in the cardiolipin con-
tent, monolysocardiolipin content or fatty acid composition
between iPLA2-VIA! /! and control w1118 fly brains
(Supplementary Fig. 4). Similar results have previously
been reported in whole flies lacking iPLA2-VIA
(Malhotra et al., 2009). Furthermore, we found that oxi-
dized cardiolipin was not detected in significant amounts in
either the iPLA2-VIA! /! or control w1118 fly head hom-
ogenates (Supplementary Fig. 4). Oxidized cardiolipin
Figure 3 Flies lacking iPLA2-VIA have reduced mitochondrial membrane potential and decreased mitochondrial respiratory
chain activity. (A) The mitochondrial membrane potential measured using TMRM fluorescence in the brains of 25-day-old flies was significantly
decreased in iPLA2-VIA! /! brains compared to w1118 controls (***P5 0.001; n = 6 brains for each genotype). (B) The respiratory chain activity
was measured by assessing oxygen consumption and demonstrated that mitochondria from young Day 2 and old Day 32 iPLA2-VIA! /! flies have
reduced complex I and II–dependent respiration compared with w1118 control flies, manifested as significantly decreased oxygen consumption in
state 3 respiration (*P5 0.05, **P5 0.001). (C) The respiratory control ratio was significantly lower in iPLA2-VIA! /! mitochondria compared
with age-matched control w1118 mitochondria. Furthermore, the respiratory control ratio of iPLA2-VIA! /! flies in the presence of glutamate/
malate was dependent on the age of the flies: older flies having lower respiratory control ratio values (*P5 0.05, **P5 0.001).
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species would be expected to be present as additions of + 7/
8m/z on the scan spectra. Our results therefore do not
support a role for oxidized cardiolipin in causing mitochon-
drial dysfunction and neurodegeneration in flies lacking
iPLA2-VIA activity.
Loss of iPLA2-VIA promotes brain lipid
peroxidation and reduces whole body
triacylglycerol levels
Despite the absence of changes in oxidized cardiolipin, we
hypothesized that loss of PLA2G6 may lead to abnormal
and excessive oxidation of other mitochondrial membrane
lipids, which in turn would lead to the observed mitochon-
drial dysfunction. We therefore studied the effect of knock-
ing out iPLA2-VIA on lipid peroxidation in Drosophila.
Rates of lipid peroxidation were measured by live imaging
of Day 25 iPLA2-VIA! /! and w1118 control dissected fly
brains, using the fluorescent ratiometric oxidation-sensitive
dye C11 BODIPY581/591, which shifts its fluorescence
from red to green in a time-dependent manner, the rate
being proportional to levels of lipid peroxidation. The
changes in colour shift were detected by confocal micros-
copy. This demonstrated that levels of lipid peroxidation in
flies lacking the iPLA2-VIA gene were 3.5-fold higher than
in age-matched control fly brains (Fig. 5A).
There is evidence that PLA2G6 may play a role in the
regulation of triacylglycerol synthesis by providing
endogenous fatty acids (Gubern et al., 2009).
Triacylglycerol is the main form of lipid storage in the fly
and therefore reflects the ability of flies to respond to star-
vation conditions (Ballard et al., 2008). Measurement of
whole-body triacylglycerol levels in female flies revealed a
significant age-dependent reduction in both control w1118
and iPLA2-VIA! /! flies. However, the reduction was
significantly greater by Day 20 in the flies lacking iPLA2-
VIA activity (Fig. 5B). In keeping with an age-dependent
decrease in triacylglycerol levels, iPLA2-VIA! /! flies were
not sensitive to starvation conditions at Day 7 but became
sensitive at Day 15 compared with control w1118 flies
(Fig. 5C).
Human mutant PLA2G6 fibroblasts
display abnormal mitochondrial
physiology
Given that loss of iPLA2-VIA led to increased lipid perox-
idation and mitochondrial dysfunction in Drosophila, we
examined fibroblasts taken from a patient with a known
homozygous p.R747W mutation in PLA2G6 causing dys-
tonia-parkinsonism (Paisan-Ruiz et al., 2009). Using
TMRM fluorescence to probe for mitochondrial membrane
potential, we found that there was a significant decrease in
basal mitochondrial membrane potential in the mutant
human fibroblasts (Fig. 6A and B), similar to that seen in
fly brains lacking iPLA2-VIA.
Abnormal respiration and low mitochondrial membrane
potential can induce excessive reactive oxygen species pro-
duction in the matrix of mitochondria. Indeed the rate of
mitochondrial reactive oxygen species production, as
assessed using MitoSOX fluorescence, was increased by
28% relative to control human fibroblasts (Fig. 6C and
E). Cytosolic reactive oxygen species were also significantly
higher in the fibroblasts with a PLA2G6 mutation (Fig. 6D
and E).
Mutations in PLA2G6 are associated
with elevated mitochondrial lipid
peroxidation levels in human
fibroblasts and are reversed by
treatment with deuterated
polyunsaturated fatty acids
Following the demonstration that there is an increase in
lipid peroxidation in the brains of flies lacking iPLA2-
VIA compared with controls, we also assessed lipid perox-
idation in two human PLA2G6 fibroblast lines; one taken
Figure 4 iPLA2-VIA! /! flies have reduced ATP levels and are more sensitive to oxidative stress. (A) ATP levels are reduced in the
heads of Day 25 iPLA2-VIA! /! flies compared with age-matched w1118 control flies (*P5 0.05). (B) Aged Day 15 iPLA2-VIA! /! flies show reduced
survival when treated with 5% hydrogen peroxide (H2O2) (P = 5.6 " 10!7) and (C) 20mM paraquat (P = 4.6 " 10!7) compared with w1118
control flies (n = 150 flies per genotype).
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from a patient with dystonia-parkinsonism with a
p.R747W mutation (Paisan-Ruiz et al., 2009) and the
other from a child with infantile neuroaxonal dystrophy.
We assessed lipid peroxidation levels using the fluorescent
ratiometric oxidation-sensitive C11 BODIPY581/591 dye.
This demonstrated that PLA2G6 mutant fibroblasts had
an increased level of lipid peroxidation compared to con-
trols (Fig. 7A), suggesting therefore that lipid peroxides
may be a potential therapeutic target.
Natural polyunsaturated fatty acids (PUFAs) such as lino-
leic acid undergo autoxidation by reactive oxygen species,
resulting in the production of toxic reactive carbonyl com-
pounds that can mediate DNA damage, carcinogenesis and
inflammation. However, replacement of the bis-allylic
hydrogen atoms with deuterium atoms (termed site-specific
isotope-reinforcement) arrests PUFA autoxidation due to
the isotope effect. Indeed, even small amounts of isotope-
reinforced D-PUFA are able to protect yeast from lipid aut-
oxidation-mediated cell killing (Hill et al., 2011, 2012).
These benefits have also been confirmed in vivo with the
demonstration that D-PUFAs reduce nigrostriatal degener-
ation in a mouse model of Parkinson’s disease (Shchepinov
et al., 2011). We therefore pretreated human PLA2G6
mutant fibroblasts for 24 h with D-PUFA (D4-linoleic
acid) and found that this decreased lipid peroxidation in
the cells to below control levels (Fig. 7A). This was also
associated with a rescue in the reduced mitochondrial mem-
brane potential (Fig 7B). Moreover, assessment specifically
of lipid peroxidation levels in digitonin-permeabilized cells,
which destroys all cell membranes except mitochondrial
ones, also demonstrated that lipid peroxidation was sub-
stantially increased. In addition, when rotenone was added
to the fibroblasts there was no further significant increase in
the lipid peroxidation level, indicating that the lipid perox-
idation was predominantly produced by mitochondria in
the cell (Fig. 7C).
Deuterated linoleic acid partially
rescued the locomotor abnormalities
of flies lacking iPLA2-VIA
Finally, we tested the effect of inhibiting lipid peroxidation
with D-PUFAs on the neurodegenerative locomotor pheno-
type seen in flies lacking iPLA2-VIA. Crosses for iPLA2-
VIA! /! and w1118 control flies were set up on food
containing vehicle (H20), 10 or 100mM D2-linoleic acid.
Eclosed offspring were also kept on standard food contain-
ing either vehicle or D2-linoleic acid and aged while their
climbing ability was assessed. iPLA2-VIA! /! flies treated
with 10 mM D2-linoleic acid had significantly improved
motor performance in old age compared to flies treated
with control food (Fig. 7D). There was a trend towards
improved climbing ability at older ages when iPLA2-
VIA! /! flies were treated with 100mM D2-linoleic acid,
but this was not statistically significant. The rescuing
effect of D2-linoleic acid on climbing ability was specific
to iPLA2-VIA! /! flies, as the climbing ability of control
w1118 flies treated with 10 mM D2-linoleic acid was indis-
tinguishable from controls (Supplementary Fig. 5B). The
effect of D2-linoleic acid on the survival of iPLA2-VIA
! /!
flies was also assessed. There was no significant effect of
10mM D2-linoleic acid on the lifespan of flies lacking
iPLA2-VIA. Indeed, at the higher concentration of 100mM
D2-linoleic, the lifespan of the iPLA2-VIA
! /! flies was
reduced compared to control w1118 flies demonstrating that
D2-linoleic acid is toxic to flies at higher concentrations
(Supplementary Fig. 5B). Despite the lack of lifespan-
prolonging effects, the fact that deuterated linoleic acid
significantly improved the locomotor abnormalities of
iPLA2-VIA flies suggests that low concentrations of
D-PUFAs, or similar compounds, may act as potential thera-
peutic compounds for the treatment of PLA2G6-associated
neurodegeneration.
Figure 5 Flies lacking iPLA2-VIA have increased lipid peroxidation in their brains and reduced triacylglycerol (TAG) levels.
(A) Lipid peroxidation was measured using C11-BODIPY581/591 and demonstrated that Day 25 iPLA2-VIA! /! fly brains have elevated levels of
lipid peroxidation compared with age-matched w1118 controls (n = 6 fly brains per experiment; **P5 0.01). (B) Whole-body triacylglycerol levels
are decreased in iPLA2-VIA! /! flies in an age-dependent manner compared with w1118 control flies. (***P = 0.005 Day 20 and *P = 0.01 Day 32).
(C) Day 15 iPLA2-VIA! /! flies are more sensitive to starvation conditions than age-matched w1118 control flies (P = 0.001; n = 150 flies per
genotype).
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Discussion
As the energy factories of cells, mitochondria play an es-
sential role in neurons, in which oxidative phosphorylation
is the main source of ATP. A previous study in a mouse
model demonstrated that knockout of Pla2g6 results in
abnormal mitochondrial membrane morphology (Beck
et al., 2011). These findings lead to the question as to
how loss of normal PLA2G6 gene function leads to abnor-
mal mitochondrial morphology, and whether mitochondrial
dysfunction is an early feature of PLA2G6-associated
neurodegeneration.
Figure 6 Human mutant PLA2G6 fibroblasts have reduced mitochondrial membrane potential and increased levels of mito-
chondrial and cytosolic reactive oxygen species levels. (A) The mitochondrial membrane potential of human p.R747W mutant PLA2G6
fibroblasts is reduced compared with control human fibroblasts (*P5 0.05 control 1 and **P5 0.002 control 2) as measured by TMRM fluor-
escence. (B) This is clearly seen as a reduction in red TMRM staining in the p.R747W mutant PLA2G6 human fibroblasts compared with control
fibroblasts (Scale bars = 44mm). (C) Mitochondrial reactive oxygen species production is increased 28% in human p.R747W mutant PLA2G6
fibroblasts compared to control fibroblasts (P5 0.001; n = 6). (D) Cytosolic reactive oxygen species production is also increased in human
p.R747W mutant PLA2G6 fibroblasts compared with control fibroblasts (1.47-fold increase; P5 0.001; n = 6). (E) Rates of reactive oxygen species
production in C and D are shown as a percentage. Het = dihydroethidium.
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Figure 7 Elevated lipid peroxidation is a possible therapeutic target in PLA2G6-associated disease. (A) Lipid peroxidation levels in
intact human fibroblasts taken from two patients with PLA2G6 mutations (mutant 1 fibroblasts were taken from a patient with a p.R747W PLA2G6
mutation and mutant 2 fibroblasts were from a patient with a PLA2G6 mutation and infantile neuroaxonal dystrophy) are increased compared with
fibroblasts from healthy controls. In addition, pretreatment with D-PUFAs (D4-linoleic acid) for 24 h significantly rescues the elevated lipid
peroxidation rates in the human PLA2G6 mutant fibroblasts (***P5 0.0001; n.s = non-significant). (B) The mitochondrial membrane potential of
human mutant PLA2G6 fibroblasts is considerably reduced compared with control fibroblasts and is significantly recovered below control levels
following 24 h pre-treatment with D4-linoleic acid (***P5 0.0001). (C) Lipid peroxidation levels are also increased in permeabilized mutant
p.R747W PLA2G6 fibroblasts compared with controls in the absence (***P5 0.05 for control 1 and control 2) and presence of rotenone
(***P5 0.05 for controls 1 and 2), suggesting that it is generated from a mitochondrial source. (D) Treatment of iPLA2-VIA! /! flies with 10mM D2-
linoleic acid partially rescues the climbing deficits in an age-dependent manner compared with untreated controls (n = 45 flies per group, three
repeats per group; one-way ANOVA with Bonferroni correction ***P5 0.003). There is a trend for 100 mM D2-linoleic acid to rescue the
climbing deficits of iPLA2-VIA! /! flies but this is not statistically significant. (E) Schematic diagram showing how loss of normal PLA2G6 activity
might lead to mitochondrial dysfunction. A mutation in PLA2G6 results in loss of PLA2G6 activity. In turn this results in elevated lipid peroxidation
of mitochondria, with the resultant decrease in mitochondrial membrane potential, decrease in ATP synthesis and mitochondrial reactive oxygen
species production. The mitochondria eventually degenerate and become swollen in appearance. All of these abnormalities result in mitochondrial
dysfunction and subsequent cellular dysfunction with consequent neuronal death. NBIA = neurodegeneration with brain iron accumulation;
ROS = reactive oxygen species.
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Loss of normal phospholipase A2
activity leads to mitochondrial
dysfunction, which precedes
mitochondrial membrane defects
In this study, we demonstrated that loss of normal
phospholipase A2 activity in the fruit fly and in fibroblasts
taken from patients harbouring mutations in PLA2G6,
results in striking abnormalities in both mitochondrial func-
tion and morphology. Furthermore, we demonstrate that
mitochondrial dysfunction precedes the mitochondrial mor-
phological abnormalities that are seen at the ultrastructural
level. Deficits in mitochondrial oxidative respiration are
seen in iPLA2-VIA knockout flies as young as 2 days of
age, when there are no associated mitochondrial membrane
abnormalities present on electron microscopy.
Moreover, our findings that mitochondrial dysfunction
occurs early in PLA2G6-associated neurodegeneration, is
consistent with the clinical features seen in infantile neu-
roaxonal dystrophy, neurodegeneration with brain iron
accumulation and dystonia-parkinsonism, all of which dis-
play clear early-onset phenotypes, that have previously
been associated with mitochondrial disease.
Loss of normal PLA2G6 activity
leads to reactive oxygen species
production
In addition to mitochondrial dysfunction, we also demon-
strate that loss of PLA2G6 activity is associated with raised
levels of reactive oxygen species. These species play import-
ant roles in cell signalling, but at abnormally high levels are
detrimental to cells, ultimately leading to cell death
(Martindale and Holbrook, 2002). Lipids are important
targets of reactive oxygen species and therefore elevated
reactive oxygen species levels will lead to increases in mito-
chondrial lipid peroxidation. Furthermore, it may also be
that elevated lipid peroxidation arises in the absence of
phospholipase A2 activity because some phospholipases
preferentially cleave oxidized lipids to maintain redox
homeostasis (Domijan et al., 2014). In turn, lipid peroxides
are known to trigger a cascade of events that include a fall
in mitochondrial membrane potential, mitochondrial swel-
ling and loss of mitochondrial matrix components (Castilho
et al., 1994). Furthermore, it has been shown that complex
I, the largest complex of the respiratory chain, is susceptible
to oxidative stress (Lin and Beal, 2006). Indeed we saw a
decrease in oxidative respiration in flies lacking iPLA2-VIA
when we used substrates specific for complex I of the
respiratory chain. Furthermore, Lewy body disease has
been shown to be associated with reduced levels of com-
plex I activity (Gu et al., 1998), further implicating mito-
chondrial dysfunction in neurodegeneration, and more
specifically in PLA2G6-associated neurodegeneration,
which has been linked to parkinsonism and Lewy body
pathology.
In addition, lipid peroxidation is strongly catalysed
through the Fenton reaction by iron and iron complexes
(Koster et al., 1980) and it is iron that is often deposited in
the basal ganglia of the brains of patients affected with
PLA2G6 mutations (Morgan et al., 2006). Thus, iron-
mediated oxidative insults seem to have a crucial role in
the function of PLA2G6 and in the progression of diseases
associated with mutations in this gene.
PLA2G6-associated neurodegeneration
is not likely mediated by
oxidization of mitochondrial
cardiolipin
Given the increase in levels of lipid peroxidation in flies
lacking iPLA2-VIA, we looked for elevated levels of oxi-
dized cardiolipin, one of the most common lipids in the
inner mitochondrial membrane. It has previously been
hypothesized that PLA2G6 is involved in the remodelling
of cardiolipin’s fatty acid side chains (Malhotra et al.,
2009) and in removing oxidized fatty acid side chains.
Oxidation of mitochondrial phospholipids such as cardio-
lipin leads to cytochrome c release and apoptosis (Kagan
et al., 2005). To determine whether cardiolipin is oxidized
in PLA2G6 loss-of-function, we analysed the cardiolipin
composition of iPLA2-VIA! /! fly heads using mass spec-
trometry. We demonstrated that mitochondrial membrane
disintegration and mitochondrial dysfunction occur in the
absence of any significant differences in cardiolipin amount
or side chain composition in fly brains lacking iPLA2-VIA.
Furthermore, oxidized cardiolipin was not detected in sig-
nificant amounts. This may be related to the types of fatty
acids present in Drosophila cardiolipin. Palmitic acid is the
major component of cardiolipin side chains in Drosophila
and is more resistant to oxidation than linoleic acid, the
main cardiolipin side chain in most mammalian tissues.
However, it could also point towards redundancy in the
cardiolipin remodelling enzymes. There are a number of
enzymes involved in cardiolipin remodelling and it may
be the case that fatty acid remodelling of the side chains,
in particular removal of oxidized fatty acids, can be
performed by other enzymes involved in cardiolipin remo-
delling such as tafazzin (Schlame, 2013).
The abnormal lipid peroxidation seen
in PLA2G6 knockout leads to a toxic
cascade of downstream events
In this work we report that loss of normal PLA2G6 func-
tion is strongly associated with elevated mitochondrial lipid
peroxidation. Furthermore lipid peroxidation is known to
induce mitochondrial injury, leading to a decrease in oxi-
dative respiratory chain function, reduced mitochondrial
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membrane potential, reduced cellular ATP levels and raised
reactive oxygen species levels, all features we have demon-
strated in flies and human fibroblasts lacking normal
PLA2G6 gene activity (Fig. 7D). This in turn would be
predicted to lead to cell death and neurodegeneration. As
lipid peroxides are harmful mediators of oxidative stress,
strategies focused on quenching, recycling or protecting
such products could be highly effective in the treatment
of the disease.
This work suggests that lipid peroxi-
dation-lowering strategies may be
beneficial in PLA2G6-associated
neurodegeneration
In addition to showing that lipid peroxidation is increased
in both fly brains lacking iPLA2-VIA and human PLA2G6
mutant fibroblasts, we have demonstrated that D-PUFAs
reduce the rates of lipid peroxidation in two lines of
PLA2G6 mutant fibroblasts and restore mitochondrial
membrane potential. This suggests that D-PUFAs may
have potential therapeutic roles in PLA2G6-associated
neurodegeneration and its associated mitochondrial
dysfunction.
Our data promote Drosophila as a useful model for
studying PLA2G6-associated neurodegeneration, and for
manipulating pathways and therapeutic targets in order
to reverse or prevent the deleterious effects of lipid perox-
ides. Loss of iPLA2-VIA gene function results in reduced
lifespan and locomotor ability, increased sensitivity to oxi-
dative insults as well as hypoxia, osmotic and starvation
stressors. Thus flies lacking iPLA2-VIA display phenotypes
that can be used as markers in genetic modifying screens or
in the screening of potential therapeutic compounds. To
test the validity of the fly model for drug screening and
to confirm the benefits of D-PUFAs in vivo in an organism
lacking iPLA2-VIA, we examined the effects of D-PUFAs
on the locomotor deficits of iPLA2-VIA! /! flies. This
demonstrated that treatment with D2-linoleic acid partially
rescues the climbing abnormalities in aged iPLA2-VIA
knockout flies. Therefore this approach of using com-
pounds, which act to reduce the autoxidation of lipids,
may represent a future therapeutic strategy for patients
with PLA2G6-associated neurodegeneration and warrants
further investigation.
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SUMMARY
The quest to extend healthspan via pharmaco-
logical means is becoming increasingly urgent,
both from a health and economic perspective.
Here we show that lithium, a drug approved for
human use, promotes longevity and healthspan.
We demonstrate that lithium extends lifespan in
female and male Drosophila, when administered
throughout adulthood or only later in life. The life-
extending mechanism involves the inhibition of
glycogen synthase kinase-3 (GSK-3) and activation
of the transcription factor nuclear factor erythroid
2-related factor (NRF-2). Combining genetic loss
of the NRF-2 repressor Kelch-like ECH-associated
protein 1 (Keap1) with lithium treatment revealed
that high levels of NRF-2 activation conferred
stress resistance, while low levels additionally
promoted longevity. The discovery of GSK-3 as
a therapeutic target for aging will likely lead to
more effective treatments that can modulate
mammalian aging and further improve health in
later life.
INTRODUCTION
Lithium is the most commonly prescribed drug for the treatment
of bipolar disorder. It also improves disease phenotypes in
animal models of many clinical conditions including Alzheimer
disease, depression, and stroke (Chiu and Chuang, 2010). The
effects of lithium on aging have been documented in yeast and
Caenorhabditis elegans, with lithium extending lifespan (McColl
et al., 2008; Zarse et al., 2011; Tam et al., 2014; Sofola-Adesakin
et al., 2014). The effects of lithium on Drosophila aging have pre-
viously been inconclusive, with demonstration of both positive
and negative effects on survival (Matsagas et al., 2009; Zhu
et al., 2015). Moreover, lithium concentration in the drinking wa-
ter of a large Japanese population has been associated with
reduced all-cause mortality (Zarse et al., 2011), suggesting that
lithium may be a bona fide anti-aging drug. However, the mech-
anisms by which lithium acts in humans remain poorly
understood.
In vitro studies have reported that lithium can protect against
several forms of oxidative and xenobiotic stressors (Lai et al.,
2006; Scha¨fer et al., 2004), but in vivo evidence for such pro-
tective effects of lithium is lacking. Longevity has been exten-
sively correlated with resistance to stress (Minois, 2000; Rattan,
2008; Calabrese et al., 2011; Epel and Lithgow, 2014). Tran-
scriptomic analysis of interventions known to extend lifespan
have identified particular genes likely to be involved in stress
resistance (McElwee et al., 2007; Steinbaugh et al., 2012). Up-
regulation of the transcription factor cap’n’collar C (CncC, an
NRF-2 homolog) has been shown not only to confer resistance
to toxic compounds, but also to promote longevity in C. ele-
gans and flies (Tullet et al., 2008; Sykiotis and Bohmann,
2008; Ewald et al., 2015). In flies and mammals, NRF-2/CncC
is negatively inhibited through cytosolic sequestration and pro-
teasomal degradation by the canonical Keap1 (Hayes and Din-
kova-Kostova, 2014; Pitoniak and Bohmann, 2015). However,
a second emerging upstream regulator of NRF-2/CncC is
GSK-3, a well-documented target of lithium (Jope, 2003; Hayes
and Dinkova-Kostova, 2014; Cuadrado, 2015; Hayes et al.,
2015; Blackwell et al., 2015). GSK-3 regulates NRF-2 by phos-
phorylation and nuclear exclusion, an effect that is evolution-
arily conserved from invertebrates to mammals (Salazar et al.,
2006; An et al., 2005). Interestingly, GSK-3 inhibition has
been shown to phenocopy the effects of lithium for protection
against xenobiotic stress in vitro (Lai et al., 2006; Scha¨fer
et al., 2004).
Activation of NRF-2/CncC produces hormetic effects on
lifespan, such that at low level NRF-2/CncC activity extends
lifespan while higher levels of activation limit it (Mattson,
2008; Maher and Yamamoto, 2010). Interestingly a hormetic
signature was recently reported for the survival of a mamma-
lian cell line treated with lithium (Suganthi et al., 2012),
suggesting that lithium and GSK-3 inhibition could influence
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animal lifespan and stress resistance through activation of
NRF-2.
Here we show that lithium supplementation in the diet can
modulate longevity, stress resistance, and metabolism in
Drosophila through the inhibition of GSK-3. Correspondingly,
genetic downregulation of GSK-3 and lithium treatment are
epistatic, suggesting a common molecular pathway. We also
show that lithium and the genetic inhibition of GSK-3 promote
xenobiotic stress resistance and lifespan extension through
the activation of a transcriptional response mediated by
CncC/NRF-2. Furthermore, lithium protects against a high-su-
crose diet and acts through mechanisms that only partially
overlap with those mediating lifespan extension by dietary
restriction (DR). These findings demonstrate an alternative
genetic and pharmacological target for the promotion of
longevity and stress resistance, and emphasize the potential
of pharmacological inhibitors of GSK-3 as viable anti-aging
treatments.
RESULTS
Lithium Extends Healthy Lifespan in Drosophila
To assess the role of lithium inDrosophila aging, we treated adult
female flies with lithium chloride (LiCl) by supplementation in
their food. Lithium treatment in the range of 1 to 25 mM resulted
in lifespan extension, whereas higher doses (50–100 mM) short-
ened lifespan (Figure 1A). These effects of lithium treatment on
lifespan extension were also observed in an independent genetic
background (Figure S1A) and inmales (Figure S1B). Thus, lithium
treatment extended Drosophila lifespan independently of ge-
netic background and sex.
To ensure that the increased lifespan observed with lithium
supplementation was dependent on the addition of lithium itself,
we treated flies with equivalent molar concentrations of sodium
chloride (NaCl) and found no lifespan extension (Figures S1C and
S1D). Thus, the pro-longevity effect of LiCl is specific to lithium
and not its chloride counterion.
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Figure 1. Lithium Regulated Longevity and
Metabolism in Drosophila
(A) Lithium extended lifespan of wDah Drosophila
females (n = 160 flies per condition) at concentra-
tions between 1 and 25 mM (+16% and +18%
median and maximum lifespan extension; p <
0.001), but resulted in a dose-dependent reduction
in lifespan at concentrations between 50 and
100 mM (p < 0.001).
(B) Lithium treated female w1118 flies showed a
significant improvement and protection against
age-related locomotor decline (p < 0.01, two-way
ANOVA for 10 mM).
(C) Lithium extended lifespan of aged, 32-day-old
female wDah flies at concentrations from 1 to
25 mM (30 days later than in Figure 1A): 1 mM
extended median lifespan by 5% (4 days) and
maximum lifespan by 13% (8 days; p < 0.05); 10
and 25 mM lithium increased median lifespan by
9% (6 days); 10 mM increased maximum lifespan
by 4.5% (3.5 days); wherease 25 mM lengthened it
by 8% or 6 days (p < 0.01); and 50 and 75 mM
significantly shortened lifespan (p < 0.01). n = 150
flies per condition.
(D) Brief treatment with lithium for 15 days early in
adulthood extended lifespan of female wDah flies
(p < 0.05 for 1 mM and p < 0.01 for 10 mM; n = 150
flies per condition).
(E) Lithium induced a dose-dependent reduction in
triglyceride levels. Bars represent means of six
replicas of five flies per condition ± SEM. *p < 0.01,
**p < 0.001.
(F) Female wDah flies pre-treated with lithium for
15 days were subsequently sensitive to starvation
in a dose-dependent manner (n = 90 flies per
condition).
(G) Lithium treatment significantly extended the
lifespan of w1118 female flies exposed to a four
times higher sucrose concentration (2g/L; p <
0.001; n = 120 flies per condition).
(H) The increase of triglycerides observed on a
high-sucrose diet was completely blocked after
15 days of treatment with 1 mM lithium. Bars
represent means of six replicas of fivew1118 female
flies per condition ± SEM. *p < 0.01.
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Interestingly, we observed that, unlike with many other genetic
and pharmacological interventions (e.g., DR, insulin/IGF down-
regulation, rapamycin, or trametinib treatment), lithium did not
reduce fecundity at life-extending doses or compromise feeding
behavior (Figures S1E and S1F). Moreover, it delayed locomotor
decline at two concentrations that extend lifespan (Figure 1B).
Thus, lithium promotes healthspan in adult Drosophila with
limited side effects.
Lithium Extends Lifespan in Mid-life or with Short-Term
Treatment in Young Flies
To limit the side effects of long-term use, a drug that improves
lifespan and healthspan will ideally do so with late-onset admin-
istration (Castillo-Quan et al., 2015; Longo et al., 2015). We
therefore assessed the effect of commencing lithium treatment
at older ages. Flies were switched onto food containing a range
of lithium concentrations (1–75mM) at 32 days of age (Figure 1C).
Lower doses (1–25 mM) of lithium extended lifespan, whereas
higher doses (50 and 75 mM) significantly reduced lifespan,
similar to the dose-dependent effects we observed in younger
flies.
We also tested whether transient lithium treatment early in life
could increase lifespan. We therefore exposed young flies to 1 or
10 mM lithium for 15 days and then switched them to control
food for the remainder of their lifespans. Early treatment with
these doses of lithium extended lifespan (Figure 1D). Lithium
treatment early in life, and for a transient period, can therefore in-
crease survival later in life.
Lithium Alters Lipid Metabolism and Promotes Survival
under a High-Sugar Diet
Genetic and environmental interventions that extend lifespan
often induce abnormalities in carbohydrate and lipid metabolism
(Barzilai et al., 2012;Wang et al., 2014; Lamming et al., 2013). We
therefore examined the effects of lithium on whole body treha-
lose, glycogen, and triglyceride levels. Following 15 days of
lithium treatment, and over a wide range of lithium concentra-
tions, we were unable to detect a significant change in the levels
of either trehalose or glycogen (Figures S1G and S1H). However,
we observed a dose-dependent reduction in whole body triglyc-
erides, themain lipid storage in flies (Ballard et al., 2008; Skorupa
et al., 2008) (Figures 1E and S1I). In keeping with the lowered tri-
glyceride levels (Ballard et al., 2008; Ulgherait et al., 2014),
lithium treatment reduced survival under starvation conditions
in a dose-dependent manner (Figures 1F and S1J). Moreover,
lithium also extended lifespan under dietary conditions that pro-
mote triglyceride accumulation (Skorupa et al., 2008). Flies fed a
high-sucrose diet were short lived and lithium was able to
partially rescue this defect (Figure 1G) while completely blocking
the increase in triglycerides observed with a sucrose-rich diet
(Figure 1H). Therefore, lithium can extend lifespan under obeso-
genic dietary conditions.
Lithium and DR Extend Lifespan via Partially
Overlapping Mechanisms
We next investigated whether lithium treatment was acting as a
DR mimetic. DR is a well-established anti-aging intervention
that extends healthy lifespan in diverse species (de Cabo et al.,
2014; Fontana and Partridge, 2015), and some pharmacological
and genetic interventions that extend lifespan have features of
DR mimetics (Ingram and Roth, 2015; de Cabo et al., 2014). To
determine whether lithium and DR extend lifespan by similar
mechanisms, we assessedwhether lithium could extend lifespan
beyond the maximum achievable by DR. To maximize lifespan
under DR, we varied the yeast concentration in the food while
maintaining a constant concentration of sucrose (Bass et al.,
2007), resulting in a typical tent-shaped response, with peak life-
span at food containing a 1.0 yeast concentration (Figures 2Aand
S2A–S2D). If lithium treatment and DR share overlapping path-
ways, then lithium would not be able to further extend lifespan
already maximized by DR (Gems et al., 2002; Castillo-Quan
et al., 2015). All lithium doses tested significantly extended me-
dian lifespan in both the yeast condition that maximized lifespan
(1.0 yeast; Figures 2A and S2C) and under full feeding (2.0 yeast;
Figures 2A and S2D), with greatest extension of median lifespan
with 10 mM lithium under full feeding. However, under reduced
yeast concentrations that shorten lifespan (0.2 and 0.5 yeast),
10 mM lithium either significantly reduced lifespan (Figure S2B)
or did not confer a significant lifespan benefit (Figure S2A). Cox
proportional hazards analysis showed a significant interaction
between lithiumandyeast concentrations for lifespan (interaction
termp< 0.0001). The extension of lifespan from lithium increased
with the level of yeast in the fly diet, suggesting partially overlap-
ping mechanisms to those of DR.
Lithium Extends Lifespan through Inhibition of GSK-3
A well-known target of lithium is GSK-3 (Phiel and Klein, 2001;
Jope, 2003; Eldar-Finkelman and Martinez, 2011). We therefore
evaluated the phosphorylation status of the fly ortholog of
GSK-3, Shaggy (Sgg), in response to lithium treatment. Lithium
addition to the fly medium resulted in a dose-dependent in-
crease in the inhibitory phosphorylation (Serine 9 or S9) of Sgg
(Figure 2B). To evaluate the role of Sgg in lithium-mediated life-
span extension, we directly manipulated its activity in adult flies.
Ubiquitous overexpression of wild-type or constitutively active
Sgg (SggS9A) significantly reduced lifespan by !30% and
50%, respectively (Figures 2C and S2E). This reduction in life-
span was almost completely reversed by lithium treatment.
Furthermore, RNAi-mediated reduction in sgg expression using
two independent dsRNA-expressing transgenes significantly
increased lifespan (Figures 2D and S2F). Importantly, lithium
was unable to further increase the lifespan of these sgg RNAi
knockdownmutants flies (Figure 2D). Taken together, these find-
ings suggest that Sgg/GSK-3 inhibition and lithium treatment in-
crease lifespan by acting on the same downstream targets.
Lithium Activates the Cap’n’Collar C/NRF-2
Transcription Factor
To identify downstream mediators of lifespan extension by
lithium and of GSK-3 inhibition, we analyzed the genome-wide
transcript profiles of lithium-treated flies using microarrays.
Genes encoding ribosomal proteins were among the most upre-
gulated (Figure 3A) and downregulated (Figure S3A) gene
ontology (GO) categories in lithium-treated flies. This transcrip-
tional response could underlie the translational repression
following lithium treatment that has been previously observed
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Figure 2. Lithium Extended Lifespan beyond Dietary Restriction by Inhibiting Sgg/GSK-3
(A) Median lifespans at different lithium concentrations (0, 1, 2.5, 5, or 10 mM) are plotted for four different yeast concentrations (0.23, 0.53, 1.03, and 2.03
yeast): 1–5 mM lithium extended lifespan under all dietary conditions tested. Although 10 mM lithium prolonged life at 1.03 and 2.03, it showed no effect at 0.23
and significantly shortened lifespan at 0.53 yeast. *p < 0.05, **p < 0.01, ***p < 0.001, from 0 lithium; n = 160 flies per condition. Complete survival curves are shown
in Figures S2A–S2D.
(B) Lithium treatment for 15 days significantly increased the inhibitory phosphorylation of Sgg/GSK-3 in a dose-dependent manner. Bars represent means of
triplicates of ten flies per biological repeat ± SEM, *p < 0.05, **p < 0.01.
(C) Ubiquitous overexpression of wild-type sgg significantly shortened lifespan (p < 0.001) and this was partially rescued by lithium treatment at two concen-
trations (10 and 25 mM; p < 0.001). See Figure S2E for the interaction of sgg(S9A) and lithium treatment on lifespan.
(D) Ubiquitous RNAi-mediated downregulation of sgg extended lifespan (p < 0.001) and no further extension occurred when the flies were treated with 1 or 5 mM
lithium (p > 0.05), whereas 10 mM lithium treatment restored the lifespan to control levels (p > 0.05), and 25 mMwas significantly toxic (p > 0.05). See Figure S2F
for lifespan extension obtained with an independent RNAi line.
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in fission yeast and Drosophila heads (Sofola-Adesakin et al.,
2014). In addition, five GO terms for genes encoding enzymes
in the detoxification pathway were also in the ten most upregu-
lated categories (Figure 3A).
The responses to xenobiotics and oxidative stress in
Drosophila are regulated by the transcription factors dFOXO,
CncC, and DHR96 (Salih and Brunet, 2008; Sykiotis and
Bohmann, 2010; Tullet, 2015; Hoffmann and Partridge, 2015;
Blackwell et al., 2015). We therefore assessed whether the tran-
scriptional responses to activation of these transcription factors
overlapped with that of lithium treatment. The transcriptomic
response to lithium did not overlap with that of dFOXO-depen-
dent or -independent transcriptional regulation downstream of
IIS (Figures S3B and S3C) (Alic et al., 2011). Furthermore,
although we detected a significant overlap in the transcriptional
signatures of lithium and DHR96 (King-Jones et al., 2006), they
did not share the same directionality (Figure S4). However, we
found a significant overlap (Figure 3B) between the genes that
were upregulated by lithium and cncC overexpression (Misra
et al., 2011), but not between genes downregulated by both
treatments (Figure S5A), suggesting that lithium might activate
a CncC transcriptional response downstream of GSK-3. The
barbiturate phenobarbital activates CncC and induces a similar
transcriptional response to that of cncC overexpression (Misra
et al., 2011). We therefore analyzed the overlap between the
transcriptional profiles induced by lithium and phenobarbital
treatment, and again found a significant overlap (Figure 3B) be-
tween upregulated, but not downregulated, genes (Figure S5B).
The genes upregulated in common between lithium treatment,
phenobarbital treatment and cncC overexpression (Figures 3B
and S5C) encoded enzymes that participate in all three phases
of xenobiotic metabolism (Figure 3C). To further confirm the acti-
vation of CncC by lithium, we used a previously generated CncC
reporter that responds to both chemical and genetic inducers of
CncC (Sykiotis and Bohmann, 2008). Flies carrying the GstD-
eGFP CncC reporter showed a dose-dependent increase in
GFP expression with increasing concentrations of lithium (Fig-
ure 3D). Taken together, our results suggest that lithium activates
CncC to upregulate the expression of genes in the detoxification
pathway.
Lithium Induces Lifespan-Extension, Hormesis, and
Protection against Xenobiotics via CncC-Dependent
Mechanisms
We next assessed whether CncC activity is required for the pro-
longevity effects of lithium. Ubiquitous, RNAi-mediated knock-
down of cncC expression blocked the lifespan extension of
1 to 10mM lithium, but was detrimental to survival in flies treated
with 25 mM lithium, the highest dose that extends lifespan under
basal conditions, albeit to a lesser extent (Figure 4A). Thus,
lithium treatment requires CncC activity to confer its longevity
benefits.
Because CncC/NRF-2 can induce hormesis (Mattson, 2008;
Maher and Yamamoto, 2010), we assessed whether lithium
can also do this. To test for a hormetic effect of lithium at low
doses, we pre-treated flies with a range of concentrations of
lithium and then challenged them with a toxic dose of 500 mM.
Most pre-treatment doses of lithium induced subsequent resis-
tance to the toxic dose (Figure 4B). To assess whether the hor-
metic response of lithium was mediated by CncC, we knocked
down expression of cncC using RNAi, and treated the flies with
1–25 mM lithium. Reduction in cncC expression completely
blocked the hormetic response induced by 10 mM lithium pre-
treatment, and significantly reduced the effect of 25 mM lithium
(Figure 4C).
We next assessed the ability of lithium pre-treatment to pro-
tect against other xenobiotics. Flies pre-treated with increasing
concentrations of lithium ranging from 1 to 100 mM were signif-
icantly resistant to a toxic concentration of phenobarbital, with
lithium doses between 1 and 75 mM almost doubling survival
(Figure 4D). Lower doses of lithium also protected against a toxic
dose of the anti-malarial drug, chloroquine (Figure S5D;
1–10 mM), and the pesticide paraquat (Figure 4E). Thus, low to
intermediate concentrations of lithium protect against xenobiotic
toxicity. To determine the role of CncC activity in lithium-medi-
ated protection against phenobarbital, we used RNAi to knock
down expression of cncC, which sensitized the flies to pheno-
barbital and completely abrogated the protection against pheno-
barbital afforded by lithium supplementation (Figure 4F). Thus,
CncC is at least partly responsible for the hormetic effect
induced by low-level treatment with lithium.
To confirm that Sgg, upstream of CncC, is also necessary for
the resistance to xenobiotic stress (Blackwell et al., 2015; Cua-
drado, 2015; Hayes et al., 2015), we assessed the effect of ubiq-
uitous overexpression of wild-type sgg or the constitutively
active Sgg(S9A) on xenobiotic resistance. Both significantly
sensitized flies to phenobarbital (Figures 5A and S5E). We
confirmed that sgg or sgg(S9A) overexpression regulated
CncC by showing significantly lower levels of MRP and keap1
(Figures 5B and S5F), both CncC target genes. Correspondingly,
RNAi-mediated knockdown of sgg resulted in resistance to
phenobarbital (Figure 5C), and paraquat (Figure S5G). An in-
crease of mRNA levels of cncC, keap1, and gstD2 confirmed
that CncC was active in sgg knockdown flies (Figure 5D). Thus,
increased Sgg activity sensitizes against xenobiotic stressors,
whereas its inhibition protects against them.
Lifespan and Stress Resistance Depend on the Degree
of Activation of CncC by Keap1 and Lithium Treatment
In addition to activating CncC by repressing Sgg/GSK-3, lithium
could potentially increase CncC activity by inhibiting its canoni-
cal repressor Keap1 (Cuadrado, 2015; Pitoniak and Bohmann,
2015). Hence, we analyzed the interaction between lithium treat-
ment and Keap1. Overexpression of Keap1, which inhibits CncC
activity in vivo (Sykiotis and Bohmann, 2008), was unable to
prevent the lifespan-extending properties of lithium (Figure 6A),
suggesting that the longevity effect of lithium treatment is inde-
pendent of Keap1. Next, we analyzed the interaction of loss of
Keap1 and lithium treatment. We generated a deletion of the
keap1 coding sequence by P-element-mediated male recombi-
nation using a previously described P-element insertion line
(Sykiotis and Bohmann, 2008) (Figure 6B). The keap1 deletion
(keap1Del) was homozygous lethal, but activated CncC 4-fold in
the heterozygous state, as measured by the CncC reporter (Fig-
ure 6C). Lithium treatment of the keap1Del flies further activated
CncC (Figure 6C). We next tested whether this effect on CncC
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activation protected against paraquat and lithium toxicity.
keap1Del flies were significantly resistant to both paraquat and
lithium (Figures 6D and 6E), and pre-treatment with lithium
further protected them.We confirmed these findings using a pre-
viously described heterozygous loss-of-function mutation in the
keap1 gene (keap1EY5) (Sykiotis and Bohmann, 2008) (Figures
Figure 3. Lithium Activated a Transcriptional Response Similar to that of CncC/NRF-2
(A) Ten most significantly upregulated GO categories induced by lithium treatment of w1118 female flies. See Figure S3A for downregulated GO categories.
(B) Lithium treatment of w1118 females flies induced a transcriptional response that significantly overlapped with that induced by cncC overexpression (p =
7.83 3 10!8) or phenobarbital treatment (p = 3.85 3 10!14) (Misra et al., 2011). Heatmap showing the 57 genes most significantly changed by lithium or
phenobarbital treatment and overexpression of cncC.
(C) Genes upregulated by lithium treatment mapped to the three phases of the xenobiotic detoxification pathway in flies.
(D) Lithium treatment ofwDah female flies upregulatedGst-Dprotein levels. Bars representmeans of triplicates of ten flies per condition±SEM. *p< 0.05, **p < 0.01.
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Figure 4. Lithium-Induced Xenobiotic Resistance and Longevity Were Mediated by CncC
(A) Ubiquitous knockdown of cncC blocked lifespan extension by lithium.
(B) Pre-treatment with increasing concentrations of lithium protected against a subsequent toxic dose of lithium (500 mM; p < 0.01 for doses from 10 to 100 mM;
p < 0.05 for 1 mM).
(C) Ubiquitous downregulation of cncC blocked the protective effect of 10 mM lithium pre-treatment against a subsequent toxic dose and partially blocked the
protective effect of 25 mM lithium pre-treatment.
(D) 1 to 100 mM lithium pre-treatment protected against a 6% phenobarbital (p < 0.001 for all doses).
(E) Lithium pre-treatment (for 15 days) protected against the herbicide paraquat in a dose-dependent manner (p < 0.001 for all doses, with maximal protection at
50 mM).
(F) RNAi-mediated downregulation of cncC completely blocked the protective effect of lithium against phenobarbital.
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S6A and S6B). Thus, the combination of loss of keap1 and lithium
treatment further protected against paraquat and lithium-
induced toxicity, suggesting that stronger CncC activation re-
sults in greater protection against these xenobiotics.
We subsequently evaluated the interaction between loss of
keap1 and lithium treatment for longevity. Survival analysis
showed that the lifespan of keap1Del mutant flies was indistin-
guishable from controls, but that addition of 1 mM lithium
marginally, yet significantly, extended lifespan (Figure 6F).
Increasing the dose of lithium to 10 mM restored longevity to
control levels. The keap1EY5 mutant flies showed a significant
lifespan extension (Figure 6G). However, supplementation of
either 1 or 10 mM lithium to the keap1EY5 mutant shortened life-
span in a dose-dependent manner. These results suggest that
the level of activation of CncC that maximizes extension of life-
span is considerably lower than that which maximizes protection
against toxic doses of lithium and paraquat.
Lithium Does Not Induce or Require Autophagy to
Promote Longevity
Activation of autophagy has been proposed as a mechanism for
the beneficial effects of lithium (Sarkar et al., 2005). We therefore
analyzed the induction of autophagy by LC3-I/LC3-II (Atg8 in
Drosophila) levels without detecting statistically significant
changes. Indeed, there was a tendency for lower LC3-I that did
not reach statistical significance (Figure S7A). Moreover, lithium
treatment was able to extend the lifespan of flies with autophagy
defects due to heterozygous loss of atg1 (Figure S7B) (Lee et al.,
2007). Thus, taken together our results do not immediately sup-
port a role for autophagy in the pro-longevity effects of lithium
treatment, and strengthen our conclusion that they are mediated
through the inhibition of GSK-3 and the subsequent activation of
CncC/NRF-2 (Figure 7). However, it remains possible that induc-
tion of autophagy occurs in atg1-deficient flies, or that lithium in-
duces autophagy in a tissue-specific manner.
DISCUSSION
Lithium Acts as a Pro-longevity Drug
Drug repurposing is themost promising approach for developing
pharmacological agents to improve healthy aging. So far, two
medically approved drugs, metformin and rapamycin, have
been reported to promote longevity and provide health benefits
across species from invertebrates to mammals (de Cabo et al.,
2014; Madeo et al., 2014; Riera and Dillin, 2015). We and others
have shown that lithium can extend lifespan in fission yeast,
C. elegans, and Drosophila (McColl et al., 2008; Matsagas
et al., 2009; Sofola-Adesakin et al., 2014). We also showed
that this effect was common between two different laboratory
strains and, unlike other interventions that seem to be more
effective in females (Austad and Bartke, 2015), lithium similarly
extended lifespan in both sexes.
Lifespan-extending drugs can often act like DR mimetics
(Madeo et al., 2014; Ingram and Roth, 2015); hence, it was
important to determine whether lithium was acting in a similar
manner. While low doses of lithium were able to extend life-
span at all dietary levels tested, median lifespan extension
was greatest under full feeding conditions. Our data thus sug-
gest that lithium and DR act via partially overlapping mecha-
nisms and confirms the observation made in C. elegans that
lithium extends lifespan of eat-2 mutants (McColl et al.,
2008), a genetic model of DR in worms. Lithium also extended
the lifespan of flies fed a diet enriched with sucrose, possibly
by modulating lipid metabolism (Sykiotis et al., 2011; Pang
et al., 2014; Karim et al., 2015; Steinbaugh et al., 2015).
However, the role of CncC in modulating the triglyceride
phenotype of lithium remains to be explored. Overall, our ob-
servations strongly suggest that lithium is a pro-longevity drug
capable of extending lifespan at low doses independent of sex
and genetic background, and under a variety of dietary
conditions.
D
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A Figure 5. Reduced Activity of GSK-3
Increased Resistance to Xenobiotics
(A) Ubiquitous overexpression of wild-type sgg
significantly (p < 0.05) reduced survival under
xenobiotic stress with phenobarbital. n = 75 flies
per condition.
(B) Overexpression of wild-type sgg significantly
reduced multidrug-resistance like protein 1
(MRP) mRNA levels (p < 0.05, paired t test),
whereas non-significant trends were detec-
ted for glutathione S transferase D2 (gstD2)
and cncC mRNA levels (p > 0.05). A non-sig-
nificant increase of keap1 mRNA levels was
observed.
(C) RNAi-mediated knockdown of sgg protected
against phenobarbital stress (p < 0.001). n = 75
flies per condition.
(D) Knockdown of sgg increased mRNA levels of
cncC, keap1 and gstD2 (p < 0.05), while a non-
significant increase was observed forMRPmRNA
levels.
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Figure 6. Higher Activation Levels of CncC Promote Xenobiotic Resistance but Not Lifespan
(A) Overexpression of keap1 did not prevent the lifespan-modulatory effects of lithium treatment. n = 150 flies per condition.
(B) Schematic of the keap1 gene showing the portion deleted in the keap1Del mutant (top) and agarose gel showing start and end of P-element disrupting keap1
coding sequence in the keap1Del mutant (bottom).
(C) Combination of heterozygous deletion of keap1 and lithium treatment showed a greater activation of CncC than on their own. Bars represent means of four
replicas of five flies per repeat ± SEM. **p < 0.01.
(legend continued on next page)
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Lithium Toxicity, Hormesis, and Stress Resistance
In humans, the therapeutic window for lithium treatment of
bipolar disorder lies between 0.5 and 1 mM in serum, whereas
concentrations of 1.5 mM and above severely increase the risk
of tissue damage (Malhi and Tanious, 2011). Previous work in
Drosophila suggests that the dose range at which we observed
lifespan extension (0.5–25 mM) translates to Drosophila tissue
concentrations below0.5mM (Dokucuet al., 2005). Aspreviously
reported for C. elegans and Drosophila (McColl et al., 2008; Zhu
et al., 2015), concentrations above 50 mM were highly toxic.
Drug interventions to promote healthy lifespan are less likely to
have side effects if started late in life (Castillo-Quan et al., 2015).
Only a handful of drugs approved by the US Food and Drug
Administration , namely rapamycin, metformin, and the Ras in-
hibitor trametinib, induce lifespan extension when commenced
at later ages in model organisms (Harrison et al., 2009; Cabreiro
et al., 2013; Martin-Montalvo et al., 2013; Slack et al., 2015). We
found that lithium extends lifespan when first administered in
mid-late life. In humans, long-term treatment with lithium for psy-
chiatric disorders is associated with progressive and permanent
renal damage (Malhi and Tanious, 2011). We showed that short
treatment periods in Drosophila, 15 days during early adulthood,
are sufficient to prolong life. Taken together, our data suggest
that when testing lithium as a pro-longevity drug in mammals,
lower doses than those used in psychiatric disorders are likely
to be sufficient, and other strategies such as alternate-day
dosing or transient treatment periods (either early or late in
life), may be sufficient to reduce undesirable side effects and
maximize the potential health benefits.
Interestingly, doses of lithium that shortened lifespan were
protective against certain forms of xenobiotic stress. In vitro
studies in mammalian cells have shown that lithium, and other
GSK-3 inhibitors, protect against cell death caused by rote-
none-induced oxidative stress (Lai et al., 2006), glutamate
excitotoxicity, and H2O2 (Scha¨fer et al., 2004). This is likely
mediated through a hormetic response (Suganthi et al., 2012),
in this case orchestrated by NRF-2 activation. We observed
that while simultaneous activation of CncC by loss of Keap1
and lithium treatment is additive and confers greater stress
resistance to xenobiotics, the threshold for lifespan extension
is perhaps considerably lower. A similar situation has been
observed in C. elegans in which strong activation of the endo-
plasmic reticulum unfolded protein response conferred stress
resistance benefits, while shortening lifespan (Taylor and Dillin,
2013). Our findings thus suggest that while NRF-2 activation
either by loss of Keap1 or inhibition of GSK-3 is beneficial for
longevity and stress resistance, at low levels of activation,
stronger induction is detrimental for lifespan. This suggests
that the hormetic benefits of lithium are more likely to occur
at low levels under basal non-stress conditions (Calabrese,
2013). Hence, when testing for GSK-3 inhibitors or NRF-2 acti-
vators in modulating animal (and especially mammalian) aging,
the degree of NRF-2 activation within the hormetic curve will
determine positive or negative longevity outcomes. Future
work studying the convergence of the salutary and damaging
effects of lithium will aid in understanding to what extent the
molecular mechanisms are shared (Calabrese and Mattson,
2011; Calabrese et al., 2013; Epel and Lithgow, 2014). Addi-
tionally, our microarray analysis was performed in heads and
thoraces; therefore, it remains to be explored to what extent
systemic or localized activation of NRF-2 modulates longevity,
stress resistance, and lipid metabolism at the tissue level
(Douglas et al., 2015).
(D) Deletion of keap1 in flies treated with lithium showed greater protection against paraquat than either treatment on its own, with maximal effects observed at
25 mM (p < 0.001).
(E) The keap1 deletion protected against toxic concentrations of lithium (500 mM), and this protection was augmented with lithium pre-treatment (p < 0.01).
(F) Deletion of keap1 did not extend lifespan: 1mM lithium (p < 0.05), but not 10mM (p > 0.05), treatment of keap1 flies resulted in a small but significant extension.
n = 150 flies per condition.
(G) keap1EY5 mutant flies showed significant lifespan extension (p < 0.001), that was dose-dependently abolished (p > 0.05) by lithium, likely as a result of over-
activation of CncC. n = 150 flies per condition.
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Figure 7. Lithium Regulates Longevity, Metabolism, and Stress
Resistance by Inhibiting GSK-3 and Activating NRF-2
(A) Summary of findings with lithium for longevity, stress resistance, starvation,
and triglyceride levels.
(B) Proposed model showing the mechanism by which lithium, Sgg/GSK-3,
and CncC/NRF-2 act in the same pathway to modulate longevity and xeno-
biotic resistance.
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GSK-3 and NRF-2 as Drug Targets for Aging
Complete absence of GSK-3 inC. elegans,Drosophila, andmice
shortens lifespan or prevents development (Hoeflich et al., 2000;
McColl et al., 2008; Bourouis, 2002), while moderate inhibition
has been associated with most of its positive effects (Avrahami
et al., 2013). GSK-3 is upregulated in many disease states,
including neurodegeneration, diabetes, inflammatory condi-
tions, and some cancers (Takahashi-Yanaga, 2013). We have
shown that adult-specific geneticmanipulation of the fly ortholog
of GSK-3, Sgg, affects longevity. Downregulation of Sgg pro-
longed lifespan and lithium was unable to further extend the life-
span, suggesting that lithium and inhibition of Sgg act through a
common molecular pathway to extend lifespan.
In C. elegans and mammalian cells, GSK-3 directly interacts
with NRF-2 to repress its activity, independently of Keap1 (An
et al., 2005; Salazar et al., 2006; Rojo et al., 2008; Rada et al.,
2012). Therefore, we hypothesized that lithium might act via
Sgg/GSK-3, to de-repress CncC, the fly ortholog of NRF-2 and
activate the oxidative and xenobiotic stress transcriptional
signature (An et al., 2005; Hayes et al., 2015), which in turn would
induce a CncC/NRF-2-dependent protective response (Jones
et al., 2015; Blackwell et al., 2015). GO enrichment analysis iden-
tified a transcriptional signature that indeed suggested that
lithium acts via CncC/NRF-2. CncC activity was indispensable
for the lifespan extension conferred by lithium. In keeping with
our results, work in rodents and mammalian cell lines has shown
that lithium treatment and GSK-3 inhibition activate NRF-2 (Lee
et al., 2014; Rizak et al., 2014). Because activation of CncC/
NRF-2 modulates longevity in C. elegans and Drosophila (Tullet
et al., 2008; Sykiotis and Bohmann, 2008; Ewald et al., 2015),
our results provide evidence that GSK-3 is a viable therapeutic
target to promote longevity via activation of NRF-2.
To date, the only GSK-3 inhibitor approved for human use is
lithium (Williams and Harwood, 2000; Meijer et al., 2004; Marti-
nez et al., 2011). However, researchers and pharmaceutical
companies have developed more selective GSK-3 inhibitors,
some of which have already entered the early stages of clinical
trials for obesity, Alzheimer disease, and progressive supranu-
clear palsy (Eldar-Finkelman and Martinez, 2011). Our results
call for a reassessment of the potential use of GSK-3 inhibitors
and NRF-2 activators as potential anti-aging compounds.
EXPERIMENTAL PROCEDURES
Fly Stocks and Husbandry
The w1118 stock was obtained from Bloomington Drosophila Stock Center.
The control white Dahomey (wDah) stock has been maintained in large popu-
lation cages with overlapping generations since 1970. The wDah stock was
initially derived by incorporation of the w1118 mutation into the outbred
Dahomey background by backcrossing (Bass et al., 2007). Further details
concerning fly mutants can be found in the Supplemental Experimental
Procedures.
Lithium Treatment
LiCl (Sigma) or NaCl (Sigma) were dissolved in ddH2O at a concentration of 5M
before supplementing to the medium. Equivalent volumes of vehicle were
supplemented to the medium to compensate for dilution.
Dietary Restriction Protocol
The DR protocol was performed as described previously (Bass et al., 2007).
Statistical Analyses
Statistical analyses were performed using Excel, GraphPad Prism, or JMP
software version 9 (SAS Institute). Survival experiments were analyzed using
log rank test. Other data were tested by one-way analyses of variance
(ANOVA) and planned comparisons of means were made using Tukey-Kramer
HSD test. Cox proportional hazards analysis was performed to compare inter-
actions for survival.
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SUMMARY
Glucose hypometabolism is a prominent feature of
the brains of patients with Alzheimer’s disease (AD).
Disease progression is associated with a reduction
in glucose transporters in both neurons and endothe-
lial cells of the blood-brain barrier. However, whether
increasing glucose transport into either of these cell
types offers therapeutic potential remains unknown.
Using an adult-onset Drosophila model of Ab (amy-
loid beta) toxicity, we show that genetic overex-
pression of a glucose transporter, specifically in neu-
rons, rescues lifespan, behavioral phenotypes, and
neuronalmorphology. This ameliorationofAb toxicity
is associated with a reduction in the protein levels of
the unfolded protein response (UPR) negativemaster
regulator Grp78 and an increase in the UPR. We
further demonstrate that genetic downregulation of
Grp78 activity also protects against Ab toxicity, con-
firming a causal effect of its alteration on AD-related
pathology. Metformin, a drug that stimulates glucose
uptake in cells, mimicked these effects, with a
concomitant reduction in Grp78 levels and rescue of
theshortened lifespanandclimbingdefectsofAb-ex-
pressing flies. Our findings demonstrate a protective
effect of increased neuronal uptake of glucose
against Ab toxicity and highlight Grp78 as a novel
therapeutic target for the treatment of AD.
INTRODUCTION
46.8 million people live with dementia worldwide [1], with Alz-
heimer’s disease (AD) being the most common type. Prevalence
continues to rise with increasing life expectancy. Currently there
are no cures, and there is an urgent need to identify ways of pre-
venting or modifying disease progression. AD is thought to be
triggered by the accumulation of extracellular Ab (amyloid
beta) peptides, derived from the misprocessing of amyloid pre-
cursor protein (APP) [2], leading to cellular stress, accumulation
of toxic intracellular Tau, and eventual neuronal cell death [2].
However, recent evidence suggests that Ab might also poten-
tially play a protective, antimicrobial role [3].
A prominent feature of AD progression is a substantial reduc-
tion in glucose metabolism [4]. This drop precedes the onset of
clinical symptoms [4], worsens with disease progression [4],
and is a more accurate marker of neuronal atrophy than is Ab
accumulation itself [5]. Patients with type 2 diabetes, who are
at higher risk of AD, display increased insulin resistance, which
has been linked both to reduced glucose uptake in the brain
and to memory impairments [6]. Mouse models of AD also
show a decrease in glucose metabolism, suggesting that it
may be part of the disease process [7]. However, the exact
role of lowered glucose metabolism in disease progression is
unknown.
Glucose does not freely cross cell membranes and is, instead,
actively shuttled by transporters. In humans, there are 12
glucose transporters, with different expression patterns and
affinities. In the brain, Glut1 is expressedmainly in glia and endo-
thelial cells, whereas Glut3 is expressed in neurons [7]. A reduc-
tion in expression of a number of glucose transporters has been
observed in the brains of mouse AD models [8] and of human
patients [7]. The timing of this decrease correlates with increases
in Tau phosphorylation and neurofibrillary tangles (NFTs) [7]. In a
mouse model of AD pathogenesis, a reduction in neuronal Glut3
expression coincided with a reduction in glucosemetabolism [8],
while a drop in Glut1 in endothelial cells exacerbated pathology
in another mouse AD model [9].
Whether impaired neuronal glucose metabolism plays a
causal role in neurodegeneration in AD awaits investigation.
The drop in glucose metabolism could contribute to disease
progression in several ways. It could lead to a reduction in
ATP in neurons, since glucose is the main source of energy.
Downregulation of the hexosamine pathway, which relies on
glucose for GlcNAc production, would lead to a reduction in
Tau GlcNAcylation, which, in turn, could drive up toxic Tau phos-
phorylation, since the two are negatively correlated [10]. Hypo-
metabolism and glucose deprivation have been shown to induce
the unfolded protein response (UPR) [11]; this, too, could drive
Tau phosphorylation [11]. Any or all of these mechanisms could
contribute to neurodegeneration.
To begin to experimentally test the role of glucose transport
and metabolism in AD pathogenesis, we used a model of Ab
toxicity in the fruit fly Drosophila melanogaster [12]. Drosophila
has proved to be an excellent model system in which to study
neurodegenerative diseases. The fly has a distinct brain struc-
ture with cell types analogous to the human brain, as well as a
blood-brain barrier (BBB), and is, therefore, ideal for studying
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the neurodegenerative process in a complex tissue. The meta-
bolic coupling between glia and neurons observed inmammalian
brains is also conserved in flies [13]. The fly AD model that we
used expresses pathogenic Arctic Ab42 tagged with an endo-
plasmic reticulum (ER) export signal peptide [14] exclusively in
the neurons of the adult fly, thereby removing any confounding
developmental effects. These flies have shortened lifespans,
behavioral defects, and neurodegeneration [12].
If lowered glucose metabolism in neurons is part of the patho-
genic cascade from toxic Ab, then experimentally increasing
glucose metabolism in neurons should ameliorate the pathogen-
esis in the AD model. Therefore, we assessed the effect of over-
expressing a glucose transporter, Glut1, in the neurons of the AD
flies. We found that this partially rescued the Ab phenotypes,
without affecting the expression level of the toxic Ab peptide.
Glut1 overexpression led to downregulation of the expression
of Grp78 (glucose-regulated protein 78/BiP), the negativemaster
regulator of the UPR. This, in turn, increased the UPR, in associ-
ation with an improvement in protein homeostasis. Interestingly,
feeding the flies the drug metformin, which increases glucose
transport, also caused a drop in Grp78 levels and an increase
in lifespan, suggesting a possible pharmacological therapeutic
avenue.
RESULTS
Drosophila melanogaster has two glucose transporters: Glut1
and Glut3. Glut3 is expressed only in testes, while Glut1 is ex-
pressed ubiquitously [15]. In order to increase glucose meta-
bolism, we cloned Glut1 under the control of the UAS (upstream
activating sequence) promoter and drove its expression with a
constitutive and ubiquitous daGal4 driver. This led to increased
uptake of a glucose analog (Figure S1A), demonstrating that
increased Glut1 expression can, indeed, increase transport of
glucose into cells.
Next, we overexpressed Glut1 in the neurons of adult flies,
using an inducible elavGS (elav-GeneSwitch-Gal4) driver and
confirmed the overexpression by qPCR in fly heads (Fig-
ure S1B). Overexpression of Glut1 had no effect on the lifespan
of wild-type flies (Figure S1C), but it increased lifespan in
Arctic-Ab42(Ab)-expressing flies (Figure 1A) and slowed their
decline in climbing ability, a behavioral measure of neuronal
health (Figure 1B). Interestingly, the climbing ability of flies ex-
pressing Ab and Glut1 was worse than that of flies expressing
Ab alone at early time points, possibly suggesting that Glut1
expression could impair climbing ability in early life, before its
beneficial effect on disease development takes effect (Fig-
ure 1B). Sleep pattern, too, is directly controlled by neuronal
activity. Flies are diurnal, sleeping mainly at night. Expression
of Ab rendered the flies more arrhythmic, with fewer flies
showing a clear change in sleep pattern between day and
night, largely as a consequence of a substantial increase in
day sleep (Figure 1C). The Ab flies also spent more total time
sleeping than did non-induced controls (Figure 1C). Overex-
pression of Glut rescued this pattern, with the flies partially
recovering their diurnal sleep pattern and spending less total
time sleeping (Figure 1C). To confirm that the phenotypic
rescue of the Ab toxicity was, indeed, due to increased glucose
uptake and not some other activity of Glut1, we checked
whether altering sugar concentration in the food could modu-
late the Glut1 rescue of lifespan in Ab-expressing flies (Fig-
ure S1D). We found that reducing dietary sugar intake differen-
tially affected the lifespans of flies expressing Ab alone, relative
to the flies expressing Ab and Glut1, with no rescue of lifespan
by Glut 1 at the lowest sugar concentration of 2.5%. As the
sugar in the food was reduced, so did the lifespan extension af-
forded by Glut1. This suggests that the phenotypic rescue is
linked to an increased uptake of sugar.
To determine whether Glut1 could rescue neurodegeneration
after adult induction of Ab, we marked a sub-population of neu-
rons with GFP driven by the Q system [16], using nSyb-QF2 >
GFP [17], which marks a set of neurons in the central portion of
the Drosophila brain (Figure 1D) while, at the same time, driving
Ab pan-neuronally with the UAS system. The two misexpression
systems are independent of each other, and we could thus
monitor the morphology of a sub-population of neurons in the
presence of Ab and of overexpression of Glut1. When Ab was
expressed, a number of filamentous structures clearly visible in
the wild-type brain were lost, reflecting the degeneration of
axons or dendrites. Strikingly, when Glut1 was overexpressed,
the neuronal morphology was completely restored (Figure 1D).
Surprisingly, Glut1 overexpression did not affect Ab protein or
mRNA levels in heads (Figures 1E and 1F), suggesting that Glut1
reduced the toxicity, rather than the total load, of Ab.
In humans and mouse models of AD, disease progression has
been linked to a decrease in glucose transporters [8], and in
mouse AD models, a reduction of glucose transporters in endo-
thelial cells exacerbates disease development. Similarly, in our
Drosophilamodel, RNAi of Glut1 in neurons (Figure S1E) reduced
the lifespan of Ab-expressing flies, indicating that reduction of
glucose import into neurons worsens Ab toxicity, similar to the
mechanism suggested in humans.
In both mammalian and fly brains under normal physiological
conditions, glycolysis occurs primarily in glia [13]. Therefore,
we assessed whether increasing glucose uptake in glia could
also affect pathology. For this, we generated a fly model
concomitantly expressing Ab in neurons and Glut1 in glia. Ab
was driven in neurons by the nSyb-QF2 driver [17], which was
induced starting from eclosion, whereas Glut1 was induced by
the constitutive glial driver repo-Gal4. Overexpression of Glut1
in glia did not rescue the toxicity of neuronal Ab, as assessed
by lifespan (Figure S1F). Hence, either the Ab toxicity in neurons
was too great for the induction of Glut1 that we achieved to
rescue it, or Glut1 in glia cannot rescue Ab toxicity.
Glucose uptake can influence many cellular processes and
could, therefore, rescue Ab toxicity in several ways. The most
obvious candidate is energy metabolism, since glucose is the
source of most cellular energy. However, we did not observe
an obvious energy deficit in the brains of our Ab-expressing flies,
and the ADP/ATP ratio in brains was unchanged when Glut1 was
overexpressed (Figure S1G).
Next, we considered whether Glut1 overexpression reduced
Ab toxicity by acting through the hexosamine biosynthetic
pathway, by increasing protein GlcNAcylation. However, upre-
gulation in neurons of GFAT2, the first and rate-limiting enzyme
in the hexosamine biosynthetic pathway, shortened the lifespan
of the Ab-expressing flies (Figure S1H), contrary to what would
be predicted from this hypothesis.
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Glucose uptake can affect the UPR [18], which is becoming
increasingly recognized as important in neurodegenerative dis-
eases, including AD [19], although whether it plays a protective
or detrimental role remains unclear [19]. The UPR signaling
cascade is activated in response to ER stress, allowing the
cell either to restore protein homeostasis or to enter apoptosis
[19], and is mediated by three trans-membrane proteins:
pancreatic ER kinase (PERK), inositol-requiring enzyme 1
(IRE1), and activating transcription factor 6 (ATF6). Grp78, also
known as BiP, binds and keeps these three proteins in an inac-
tive state. Upon ER stress, Grp78 targets misfolded proteins to
act as a chaperone, and thus releases PERK, IRE1, and ATF6 to
activate a series of downstream cascades, leading to the phos-
phorylation of eIF2alpha and reduction of protein translation,
activation of downstream transcription factors such as ATF4
and Xbp1, and increases in chaperones such as Grp78 itself
(Figure S2A) [19].
The main marker of PERK activation, eIF2alpha phosphoryla-
tion, was not affected by either Ab or Glut1 expression in neurons
(Figure 2A); however, we did confirm that the antibody we used
was able to detect eIF2alpha phosphorylation in response to
a strong UPR inducer (Figure S2B). However, Grp78 mRNA
expression, a marker of ATF6 activation, was increased in flies
expressing Ab (Figure 2B). Xbp1 splicing, a marker of IRE1 acti-
vation, increases in response to Ab in flies [20]. In our model, we
noticed a trend toward an increase in the fluorescence of a GFP
reporter for Xbp1 splicing, but this did not reach significance
(Figure 2C). However, when we measured the spliced Xbp1 iso-
form by qPCR, it was significantly increased in response to Ab
(Figure 2D), in agreement to what has previously been described
[20]. Ab thus induces the ATF6 and IRE1, but not the PERK,
branches of the UPR. Unexpectedly, co-expression of Glut1
increasedGrp78mRNA (Figure 2B) andXbp1 splicing (Figure 2C)
even further, suggesting an additional increase of the UPR in
A
C
D
E F
B Figure 1. Glut1 Overexpression Rescues
Ab Toxicity
(A) Survival curves of flies expressing Ab or Ab
Glut1 in adult neurons (+RU) and uninduced
controls (-RU). p < 0.01, when comparing Ab +RU
and Ab Glut1 +RU by log-rank test.
(B) Climbing assay performance index of flies of
the same genotypes. p < 1E-10 when comparing
Ab response to RU relative to AbGlut response by
ordinal logistics regression.
(C). 24-hr sleep profile of 21-day-old flies ex-
pressing Ab or Ab Glut1 in neurons (+RU) and
uninduced controls (-RU) on day 3 in the LD cycle.
At the right, total sleep amount for females of each
genotype are shown (plotted as means ± SEM).
*p < 0.01; **p < 0.001; and ***p < 0.0001, by two-
way ANOVA. Genotypes: UAS Ab/UAS Glut1;
elavGS, UAS Ab; elavGS.
(D) Confocal images of brains of 21-day-old con-
trol flies (-RU) and flies expressing Ab or Ab Glut1
driven by elavGS (+RU). The nSyb-QF2 driver,
kept in an inactive state by the tub-QS repressor,
drives GFP. Once flies eclosed, they were fed
QA, which binds QS to induce expression of GFP,
thus labeling a subset of neurons. Fluorescence
intensity scores are plotted as means ± SEM.
*p < 0.05, by ANOVA (n = 3–4). Genotypes:
UAS cd8GFP; nSyb2QF2 tubQS/elavGS, UAS
cd8GFP/UAS Ab; elavGS/nSyb2QF2 tubQS, UAS
cd8GFP/UAS Ab UAS Glut1; elavGS/nSyb2QF2
tubQS.
(E) Ab42 protein levels, measured by ELISA, in the
heads of 9-day-old flies expressing Ab or AbGlut1
in neurons (+RU) and uninduced controls (-RU),
plotted as means ± SEM (n = 3). ***p < 0.0001, by
ANOVA; ns, not significant.
(F) Ab42 mRNA levels (relative to eIF1A) in the
heads of similar 14-day-old flies, measured by
qPCR, plotted as means ± SEM (n = 4). ***p <
0.0001, by ANOVA; ns, not significant. Geno-
types: UAS Ab; elavGS, UAS Ab/UAS Glut1;
elavGS.
See also Figure S1.
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response to glucose uptake. Grp78 protein levels are tightly
controlled at the level of translation [21], and an increase in the
mRNA, therefore, does not necessarily indicate higher protein
levels. Therefore, we measured Grp78 protein and found that it
also increased in the presence of Ab, albeit to a smaller extent
(Figure 2E). However, surprisingly, overexpression of Glut1 re-
sulted in reduced expression of Grp78 protein (Figure 2E), sug-
gesting that Glut1 and the increased glucose uptake that it
produced reduced either Grp78 translation or stability.
Grp78 is broadly considered a negative regulator of the UPR,
since it binds and maintains ATF6 and IRE1 in an inactive state.
Overexpression of Grp78 can attenuate UPR signaling both in
non-neuronal cells [22] and in neurons [19], and its knockdown
can lead to increased activation of the UPR upon ER stress
[23]. Our results point to a similar mechanism, with a drop in
Grp78 protein levels upon Glut1 expression leading to an in-
crease in ATF6 and IRE1 activity. Ab induced only the IRE1
and ATF6 branches of the UPR, similar to tunicamycin treatment
[24]. Therefore, we determined whether Glut1 overexpression
A
C
E
B
D
Figure 2. UPR Components Activated in
Ab-Expressing Flies Are Induced Even
Further by Glut1 Overexpression
(A) Western blot of eIF2 phosphorylation levels in
heads of Ab- and AbGlut1-expressing flies (+RU)
and in controls (-RU), showing no significant dif-
ference. Bottom: plotted as means ± SEM (n = 3).
Top: a representative gel from the same samples.
(B) Grp78 mRNA levels in heads of 18-day-old flies
expressing Ab or Ab Glut1 in neurons (+RU) and
uninduced controls (-RU), measured by qPCR
(relative to eIF1A), plotted as means ± SEM. Ge-
notypes: UAS Ab; elavGS, UAS Ab/UAS Glut1;
elavGS.
(C) Quantification of GFP fluorescence in fly brains
expressing an Xbp1GFP splicing reporter, plotted
as means ± SEM (n = 6–13). Genotypes: elavGS/
UAS-Xbp1GFP, UAS Ab; elavGS/UAS-Xbp1GFP,
UAS Ab/UAS Glut1; elavGS/UAS-Xbp1GFP.
(D) Spliced Xbp1 mRNA levels in heads of 18-day-
old flies expressing Ab or Ab Glut1 in neurons
(+RU) and uninduced controls (-RU), measured by
qPCR (relative to eIF1A), plotted as means ± SEM
(E) Western blot of Grp78 in 14-day-old flies of the
same genotypes, plotted below as means ± SEM
(n = 6–16). The image is a representative gel of the
same samples. Genotypes: UAS Ab; elavGS, UAS
Ab/UAS Glut1; elavGS.
*p % 0.05; **p % 0.01, by ANOVA. See also Fig-
ure S2.
could also increase resistance to tuni-
camycin. Indeed, Glut1 overexpression
protected flies from tunicamycin stress
(Figure 3A), accompanied by a block in
Grp78 induction (Figure 3B) and a trend
toward a further increase in UPR markers
upon Glut1 expression (Figures 3C and
3D), similar to what was observed in the
Ab expressing brains. Glut1 could, there-
fore, protect against UPR stress, attribut-
able to a reduction in Grp78 levels.
If Glut1 overexpression protects against Ab-induced UPR
stress by reducing Grp78 levels, then a reduction in Grp78 activ-
ity should also rescue Ab toxicity. We tested this by overexpress-
ing a dominant-negative version of Grp78, Grp78K97S, which
carries a point mutation affecting the coupling of ATP binding
to substrate release [25]. Expression of Grp78K97S in neurons
increased both the lifespan and the climbing ability of Ab-ex-
pressing flies (Figures 4A and 4B), suggesting that, indeed,
reduced Grp78 activity is causal in the amelioration of Ab toxicity
by Glut1.
AD is characterized by a deregulation of protein homeo-
stasis [26], which could contribute to disease. Therefore, we
hypothesized that increased glucose metabolism in neurons
allows the UPR to increase even further and, thus, to restore
protein homeostasis. To test this idea, we measured insol-
uble ubiquitinated protein levels in heads and found that Ab
expression led to the accumulation of insoluble ubiquitinated
proteins, which was abrogated by Glut1 overexpression (Fig-
ure 5), Glut1 overexpression, therefore, allowed neurons to
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re-establish protein homeostasis, presumably via upregulation
of the UPR.
Metformin is a drug used to treat type 2 diabetes, and it in-
creases glucose uptake in several tissues [27, 28] by increasing
the translocation of glucose transporters to the plasma mem-
brane [27]. Therefore, we treated our Ab-overexpressing flies
with metformin to determine whether we could recapitulate
the rescue observed by overexpressing Glut1. Indeed, feeding
Ab-overexpressing flies with a range of metformin concentra-
tions resulted in a significant lifespan extension (Figure 6A) and
increase in climbing ability (Figure 6B) without altering Ab levels
(Figure 6C). Interestingly, 80 mMmetformin reduced the lifespan
of flies that did not express Ab and was also less effective than
lower doses at extending the lifespan of Ab-expressing flies,
but it gave the strongest rescue of climbing ability. These results
suggest that this high concentration of metformin shows a bene-
ficial effect on neuronal-related health before 25 days but that
continuous exposure to a high dose of metformin leads, at later
ages, to systemic toxicity and reduced lifespan. The rescue was
dependent on Glut1 expression, since RNAi of Glut1 blocked the
lifespan extension frommetformin treatment (Figure 6D). Metfor-
min treatment, like Glut1 overexpression, also blocked the in-
crease inGrp78 levels associatedwith Ab expression (Figure 6E).
Metformin could, therefore, be a potential therapeutic modulator
of Ab pathology by blocking toxic Grp78 induction.
DISCUSSION
Glucosemetabolism has been strongly implicated the pathogen-
esis of AD [5, 7]. Patients display a marked reduction in glucose
metabolism in brain areas vulnerable to degeneration, and this
precedes the onset of clinical symptoms and mirrors disease
progression more closely than does Ab deposition [4]. Expres-
sion of neuronal glucose transporters also drops in AD patients
A
C D
B
Figure 3. Glut1 Protects Flies from Tunicamycin-Induced ER Stress
(A) Survival of Glut1-overexpressing flies on food containing tunicamycin (p < 0.05 for effect of Glut1 relative to driver-alone control by log-rank test).
(B) Western blot of Grp78 in whole flies after 48 hr on tunicamycin, plotted below as means ± SEM (n = 5–8); the image shows representative gels of similar
samples. *p% 0.05 by ANOVA.
(C) qPCR of Xbp1-spliced isoform levels (normalized to eIF1A), in flies treated for 48 hr with tunicamycin, plotted asmeans ± SEM (n = 3–4). **p% 0.01 by ANOVA.
(D) qPCR of Grp78 (normalized to eIF1A), in flies treated for 48 hr with tunicamycin, plotted as means ± SEM (n = 3–4). *p % 0.05; **p % 0.01, by ANOVA.
Genotypes: daGal4, UASGlut1; daGal4.
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and in AD mouse models [7]. Recently, it was shown that reduc-
tion of glucose transport across the BBB in mouse AD models
exacerbates Ab toxicity [9]. However, whether impaired glucose
metabolism in neurons plays a causal role in AD pathogenesis
has not been addressed directly.
Our study has shown that experimentally increasing glucose
uptake in neurons can protect against Ab toxicity. In our
Drosophila AD model, Glut1 overexpression led to a lifespan
increase, an amelioration of phenotypes linked to neuronal
health—namely, climbing and sleep—and a restoration of normal
neuronal morphology. This improvement was associated with
a reduction in Grp78 protein levels and an upregulation of
the UPR.
In AD patients, the UPR is activated early in disease pathogen-
esis [11]. Similarly, Ab expression in the neurons of adult flies led
to the induction of the UPR. Grp78 levels were increased, simi-
larly to those of mice models of AD [29], of AD patients early in
disease development [30], and in neuronal cells derived from
AD patients’ induced pluripotent stem cells (iPSCs) [31].
Intriguingly, the rescue of Ab toxicity by Glut1 was associated
with a reduction in Grp78 expression. Grp78 is becoming an
increasingly important therapeutic target, especially in cancer
biology, where its inhibition increases cells’ susceptibility to
chemotherapy agents [32]. Its role in neurodegeneration is less
well defined. In rat models of Parkinson’s disease, activation of
Grp78 is protective [33], and its downregulation is detrimental
[34]. However, its role in AD models has not been tested. Our
studies suggest that Grp78 downregulation can ameliorate Ab
toxicity by allowing upregulation of the UPR. Already, it has
been shown in flies that overexpression of Xbp1 can ameliorate
Ab42 toxicity [20], supporting the idea that upregulation of UPR
components could be beneficial in AD models. The role of
Grp78 has not been tested in other models of neurodegenera-
tion, and a complex picture is emerging regarding the role of
downstream UPR effectors, where, depending on the precise
experimental conditions, upregulation of the UPR appears to
be protective or detrimental [19]. For example, downregulation
of PERK is protective in some ALS (amyotrophic lateral sclerosis)
or prion disease models, whereas increased Xbp1 can be pro-
tective in Parkinson’s and Huntington’s disease models [19].
This could be because the UPR is a complex pathway with
extensive crosstalk between the different signaling cascades,
so it would be difficult to predict reliably the outcome of an inter-
vention. Alternatively, a mild upregulation of the UPR could allow
the induction of an ER-hormetic response, increasing ER proteo-
stasis to allow a neuron to deal with an increase in misfolded
proteins, whereas, in other conditions, a strong induction of
the UPR could lead to apoptosis, and, therefore, blocking this
response could also increase neuronal survival [19].
How glucose regulates Grp78 expression is unclear. It is
well established that glucose starvation induces expression of
Grp78 [35], and, in one study, increased glucose reduced
Grp78 expression in cultured neurons [36]. However, little is
known about how physiological changes in glucose metabolism
modulate Grp78, and it will be important to identify the mecha-
nisms at work.
Our study suggests a model where Ab accumulation in the
brain induces the UPR, and increased glucose uptake in neurons
blocks the negative feedback loop linked to Grp78 upregulation,
resulting in even further increased UPR, which allows neurons
to clear insoluble ubiquitinated proteins and restore protein
homeostasis, resulting in the rescue of neurodegeneration and
increased lifespan. This mechanism of action could be relevant
to the benefits observed by administration of insulin nasal
spray in AD patients [37]. Insulin is thought to act via PI3K/
MAPK (phosphatidylinositol 3-kinase/mitogen-activated protein
kinase) to influence Ab trafficking and decrease Tau phosphory-
lation by inhibiting Gsk3 [38]. However, insulin can upregulate
glucose transporters in neurons [39] and increase glucose meta-
bolism [39]. It would be interesting to determine whether insulin
administration also upregulates the UPR.
Glucosemetabolism has also been implicated in the increased
risk of AD associated with type 2 diabetes. The link is well estab-
lished, but the mechanism is less so [40]; possibilities include
increased vascular risk factors associated with metabolic syn-
drome in type 2 diabetes, as well as hyperglycemia-linked dysre-
gulation of cellular signaling pathways, leading to advanced
glycation products and increased reactive oxygen species.
Also, the rise in brain insulin resistance, which could, in part,
lead to increased production of Ab [40], could also result in
decreased glucose transporters and glucose metabolism within
neurons, leading to an upregulation of Grp78.
Metformin, a type 2 diabetes therapy, is a drug that has been
shown to increase glucose uptake in cells. Interestingly, treat-
ment with a metformin dose known not to affect lifespan in
wild-type Drosophila [41] increased the lifespan of Ab-express-
ing flies. In accordance with previous studies [42], we also found
that metformin decreased expression of Grp78, suggesting that
the rescue of Ab toxicity could be due to increased UPR. Metfor-
min’s effect in AD is controversial, with some studies reporting
patient benefits [43] but others finding that it worsened cognitive
performance [44], possibly related to metformin’s ability to
A B Figure 4. Grp78 Dominant-Negative Version
Rescues Ab Toxicity
(A) Lifespan survival curves of flies expressing
Ab or the Ab Grp78 dominant-negative version
in neurons (+RU) and uninduced controls (-RU).
(Ab+RUand AbGrp78 dominant-negative +RU are
different. p < 1E-13 by log rank).
(B) Climbing assay performance index for the same
flies plotted over time (p < 0.005 when comparing
Ab response to RU relative to Ab Grp78.K97S
response by ordinal logistics regression). Geno-
types:UASAb; elavGS,UASAb/UASGrp78.K97S;
elavGS.
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increase APP levels and processing to increase Ab production
[45]. Our study points to a novel and unexplored role of met-
formin as a modulator of the UPR in neurodegeneration down-
stream of Ab accumulation, which could provide a useful
therapeutic avenue in a clinical context where AD patients
present quite late in disease development and have already
accumulated Ab peptide in their brain.
EXPERIMENTAL PROCEDURES
Fly Husbandry and Stocks
All flies were reared at 25!C on a 12-hr:12-hr light:dark (LD) cycle at constant
humidity and on standard sugar-yeast-agar (SYA) medium (agar, 15 g/l; sugar,
50 g/l; autolyzed yeast, 100 g/l; nipagin, 100 g/l; and propionic acid, 2 ml/l).
Adult-onset, neuron-specific expression of UAS constructs was achieved as
described elsewhere [12]. Briefly, 24–48 hr after eclosion, female flies carrying
a heterozygous copy of elavGS and at least one UAS construct were fed SYA
medium supplemented with 200 mMmifepristone (RU486) to induce transgene
expression. For induction with quinic acid (QA), flies were put on food contain-
ing 7.5 g of QA per liter. Metformin was added to the food at the stated con-
centrations. ElavGS was derived from the original elavGS 301.2 line [46] and
obtained as a generous gift from Dr. H. Tricoire (CNRS); the UAS-Ab42Arc
(UAS Ab) stock was a gift from Dr. D. Crowther (University of Cambridge).
The nSyb-QF2 stock was a gift from Dr. C. Potter (Johns Hopkins School
of Medicine) [17]. W1118, tubulin-QS (tub-QS), UAS-Grp78.K97S, UAS-
Xbp1GFP, daughterless-Gal4 (daGal4), Glut1 RNAi line (TRiP.HMS02152)
and Repo-Gal4 were obtained from the Bloomington Drosophila Stock Center.
All transgenes were backcrossed into the w1118 background to ensure a
homogeneous genetic background between transgenic lines. All experiments
were carried out on mated females, unless otherwise stated.
Lifespan Analysis
Flies were raised at standard density in 200-ml bottles. After eclosion, flies
were allowed to mate for 24–48 hr. At least 110–150 females of the appropriate
genotype were split into groups of 15 and housed in vials containing SYA me-
dium with or without drugs. Deaths were scored, and flies tipped onto fresh
food three times a week. Data are presented as cumulative survival curves,
and survival rates were compared using log-rank tests or Cox proportional
hazards performed in JMP (version 9.0) software (SAS Institute). All lifespans
were performed at 25!C unless otherwise stated.
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Figure 5. Glut1 Reduces Accumulation of
Insoluble Ubiquitinated Proteins
Western blots of SDS-soluble protein fraction from
the heads of day-17 flies expressing Ab or AbGlut1
in neurons (+RU) and uninduced controls (-RU),
probed for ubiquitinated proteins (FK2) and for
actin, plotted below as means ± SEM (n = 4). The
two blots shown are from different experiments.
*p < 0.05; **p < 0.01, by ANOVA. Genotypes: UAS
Ab; elavGS, UAS Ab/UAS Glut1; elavGS.
Climbing Assay
The climbing assay in Figure 1 was performed as
previously described [47]. Briefly, 15 flies were
placed in a 25-cm pipette, tapped to the bottom,
and allowed to climb for 45 s. The number of flies
in the top 5 cm, center, and bottom 3 cm was
scored. A performance index was calculated for
each time point and plotted. Statistical analysis
was performed in R using ordinal logistics regres-
sion, using the individual heights for each fly as
data points. For the climbing assay in Figures 4
and 6, the assay was performed with the following
modifications: 45 flies were housed in a glass-
walled chamber 25 cm tall, and flies were tapped
to the bottom as described earlier and allowed to climb for 20 s before scoring.
The analysis was the same as described earlier.
Western Blotting
Protein samples were prepared by homogenizing in 23 SDS Laemmli sample
(4% SDS, 20% glycerol, 120 mM Tris-HCl [pH 6.8], 200 mM DTT with bromo-
phenol blue) and boiled at 95!C for 5 min. Samples were separated on
pre-cast 4%–12% Invitrogen Bis-Tris gels (NP0322) and blotted onto PVDF
(polyvinylidene fluoride) or nitrocellulose membrane (for Grp78) in Tris-glycine
buffer supplemented with 10% ethanol. Membranes were blocked in 5%
milk and 1% BSA in TBS-T (Tris-buffered saline with 0.05% Tween-20) for
1 hr at room temperature (RT) and then incubated with primary antibodies
in block. Ubiquitin westerns were blocked in 1% BSA. Primary antibody
dilutions used were as follows: anti-Grp78, 1:1,000 (Novus Biologicals,
NBP1-06274); anti-actin, 1:10,000 (Abcam, ab1801); anti-Ubiquitin, 1:1,000
(Millipore, FK2); and anti-eIF2A-phospho, 1:1,000 (Cell Signaling, 3597). Sec-
ondaries used were anti-rabbit and anti-mouse (Abcam, ab6789 and ab6721)
at 1:10,000 dilutions for 1 hr at RT. Bands were visualized with Luminata
Forte (Millipore) and imaged with ImageQuant LAS4000 (GE Healthcare
Life Sciences). Quantification was carried out with ImageQuant software or
ImageJ.
Preparation of Detergent-Soluble Fractions for Insoluble
Ubiquitinated Protein Gels
The method was adapted from [48]. Briefly, 10–20 heads were extracted in
75 ml Triton X extraction buffer and spun at 13,000 3 g for 10 min at 4!C,
and the supernatant was collected as the Triton X soluble fraction. The pellet
was re-suspended in 50 ml SDS extraction buffer and spun again, and the
supernatant was collected as the SDS soluble fraction. Samples were stored
at "80!C and run as described earlier.
qPCR
Total RNAwas extracted from heads or whole flies (for Figure 3) and converted
to cDNA (see Supplemental Experimental Procedures for details). qPCR was
performed using the PRISM 7000 sequence detection system (Applied Bio-
systems). Each sample was analyzed in duplicate, and values are the mean
of three or four independent biological repeats ±SEM.
Quantification of Ab42
Five fly heads were homogenized in 50 ml GnHCl extraction buffer (5 M guani-
dinium HCl, 50 mM HEPES [pH 7.3], 1:10 dilution of protease inhibitor cocktail
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[Sigma, P8340], and 5 mM EDTA) and centrifuged at 21,000 3 g for 5 min at
4!C, and cleared supernatant was retained as the total fly Ab42 sample.
Ab42 was measured with an ELISA kit (Millipore, EZHS42), according to the
manufacturer’s instructions, and protein was measured with a Bradford assay
(Bio-Rad protein assay reagent), and the amount of Ab42 in each sample was
expressed as a ratio of the total protein content (picograms per microgram of
total protein). Data are expressed as the mean ± SEM obtained from three bio-
logical repeats for each genotype.
A
C
E
D
B
Figure 6. Metformin Extends the Lifespan of Ab-Expressing Flies
(A) Lifespan survival curves of flies expressing Ab (+RU) and controls (-RU) in the presence of different metformin (Met) concentrations (all the metformin-
treated +RU flies were significantly longer lived than the +RU-alone control: p < E-4 for 5mM, p < E-6 for 10mM, p < E-8 for 20mM, and p < 0.01 for 80mMby log-
rank test).
(B) Climbing assay performance index (PI) for the same flies (p < 1E-5 when comparing the +RU control relative to the +RU flies treated with 20 mM or 80 mM
metformin by ordinal logistics regression).
(C) Ab42 protein levels, measured by ELISA, in the heads of 15-day-old flies expressing Ab (+RU) and controls (-RU) in the presence or absence of 10 mM
metformin, plotted as means ± SEM (n = 3). *p < 0.0001, by ANOVA; ns, not significant.
(D) Lifespan survival curves of flies expressing Ab Glut1 RNAi (+RU) and controls (-RU) in the presence or absence of 10 mM metformin (no difference
between +RU-treated flies by log-rank test). Genotype: wv; UAS Ab; elavGS/Glut1RNAi. (C).
(E) Western blots for Grp78 and actin control in the heads of flies treated with 10 mM meformin, plotted as means ± SEM (n = 4). *p < 0.01, by ANOVA; ns, not
significant.
Genotype for (A)–(C) and (E): UAS Ab; elavGS.
2298 Current Biology 26, 2291–2300, September 12, 2016
Microscopy
Brains were dissected in 4% paraformaldehyde in PBS with Tween 20 (PBST),
incubated for 20 min, rinsed in PBST, mounted in Vectashield with DAPI, and
imaged on a Zeiss LSM510 inverted confocal microscope. Images were taken
on the 203 or 403 objective as stacks and are shown as maximum intensity
projections of the complete stack. The same size stacks were taken for exper-
imental and control samples. All images for one experiment were taken at the
same settings. For Xbp1 fluorescence (in Figure 2C), total fluorescence inten-
sity of a given area of the brain was measured with ImageJ. Values shown are
the averages for 6–13 brains ± SEM. Samples were compared by ANOVA. For
neuronal GFP, images were blind scored and given a score from 1 to 5 based
on fluorescent intensity; average scores are presentedwith their SEM (n = 3–5).
Analysis of Activity and Sleep
Individual, 21-day-old, mated female flies were placed in glass tubes (65mm3
5 mm) containing standard 13 SYA, and activity was recorded using the DAM
System (Drosophila Activity Monitoring System; TriKinetics) as described pre-
viously [49]. Flies were entrained to a 12-hr:12-hr light:dark (LD) cycle at 25!C
and 65% humidity 24–36 hr before recording. 5 days of the 12:12 hr LD cycle
were recorded, followed by 5 days of a 12-hr:12-hr dark:dark (DD) cycle. Anal-
ysis of locomotor activity was performed using the fly toolbox and MATLAB
software (MathWorks), as described previously [50]. Sleep was defined as a
bout of inactivity lasting 5 min or more, and sleep analysis was performed
with pySOLO [51]. All behavioral data (activity and sleep duration) are repre-
sented by mean values with their SEM.
Tunicamycin Stress Assay
Flies were tipped into vials containing 1% agar, 1.5% sucrose, and 10 mg/l of
tunicamycin. Dead flies were scored at regular intervals, and lifespan curves
were compared with log-rank test.
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A DrosophilaModel of Neuronopathic Gaucher Disease
Demonstrates Lysosomal-Autophagic Defects and Altered
mTOR Signalling and Is Functionally Rescued by Rapamycin
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Glucocerebrosidase (GBA1) mutations are associated with Gaucher disease (GD), an autosomal recessive disorder caused by functional
deficiency of glucocerebrosidase (GBA), a lysosomal enzyme that hydrolyzes glucosylceramide to ceramide and glucose. Neuronopathic
forms of GD can be associated with rapid neurological decline (Type II) or manifest as a chronic form (Type III) with a wide spectrum of
neurological signs. Furthermore, there is now a well-established link between GBA1 mutations and Parkinson’s disease (PD), with
heterozygote mutations in GBA1 considered the commonest genetic defect in PD. Here we describe a novelDrosophilamodel of GD that
lacks the two fly GBA1 orthologs. This knock-out model recapitulates the main features of GD at the cellular level with severe lysosomal
defects and accumulation of glucosylceramide in the fly brain.We also demonstrate a block in autophagy flux in associationwith reduced
lifespan, age-dependent locomotor deficits and accumulation of autophagy substrates in dGBA-deficient fly brains. Furthermore,mech-
anistic target of rapamycin (mTOR) signaling is downregulated in dGBA knock-out flies, with a concomitant upregulation ofMitf gene
expression, the fly ortholog of mammalian TFEB, likely as a compensatory response to the autophagy block. Moreover, the mTOR
inhibitor rapamycin is able to partially ameliorate the lifespan, locomotor, and oxidative stress phenotypes. Together, our results
demonstrate that thisdGBA1-deficient flymodel is auseful platform for the further studyof the role of lysosomal-autophagic impairment
and the potential therapeutic benefits of rapamycin in neuronopathic GD. These results also have important implications for the role of
autophagy and mTOR signaling in GBA1-associated PD.
Key words: autophagy; Drosophila; Gaucher disease; glucocerebrosidase; mTOR; rapamycin
Introduction
Homozygousmutations in the glucocerebrosidase gene (GBA1) can
cause Gaucher disease (GD), the commonest lysosomal storage dis-
order. GBA1 encodes glucocerebrosidase (GBA, also known as glu-
cosylceramidase [GCase]), whichmediates the lysosomal hydrolysis
of glucosylceramide to form ceramide and glucose. Loss of GBA
activity leads to lysosomal accumulation of glucosylceramide and its
nonacylated analog glucosylsphingosine in a number of cell types,
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Significance Statement
We developed a Drosophila model of neuronopathic GD by knocking-out the fly orthologs of the GBA1 gene, demonstrating
abnormal lysosomal pathology in the fly brain. Functioning lysosomes are required for autophagosome-lysosomal fusion in the
autophagy pathway. We show in vivo that autophagy is impaired in dGBA-deficient fly brains. In response, mechanistic target of
rapamycin (mTOR) activity is downregulated in dGBA-deficient flies and rapamycin ameliorates the lifespan, locomotor, and
oxidative stress phenotypes. dGBA knock-out flies also display an upregulation of the Drosophila ortholog of mammalian TFEB,
Mitf, a response that is unable to overcome the autophagy block. Together, our results suggest that rapamycinmay have potential
benefits in the treatment of GD, as well as PD linked to GBA1mutations.
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including macrophages and neurons, giving rise to the visceral and
neurological manifestations of GD, respectively (Cox, 2010). GD is
classified into threeclinical subtypesbasedontheabsence(TypeI)or
presence (Types II and III) of neurological involvement. Type II, or
acute neuronopathic GD, is rare but results in rapidly progressive
neurologicaldecline,withawide spectrumofclinical signsanddeath
in infancy or early childhood. Type III, or chronic neuronopathic
GD, is amore slowlyprogressivedisorderwithneurological features,
including eye movement abnormalities, myoclonic epilepsy, ataxia,
and dementia (Sidransky, 2004). There are currently no therapies
available that target the neuronal pathology associated with GD be-
cause existing treatments, such as recombinant enzyme replacement
therapy, fail to permeate the blood–brain barrier (Cox, 2010).
As well as causing GD, heterozygous GBA1 mutations are
now well-established genetic risk factors for PD and other sy-
nucleinopathies, characterized by the presence of intraneuronal
aggregates called Lewy bodies (LBs), predominantly containing
!-synuclein as well as ubiquitin (Shults, 2006). Both loss-of-
function and gain-of-function hypotheses have been put forward
to explain howmutations inGBA1 lead to lysosomal dysfunction
and neurodegeneration, and there is mounting evidence in sup-
port of the loss of GBA function hypothesis (Kinghorn, 2011).
Lysosomal dysfunction in GD has far-reaching implications, not
only for the degradation of !-synuclein, but also for the au-
tophagic degradation of other superfluous or damaged cellular
material and organelles, as the fusion of lysosomes with autopha-
gosomes is a critical step in the autophagic pathway (Ravikumar
et al., 2010). The process of macroautophagy can be divided into
key stages, including initiation, elongation, and maturation of
autophagosomes, followed by the fusion with lysosomes.
In keepingwith the importance of lysosomes in the autophagy
pathway, it was recently shown in macrophages and induced
pluripotent stem cell (iPSC)-derived neuronal cells from GD pa-
tients that autophagy is impaired (Awad et al., 2015; Aflaki et al.,
2016). Furthermore, this defect in autophagy was shown to trig-
ger inflammasome activation and the production of inflamma-
tory cytokines (Aflaki et al., 2016). Moreover, Osellame et al.
(2013) demonstrated that there is accumulation of dysfunctional
and fragmented mitochondria in a neuronopathic mouse model
of GD, thought to be secondary to autophagic and proteasomal
defects.
To further understand the mechanisms linking loss of GBA
activity to neurodegeneration in neuronopathic GD, and also
to determine whether autophagy plays a role in neurons in
vivo, we developed a novelDrosophilamodel that lacks the two
GBA1 orthologs, dGBA1a and dGBA1b. The fruit fly has
proven to be a useful model system for studying neurodegen-
erative diseases (Kinghorn et al., 2015) and lysosomal storage
disorders, including those affecting the nervous system, such
as neuronal ceroid lipofuscionoses (Myllykangas et al., 2005;
Hindle et al., 2011). It is therefore a useful model for studying
the mechanisms of pathogenesis of GD as well as the role of
GBA1 in neurodegeneration.
The dGBAknock-out flies proved to be faithfulmodels of GD,
with significant lysosomal dysfunction and buildup of the dGBA
substrate, glucosylceramide, in the fly brain. Furthermore, there
was significant neuronal autophagy impairment, which was as-
sociated with reduced survival and age-dependent locomotor ab-
normalities. At the cellular level, we demonstrated accumulation
of p62 and polyubiquitinated proteins, both of which accumulate
to form LBs in PD (Zatloukal et al., 2002), in addition to mito-
chondrial abnormalities. Moreover, dGBA-deficient flies dis-
played decreased mechanistic target of rapamycin (mTOR)
signaling with a reduction in p70 S6 kinase (S6K) phosphoryla-
tion, and the mTOR inhibitor rapamycin was able to partially
ameliorate the neurodegenerative phenotypes. Our results thus
show an important role of autophagy and mTOR signaling in
GD, and provide a useful model for the further study of patho-
genic mechanisms downstream of lysosomal dysfunction.
Materials andMethods
Fly stocks and husbandry. All fly strains used were backcrossed at least 6
generations into the w1118 background to obtain isogenic lines. All fly
stocks were maintained at 25°C on a 12:12 h light: dark cycle at constant
humidity on a standard sugar-yeast medium (15 g/L-1 agar, 50 g/L-1
sugar, 100 gl-1 autolyzed yeast, 3g/L nipagin, and 3ml/L propionic acid).
For all experiments, flies were raised at a controlled density on standard
sugar-yeast medium in 200 ml bottles.
Generation of dGBA1a and dGBA1b mutants by ends-out homologous
recombination. The genes encoding dGBA1a (CG31148) and dGBA1b
(CG31414) are located in close proximity onDrosophila chromosome 3,
separated by the CG31413 gene (see Fig. 1A). We generated specific mu-
tants for dGBA1a, dGBA1b and a dGBA1a and dGBA1b double-mutant,
without affecting the coding sequence of CG31413 by ends-out homol-
ogous recombination (Gong and Golic, 2004). dGBA1a was mutated by
replacing the whole ORF with a whitehs marker gene. dGBA1b was mu-
tated by introducing a stop codon and a subsequent frame shift mutation
12 bp downstream of the predicted ATG start codon. In addition, an
EcoRV restriction site was introduced to allow PCR screening of the
introduced mutations. To clone the donor construct for homologous
recombination, !4 kb of 5" and 3" flanking sequences of the dGBA1a
gene were cloned into the pBluescript II SK# vector (Stratagene) by ET
recombination using BAC clone CH321–50J5 (BACPAC Resource Cen-
ter, Oakland, California) as template and primers SOL474/475 and
SOL476/477 for the 5" and 3" arms, respectively. Mutations in the 3" arm
were introduced using the QuikChange site-directed mutagenesis kit
(Agilent Technologies) and primers SOL482/483. Both 5" and 3" homol-
ogous arms were subcloned into the pW25 vector (Gong and Golic,
2004) and full-length sequenced. pW25 was obtained from theDrosoph-
ila Genomics Resource Centre. The dGBA donor construct was trans-
formed into the germline of Drosophila melanogaster by P-element-
mediated germ line transformation using the Best Gene Drosophila
Embryo Injection Service. Crosses for ends-out homologous recombina-
tion were performed according to the rapid targeting scheme (Gong and
Golic, 2004). Subsequently, the whitehs marker gene was genetically
mapped and homologous recombination events were identified by PCR.
Point mutations introduced into dGBA1b were identified by PCR with
primers SOL484 and SOL485 and subsequent digestion with EcoRV,
which results in two specific DNA fragments of 120 and 193 bp from the
uncut 313 bp wild-type DNA fragment. Oligonucleotide primers used
for cloning and genotyping are listed in Table 1.
qRT-PCR. Total RNA was extracted from 25 heads or 25 thoraces and
abdomens of 6-d-old adult flies per sample using Trizol (Invitrogen) and
further purified over an RNeasy Mini column (QIAGEN) with on-
column DNase digestion. cDNA was prepared from 2.5 "g RNA using
the SuperScript Vil cDNA synthesis kit (Invitrogen). qRT-PCR data were
performed with TaqMan primers (Applied Biosystems) in a 7900HT
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real-time PCR system (Applied Biosystems). The TaqMan primers used
were as follows: Dm02150554_m1 for dGBA1b, Dm02143806_g1 for
dGBA1a, Dm02150538_s1 for CG31413, and a custom-made probe
against Rpl32. For each sample, 4 biological replicates and 4 technical
replicates were used. Relative expression was calculated using the !!CT
method and Rpl32 as normalization control.
For assessment ofMitf andAtg8a gene expression levels, total RNAwas
extracted from 20–25 fly heads per sample using TRIzol (Invitrogen)
according to the manufacturer’s instructions. Then 5 !g of total RNA
was subjected to DNA digestion using DNase I (Ambion), immediately
followed by reverse transcription using the SuperScript II system (Invit-
rogen) with oligo(dT) primers. qPCR was performed using the PRISM
7000 sequence-detection system (Applied Biosystems) and SYBR Green
(Invitrogen) by following the manufacturer’s instructions. Each sample
was analyzed in duplicate, and values are the mean of the 3 or 4 indepen-
dent biological repeats. The primers used were as follows: atg8, ATTCC
ACCAACATCGGCTAC and GCCATGCCGTAAACATTCTC;Mitf, GC
GTTCTTCTTCAGGGATTG and ACTTACGCTCGGCGAAATAG; and
RP49, ATCGGTTACGGATCGAACAA and GACAATCTCCTTGCG
CTTCT.
Lifespan, climbing, and fecundity analyses. The survival, climbing, and
fecundity assayswere performed as previously described (Kinghorn et al.,
2015). For the lifespan experiments, 150 female flies (unless otherwise
stated) were housed in groups of 15 and the flies were transferred every
2–3 d onto fresh food and the number of dead flies recorded.
Feeding assay (proboscis extension). Feeding rates of flies were mea-
sured using a proboscis-extension assay in undisturbed conditions as
previously described (Wong et al., 2009). Briefly, flies were housed in
groups of 5 per vial and kept undisturbed for 24 h before recording
observation. Feeding rate was scored by a brief but continuous observa-
tion for at least 1 h of the number of flies actively extending their probos-
cis on the fly medium. Observation recordings were made blindly.
Feeding ability was calculated by the number of feeding events divided by
the number of flies in the vial over the time periodmeasured and then by
averaging this for all of the vials per genotype.
Stress experiments and rapamycin treatment. For all stress assays, flies
were reared and housed as for lifespan experiments, and oxidative
stress and starvation assays were performed as previously described
(Kinghorn et al., 2015). Rapamycin (LC Laboratories) was dissolved
in 100% ethanol to give a 50 mM stock concentration. It was then
added to the standard fly medium to give the desired final concentra-
tion. Equivalent volumes of vehicle were supplemented to the me-
dium to compensate for dilution.
Measurement of dGBA activity. dGBA activity was measured using a
similar method to that previously described (Davis et al., 2016). Briefly,
20 fly heads of each genotype were homogenized and debris cleared by
centrifugation. Lysates (7.5 !g protein) were mixed with 0.1 M sodium
acetate, pH 4.5, and 5 mM 4-methyllumbelliferyl-"-D-glucopyranoside
and incubated at 37°C. The reaction was stopped with 0.25 M glycine
buffer, pH 10.4, and fluorescence measured on fluorescent plate reader
(excitation, 360 nm; emission, 460 nm). dGBA activity was also mea-
sured in the presence of the inhibitor conduritol-"-epoxide (100 !M)
and dGBA activity calculated as total GBA activity minus CBE-sensitive
GBA activity and expressed as pmol/h/mg protein. Approximately 50%
of the total dGBA activity was abolished by incubation with conduritol-
"-epoxide in w1118 control flies.
Measurement of glucosylceramide levels. Fly heads (n" 70) were analyzed
for glucosylceramide accumulation. The substratewas extracted in 500!l of
chloroform/methanol (2:1 v/v) containing 80 !g/ml of d4-C16:0-glucosyl-
ceramide internal standard, which was synthesized in house (Mills et al.,
2005). The samples were shaken for 30min at room temperature before the
addition of 100!l of PBS for phase separation.After a 10min centrifugation
at 16,000# g, upper and lower phases were collected and 5 !l of each was
injected into the ultra-performance liquid chromatography-tandem mass
spectrometry system. Synthetic glucosylceramide standard (Matreya) was
also analyzed to confirm analyte identity.
The samples were injected onto Waters ACQUITY UPLC system op-
erated in partial loop mode and separated on Waters ACQUITY UPLC
BEHC18 column (130Å, 1.7!m, 2.1mm# 50mm) under the following
gradient conditions: 0.00–0.20¡ 80% A; 0.20–5.00¡ 0.1% A; 5.00–
9.00¡ 0.1%A; 9.01–11.00¡ 80%A, wheremobile Phase A was ddH2O
[0.1% FA] and Phase Bwasmethanol. Column and sample temperatures
were kept at 40°C and 10°C, respectively. Weak wash solvent was ddH2O
(0.1% FA), and strong wash solvent was acetonitrile: methanol:isopro-
panol:ddH2O (1:1:1:1 v/v). The eluting analytes were detected on a Wa-
ters XEVO TQ-S triple quadrupole mass spectrometer, which was
equipped with the electrospray ion source and operated in MRM and
positive ion mode with the tune page parameters set to achieve the max-
imum sensitivity for glycosphingolipids as described previously (Auray-
Blais et al., 2015). The data were processed with MassLynx version 4.1.
Measurement of lysosomal enzymes. Twenty flies were homogenized in
RIPA buffer (150 mM NaCl, 50 mM Tris, pH 8.0, 1% (v/v) NP-40, 1%
(w/v) sodium deoxycholate, 0.1% (w/v) SDS, protease inhibitor mix-
ture) with a micro-pestle. Debris was pelleted at 17, 000# g and protein
concentration of the supernatant was determined using the protein BCA
kit (Pierce). "-Hexosaminidase activity (10!g protein) wasmeasured in
McIlvaine citrate buffer, pH 4.2, with 2 mM 4-methylumbelliferyl-N-
acetyl-glucosamide substrate. "-Galactosidase activity (10 !g protein)
was measured in McIlvaine citrate buffer, pH 4.1, with 0.25 mM
4-methylumbelliferyl-"-D-galactopyransoside substrate. Both enzyme
assays were incubated at 37°C for 30 min and the reaction stopped by
addition of 0.25 M glycine, pH 10.4. Fluorescent product was measured
using a plate reader (excitation, 340 nm; emission, 460 nm) and com-
pared against 1 nmol 4-methyllumbelliferone standard.
Triacylglyceride and ATP assays. Levels of triacylglyceride (TAG) in
adult females were measured using the Triglyceride Infinity Reagent
(Thermo Scientific) and normalized to total body protein using a BCA
assay (Sigma). The ATP concentration of whole female flies was deter-
mined using the ATP Bioluminescence Assay Kit HS II (Roche) as pre-
viously described (Kinghorn et al., 2015).
Table 1. The oligonucleotide primers used for cloning and genotyping in the generation of the dGBA knockout flies
Name Gene Sequence RS Comment
SOL474 GBA1a TTCGTAAACAATTTATTTTTCCGATAAAATTCGAATCTCCTATTATTAAACGTACGcacaacatacgagccggaagcata BsiWI ET Rec
SOL475 GBA1a CTCCAGTTGCGTTTTGCCAAAAGAACCAGGTGTCAATCAGGTGGCAGCGTGGCGCGCCatgtgcgcggaacccctatttg AscI ET Rec
SOL476 GBA1a AACATGTCTTTATTTAATTTTTTGTTTTGTTTAGAAAAAATAAGTTTTCAGCATGCcacaacatacgagccggaagcata SphI ET Rec
SOL477 GBA1a CGCTCCTCCCGCAACAATTCGCTGAACTACTTGGATGGCCTAGCTGTTCAGCGGCCGCatgtgcgcggaacccctatttg NotI ET Rec
SOL482 GBA1b ATGCCAGATATCTAGTACACCACTGCTTGG
SOL483 GBA1b CCAAGCAGTGGTGTACTAGATATCTGGCAT
SOL484 GBA1b ATTCGCCGGTCCGGCTGCTT
SOL485 GBA1b CTGCAATGCGTTTCATTTGAGG
SOL804 CG31468 TAATCTACGCCCAGCCCACTTG
SOL846 CG31468 ACGCTGCCACCTGATTGACA
SOL847 GBA1a ATGGGAAAAATGTTCGCCAGC
SOL848 GBA1a CTGTACAGCAGAGTGTGAATGG
SOL850 CG31413 CATCAGTGGCAGTTTACCAGTC
SOL851 CG31413 AAGCAGCCGGACCGGCGAAT
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Antibodies andWestern blotting. For Atg8Western blotting, 10 to 15 fly
headsor5headlessbodieswerehomogenized in2!Laemmli loadingbuffer
(100mMTris 6.8, 20%glycerol, 4%SDS)containing5%!-mercaptoethanol
and then boiled for 5 min. Approximately 40 "g of protein extract was
loaded per lane. Proteins were separated on SDS polyacrylamide gels and
transferred to anitrocellulosemembrane. ForubiquitinWesternblots, 12 fly
heads per sample were homogenized in Triton-X buffer (1% Triton-X, 10
mM NEM, 50 "m MG132, Complete Mini protease inhibitors, Roche, in
PBS). After centrifugation, the insoluble pellet was resuspended in SDS buf-
fer (2% SDS, 10 mMNEM, 50 "mMG132, complete mini protease inhibi-
tors, Roche, 50mMTris, pH 7.4), centrifuged, and the supernatant collected
as the insoluble sample for Western blot. Proteins were separated on 4%–
12% NuPage Bis-Tris gels (Invitrogen) and transferred to a PVDF mem-
brane. The membranes were then blocked in 5% BSA in TBST (TBS with
0.05%Tween20) for 1 h at room temperature, afterwhich theywere probed
with primary antibodies diluted in 5% BSA in TBST overnight at 4°C. Blots
were developed using the ECL detection system. The following primary an-
tibodies were used: !-actin (Abcam, #ab1801; 1:5000), mouse anti-poly-
ubiquitinated proteins (clone FK2, Millipore, 1:1000) and anti-Atg8 (1:
1000) (Castillo-Quan et al., 2016).
For detection of S6K and tS6K protein levels, 15 fly heads in each
sample were prepared by homogenization in 2 ! SDS Laemmli sample
buffer (4% SDS, 20% glycerol, 120 mM Tris-HCl, pH 6.8, 200 mM DTT
with bromophenol blue), and boiled at 95°C for 5 min. Samples were
separated on precast 4%–12% Invitrogen Bis-Tris gels (NP0322) and
blotted onto nitrocellulose paper in Tris-glycine buffer supplemented
with 10% ethanol. They were then blocked as above, and the primary
antibodies used were anti-phosphorylated S6K anti-phospho-Thr398-
S6K (Cell Signaling Technology, #9209, 1:1000), anti-total-S6K (1:1000)
(Sofola-Adesakin et al., 2014). The appropriate secondary antibodies
(Abcam) were diluted 1:10,000 in 5% BSA in TBST for 1 h at room
temperature. Bands were visualized with Luminata Forte (Millipore).
All blots were imaged with ImageQuant LAS4000 (GE Healthcare
Life Science). Quantification was performed using the ImageJ pro-
gram (National Institutes of Health).
Immunohistochemistry, LysoTracker, confocal imaging, and quantification.
For immunohistochemistry, adult brains were dissected in PBS and imme-
diately fixed in cold 4% PFA (v/v) for 20 min at room temperature. After
fixation, the samples were washed in PBT (PBS containing 0.3% Triton
X-100, v/v) four times for 20min then blocked in PBT containing 10%BSA
(PBT-BSA) for 2 h at 20°C-30°C. For primary antibody treatment, samples
were incubated in PBT-BSA containing the primary antibody for 3 d at 4°C.
After primary antibody incubation, brains were washed in PBT, four times
for20minat20°C-30°C, then incubated inPBT-BSAcontaining the second-
ary antibody for 24 h at 4°C. Brains were washed four times with PBT for 20
min at 20°C-30°C. Brains were finally mounted in Vectashield containing
DAPI overnight (Vector Laboratories). Antibodies were used at the follow-
ing dilutions: rabbit anti-Ref(2)P (Abcam) 1:200; mouse anti-
polyubiquitinated proteins (FK2, Millipore) 1:200; mouse anti-Bruchpilot
(DSHB antibody nc82), 1:100; secondary goat anti-rabbit AlexaFluor-568
1:250, and secondary goat-anti-mouse AlexaFluor-488 1:250.
For Ref(2)P and ubiquitin staining, image stacks of specimens were
obtained on a Zeiss LSM700 confocal microscope using a 10! objective
for whole-brain imaging. Stacks of 7.25"M Z distance and 14 images per
stack were taken. Images were quantified using ImageJ software. Briefly,
confocal stacks were merged into a single plane by using the maximum
projection function. A region of each central brain wasmanually selected
(200 "m high, 100 "mwide) from the dorsal to the ventral aspect of the
brain. Thresholds were then set for p62/Ref(2)P and ubiquitin, and the
area above threshold within this region was measured.
ForBruchpilot staining, imagestackswereobtainedusinga40!objective
in the region encompassing the ventral edge of the antennal lobe and dorsal
edge of the subesophageal ganglion. Stacks of 1.00 "M Z distance and 11
images per stack were taken. Images were quantified using ImageJ software.
Briefly, confocal stacks weremerged into a single plane by using the average
projection function. Two regions of each image were manually selected (10
"mhigh, 10"mwide), one in the center of the antennal lobe region andone
in the center of the suboesphageal ganglion region, by anobserver blinded to
genotype. Themean intensity of Bruchpilot staining was thenmeasured for
each region of interest.
For LysoTracker staining, adult brains were dissected in PBS and im-
mediately transferred to a solution of PBS with 1 "M LysoTracker Red
DND-99 (Invitrogen) and 1"MDAPI. Brains were mounted on slides in
this solution and imaged within 15 min of dissection on a Zeiss LSM700
confocalmicroscope using a 40! objective. For each replicate within the
experiment, one control and onemutant brain were imaged side by side,
with identical microscope settings and images taken from the same re-
gion of the subesophageal ganglion for each brain. Images were quanti-
fied using ImageJ software, by setting a threshold for LysoTracker and
measuring the area above threshold.
Electronmicroscopy of fly brains and image analysis.The flies were decap-
itated and the proboscis removed to allow penetration of the fixative.
They were then processed and visualized using previously described
methods (Kinghorn et al., 2015). Cross-sectional mitochondrial and
rhabdomere areas were measured manually using ImageJ software.
Statistical analyses.Survival experimentswereanalyzedusing log rank test.
Single comparisonswere analyzed using the Student’s t test.Other datawere
tested by ANOVA, and planned comparisons of means were made using
Tukey-Kramer HSD test. Statistical analyses were performed using Excel,
GraphPad Prism, or JMP software version 9 (SAS Institute).
Results
Knock-out of theDrosophila orthologs of GBA1 using
homologous recombination
Drosophilamelanogasterhas twoorthologsof thehumanGBA1gene,
CG31148 andCG31414, whichwe refer to as dGBA1a and dGBA1b,
respectively. These two genes are found on the same chromosome,
separated by the CG31413 gene (Fig. 1A), and show differential
tissue expression. dGBA1b is expressed in the adult brain, albeit at
low levels, as well as moderately expressed in the adult fat body.
dGBA1a is predominantly expressed in the adult fly digestive system
and shows no expression in the adult brain (Flyatlas) (Robinson et
al., 2013). To study the function of the dGBA1 genes, we pro-
duced loss-of-function mutants lacking dGBA1a (dGBA1a"/"),
dGBA1b (dGBA1b"/"), or double-mutants lacking both genes
(dGBA1a,b"/") using ends-out homologous recombination. The
complete open reading frame of dGBA1a was knocked out by ho-
mologous recombination, whereas dGBA1b expression was dis-
rupted by the introduction of a stop codon and a frame shift 12b
downstream of the putative ATG start codon (Fig. 1A; for more
details, seeMaterials andMethods). Deletion of dGBA1a and integ-
rity of theCG31413 genewere confirmed by PCR on genomicDNA
(Fig. 1B). Furthermore, introduction of specific point mutations
within the dGBA1b gene were verified by PCR (Fig. 1C) and se-
quencing.To testwhether thesemutations affected expressionof the
dGBAgenes and the interjacentCG31413gene,wemeasuredmRNA
transcript levels by qRT-PCR data in female heads and bodies for
dGBA1b (Fig. 1D), in female bodies for dGBA1a (Fig. 1E), and in
male bodies for CG31413 (Fig. 1F). The latter gene is specifically
expressed inmale accessory glands (Flyatlas) (Robinson et al., 2013).
dGBA1b transcript levelswere barely detected in dGBA1b"/" single-
mutant and dGBA1a,b"/"double-mutant flies (Fig. 1D), suggesting
that the introduced point mutations affect the stability of the
dGBA1b transcript. dGBA1a expression was absent from
dGBA1a"/" single-mutant and GBA1a,b"/" double-mutant flies
(Fig. 1E) and CG31413 expression was slightly reduced in
dGBA1a,b"/" double-mutants (Fig. 1F). Thus, the qRT-PCR data
suggest that both dGBA1a"/"and dGBA1b"/" are loss-of-function
alleles for the respective dGBA genes, with the single mutations not
affecting expression of the CG31413 gene, and the doublemutation
very slightly reducing it. Knock-out of dGBA1a, dGBA1b, or both
genes was not associated with any gross changes in body size or
obvious differences in morphology (data not shown). In keeping
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with the expression of dGBA1b, and not dGBA1a, in the fly brain,
dGBAactivity levelswere decreased by 95% indGBA1b!/! fly heads
and were undetectable in the heads of dGBA1a,b!/! flies. Con-
versely, the levels of dGBA activity in dGBA1a!/! fly headswere not
statistically different from that of controls, consistent with its pre-
dominant expression within the fly midgut (Fig. 1G).
Flies lacking dGBA displayed reduced lifespan and
progressive age-dependent locomotor deficits
The lifespan of flies lacking dGBA1a (dGBA1a!/!), dGBA1b
(dGBA1b!/!) or both dGBA1 genes (dGBA1a,b!/!) was assessed.
dGBA1b!/! flies displayed reduced survival compared with control
flies. However, dGBA1a!/! flies, which lack the dGBA isoform ex-
Figure 1. Generation of flies lacking the dGBA1a and dGBA1b genes. A, Schematic view of the dGBA1 gene locus. dGBA1a and dGBA1b are located in close proximity separated by the CG31413
gene, the function of which is unknown. Gray bars represent donor constructs for ends-out homologous recombination. Gaps between gray bars indicate genomic regions replaced by a whitehs
marker gene. Black boxes represent coding parts of exons. White boxes represent noncoding regions. dGBA1awas mutated by introduction of a stop codon and a frame shift 12 kb downstream of
the ATG start codon. Black bars A–D represent genomic regions PCR amplified in B, C. B, PCR on genomic DNA of dGBA1b!/!, dGBA1a!/!, dGBA1a, b!/!mutants andw1118 control flies. C, PCR
verification of point mutations in dGBA1bmutants. An EcoRV restriction site accompanied the introduced stop codon and frame shift mutation. Top, Undigested PCR product. Bottom, PCR product
restrictedwith EcoRV. A specific double band is apparent only in dGBAb!/! and dGBA1a, b!/!mutants.D–F, Quantitative real-timePCRwith probes directed against dGBA1b (D), dGBA1a (E), and
CG31413 (F ). Total RNA was isolated from female heads (left) and bodies (right) (D), female bodies (E), and male bodies (F ). Tissue and gender were chosen corresponding to the endogenous
expression of the respective gene.D–F, **p! 0.01 (one-way ANOVAwith Dunnett’s test relative tow1118 controls). ***p! 0.001 (one-way ANOVAwith Dunnett’s test relative tow1118 controls).
G, dGBA activity in fly heads was decreased by"95% in dGBA1b!/! flies (**p# 0.01) and was undetectable in dGBA1a,b!/! flies (***p# 0.006). Conversely, the dGBA activity measured in
dGBA1a!/! fly heads was not significantly different from that of controls ( p# 0.39).
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pressed mainly in the digestive system, showed a significantly in-
creased survival comparedwith control flies (Fig. 2A), and this trend
was seen using 4 additional dGBA1a null mutant fly lines (Fig. 2B).
Interestingly, double-mutantdGBA1a,b!/! flies displayed a lifespan
that was similar to that of the single dGBA1b knock-out line (Fig.
2A), suggesting that the detrimental effects of dGBA1bdeficiency on
lifespan cannot be reversed by the prolongevity effects of
dGBA1a knock-out. Given that GBA1 mutations are usually
found in the heterozygous state in PD and other synucleinopa-
thies, we also assessed dGBA1b and dGBA1a heterozygote
knock-out flies (dGBA1b!/" and dGBA1a!/") and found that
the lifespans of these flies were not significantly different from
those of controls (Fig. 2C).
In keeping with the lifespan phenotypes, dGBA1b!/! and
dGBA1a,b!/! flies, which lack the dGBA isoform expressed in
the brain, also displayed progressive age-dependent locomo-
tor deficits, with the climbing ability of dGBA1b!/! and
dGBA1a,b!/! flies in response to light tapping falling below
that of controls at older ages (Fig. 2D). Knock-out of dGBA1a,
despite its prolongevity effects, did not have any significant
effect on climbing ability over time compared with control
flies (Fig. 2E). Therefore, because loss of dGBA1a was not
associated with any lifespan defect or change in locomotor
ability, and has no expression in the adult brain, we concen-
trated on studying the dGBA1b!/! and dGBA1a,b!/! flies in
the subsequent experiments.
We also assessed the fecundity of dGBA1b!/! and
dGBA1a,b!/! female flies as a furthermeasure of healthspan. The
number of eggs laid per female significantly declined with age
comparedwith age-matched control flies, and day 30 nullmutant
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Figure 2. Lack of dGBA activity led to reduced survival and locomotor deficits.A, dGBA1b!/! and dGBA1a,b!/! female flies had significantly reduced lifespan comparedwithw1118 control flies
( p# 3$ 10!39 and p# 7$ 10!27). Furthermore, dGBA1a!/! flies displayed a significant lifespan extension compared with control flies ( p# 8$ 10!52). B, This lifespan extension was
consistent using a further 4 independent dGBA1a!/! lines (all p % 6 $ 10!12, n # 150 flies per genotype). C, Flies heterozygous for dGBA1b or both dGBA1 genes (dGBA1b!/" and
dGBA1a,b!/") did not display a lifespanphenotype ( p#0.69 andp#0.33).D,dGBA1b!/! anddGBA1a,b!/! flies showedanage-dependent reduction in climbing ability comparedwithw1118
control flies ( p# 0.0001 and p# 0.0004; n# 45 flies per genotype, 3 repeats each). E, The climbing ability of dGBA1a!/! flies was indistinguishable from that of controls ( p# 0.38). F, The
fecundity of dGBA1b!/! and dGBA1a,b!/! flies was significantly reduced at day 20 compared with age-matched control flies. ***p# 3$ 10!6 . ***p# 2$ 10!5. They were almost
completely infertile at day 30, whereas&20% of the control flies were still able to lay eggs.
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Figure 3. Loss of dGBA activity resulted in lipid defects and substrate accumulation in fly brains. A, Mass spectroscopic analysis revealed an!7-fold increase in accumulation of the
dGBA substrate, glucosylceramide, in the heads (n" 70) of 25-d-old dGBA1b#/# compared with age-matched w1118 control flies. **p" 0.01. The isoforms that were predominantly
elevated were C16:0, C18:0, and C20:0. B, Similar results were seen in dGBA1a,b#/# fly heads (n " 70 heads per sample, 3 technical repeats). ***p " 0.0008. C, There was no
age-dependent decrease in hexosaminidase (HEX) activity or (D) !-galactosidase (!-GAL) activity in dGBA1b#/# fly heads. There was a significant increase in !-GAL activity in older
25-d-old dGBA1b#/# fly heads compared with age-matched w1118 control flies. ***p" 2$ 10#5. Data are the mean% SEM of three independent experiments. E, The 25-d-old
dGBA1b#/# and dGBA1a,b#/# flies had reduced whole-body levels of TAG compared with age-matched controls. *p" 0.046 (paired t test). ***p" 0.00082 (paired t test). F, Day 15
dGBA1b#/# and dGBA1a,b#/# flies were more sensitive to starvation conditions than age-matched w1118 control flies ( p" 3$ 10#20 and p" 5$ 10#51; n" 150 flies per
genotype). G, Day 15 dGBA1b#/# flies had reduced feeding activity as assessed by the proboscis-extension assay (n" 55 flies per genotype). *p" 0.040.
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dGBA1b and the double-mutant dGBA1a,b!/! flies were almost
completely infertile (Fig. 2F).
Knock-out of dGBA resulted in changes in lipid metabolism
and accumulation of glucosylceramide
We next assessed whether knock-out of dGBA activity in the
fly is associated with accumulation of its substrate, glucosyl-
ceramide. Indeed, using lipid mass spectrometry, we found
that dGBA1b!/! and dGBA1a,b!/! flies displayed significant
accumulation of glycosylceramide in their heads, whereas the
heads of w1118 control flies contained very little glycosylcer-
amide (Fig. 3A,B). Furthermore, the predominant glycosylce-
ramide isoforms produced were C:16, C:18, and C:20 fatty
chains (Fig. 3A,B). To determine whether loss of dGBA caused
any change in the activity of other lysosomal enzymes, we
also assessed hexosaminidase (Fig. 3C) and !-galactosidase
(Fig. 3D). There was no age-dependent decrease in the activity
of these two enzymes in the heads of dGBA1b!/! flies com-
pared with controls. Indeed, the activity of !-galactosidase in
day 25 dGBA1b!/! fly heads was significantly higher than in
the controls (Fig. 3D).
In addition to specific lipid defects caused by the loss of
dGBA we also looked at more general lipid abnormalities. As
mentioned above, dGBA1 is expressed in both the midgut and
the fat body of the fly, an organ analog of vertebrate adipose
tissue and liver that acts as a major organ of energy metabo-
lism and nutrient storage (Tatar et al., 2014). We therefore
assessed whether loss of dGBA in these tissues might result in
general defects in lipid metabolism. TAG is the main form of
lipid storage in the fly and therefore reflects the ability of flies
to respond to starvation conditions (Ballard et al., 2008). Mea-
surement of whole-body TAG levels in day 25 female flies
revealed a significant reduction in dGBA knock-out flies
compared with age-matched controls (Fig. 3E). In particular,
there was a greater reduction in TAG levels in double-mut-
ant dGBA1a,b!/! flies compared with the single-mutant
dGBA1b!/! flies (Fig. 3E). The physiological relevance of the
decrease in TAG levels was confirmed in both dGBA1b!/!
and, to a greater extent, in dGBA1a,b!/! flies, which were
more sensitive to starvation conditions compared with con-
trols (Fig. 3F ). Furthermore, assessment of feeding behavior
by measuring proboscis-extension (Wong et al., 2009) dem-
onstrated that dGBA1b!/! flies had significantly reduced feed-
ing activity compared with controls (Fig. 3G). This suggests
that reduced food intake may contribute to the reduced TAG
levels and hypersensitivity to starvation.
Loss of dGBA activity led to lysosomal-autophagic deficits
To determine whether the accumulation of the dGBA substrate
corresponds with abnormal lysosomal pathology, which is
characteristic of GD, we stained the brains of dGBA1b!/!
and dGBA1a,b!/! flies with LysoTracker and visualized the
lysosomes with confocal microscopy. Aged dGBA1b!/! and
dGBA1a,b!/! flies displayed numerous enlarged and abnormal
lysosomes in their brains, which were not seen in age-matched
control brains (Fig. 4A,B). Given that normal lysosomes are re-
quired to fuse with autophagosomes to form autophagolyso-
somes in the process of autophagy (Rubinsztein et al., 2012), we
next studied autophagy. During the elongation phase, the
cytosolic form of protein microtubule-associated protein 1 light
chain 3 (LC3), LC3-I, is conjugated to phosphatidylethano-
lamine to form LC3-II, which is specifically targeted to the au-
tophagosome membrane, where it remains until fusion with
lysosomes. LC3 is therefore considered a good marker for study-
ing autophagy (Ravikumar et al., 2010). We therefore measured
the accumulation of Atg8, the fly ortholog of LC3, in both the
heads of dGBA1b!/! and headless bodies of dGBA1a,b!/! flies,
respectively (Fig. 5A,B).Western blot analysis demonstrated that
Atg8-I and Atg8-II accumulated in the heads of flies lacking
dGBA1b!/! (Fig. 5A). Atg8-II also accumulated in the headless
bodies of flies lacking both dGBA1 genes (dGBA1a,b!/!) (Fig.
5B) compared with controls. Increased steady-state levels of
Atg8-II suggests increased autophagosome number, but the
marked increase in Atg8-I also could indicate a stall in flux activ-
ity in the brains of dGBA1b!/! flies (Fig. 5A). Analysis of the
Atg8-II/Atg8-I ratio also confirmed increased autophagosome
formation and autophagy block in the dGBA knock-out fly heads
and bodies (Fig. 5A,B). Furthermore, Atg8 levels in homogenates
of heads from control and dGBA1b!/! mutant flies demon-
strated that this tissue was unresponsive to nutrient depriva-
tion (Fig. 5A), unlike headless bodies, in which a brief 48 h
period of prior starvation slightly increased Atg8-II levels,
suggestive of autophagy induction (Fig. 5B).
p62 and polyubiquitinated proteins accumulated in
dGBA-deficient fly brains
To study the downstream effects of autophagic dysfunction, we
next performed immunostaining on the brains of dGBA-
deficient flies with antibodies against ubiquitin and p62, markers
of lysosomal-autophagic degradation (Bartlett et al., 2011). Un-
der normal physiological conditions, p62 can link ubiquitinated
proteins to the autophagy machinery (e.g., Atg8-II), targeting
them for degradation (Rogov et al., 2014). Moreover, both ubiq-
uitin and p62 accumulate when autophagy is inhibited (Bartlett
et al., 2011) and are abundant constituents of protein inclusions
associated with neurological diseases, including LBs in PD
(Zatloukal et al., 2002; Bartlett et al., 2011). We first dissected
Drosophila brains and visualized these proteins using antibodies
against polyubiquitinated proteins and the fly ortholog of p62,
Ref(2)P. Aged dGBA1b!/! brains displayed elevated levels of
both ubiquitinated proteins and p62/Ref(2)P-containing aggre-
gates under the confocal microscope, which were not seen in
age-matched control fly brains (Fig. 6A). We also confirmed
elevated levels of polyubiquitinated proteins in dGBA1b!/! fly
heads using Western blot analysis (Fig. 6B). Thus, dGBA
knock-out led to lysosomal-autophagic defects and the accu-
mulation of ubiquitin and p62/Ref(2)P-containing deposits in
the fly brain.
Knock-out of dGBA in the fly brain led to synaptic loss
and neurodegeneration
To study the effect of dGBA deficiency on synaptic viability, we
performed immunostaining for Bruchpilot, an essential compo-
nent of synaptic active zones in Drosophila (Wagh et al., 2006).
This revealed significantly reduced Bruchpilot in the brains of
dGBA1b!/! flies compared with controls, suggesting synaptic
loss (Fig. 7A).
We also performed an ultrastructural examination of
dGBA1b!/! fly brains using transmission electron microscopy.
This demonstrated grossly abnormal morphology of the omma-
tidia, the units of the compound eye, in dGBA1b!/! flies com-
pared with controls (Fig. 7B). Quantitative analysis showed that
the average rhabdomere area within each ommatidium was sig-
nificantly reduced in the eyes of dGBA1b!/! flies (Fig. 7B).
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Knock-out of dGBA in the brain was associated with
mitochondrial abnormalities and hypersensitivity to
oxidative stress
Ultrastructural examination of the brains of flies lacking dGBA
using electronmicroscopy revealed giant mitochondria in day 25
dGBA1b!/! fly brains compared with age-matched controls (Fig.
8A) or younger day 5 dGBA1b!/! brains (data not shown), with
an "25% increase in the average mitochondrial area (Fig. 8B).
The presence of giantmitochondria, in addition to the increase in
autophagy substrates and increased Atg8-II, further supported
the conclusion that there was impaired autophagic flux.
In keeping with our ultrastructural data, mitochondrial dys-
function has been shown in a mouse model of GBA deficiency
(Osellame et al., 2013) and GD human fibroblasts (de la Mata et
al., 2015). To assess mitochondrial function, we measured ATP
levels and found that they were reduced by"40% in the brains of
dGBA1b!/! flies as well as in thewhole bodies of dGBA1b!/! and
dGBA1a,b!/! flies compared with controls (Fig. 8C,D). Mito-
chondrial dysfunction can lead to decreased resistance to reactive
oxygen species, which has been implicated in many neurodegen-
erative diseases (Kinghorn et al., 2015). To explore the role of
dGBA in resistance to oxidative stress, we examined the survival
of dGBA-deficient flies after exposure to the potent oxidizer hy-
drogen peroxide (H2O2) and paraquat, a free radical generator.
Consistent with the mitochondrial abnormalities in aged flies,
day 15 dGBA1b!/! and dGBA1a,b!/! flies showed increased sen-
sitivity to H2O2 and paraquat stress (Fig. 8E,F).
Targeting downstream autophagy defects with the mTOR
inhibitor rapamycin
The nutrient-sensing mTOR pathway regulates lysosomal bio-
genesis and autophagy (Ravikumar et al., 2010). We hence as-
sessed the activity of mTOR by measuring the phosphorylation
level of S6K, which acts downstream of mTOR complex 1
(mTORC1) (Castillo-Quan et al., 2015). Western blot analysis
revealed a decrease in S6K phosphorylation in the heads of
dGBA1b!/! flies compared with controls, indicating downregu-
lation ofmTORC1 (Fig. 9A), which would be predicted to lead to
an increase in autophagy. We also tested whether rapamycin, a
known mTORC1 inhibitor (Bjedov et al., 2010), could further
downregulate mTOR in dGBA-deficient flies. Treatment of con-
trol flies with 200 !M rapamycin resulted in a#50% decrease in
S6Kphosphorylation. Therewas a trend for rapamycin treatment
of dGBA1b!/! flies to further decrease S6K phosphorylation, al-
though this was not statistically significant. We therefore tested
the effect of rapamycin on the lifespan of dGBA1b!/! flies. Inter-
estingly, we found that rapamycin supplementation to the fly
medium (both 200 and 400 !M) from 2 d of age was able to
partially ameliorate the lifespan defect in dGBA1b!/! flies (Fig.
9B). Consistent with previous work (Bjedov et al., 2010), rapa-
Figure 4. dGBA deficiency was associated with lysosomal defects. A, Brains dissected from 15-d-oldw1118 control or dGBA1b!/! flies were stained with LysoTracker and imaged live within 15
min of dissection, using the same microscope settings to capture images from the same region of the subesophageal ganglion in each brain. dGBA1b!/! flies displayed abnormal staining with
numerous enlarged lysosomes that were not seen in age-matched control flies. For each image, the area of LysoTracker staining above a uniform threshold was quantified, revealing a significantly
increased area of LysoTracker staining indGBA1a,b!/! flies (n$6experimentswith one control andonedGBA1b!/!brain in each experiment). **p%0.005 (paired t test).B, Similar resultswere
also seen in thebrains of 25-d-olddGBA1a,b!/! flies comparedwith age-matched control flies (n$6 experimentswith one control andonedGBA1a,b!/!brain in each experiment). **p%0.005
(paired t test).
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mycin also increased the lifespan of control flies (Fig. 9B). In
keeping with the effect on lifespan, 400 !M rapamycin, but not
200 !M (data not shown), was also able to partially rescue the
locomotor deficits in aged dGBA1b!/! flies (Fig. 9C). An even
greater rescue was seen in flies lacking both dGBA1 genes
(dGBA1a,b!/!). This effect of rapamycin appeared to be specific
to dGBA knock-out flies, as rapamycin did not have a significant
effect on the climbing ability of age-matched control flies (Fig.
9C). We also assessed the effect of rapamycin on the response to
oxidative stress. Treatment with 200 !M rapamycin from 2 to
15 d of age subsequently prolonged the survival of dGBA1b!/!
flies on food containing H2O2 (Fig. 9D). This effect was also
specific to dGBA-deficient flies, as surprisingly rapamycin-
treated control flies had reduced lifespan on exposure to H2O2
(Fig. 9D).
Rapamycin treatment is also associated with an increased
resistance to starvation in wild-type flies (Bjedov et al., 2010).
We therefore treated dGBA1b!/! flies with rapamycin for the
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Figure5. Flies lacking dGBAdisplayed a block in autophagy.A,Western blot analysiswith an antibody against the fly LC 3 ortholog, Atg8, demonstrated increased levels in dGBA1b!/! fly heads
compared with age-matchedw1118 control flies. Both Atg8-I and Atg8-II were increased compared with controls, and the ratio of Atg8-II/Atg8-I in dGBA1b!/! flies indicated increased autopha-
gosome formation (n" 3 experiments). *p# 0.05. B, Western blot analysis of Atg8 levels in the headless bodies of dGBA1a,b!/! flies demonstrated no significant change in Atg8-I levels, with
an increase in Atg8-II levels and an increased Atg8-II/Atg8-I ratio. This effect was more pronounced after starvation in dGBA1a,b!/! flies (n" 3 experiments). *p# 0.05.
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first 15 d of adulthood before exposing them to starvation
conditions. The 200 !M rapamycin was able to rescue the
survival of dGBA1b!/! flies and control flies under starvation
conditions (Fig. 9E). These findings suggest that, despite the
autophagy block in flies lacking dGBA, rapamycin is still able
to exert protective effects on lifespan, locomotor defects,
and oxidative and starvation stress responses, likely by exert-
ing a small but functionally significant increase in mTOR
inhibition.
Loss of dGBA function in the brain resulted in an
upregulation ofMitf gene expression and its downstream
target gene Atg8a
To further study the effects of dGBA deficiency and rapamycin
treatment on autophagy, we measured the expression levels of
Mitf and its downstream target Atg8a. Mitf is the fly ortholog of
the mammalian transcription factor EB (TFEB) gene, the master
regulator of lysosomal biogenesis and autophagy (Bouche´ et al.,
2016; Tognon et al., 2016). TFEB is critical for the autophagic
cellular clearance of abnormal proteins and organelles, as well as
lipid metabolism. TFEB acts by coordinating the expression of a
number of genes belonging to the Coordinated Lysosomal Ex-
pression and Regulation (CLEAR) network, by directing binding
to specific CLEAR-box sequences located near their promoters.
TFEB is usually cytosolic where it interacts with mTORC1 at the
surface of the lysosome (Roczniak-Ferguson et al., 2012), but
during starvation it translocates to the nucleus where it induces
target gene transcription. Studies have shown that Mitf has
conserved regulatorymechanismswithmammalianTFEB, trans-
locating to the nucleus when Drosophila mTORC1 is inhibited
(Bouche´ et al., 2016).
We first measured Mitf gene expression in the heads of
dGBA1b!/! flies. qRT-PCR data analysis showed that, in re-
sponse to the loss of dGBA activity in the brain, there is a highly
significant upregulation of Mitf gene expression (Fig. 10A). We
next studied the levels of the Atg8a gene, the fly ortholog of the
mammalian GABARAPL1 gene, which acts downstream ofMitf.
This gene is involved in themain steps of autophagosome forma-
tion and maturation. In keeping with the upregulation ofMitf in
dGBA1b!/! fly heads, Atg8a was also upregulated in response to
dGBA knockdown in the fly brain (Fig. 10B).
We also studied the effect onMitf and Atg8a gene expression
of treating dGBA-deficient and control flies with 200 !M rapa-
mycin from day 2 (Fig. 10A,B). Interestingly, we did not see any
increase inMitf gene expression in dGBA1b!/! flies treated with
rapamycin compared with untreated flies (Fig. 10A). Moreover,
the levels of Atg8a in rapamycin-treated dGBA1b!/! flies were
significantly downregulated compared with untreated flies (Fig.
10B). Rapamycin significantly increased the expression levels of
Mitf in control flies (Fig. 10A); and although there was a trend
Figure 6. dGBA-deficient flies showed accumulation of p62/Ref(2)P and polyubiquitinated proteins in their brains. A, Immunostaining with antibodies against Ref(2)P, the fly ortholog of p62,
and polyubiquitinated proteins demonstrated increased Ref(2)P- and ubiquitin-positive puncta within the dGBA1b!/! fly brains. *p" 0.05 (t test). **p" 0.001 (t test). n# 5 or 6 brains per
genotype. B, Western blotting of Triton-insoluble head extracts confirmed the presence of significantly increased levels of polyubiquitinated proteins in dGBA1b!/! flies. **p" 0.05. n# 4
samples per genotype, 10–15 heads per sample.
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toward increasing Atg8a levels, it was not statistically significant
(Fig. 10B). Thus, loss of dGBA activity in the brain is associated
with increased expression levels ofMitf, and its downstream tar-
get gene, Atg8a, but upregulation of Mitf expression is not re-
sponsible for the protective effect of rapamycin on lifespan,
locomotor, and oxidative stress phenotypes.
Discussion
We generated a Drosophilamodel of neuronopathic GD. Simple
genetics could not be used to precisely excise both Drosophila
GBA1 genes, dGBA1a and dGBA1b, due to the presence of the
CG31413 gene between them. Therefore, we used serial homolo-
gous recombination to knock out both dGBA1 genes separately
or together in the fly. Of the two fly GBA orthologs, only dGBA1b
is expressed in the fly brain (Flyatlas). dGBA1b!/! fly heads, lack-
ing dGBA1b expression, displayed accumulation of the dGBA
substrate glucosylceramide. Furthermore, the glucosylceramide
isoforms (C16:0, C18:0, C22:0) were similar to those found in
human spleen tissue (with the addition of hydroxylated or longer
chain isoforms including C18:0-OH, C20:0-OH, C24:1, and
C24:0 in the human tissue (N. Sebire and S. Paine, unpublished
data). Moreover, this is consistent with data showing accumula-
tion of glucosylceramide and glucosylsyphingosine in Types II
and III GD patient brains (Orvisky et al., 2002).
Abnormally engorged lysosomes in dGBA1b!/! fly brains
were visualized with LysoTracker, confirming the validity of this
neuronopathicGD flymodel. Lysosomal integrity is necessary for
normal functioning of the autophagy degradation machinery
(Xu and Ren, 2015), and accordingly we observed autophagy
dysfunction in dGBA1b!/! brains, with accumulation of the au-
tophagolysosomal protein Atg8/LC3. Thus, we demonstrate au-
tophagy defects at the level of the autophagicmachinery in vivo in
a GDDrosophilamodel, following on from in vitro studies in GD
macrophages and iPSCs showing impaired autophagy (Awad et
al., 2015; Aflaki et al., 2016; Fernandes et al., 2016).
Neuronal-specific autophagy deficits, through loss of the
mouse autophagy genes atg7 or atg5, result in accumulation of
polyubiquitinated proteins, behavioral defects, and reduced lon-
gevity (Hara et al., 2006; Komatsu et al., 2006). Consistent with
this, we found that dGBA1b!/! flies displayed reduced survival
and locomotor ability and brain accumulation of p62/Ref(2)P
andpolyubiquitinated proteins. Both p62 andubiquitin accumu-
late in neurodegenerative diseases, such as Alzheimer’s disease
and PD (Zatloukal et al., 2002; Bartlett et al., 2011), and multiple
pathogenic proteins, including p62 and !-amyloid, have been
identified in neuronopathic GD mouse brains (Xu et al., 2014).
Surprisingly, knock-out of dGBA1a, which is predominantly
expressed in the digestive system, significantly increased survival.
This finding parallels recent research in Drosophila and Caeno-
rhabditis elegans demonstrating that the intestine is an important
target organ for mediating lifespan extension at the organismal
Figure 7. Deficiency of dGBA resulted in synaptic loss and neurodegeneration.A, Immunostaining for Bruchpilot (brp), a critical synaptic component, demonstrated reduced staining (red) in the
brains of day 25dGBA1b!/! flies comparedwith controls. Antennal lobe (AL) and suboesphageal (SOG).n"7–8brains per genotype.B, EMof the eyes of day 25dGBA1b!/! flies revealedgrossly
abnormalmorphology of the ommatidia comparedwith age-matched controls (#5600). Scale bars, 2"m. In addition, quantitative analysis revealed a reduction in average rhabodomere (*) area
in dGBA1b!/! fly eyes (***p" 4# 10!6; at least 80 consecutive rhabdomeres studied for each genotype).
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level, with single-gene manipulations specifically in the gut pro-
longing lifespan (Rera et al., 2011; Tatar et al., 2014). The role of
dGBA in the gut in regulating lifespan was beyond the scope of
this study but is an area that warrants further investigation. We
demonstrated, however, that the lifespan extension seen in
dGBA1a!/! flies is not associated with any improvement in lo-
comotor ability.
Mitochondrial integrity is necessary for normal autophagy-
lysosomal system functioning (Palikaras and Tavernarakis, 2012;
Ashrafi and Schwarz, 2013). Indeed, mitochondrial dysfunction
occurs in GD mouse models (Osellame et al., 2013; Xu et al.,
2014), likely due to defects in the autophagic removal of damaged
mitochondria (Osellame et al., 2013). In keeping with this, the
deficiency of the Drosophila autophagy gene atg7 is associated
with sensitivity to oxidative stressors (Juha´sz et al., 2007).
Accordingly, we demonstrated mitochondrial abnormalities
in dGBA1b!/! flies, with giant mitochondria, reduced ATP
and hypersensitivity to oxidative stress. Enlarged mitochon-
dria and decreased ATP occur in neuronopathic GD mice (Xu
et al., 2014), and giant mitochondria are directly linked to
Drosophila autophagy defects (Bouche´ et al., 2016). Therefore,
the accumulation of autophagic substrates and giant mito-
chondria in dGBA1b!/! flies is consistent with autophagy
block (Fig. 10C).
Figure 8. dGBA-deficient fly brains displayed mitochondrial abnormalities. A, EM analysis of the brains of day 25 dGBA1b!/! flies showed giant mitochondria (arrows) compared with
mitochondria (arrows) in age-matchedw1118 control fly brains ("11,500magnification). Scale bar, 1!m.B, Averagemitochondrial areawas increased in dGBA1b!/! flies (n# 200mitochondria
per genotype). ***p$ 4" 10!5. C, Thesemitochondrial structural abnormalitieswere associatedwith decreased ATP levels in day 25 dGBA1b!/! fly heads (**p$ 0.0016) and (D) in thewhole
bodies ofdGBA1b!/! flies comparedwithage-matched controls (*p$0.02). Therewasa trend for reducedATP levels in thedGBA1a,b!/! flies, but this didnotquite reach significance ( p$0.06).
E,dGBA1b!/!anddGBA1a,b!/! flies displayed reduced survival onexposure to5%H2O2 ( p$3"10
!12 andp$5"10!15) and (F ) 20mMparaquat ( p$0.003andp$2"10!6;n$150
flies per genotype).
11666 • J. Neurosci., November 16, 2016 • 36(46):11654–11670 Kinghorn et al. • Autophagy Defects in Neuronopathic Gaucher Disease
Furthermore, we demonstrated that the neuropathological
defects in dGBA1b!/! flies occur independently of !-synuclein,
confirming that dGBA deficiency is sufficient to cause neurode-
generation (Fig. 10C). A recent study using a deletion mutant
harboring imprecise removal of the dGBA1b gene, as well as the
incomplete removal of the dGBA1a gene and excision of the in-
terjacentCG31413 gene, provides further validation of ourmodel
for studyingGBA1-associated neurodegeneration. Loss of 60%of
GCase activity was also associated with reduced survival and
climbing ability in addition to accumulation of autophagy sub-
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exposure to food containing 5% H2O2 ( p" 2.5$ 10
!9). This protective effect was specific to dGBA-deficient flies as 200"M rapamycin was toxic to control flies under similar conditions ( p"
0.0007; n" 60 flies per group). E, The 200"M rapamycinwas also able to increase survival of dGBA1b!/! flies in response to subsequent exposure to starvation conditions from 15 d of age. *p"
0.004. The time point shown is after 3 d of starvation stress (n" 60 flies per condition). Under similar conditions, 200"M rapamycin also rescued the survival of controlw1118 flies (n" 60 flies per
group). *p" 0.023. The bar chart represents survival after 8 d of exposure to starvation.
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strates (Davis et al., 2016). GCase deficiency was also shown to
enhance !-synuclein pathology in the fly (Suzuki et al., 2015;
Davis et al., 2016). Our model has the advantage over existing
models, as it allows the precise and complete knock-out of each of
the dGBA genes, and the dissection of the role of dGBA in differ-
ent tissues. The ability to knock out only brain-specific dGBA1b is
particularly relevant given our finding that loss of dGBA in the
gut causes prolongevity effects. Our model also avoids the pro-
duction of truncated, possibly pathogenic, variants of dGBA.
The nutrient-sensing mTOR is localized to the lysosomal sur-
face (Efeyan et al., 2012; Betz andHall, 2013), where it modulates
autophagy (Yu et al., 2010; Zoncu et al., 2011). It has thus been
speculated that abnormal lysosomal function leads to activation
of autophagy by mTOR downregulation (Li et al., 2013). Indeed,
a recent study reported increased expression of mTOR signaling
pathway genes in neuronopathic GD mice (Dasgupta et al.,
2015). In view of the autophagy defect in dGBA1b!/! flies, we
probedmTOR signaling by analyzing S6K phosphorylation dow-
nstreamofmTORC1. Interestingly, we detected a decrease in S6K
phosphorylation and hence downregulation of mTORC1 com-
pared with controls. Furthermore, although not statistically sig-
nificant, therewas a trend formTOR to be further downregulated
in dGBA1b!/! flies treated with rapamycin, a known mTORC1
inhibitor. Because rapamycin has protective effects in animal
Figure 10. Knock-out of dGBA activity in the fly brain was associated with upregulation ofMitf and its downstream target Atg8a. A, qRT-PCR data analysis revealed that day 15 dGBA1b!/! fly
heads had increased expression levels ofMitf compared with controls. ***p" 9.7# 10!5. In addition, treatment with 200"M rapamycin from 2 d of age had no significant effect onMitf gene
expression in dGBA1b!/! flies ( p" 0.32). However, rapamycin treatment led to a significant increase in the expression levels ofMitf in control flies (**p" 0.016).B,Atg8a gene expression levels
were greater in dGBA1b!/! fly heads comparedwith controls. ***p" 2.8# 10!7. Treatmentwith 200"M rapamycin resulted in a decrease inAtg8agene levels in dGBA1b!/! fly heads (**p"
0.002); and although therewas a trend toward increasedAtg8a gene expression in control flieswith rapamycin treatment, it did not reach statistical significance ( p" 0.054). ThemRNA expression
levels of all genes are shown relative to the expression levels of a control gene, RP49. C, Schematic diagram showing the downstream effects of impaired autophagy flux in dGBA-deficient flies.
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models of PD and other neurodegenerative diseases (Malagelada
et al., 2010; Cheng et al., 2015), we treated dGBA1b!/! flies with
rapamycin and found that, despite the autophagy block, it was
able to partially ameliorate many neurotoxic phenotypes. Rapa-
mycin treatment led to an improvement in the lifespan and
climbing phenotypes, in addition to the hypersensitivity to oxi-
dative and starvation stressors seen in dGBA1b!/! flies. These
results are somewhat surprising given that rapamycin treatment
of iPSC-derived neuronal cells from GD patients caused cell
death (Awad et al., 2015), demonstrating that drug effects in vitro
vary to those at the organismal level. Furthermore, although
rapamycin increases the lifespan and protects against starvation
conditions in control flies (Bjedov et al., 2010), the rescue of
age-related climbing defects and oxidative stress appeared to be
specific to dGBA-deficient flies. Indeed, rapamycin had no effect
on the climbing ability of control flies, and rapamycin-treated
control fliesweremore sensitive toH2O2 thanuntreated flies. The
reason for the opposing effects of rapamycin on the oxidative
stress responses of dGBA1b!/! and control flies is unclear, but
may be related to the differential activation of oxidative stress
pathways between dGBA1b!/! and healthy controls.
Lastly, we demonstrated that knock-out of dGBA in the brain
results in an upregulation of Mitf and its downstream target,
Atg8a, suggesting a compensatory response to the autophagy
block. This is in contrast to findings in a recent study showing
downregulation of TFEB expression in GD iPSC-derived cells
(Awad et al., 2015). The reasons for these differing results is not
clear, but possible explanations may relate to variations in au-
tophagy block between models, and the fact that neuronal cells
are newly differentiated and may reflect early disease compared
with adult flies. Mitf gene expression may also vary in the pres-
ence of mutant dGBA. Our fly model displays very little dGBA
expression compared with iPSC cells, which are derived from
mutant carriers, and therefore, despite showing very low levels of
GCase activity, express mutant GBA. Mutant GCase is known to
exert gain-of-function toxic effects, including inDrosophila, with
upregulation of the unfolded protein response (Maor et al., 2013,
2016). Knockdown ofMitf in Drosophila leads to similar pheno-
types to those in dGBA1b!/! flies, including autophagy substrate
accumulation, upregulation of Atg8-II, giant mitochondria, as
well as enlarged lysosomes (Bouche´ et al., 2016). Thus, the au-
tophagy defects seen in dGBA deficiency appear to phenocopy
Mitf downregulation in the fly. This suggests that upregulating
Mitf as a potential therapeutic strategy inGDandGBA-linked PD
may be limited in its efficacy due to the inability of GBA-deficient
neuronal tissue to stimulate autophagy. Further studies are war-
ranted to explore the complex interaction betweenmTORC1 and
TFEB/Mitf in GD.
Rapamycin treatment of dGBA1b!/! flies did not upregulate
Mitf gene expression, suggesting that rapamycin does not act
through Mitf signaling to rescue the neurotoxic phenotypes of
dGBA-deficient flies. We hypothesize, therefore, that mTOR is
downregulated in dGBA-deficient flies as a compensatory response
to lysosomal-autophagy block. Possibly as a consequence of lyso-
somal dysfunction in dGBA-deficient flies, the normal interaction
between mTORC1 and TFEB/Mitf at the surface of the lysosome is
disrupted, leading to changes inTFEB/Mitf gene expression. There-
fore, by exerting small additional effects on mTORC1 signaling,
rapamycin may mediate its beneficial effects (Fig. 10C). Further-
more,Mitf also plays a critical role in lipid metabolism and recapit-
ulates the functionofTFEB inmammals in this regard(Bouche´ et al.,
2016).Mitf expressionmay therefore contribute to the reducedTAG
that we see in dGBA1b!/! flies.
In conclusion, the autophagy defects seen in our GD flies,
likely as a result of failure of the fusion of autophagosomes and
lysosomes,may also be relevant to PD linked toGBA1mutations.
Our results raise the possibility that therapies aimed at amelio-
rating not only lysosomal dysfunction, but also at autophagic
abnormalities, including lowering mTOR activity, may be effec-
tive in treating GBA1-associated disease. They also suggest that
rapamycinmay offer significant health benefits in neuronopathic
GD and in GBA1-related synucleinopathies. Together, our data
demonstrate that these Drosophila models of dGBA-deficiency
are a useful platform to further study the downstream effects of
lysosomal-autophagic dysfunction and to identify genetic modi-
fiers and new therapeutic targets in neuronopathic GD and
GBA1-associated PD.
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